cx	cy	x	y	score	nptumor	nphit	tumor	name	status	top
1078.9268201719037	-37.1050260386424	1111.2007573084297	5.58663553646602	0.996	264	41	SKCM	PAZOPANIB	Approved in cancer	KIT | KRAS | VHL
214.1265942980783	-59.8491244652245	199.60929096136715	-13.633258668021	0.0008	264	31	SKCM	AT7867	Experimental	KRAS | PTPN11 | AKT3
697.424668901974	-2.03071987269328	678.2440189643753	-4.72835311509243	0.544	934	245	BRCA	APITOLISIB	Clinical trials in cancer	KRAS | STK11 | AKT1
213.82427179355687	-22.61899104541	197.8200562233146	23.9820858137487	0.0006	423	66	COAD	OBLIMERSON	Experimental	TP53 | MTOR | BRAF
723.0019786813432	-70.5441778160958	724.5113405346947	-3.04787240867745	0.594	264	34	SKCM	ORANTINIB	Clinical trials in cancer	VHL | ARNT | HSPG2
535.2560016350461	-39.3103750592035	542.99967118567	-0.000187785878438262	0.381	222	58	LGG	EDARAVONE	Approved in other pathologies	TP53 | BRAF | MTOR
1069.5847960643548	46.5381775925475	1078.5415565581052	18.9137565166055	0.984	169	46	READ	ARSENIC TRIOXIDE	Approved in cancer	KRAS | SMAD4 | NRAS
1107.8850093768629	31.4460957280685	1080.5544558623174	1.8072359075818	0.98	389	41	LUSC	TRAMETINIB	Approved in cancer	KRAS | FGFR2 | BRAF
593.5074285166012	21.9034713437027	590.3812543322897	-5.39942762867577	0.421	512	80	UCEC	937174-76-0	Clinical trials in cancer	PIK3CA | PRKACA
656.1856398749866	-40.673609330318	665.3295349318493	-2.22999789815231	0.517	543	67	LUAD	NVP-BGJ398	Clinical trials in cancer	KRAS | PIK3CA | KDR
163.98293450705359	-46.7792243709368	224.7149312733726	8.58496385148874	0.022	343	45	HNSC	TG100-115	Clinical trials	PIK3CA
240.2786103612259	22.1449765132991	228.28756743358608	-30.0880067367557	0.0006	512	96	UCEC	CHEMBL205098	Experimental	PTEN | KDR | PRKACA
1005.0645449288836	59.2141304054596	1042.463602112376	0.00375284479571292	0.933	222	64	LGG	BORTEZOMIB	Approved in cancer	TP53 | KRAS | BRAF
710.1991719373201	146.630445728125	685.9244492677753	-11.8198239748444	0.54	222	143	LGG	SELUMETINIB	Clinical trials in cancer	NF1 | KRAS | NRAS
712.2919596481902	2.26000275181684	772.4360780445794	-7.92302636889917	0.595	512	165	UCEC	PX-866	Clinical trials in cancer	KRAS | NRAS | ZAP70
594.324951065274	-39.9084892369109	584.1006913564472	0.520515980842788	0.422	202	23	LAML	FAMITINIB	Clinical trials in cancer	FLT3 | KIT | KDR
921.0985570785169	8.04438010445637	949.835231418242	7.82194279002351	0.823	934	216	BRCA	CARBOPLATIN	Approved in cancer	KRAS | PIK3CA | PDGFRA
172.02242829025266	-14.5004193649312	192.4395261184929	0.585161731043172	0.0006	264	35	SKCM	TRIAZOLOPYRIDINE	Experimental	CYBB | AKT3 | GNAS
788.611474550647	-9.02852613480079	710.780899196192	17.4807087645077	0.593	512	116	UCEC	CC-223	Clinical trials in cancer	KRAS | TSC2 | TSC1
548.6088130893261	-13.6309781598864	596.7139523149826	-1.68312733789003	0.432	512	108	UCEC	CUDC-907	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
234.14790041015647	73.1786137893679	218.17336982541906	5.90430224754289	0.0006	169	39	READ	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	Experimental	KRAS | MAP4K1 | RRAS2
221.05679566690216	7.19750405242695	194.0645407752737	3.85632556981091	0.0004	934	216	BRCA	PKI-402	Experimental	KRAS | PIK3CA
393.6305192571651	-5.75473375337455	391.00007995237075	-0.00030391603922908	0.212	543	62	LUAD	CAPSAICIN	Approved in other pathologies	KRAS | ABCB1
138.52854590768956	21.2553494328632	202.96562139835362	1.61109708580739	0.012	934	216	BRCA	TG100-115	Clinical trials	PIK3CA
514.6068612194174	-48.9417932822459	515.9985469166346	-0.00272814844538516	0.351	264	37	SKCM	SEMAXANIB	Approved in other pathologies	KIT | VHL | CTNNB1
643.2292052344898	51.1475344428401	628.9302196605797	31.9424509980996	0.453	57	24	PAAD	GDC-0068	Clinical trials in cancer	KRAS
699.2780454817394	73.0398733912451	734.8825385535567	2.02320039392634	0.593	343	60	HNSC	XL147	Clinical trials in cancer	PTEN | RAC1 | CD247
385.64406607401594	4.54180739455811	374.04435748205447	0.0241961130413415	0.193	169	47	READ	QUERCETIN	Clinical trials	KRAS | PTPN11 | NRAS
581.191311429451	39.8864655313361	575.4358056112968	-3.44802544964728	0.422	435	185	THCA	952021-60-2	Clinical trials in cancer	KRAS | BRAF
934.9513814540047	65.4219597491334	971.4453831682703	3.9026761842635	0.84	57	24	PAAD	TRAMETINIB	Approved in cancer	KRAS
1000.565350484153	73.2187987558207	1056.1503638763766	-2.30120488650797	0.93	57	25	PAAD	PALBOCICLIB	Approved in cancer	KRAS | SMAD4
718.7839965615319	-129.488843995469	731.759457332764	74.0873419115246	0.597	264	197	SKCM	PKI-587	Clinical trials in cancer	NRAS | KIT | KRAS
806.552334396929	11.6354605940398	756.5587918452684	-31.283433250514	0.586	264	124	SKCM	XL765	Clinical trials in cancer	NRAS | KIT | KRAS
314.9545076221778	27.677479400546	231.81205496067358	-33.7778315492612	0.0004	435	183	THCA	878739-06-1	Experimental	BRAF
540.7339027593683	11.6384899814912	566.3028949490642	7.22219281064645	0.412	934	216	BRCA	GSK1059615	Clinical trials in cancer	PIK3CA
72.5599532082998	-11.4121669831344	200.3778039464232	10.4775414045462	0.0004	934	218	BRCA	154447-36-6	Experimental	KRAS | PIK3CA | MTOR
709.3134435049667	-55.4949574718173	727.1321199367424	-3.39216472181715	0.597	153	23	BLCA	PKI-587	Clinical trials in cancer	NRAS | PTEN | PIK3CA
962.4417644646345	-17.6050294293049	962.1857457139193	-1.7292300479769	0.843	543	76	LUAD	PEMETREXED	Approved in cancer	KRAS | EGFR | PIK3CA
1106.8686871461518	-61.3745938990381	1086.6282498549033	-13.5385673469036	0.99	423	91	COAD	DASATINIB	Approved in cancer	KRAS | SMAD4 | ESR1
782.1331703359041	-23.6399582762594	769.9992347449753	-0.000303994237810912	0.633	543	77	LUAD	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | BRAF
553.6157496983445	-27.8814427551711	557.8305413892093	-3.56881057081	0.381	264	41	SKCM	APREMILAST	Approved in other pathologies	RB1 | VHL | AKT3
594.8842651644421	99.2571237526068	626.4133088137162	2.92544406830098	0.513	435	211	THCA	1032350-13-2	Clinical trials in cancer	KRAS | NRAS | BRAF
513.7295435791051	-41.8428873620124	540.920517345841	3.102087167842	0.381	423	92	COAD	ISOPRENALINE	Approved in other pathologies	KRAS | NRAS | BRAF
1147.3845593888955	10.520256042916	1081.8332144017688	-17.5065506474732	1.0	512	126	UCEC	DABRAFENIB	Approved in cancer	KRAS | NF1 | NRAS
719.7338995188921	-36.4553527186885	754.8355782890073	11.4917464299278	0.598	423	67	COAD	OSI-027	Clinical trials in cancer	KRAS | MTOR | PIK3CA
1120.8854285183613	-35.5726360916486	1101.1345526494144	4.337491441579	1.0	292	43	STAD	SORAFENIB	Approved in cancer	KRAS | NF1 | PTPN11
196.23974715267153	72.4769916433727	219.72522562296052	-6.7234681026905	0.0006	502	62	KIRC	7-NITROINDAZOLE	Experimental	VHL | AKT3 | MTOR
522.9198520385088	-40.6782659451149	583.3506221175286	5.30044536585865	0.422	423	57	COAD	GDC-0994	Clinical trials in cancer	KRAS | MAPK1
766.4325461094073	79.500844194066	734.2954537535041	-31.2117009716517	0.597	169	48	READ	PKI-587	Clinical trials in cancer	KRAS | PTPN11 | NRAS
182.2819358840878	48.695565172455	218.2721895092072	-17.7264298227101	0.0004	512	110	UCEC	AT13148	Experimental	KRAS | PIK3CA | ERBB2
585.1161474942874	69.2324062666639	704.6235396273238	-7.70650501765999	0.524	435	183	THCA	ZSTK474	Clinical trials in cancer	BRAF | SOS1 | PIK3CA
1099.402534872491	4.85809366930272	1089.9699461337564	-3.70811089084737	0.982	292	36	STAD	TRAMETINIB	Approved in cancer	KRAS | NF1 | CTNNB1
556.9983338437648	-41.6428639082563	575.9178914794951	9.81689182634773	0.423	343	48	HNSC	RIGOSERTIB	Clinical trials in cancer	PIK3CA | HRAS
1104.4515369432695	5.96134695296442	1096.2476027744892	2.83079049582022	0.996	389	53	LUSC	DASATINIB	Approved in cancer	KRAS | PTEN | BRAF
236.69714175538738	-20.0164819035371	196.6210599866707	-17.8371969097179	0.0006	502	61	KIRC	BROLUCIZUMAB	Experimental	VHL | MTOR | HSPG2
998.4940712986522	-55.8108721241509	1051.2665946503237	-13.0547862080034	0.939	934	244	BRCA	SORAFENIB	Approved in cancer	KRAS | NF1 | AKT1
1091.6913909807886	39.2199740596016	1049.9133170523992	-8.12966073725124	0.939	202	53	LAML	SORAFENIB	Approved in cancer	KRAS | FLT3 | NF1
209.1830793072934	11.4269295069957	178.72685640133818	-8.76070736142174	0.0008	512	56	UCEC	NETOGLITAZONE	Experimental	TSC2 | TSC1 | CTNNB1
269.27915785337433	12.5028383500226	205.12448306207145	-3.45600752237647	0.0004	202	22	LAML	GTP-14564	Experimental	FLT3 | KIT | PDGFRB
785.383031639838	-51.6346259396342	679.316977642428	-12.2616535807791	0.535	169	41	READ	GDC-0032	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
1126.0662163296513	-41.0031126698736	1092.9205439060502	2.35221979202879	0.983	423	97	COAD	ARSENIC TRIOXIDE	Approved in cancer	KRAS | NRAS | SMAD4
212.318576671354	-86.1971159216883	211.9135068258184	-0.62161436037286	0.0004	934	216	BRCA	GDC-0077	Experimental	PIK3CA
138.96764312534665	47.5730277691789	196.68547067300602	19.3824631062407	0.0004	934	233	BRCA	MSC-2363318A	Experimental	AKT1 | PIK3CA
582.3147710504624	4.96994495483113	554.8581901853208	4.0094699985882	0.395	512	60	UCEC	IRBESARTAN	Approved in other pathologies	CTNNB1 | CHD8 | MAPK7
188.21188723578933	54.0406044165074	216.3000756972049	30.3235932278285	0.0004	512	106	UCEC	AZD8186	Experimental	KRAS | PIK3CA
190.42777020962325	-30.8624780333386	192.0377535580412	-5.8422586641791	0.0008	543	78	LUAD	FR 180204	Experimental	KRAS | NRAS | BRAF
891.0045769552975	-1.84205858255214	906.6817889758036	0.000316128768190538	0.784	264	33	SKCM	CELECOXIB	Approved in other pathologies and in clinical trials in cancer	PTPN11 | PTEN | CTNNB1
198.3422782512178	-52.9330373229936	205.01728741785766	21.8284909468748	0.0008	343	51	HNSC	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE	Experimental	RAC1 | PIK3CA | SOS1
929.9648290370617	-51.2884416835925	916.5158711166017	-15.6791159974725	0.812	57	24	PAAD	IXABEPILONE	Approved in cancer	KRAS
726.0246121148058	-38.5226022460033	729.2676763953248	-2.2590678612828	0.593	343	61	HNSC	SF1126	Clinical trials in cancer	STK11 | PTEN | RAC1
953.930034704988	-54.1171980191303	946.6016594094286	-0.862933334352874	0.822	264	108	SKCM	DABRAFENIB MESYLATE	Approved in same tumor type	BRAF | MAP2K1 | MAP2K2
543.813060010716	-33.1225099815105	524.9360912495833	-3.68078901878425	0.371	264	30	SKCM	IRBESARTAN	Approved in other pathologies	AKT3 | CTNNB1 | MAP2K1
365.7201130860823	-3.10238089171611	367.71884610203773	3.72506134069454	0.181	264	34	SKCM	ELLAGIC ACID	Clinical trials	GNA11 | BTK | GNAS
941.7523680690099	32.6768974411975	963.8994290978102	-4.97591979354752	0.852	512	111	UCEC	IRINOTECAN	Approved in cancer	KRAS | PIK3CA | ERBB2
684.8672267979881	-11.6185962579439	686.7493967308084	-10.8052346304829	0.526	202	31	LAML	PIMASERTIB	Clinical trials in cancer	KRAS | NF1 | KIT
168.4155639818607	-45.1692084074043	199.83368601485873	-4.18272032395271	0.0006	264	35	SKCM	CHEMBL94417	Experimental	CYBB | AKT3 | GNAS
970.8347925454312	84.4397550434427	1063.830869567794	0.191167955720175	0.93	435	185	THCA	DASATINIB	Approved in cancer	KRAS | BRAF | SOS1
1093.2584430920242	-36.647190004411	1055.6039894207163	4.78806717841485	0.954	543	107	LUAD	PACLITAXEL	Approved in same tumor type	KRAS | TP53 | BRAF
859.1890246465885	1.06494552714668	872.0429634657924	-0.00833309521613046	0.744	512	82	UCEC	RALOXIFENE	Approved in other pathologies and in clinical trials in cancer	PIK3CA | PRKACA | RAF1
684.5344076241739	-5.07525620075253	706.7933008735764	1.60350016121549	0.562	599	77	GBM	GSK2636771	Clinical trials in cancer	NRAS | KRAS | PTPN11
138.87301159391328	-127.947698491292	220.56475877830744	85.1369620763412	0.0008	264	194	SKCM	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	NF1 | NRAS | KIT
342.87441989641286	37.3000818085893	244.48759715925067	8.94804782924734	0.0006	57	24	PAAD	HYPOTHEMYCIN	Experimental	KRAS
1102.7598806624417	37.391118009856	1096.7463434163767	0.682522263242959	0.984	222	66	LGG	PACLITAXEL	Approved in cancer	TP53 | KRAS | BRAF
195.25906301787452	-17.9836988124554	181.33017186088463	-23.4433517288105	0.0006	512	76	UCEC	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
198.74567279225252	-45.0203290542095	190.46303385298063	4.50500789504122	0.0008	264	27	SKCM	O-PHOSPHO-L-TYROSINE	Experimental	KIT | PTEN | GNAS
1179.7579545927802	8.50566131138436	1020.0963741463064	-34.4997370496487	0.94	435	211	THCA	DABRAFENIB	Approved in cancer	KRAS | NRAS | BRAF
744.5152752794506	-35.0569123418304	739.1559935051838	10.7735664749684	0.594	423	83	COAD	SF1126	Clinical trials in cancer	KRAS | NRAS | ESR1
1117.5573890077223	-29.9031547007797	1082.671734562669	5.64630326650126	0.987	543	104	LUAD	BOSUTINIB	Approved in cancer	KRAS | RB1 | SMAD4
993.4361114221275	-21.3705203064882	1031.777399065392	2.64202400737554	0.93	543	83	LUAD	ERLOTINIB	Approved in same tumor type	KRAS | BRAF | EGFR
297.5667107415273	-0.879605734643661	179.3191831692402	-41.8796650050095	0.0006	435	211	THCA	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	KRAS | NRAS | BRAF
1023.194839130039	18.6002968695146	1034.6669793822566	-0.283756350626163	0.927	502	65	KIRC	BEVACIZUMAB	Approved in cancer	VHL | MTOR | PIK3CA
1135.7083670072054	-52.0107025093689	1079.7754524388602	15.2146456184946	0.982	264	132	SKCM	DOCETAXEL	Approved in cancer	KRAS | VHL | AKT3
637.010537186658	27.7942094541059	579.131045487227	40.0182343681061	0.437	57	24	PAAD	REFAMETINIB	Clinical trials in cancer	KRAS
659.1452409932959	-58.6615309210385	705.630813434723	-2.87055917769067	0.583	423	74	COAD	OBATOCLAX	Clinical trials in cancer	TP53 | NRAS | MTOR
624.7523001187784	-40.7568452189676	691.3287388426163	13.0326637449905	0.534	934	314	BRCA	NAVITOCLAX	Clinical trials in cancer	KRAS | TP53 | MAP2K1
311.17992778288465	-11.91604370762	163.4365112617384	-26.949916455343	0.0004	57	24	PAAD	PKI-402	Experimental	KRAS
1051.9227070518903	-96.5442004790591	1023.9882394039527	-28.5782147537266	0.932	264	148	SKCM	BORTEZOMIB	Approved in cancer	KIT | KRAS | VHL
260.40079764390657	111.557292024098	160.07731130801636	-39.4268732384779	0.0004	435	211	THCA	LY3009120	Experimental	KRAS | NRAS | BRAF
196.01629063668665	25.1304427314789	196.52227978756684	-16.1294156884949	0.0008	543	92	LUAD	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	KRAS | NF1 | NRAS
101.21615333100216	-46.0028951622081	224.39696498794189	10.973803422818	0.0008	264	39	SKCM	STAUROSPORINE	Experimental	RB1 | PTPN11 | PTEN
708.6940850136966	-14.0665208763153	669.0422342003164	-7.34818678268391	0.523	202	22	LAML	TANDUTINIB	Clinical trials in cancer	FLT3 | KIT | PDGFRB
142.8323676715948	15.9134098051145	207.4398832070688	-5.14566317069853	0.0004	543	68	LUAD	NSC632839	Experimental	KRAS | CTNNB1 | TRIO
1089.3454790523517	3.54771696012742	1043.6668427929524	-20.0890956495077	0.981	264	44	SKCM	TAMOXIFEN	Approved in cancer	GNA11 | BTK | MAP2K1
373.02437073862893	-9.16133305517411	357.8175018852675	1.4547412138113	0.183	264	35	SKCM	PH-797804	Clinical trials	CYBB | AKT3 | GNAS
137.42317051738715	6.69215067966013	207.67691156975957	9.4718888682537	0.011	343	46	HNSC	TRIPTOLIDE	Clinical trials	CTNNB1 | PIK3CA
1002.4118159743967	31.7886844396687	1053.2541017904705	6.26335502414213	0.95	423	83	COAD	IMATINIB	Approved in cancer	KRAS | SMAD4 | BRAF
169.8323348717595	14.7143050862653	236.86442423478215	1.78651673834588	0.0006	512	77	UCEC	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	KRAS | NF1 | NRAS
628.1217252997383	86.1683562294929	669.0860924129225	7.42135371405809	0.512	57	25	PAAD	SARACATINIB	Clinical trials in cancer	KRAS | SMAD4
971.4350087921094	-44.8174864888505	1046.8415575592712	-3.62328301908906	0.94	512	86	UCEC	FULVESTRANT	Approved in cancer	PIK3CA | ERBB2 | CDK6
171.82079229863623	-19.2751180274833	207.4469986442336	-0.523296402377127	0.0004	343	52	HNSC	PIPERLONGUMINE	Experimental	CTNNB1 | RAC1 | PIK3CA
1029.4597962497648	-22.0746473821962	1046.5916517454361	2.20456727975761	0.946	423	82	COAD	PANOBINOSTAT	Approved in cancer	KRAS | SMAD4 | BRAF
730.241831960392	4.7836502943747	676.2897166110715	0.293715909638308	0.534	202	23	LAML	DOVITINIB	Clinical trials in cancer	FLT3 | KIT | KDR
902.5823907707006	73.4377786065082	927.4182214504845	-2.85966438201493	0.822	57	24	PAAD	CRIZOTINIB	Approved in cancer	KRAS | ETV6
186.55991464625052	-29.0913633435599	196.64745387792956	9.01727974827509	0.0004	543	64	LUAD	PKI-402	Experimental	KRAS | PIK3CA
626.2135657958839	-18.0686806775897	682.9165815596194	-3.67932990360987	0.534	153	16	BLCA	ZSTK474	Clinical trials in cancer	PIK3CA | SOS1 | HRAS
1008.6596491095873	5.03935141299209	1069.3379087577848	-4.40414689309318	0.96	343	56	HNSC	COBIMETINIB	Approved in cancer	RAC1 | PIK3CA | NF1
795.9277907946414	-36.0115919733524	730.6715869262462	-5.31262600337277	0.583	292	36	STAD	CC-223	Clinical trials in cancer	KRAS | PIK3CA | ERBB4
948.9473425953718	40.9372819788164	965.9038815495578	7.12636191232531	0.854	169	41	READ	GEMCITABINE	Approved in cancer	KRAS | PIK3CA | ERBB2
962.7222362310719	-23.8740856230687	939.9816968404666	3.92991541454285	0.822	423	75	COAD	ERLOTINIB	Approved in cancer	KRAS | BRAF | ERBB2
574.6869440741904	13.8951495762377	577.160320289809	-7.88353048147201	0.422	512	59	UCEC	MK-1775	Clinical trials in cancer	KRAS | NRAS | TRRAP
664.6529958045045	52.412403617078	571.1302780432301	-5.60605221633887	0.423	512	106	UCEC	RIGOSERTIB	Clinical trials in cancer	KRAS | PIK3CA
210.0063296823439	59.3118374669517	160.06681284784415	5.80182467151167	0.0004	512	118	UCEC	PARBENDAZOLE	Experimental	TRIO | CTNNB1 | MTOR
215.46477034336706	5.73677396162822	173.35837308677017	2.86518177090397	0.0006	512	54	UCEC	BROLUCIZUMAB	Experimental	VHL | CTNNB1 | MTOR
683.9102017822313	22.8690832988199	699.9996060513187	0.00347373398722084	0.556	543	83	LUAD	RAF265	Clinical trials in cancer	KRAS | BRAF | EGFR
1002.2572914492072	-39.3279477671859	1017.3077940670313	0.0580878224150183	0.91	343	46	HNSC	ADO-TRASTUZUMAB EMTANSINE	Approved in cancer	PIK3CA | EGFR
239.61346540230232	9.81386732007593	201.01065738341126	-1.75674716237359	0.0006	502	59	KIRC	CHEMBL243978	Experimental	VHL | MTOR
487.78925162294735	-21.2792256191433	488.9998807151283	-0.000392695744039884	0.321	599	118	OV	EDARAVONE	Approved in other pathologies	TP53 | MAPK14 | MAP3K5
737.2778544778889	-84.8573675540161	684.666307345448	-6.84717140515704	0.582	264	128	SKCM	AT-101	Clinical trials in cancer	VHL | AKT3 | BRAF
234.93069192420586	-49.6000382477852	197.6151804563062	-17.6827306216262	0.0006	512	77	UCEC	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	KRAS | NF1 | NRAS
758.3920246922512	-17.918414715556	718.0034466538119	-8.73822378103205	0.6	423	92	COAD	BINIMETINIB	Clinical trials in cancer	KRAS | NRAS | NF1
523.9741702736455	115.101912653683	584.1057644718803	-18.0835744273666	0.413	435	185	THCA	1096708-71-2	Clinical trials in cancer	KRAS | BRAF
161.46145918976652	35.1633789157611	173.4576207224769	-14.9765667232177	0.0004	934	216	BRCA	GSK2334470	Experimental	PIK3CA
739.9575719701165	-56.4474124412162	742.4372707004173	-8.21862259143973	0.597	343	61	HNSC	PKI-587	Clinical trials in cancer	STK11 | PTEN | RAC1
940.6302142557249	-10.7399828408219	949.0001373621702	-0.000251941913575138	0.832	153	16	BLCA	GEMCITABINE	Approved in cancer	IDH1 | PIK3CA | HRAS
607.7118484681727	-64.3640508656056	606.0600579340025	-5.52899332912421	0.452	423	57	COAD	VOLASERTIB	Clinical trials in cancer	KRAS
918.4630996136301	68.8016796566285	977.1109437309674	-11.9480740492352	0.833	57	24	PAAD	CABOZANTINIB	Approved in cancer	KRAS
1107.7187590336011	16.6685649130588	1076.644691955014	2.28045857898223	0.981	292	39	STAD	ERIBULIN	Approved in cancer	MAP2K1 | CREBBP | TP53
580.9257135813053	11.07267456645	599.3798705051759	-17.7380475464468	0.432	934	216	BRCA	NVP-BGJ398	Clinical trials in cancer	KRAS | PIK3CA
730.1497659734324	48.5748465433358	688.2577309799399	-6.08616487131872	0.53	934	227	BRCA	391210-10-9	Clinical trials in cancer	KRAS | NF1 | MAP2K1
210.10465030800748	-7.58977936402695	206.73574409033867	20.2069537563298	0.0006	423	66	COAD	OBLIMERSEN	Experimental	TP53 | MTOR | BRAF
719.967836179762	-25.1626039210658	711.0689766548737	12.7451926207318	0.565	423	66	COAD	MLN1117	Clinical trials in cancer	KRAS | MTOR | PIK3CA
423.9767392106362	-9.71367222228582	401.2396464061449	-7.50547931105621	0.232	264	106	SKCM	NIVOLUMAB	Approved in other pathologies	KRAS | BRAF
1066.7263659240407	-39.1882505011035	1082.4125290433217	12.9266933935237	0.982	423	104	COAD	DOCETAXEL	Approved in cancer	KRAS | TP53 | MTOR
638.4658688413789	-53.9620002897774	673.3812475326207	5.04675751979664	0.525	202	31	LAML	TAK-733	Clinical trials in cancer	KRAS | NF1 | KIT
387.8455171510913	18.4616795217252	390.2733827022325	8.83639953205821	0.213	57	24	PAAD	PEMBROLIZUMAB	Approved in other pathologies	KRAS
573.7224006009662	-24.6620188226545	596.1584553413958	-7.32399847707075	0.432	343	46	HNSC	LINSITINIB	Clinical trials in cancer	PIK3CA | EGFR
713.676950365997	-95.8151354170177	749.8133616981902	-7.7611839648996	0.6	543	101	LUAD	SELUMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
728.3437711362103	-32.869540041652	729.3780629531442	8.88041630051839	0.592	153	23	BLCA	GSK2636771	Clinical trials in cancer	NRAS | PTEN | PIK3CA
881.7945013871256	-50.9772097299528	923.8011559254597	14.9818283353209	0.833	435	211	THCA	RIBOCICLIB	Approved in cancer	KRAS | NRAS | BRAF
727.7566287092849	-9.49135055166124	690.6838863076803	-0.645197185496954	0.536	502	66	KIRC	CEDIRANIB	Clinical trials in cancer	VHL | MTOR | FGFR3
983.2775033378718	-2.61238851712207	931.9835181287679	2.84954884230046	0.814	202	23	LAML	ATEZOLIZUMAB	Approved in cancer	KRAS | NRAS
226.7722973211572	-49.4766477063078	191.05588138821702	-47.2915386408254	0.012	264	68	SKCM	SCYLLO-INOSITOL	Clinical trials	NRAS
1036.7274131939967	-14.4659487454314	1027.1261241158813	2.9436917423393	0.924	599	122	OV	PACLITAXEL	Approved in cancer	KRAS | TP53 | PIK3CA
483.7308146299592	-31.3464533188587	489.2895621447785	0.00120391610244042	0.321	423	61	COAD	CHOLINE	Approved in other pathologies	KRAS | RAF1 | MAPK1
825.130334952966	-34.4362262280874	688.7488339927527	1.04851790566227	0.526	435	211	THCA	212631-79-3	Clinical trials in cancer	KRAS | NRAS | BRAF
197.00097331163894	51.6689246412148	191.85939619078212	26.5927669602968	0.0006	57	6	PAAD	OBLIMERSON	Experimental	TP53
709.0344736269648	-49.7117752193613	738.4445060326356	1.85576630792411	0.594	153	23	BLCA	APITOLISIB	Clinical trials in cancer	NRAS | PTEN | PIK3CA
929.7141993777901	24.6007888968144	957.8632791589131	2.67409664620322	0.842	512	78	UCEC	STREPTOZOCIN	Approved in cancer	PIK3CA | MMP2
190.42566978166948	-38.8926256550006	190.01556740899676	-4.08177954915618	0.0006	264	35	SKCM	3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE	Experimental	CYBB | AKT3 | GNAS
757.5554675304061	-46.6493248531414	718.5918894189671	4.61912434911551	0.575	599	74	GBM	PF-04691502	Clinical trials in cancer	NRAS | KRAS | PTPN11
478.5009521406416	4.25826358443237	572.7766372202789	3.40200173367799	0.433	169	41	READ	CUDC-907	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
194.45370473295765	18.9142553270876	188.37422325794194	16.0189377001484	0.0004	343	55	HNSC	LY2183240	Experimental	CTNNB1 | RAC1 | COL1A1
272.4647905265155	33.8528027630858	223.5924613157485	29.3125950793694	0.0004	512	82	UCEC	P-0850	Experimental	PIK3CA | BRAF | TRRAP
759.2420198006336	-27.4146421352135	739.9796192407288	-3.96483999335987	0.595	153	23	BLCA	PF-04691502	Clinical trials in cancer	NRAS | PTEN | PIK3CA
839.1547378079921	-9.78512331024083	835.2703376300996	1.87631449422497	0.704	343	47	HNSC	RALOXIFENE	Approved in other pathologies and in clinical trials in cancer	PIK3CA | MAP2K1 | PRKACA
912.8048151373436	-22.7751000608935	911.7573563994541	0.00944947421567122	0.792	264	34	SKCM	SULFASALAZINE	Approved in other pathologies and in clinical trials in cancer	TSC1 | AKT3 | BTK
559.3730503402444	15.112973135904	578.6904473163953	-2.82000866153453	0.432	512	77	UCEC	LY2780301	Clinical trials in cancer	PIK3CA
776.4932672770599	-23.2105328340283	718.3103530231341	16.8406751093257	0.593	512	78	UCEC	BMS-908662	Clinical trials in cancer	KRAS | NF1 | NRAS
717.9279830811483	28.903123667832	770.6817938083344	-10.2162410026031	0.594	264	55	SKCM	XL-999	Clinical trials in cancer	KIT | PTEN | GNAS
689.0143086009414	-22.6491127378175	689.4330918056933	2.71265066641399	0.542	153	28	BLCA	AT-101	Clinical trials in cancer	CREBBP | TP53 | CHUK
266.9968256155441	-23.9595450312349	168.27653157831267	5.76120004719252	0.0006	169	42	READ	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | PTPN11 | PTEN
1113.4533954155395	17.2601757792728	1107.135699468379	6.02152542552039	1.0	292	48	STAD	REGORAFENIB	Approved in cancer	RB1 | SMAD4 | KRAS
233.33640830405812	-10.6875773093371	205.73567628784244	1.5350388271595	0.0006	202	29	LAML	2,2,2-TRIFLUOROETHANOL	Experimental	FLT3 | KIT | PTPN11
1047.6719846783963	-22.5088372693374	1050.9217342336065	-5.3053378135487	0.953	264	28	SKCM	THALIDOMIDE	Approved in cancer	AKT3 | MAP2K1 | RAF1
266.6862352346087	85.8091817639198	197.9997728773482	-14.5749244429568	0.0006	169	43	READ	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
222.1914099433116	14.4153445291745	235.23123583847774	6.62779625981716	0.031	512	54	UCEC	7-ETHYL-10-HYDROXYCAMPTOTHECIN	Clinical trials	TRIO | CTNNB1 | ERBB4
578.4650299275911	-53.2180588388459	579.8257324069966	3.20764344041618	0.432	512	80	UCEC	UPROSERTIB	Clinical trials in cancer	PIK3CA | BRAF
906.2215811015748	24.988928816487	932.8180744712434	-2.12000026080341	0.812	169	41	READ	ERLOTINIB	Approved in cancer	KRAS | BRAF | ERBB2
769.5020971515229	48.1024903057209	745.7613252942734	14.423123621159	0.598	512	115	UCEC	OSI-027	Clinical trials in cancer	KRAS | TSC2 | TSC1
946.4626593189507	1.4427845337778	947.944036936479	3.35854809453667	0.832	423	75	COAD	OXALIPLATIN	Approved in same tumor type	KRAS | BRAF | ERBB2
989.8507531755126	-0.984317451374466	1045.7095694177967	-0.00399049369013937	0.94	599	88	GBM	DASATINIB	Approved in cancer	RB1 | KRAS | COL1A1
786.2541531028672	-17.9117691691378	830.9999175997683	-5.27757088093495e-05	0.701	934	221	BRCA	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | STK11 | ERBB2
726.109363451376	-74.8475486957827	733.6028879583495	-15.7566302503431	0.596	292	41	STAD	BUPARLISIB	Clinical trials in cancer	KRAS | PTPN11 | NGF
216.24549911390358	-27.2610639099649	189.70569051384743	-1.60970855607343	0.0004	512	78	UCEC	GSK2334470	Experimental	PIK3CA | EGFR
257.7430913072144	80.422030470969	187.75243343236173	-12.3191957914717	0.0004	169	46	READ	LY2183240	Experimental	KRAS | NRAS | BRAF
686.6387560468868	42.7476006120486	725.8446467464707	-17.0004270886043	0.584	512	95	UCEC	VOLOCIXIMAB	Clinical trials in cancer	PTEN | FLNA | EGF
567.4086868844166	-76.770324902616	541.5731394052618	-1.18818970492225	0.422	435	183	THCA	UPROSERTIB	Clinical trials in cancer	BRAF | PIK3CA
626.9531021599545	-76.9163507010595	639.9384583837725	15.3355699368349	0.491	264	128	SKCM	INDISULAM	Clinical trials in cancer	KIT | LMNA | BRAF
128.12725741431282	86.8142113917829	165.65707166536052	-21.1069873718004	0.0006	512	93	UCEC	R411	Experimental	PTEN | FLNA | EGF
637.7665690848585	-3.59656278919437	662.146220533785	-1.15221508350055	0.511	502	61	KIRC	VEGFR TYROSINE KINASE INHIBITOR II	Clinical trials in cancer	VHL | MTOR | KDR
965.8747202598644	-1.48336283201314	953.6276235632838	-3.96993625429377	0.834	343	46	HNSC	IDELALISIB	Approved in cancer	PIK3CA | MYC
683.5465181244755	-54.1494634482785	654.0002603853097	0.000287336884866818	0.504	292	30	STAD	AZD8055	Clinical trials in cancer	KRAS | PIK3CA | MAPK1
214.04458816677618	53.6941016155173	209.18776154380427	-17.357430996934	0.0006	502	61	KIRC	VARISACUMAB	Experimental	VHL | MTOR | HSPG2
543.5769497081816	85.0350227000258	625.7568973223852	-41.1415608729326	0.422	57	24	PAAD	AZD2014	Clinical trials in cancer	KRAS
713.312606021062	-60.2242661420521	742.8440119876929	6.51423590213744	0.598	153	26	BLCA	DACTOLISIB	Clinical trials in cancer	NRAS | PTEN | FGFR3
223.6203951522549	17.0715957183888	220.6308108462804	9.57897757081264	0.0006	512	52	UCEC	2-({[3-(3,4-DIHYDROISOQUINOLIN-2(1H)-YLSULFONYL)PHENYL]CARBONYL}AMINO)BENZOIC ACID	Experimental	CTNNB1 | CHD8 | GSK3B
864.5805158853141	-68.4833031639854	675.4914432740153	-29.6134009593388	0.596	264	196	SKCM	BUPARLISIB	Clinical trials in cancer	NRAS | KIT | KRAS
276.670849332969	1.24096041223052	229.21373795528882	14.8148528809998	0.0004	934	233	BRCA	WORTMANNIN	Experimental	AKT1 | PIK3CA
709.0110582811623	68.0024466077437	690.9957012918787	4.57938611342604	0.534	202	69	LAML	DACTOLISIB	Clinical trials in cancer	KRAS | FLT3 | KIT
759.8783552414661	-8.65191550127182	719.5298895623131	-7.16433016135352	0.574	153	42	BLCA	NAVITOCLAX	Clinical trials in cancer	CREBBP | CTNNB1 | TP53
208.48803093459458	65.9140030248784	188.0400363309442	-2.55404031585022	0.0006	502	59	KIRC	L-THIOCITRULLINE	Experimental	VHL | MTOR
606.6141256080178	-23.4157347659421	567.6808260522961	1.18848887232434	0.412	512	81	UCEC	MK-2206	Clinical trials in cancer	TRIO | PIK3CA
543.5724483366207	46.7993173334814	588.9648117604771	0.471730500758099	0.422	169	41	READ	FOLFIRI REGIMEN	Clinical trials in cancer	KRAS | NRAS
141.059717854972	-34.190086480588	209.65852082673044	4.62131380782876	0.0004	343	45	HNSC	AT13148	Experimental	PIK3CA
672.5682948822848	43.7387132898685	660.1725962266742	1.18524374759801	0.512	57	6	PAAD	AT-101	Clinical trials in cancer	TP53
169.70016582472167	-58.7768937883922	215.45432475551453	-33.7442586166676	0.0006	264	32	SKCM	UNII-414MEG73VU	Experimental	CYBB | CTNNB1 | MAP2K1
268.7513206308275	-38.6821787134996	206.5714517799904	6.50164208708566	0.0008	292	38	STAD	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | PTPN11 | NGF
673.0333039515156	-27.8769059926355	733.5965205259421	3.1442383251042	0.595	264	43	SKCM	LINIFANIB	Clinical trials in cancer	KIT | VHL | ARNT
167.05572736758526	-55.2261632414818	217.7472382066742	-0.560213020217816	0.0004	264	28	SKCM	KINETIN RIBOSIDE	Experimental	KIT | KRAS | CTNNB1
403.70837315485045	-32.6139956719878	394.9700398201099	8.41667049167836	0.213	435	211	THCA	PEMBROLIZUMAB	Approved in other pathologies	KRAS | NRAS | BRAF
1023.3763793257734	33.7871340139382	1040.7152319678748	-0.494189977796395	0.932	599	122	OV	DOCETAXEL	Approved in cancer	KRAS | TP53 | PIK3CA
785.6791717308707	-59.7815080200436	720.4518012765602	-0.425071567127361	0.584	543	91	LUAD	SF1126	Clinical trials in cancer	KRAS | NRAS | STK11
707.7012810858669	24.2395586008972	657.4587536311757	-2.85229226742649	0.511	502	64	KIRC	DHA-PACLITAXEL	Clinical trials in cancer	VHL | AKT3 | MTOR
1011.8179795318263	-21.9919837502947	1036.2816495280795	12.1263994269086	0.924	202	52	LAML	COPANLISIB	Approved in cancer	KRAS | FLT3 | KIT
203.395664572266	-97.1300639928005	201.52841041643086	53.1462638697963	0.0006	264	127	SKCM	OBLIMERSON	Experimental	VHL | AKT3 | BRAF
661.038782239013	152.508449746056	547.2786009653752	0.916388401344165	0.412	57	24	PAAD	602306-29-6	Clinical trials in cancer	KRAS
916.1871356106324	91.100095292906	1000.140500611211	-20.5349714502213	0.91	264	184	SKCM	CETUXIMAB	Approved in cancer	NRAS | KRAS | BRAF
137.0647324653684	-21.3444820071117	190.19821188800873	10.2465173174733	0.0004	423	88	COAD	LY3009120	Experimental	KRAS | NRAS | BRAF
262.70586915391334	51.2138345071367	202.52269110926167	30.9578981221418	0.0006	435	183	THCA	CHEMBL1236441	Experimental	BRAF
457.7957305618756	0.78347635742665	477.25953856947086	-0.0361732329515689	0.31	343	46	HNSC	PERTUZUMAB	Approved in other pathologies	PIK3CA | EGFR
685.187472475385	-17.303433360468	736.3874424096897	-3.64535283971554	0.584	543	83	LUAD	AZD5363	Clinical trials in cancer	KRAS | EGFR | PTEN
1151.1159165224462	-17.6562614720025	1083.675765037201	-35.2128653149339	0.999	264	95	SKCM	CABOZANTINIB	Approved in cancer	NRAS | KIT | KRAS
257.39450886449913	6.006592690373	212.85328449130554	10.2079478143746	0.0006	543	78	LUAD	HYPOTHEMYCIN	Experimental	KRAS | NRAS | BRAF
799.405882984477	56.9931289421169	741.595760689487	6.86762690872422	0.6	169	46	READ	391210-10-9	Clinical trials in cancer	KRAS | NRAS | BRAF
1145.8356851140354	-94.6819282984175	1106.1049348208228	-33.8959328062915	0.991	264	202	SKCM	BOSUTINIB	Approved in cancer	RB1 | NF1 | NRAS
798.8173299453006	-43.4795104198559	733.446460182485	-13.1356076470385	0.595	169	47	READ	PX-866	Clinical trials in cancer	KRAS | PTPN11 | NRAS
348.51492372085283	19.8516786513061	187.00510404543107	-59.6332823259194	0.0006	435	211	THCA	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	KRAS | NRAS | BRAF
535.6423835351035	-47.7402596450405	525.9823607542245	0.00444293734426537	0.362	512	83	UCEC	DEHYDROEPIANDROSTERONE	Approved in other pathologies	PIK3CA | AR | PRKACA
314.9613086648463	74.3816144388087	206.6214366870256	-40.224210919524	0.0004	57	24	PAAD	AZD8186	Experimental	KRAS
1103.039484307645	0.088874737509542	1090.307673461091	1.47163243974614	0.99	543	90	LUAD	RIBOCICLIB	Approved in cancer	KRAS | RB1 | SMAD4
307.25722666427737	59.9911148544766	230.30675336100785	-21.5758157696137	0.0004	57	24	PAAD	154447-36-6	Experimental	KRAS
1109.6768579425784	-49.2795122440567	1123.0098594164085	-17.5345115244054	0.996	264	108	SKCM	PONATINIB	Approved in cancer	RB1 | NRAS | KIT
684.7919678266315	3.04673742213055	667.1626117651235	-11.2529295237531	0.515	202	22	LAML	PEXIDARTINIB	Clinical trials in cancer	FLT3 | KIT | KDR
572.4648103650366	-34.9120753512316	574.0050559211098	-0.934995764474479	0.412	343	45	HNSC	GM-CSF	Clinical trials in cancer	PIK3CA
216.2940206673789	-78.3439243910739	171.3296781849775	14.4100651071319	0.0006	512	94	UCEC	N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE	Experimental	PTEN | KDR | GNAS
732.0975748328879	20.3965725112577	668.9700350521118	10.264473935793	0.523	202	38	LAML	BMS-908662	Clinical trials in cancer	KRAS | NF1 | KIT
195.1189502957093	14.12201028309	197.0953947830407	-12.6098084104522	0.0006	512	54	UCEC	VARISACUMAB	Experimental	VHL | CTNNB1 | MTOR
554.3264869888251	6.97670288253676	560.2410382533549	-4.44365935156247	0.412	512	77	UCEC	1312445-63-8	Clinical trials in cancer	PIK3CA
507.440032369974	-39.6939760847265	580.4530877328352	8.20708572856506	0.423	543	64	LUAD	CUDC-907	Clinical trials in cancer	KRAS | PIK3CA
291.1357014958651	18.6593645491055	194.81615105472275	45.6147717225842	0.0004	512	116	UCEC	PNU-74654	Experimental	CTNNB1 | PIK3CA | FGFR2
928.6099600973454	76.9354793039735	949.7032706842482	6.95464968540387	0.832	169	39	READ	RAMUCIRUMAB	Approved in same tumor type	KRAS | ERBB2
1070.1400497581199	0.879311420776872	1050.890867812407	4.57132131679396	0.947	934	226	BRCA	COPANLISIB	Approved in cancer	KRAS | PTEN | MAP2K1
310.31675627078624	-37.0667404702396	247.11322239005747	-1.32993916077089	0.0004	435	185	THCA	PF-3644022	Experimental	KRAS | BRAF
718.7824824298345	-84.2149267296311	666.2013088955996	-4.09302100643117	0.565	264	119	SKCM	1224844-38-5	Clinical trials in cancer	KRAS | TSC1 | AKT3
185.03176165907544	-8.37796736842341	189.62918548452345	-12.6865649059819	0.0006	543	78	LUAD	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
751.1886669454083	-13.1808922493203	743.5168215719277	-17.5546797689731	0.586	423	107	COAD	NAVITOCLAX	Clinical trials in cancer	KRAS | TP53 | ESR1
177.33390928009325	-41.5869267042296	200.052682628937	5.2872472856875	0.0006	264	34	SKCM	TETRADECANOIC ACID	Experimental	RB1 | GNAS | HSPG2
940.7488886741529	-63.8138976821665	962.0360883548184	4.57262683728914	0.833	264	108	SKCM	IRINOTECAN	Approved in cancer	KRAS | BRAF | AKT1
904.7971948261186	-30.1017785858663	938.753560932058	-34.5776926208657	0.843	57	24	PAAD	PEMETREXED	Approved in cancer	KRAS
248.84651800737495	-121.532512659002	209.71093311949252	-2.04150596719296	0.0008	435	211	THCA	FR 180204	Experimental	KRAS | NRAS | BRAF
1135.1955258819303	60.8187628121337	1071.3297360292888	-8.97504401321299	0.987	169	48	READ	RIBOCICLIB	Approved in cancer	KRAS | SMAD4 | NRAS
779.8615413219401	-13.512432266113	688.0013050358809	6.32553744725396	0.552	512	82	UCEC	1260612-13-2	Clinical trials in cancer	PIK3CA | SOS1 | BRAF
1160.9191481572445	6.82262687778257	1087.1079727903668	-2.42222399688217	0.95	264	121	SKCM	NERATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
628.6032034018376	-22.5848330981818	687.3309634983393	-2.49517804097513	0.548	343	56	HNSC	PIMASERTIB	Clinical trials in cancer	RAC1 | PIK3CA | NF1
136.6222034383555	39.033532673833	209.67714003766025	44.6431239666299	0.0004	512	114	UCEC	GW843682X	Experimental	TRIO | CTNNB1 | MTOR
728.6735000418397	0.727848866175179	730.6298169451662	0.990440678226378	0.588	599	80	GBM	DACTOLISIB	Clinical trials in cancer	NRAS | KRAS | PTPN11
691.1416605802866	-15.1770707158054	682.9992775167024	0.00070685116952518	0.537	599	123	OV	NAVITOCLAX	Clinical trials in cancer	KRAS | TP53 | PIK3CA
147.87371219089442	20.9209826861907	226.80418532145154	-20.5277710263663	0.0008	934	229	BRCA	PI-103	Experimental	KRAS | STK11 | PTEN
683.608805049968	36.5797159247441	707.2063956797574	1.44865866154851	0.564	153	23	BLCA	AZD5363	Clinical trials in cancer	PTEN | FGFR3 | PIK3CA
181.62019375605126	111.327935042972	225.10296175920766	39.4240468007469	0.0004	57	24	PAAD	TYRPHOSTIN B42	Experimental	KRAS
216.8956204151242	-18.787450662887	203.75986176577703	-7.98409525381908	0.0006	512	56	UCEC	LAX-101	Experimental	KRAS | PSTPIP1 | NLRP3
779.5116526552812	-18.9896945280171	725.5286517577917	-0.989850089626657	0.592	389	48	LUSC	GSK2636771	Clinical trials in cancer	KRAS | PTEN | BRAF
1015.3514504724021	-13.8763136560459	1040.617026361815	12.2586263981061	0.93	543	94	LUAD	CETUXIMAB	Approved in cancer	KRAS | NRAS | BRAF
595.5288521872769	-12.1494614267123	607.4032415895293	1.14504890610851	0.432	423	87	COAD	BGB-283	Clinical trials in cancer	KRAS | NRAS | BRAF
715.0333752465134	-6.60520042038209	660.1761237858811	11.6353734964141	0.531	934	117	BRCA	DHA-PACLITAXEL	Clinical trials in cancer	TP53 | MAP2K1 | STAT3
1018.1685986916793	53.837203685299	1026.8417706535213	-10.3243975417179	0.916	57	25	PAAD	PANOBINOSTAT	Approved in cancer	KRAS | SMAD4
90.37917026980992	21.3818865482167	190.57056474866687	-12.9297334801563	0.0004	435	183	THCA	NEOPELTOLIDE	Experimental	BRAF
547.7278353743287	-40.1789181290828	542.7122142475286	-4.82433808285009	0.382	512	54	UCEC	ZIV-AFLIBERCEPT	Approved in other pathologies	VHL | CTNNB1 | MTOR
609.1272559666693	-4.56317533329388	571.2287406734971	5.42281659311402	0.412	543	60	LUAD	ULIXERTINIB	Clinical trials in cancer	KRAS
298.2197913445082	29.6325027634925	248.667193075353	-34.2893170124113	0.0006	435	184	THCA	OBLIMERSEN	Experimental	BRAF | TP53
163.66366117025984	47.4864058690315	195.38602699836326	-13.2217646749684	0.0006	502	59	KIRC	(2S)-2-METHYL-2,3-DIHYDROTHIENO[2,3-F][1,4]OXAZEPIN-5-AMINE	Experimental	VHL | MTOR
146.94503810185654	42.2999538492002	233.62103555188548	-5.13770520377716	0.0004	512	119	UCEC	NUTLIN-3	Experimental	TRIO | CTNNB1 | PIK3CA
855.4080278786334	-5.97599869887094	863.9570427180062	0.0081263830820717	0.74	512	125	UCEC	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | TSC2 | TSC1
939.0276488621423	18.8849242953286	940.6890510171729	-6.41960204413203	0.822	202	31	LAML	BEVACIZUMAB	Approved in cancer	KRAS | KIT | IDH1
301.23751311402094	-43.0199113280721	305.2918964166272	-3.98131477810307	0.111	502	60	KIRC	FG-2216	Clinical trials	VHL | AKT3 | MTOR
705.1564124787878	-4.38829753932006	719.1365261942478	-17.0929162434229	0.583	512	77	UCEC	BAY869766	Clinical trials in cancer	KRAS | NF1 | NRAS
655.563614305723	22.5842664697187	733.3411972623868	-14.291904942949	0.585	512	87	UCEC	GSK2126458	Clinical trials in cancer	NRAS | MTOR | PIK3CA
630.8859893195669	-30.5634897226363	684.796225633816	3.20856478416704	0.535	934	237	BRCA	GSK2126458	Clinical trials in cancer	AKT1 | MAP2K1 | PIK3CA
1107.4242832954722	46.9675262138538	1080.4683337185468	-3.96798389035098	0.982	169	40	READ	LENALIDOMIDE	Approved in cancer	KRAS | ERBB2 | RAF1
176.02958726792255	35.4426608212169	207.806050483684	18.6722013463952	0.0006	502	61	KIRC	ZALTRAP	Experimental	VHL | MTOR | HSPG2
222.403132492298	41.8138465084443	197.00443570928508	-6.74425793680973	0.0004	202	21	LAML	ISOEVODIAMINE	Experimental	IDH1 | MYC | MYLK2
252.86426232702982	47.196673193199	199.39967865279903	-4.08439444809142	0.0004	292	34	STAD	PARBENDAZOLE	Experimental	CTNNB1 | PIK3CA | GNAS
279.41253134430434	13.2263194660615	162.04421268948914	4.7037414232168	0.0004	264	106	SKCM	TW-37	Experimental	KRAS | BRAF | PIK3CA
222.29198157159834	-43.2367525696162	215.2474646091034	16.6767497630744	0.0004	343	46	HNSC	109511-58-2	Experimental	PIK3CA | FGFR3
1061.730903488845	40.002282567739	1016.0950286464537	-0.526167000736393	0.92	169	43	READ	NERATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
744.1663678530142	37.9639418898419	661.3763903053634	4.14993850064457	0.524	934	237	BRCA	ARQ-092	Clinical trials in cancer	AKT1 | ERBB2 | PIK3CA
706.9682123638804	-43.7555605186324	706.7354560300784	7.31962826666631	0.56	343	56	HNSC	391210-10-9	Clinical trials in cancer	RAC1 | PIK3CA | NF1
703.9180051986017	31.499146554863	744.9031239314213	-11.7288380614698	0.592	169	48	READ	GSK2636771	Clinical trials in cancer	KRAS | PTPN11 | NRAS
103.69176360921644	-33.2872850175911	250.4016347647229	7.72669270243659	0.0006	264	132	SKCM	1,6-HEXANEDIOL	Experimental	KIT | PTPN11 | GNAQ
541.5815361206757	-28.616447905275	571.7939354776843	-5.61141756812685	0.422	423	57	COAD	PHENFORMIN	Clinical trials in cancer	KRAS
744.1953633924435	-9.66885373803595	776.8865233615659	-1.1545404574681	0.643	343	45	HNSC	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	PIK3CA
144.45563597790763	-17.1318026140652	177.25838855244444	3.39133031621941	0.0008	423	92	COAD	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
444.69024163657406	10.3826302168393	602.7496365351284	-18.7095786826003	0.433	264	174	SKCM	BGB-283	Clinical trials in cancer	NRAS | KRAS | BRAF
213.07850402307713	-16.6618319495569	223.68688179798806	3.14183901532897	0.0008	343	50	HNSC	PP121	Experimental	PTEN | PIK3CA | FGA
201.30555213564026	-11.1914499599245	219.7076150346646	7.00055035099331	0.022	343	45	HNSC	SURAMIN	Clinical trials	PIK3CA
1082.6754799614605	38.4953727097865	1009.6505912373764	20.9902129157901	0.911	57	6	PAAD	ERIBULIN	Approved in cancer	TP53
923.1164491065865	-3.35816982924547	931.0000931472282	4.38143433711957e-05	0.812	543	60	LUAD	IXABEPILONE	Approved in cancer	KRAS
728.9706612401959	15.847472601858	713.3776562781048	-10.1873356250519	0.593	512	55	UCEC	MARIMASTAT	Clinical trials in cancer	CTNNB1 | CHD8 | RAC1
164.37374651298035	19.8219661054148	199.02347154679074	-13.8463241216969	0.022	934	216	BRCA	SURAMIN	Clinical trials	PIK3CA
728.8867953639578	39.0399028504723	701.112835661496	19.9496912405352	0.549	934	246	BRCA	ALPELISIB	Clinical trials in cancer	KRAS | STK11 | AKT1
817.3413676302841	-2.41252020553929	758.9238311042826	0.626362399971072	0.613	169	38	READ	DECITABINE	Approved in other pathologies and in clinical trials in cancer	KRAS
250.35337834328712	-56.8654143158548	196.51071919868858	-5.00058440634939	0.0004	934	216	BRCA	AZD-8835	Experimental	KRAS | PIK3CA
637.2990847115509	-11.9035029250394	680.334289305728	26.6351251098813	0.538	934	241	BRCA	AZD5363	Clinical trials in cancer	KRAS | AKT1 | PTEN
198.63947927012214	-15.0954297836303	199.87073738794464	16.4135688382141	0.0006	502	62	KIRC	ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	Experimental	VHL | AKT3 | MTOR
497.04555182088995	94.2524233824981	575.959064490869	-33.106969243545	0.439	57	24	PAAD	391210-10-9	Clinical trials in cancer	KRAS
733.593945236429	8.27176988706827	703.1185284989821	-1.99305600053992	0.562	599	77	GBM	PICTILISIB	Clinical trials in cancer	NRAS | KRAS | PTPN11
746.6027877155929	-54.5580015748118	745.5966193315406	5.87972716164722	0.593	543	91	LUAD	APITOLISIB	Clinical trials in cancer	KRAS | NRAS | STK11
638.86864458878	-30.037041477279	673.0741413036891	-2.89556264092971	0.525	343	51	HNSC	MLN1117	Clinical trials in cancer	RAC1 | PIK3CA | SOS1
731.6272103306321	-41.1697512124164	729.2997220716567	-0.93189194299157	0.582	264	35	SKCM	LY2228820	Clinical trials in cancer	CYBB | AKT3 | GNAS
794.3836264907967	4.3832553200042	779.4886069338711	0.00113020552100807	0.642	169	44	READ	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | PIK3CA
367.2403496712205	-12.323796759376	374.0001809341419	0.000220703983359272	0.193	423	83	COAD	QUERCETIN	Clinical trials	KRAS | NRAS | ESR1
667.0507565446653	20.2024949434729	724.9262800430432	-4.66687232830895	0.584	543	66	LUAD	OSI-027	Clinical trials in cancer	KRAS | STK11 | PIK3CA
765.2875393428757	-15.524726148263	719.6158009739697	-7.14193617358887	0.585	543	93	LUAD	AZD8330	Clinical trials in cancer	KRAS | NF1 | NRAS
678.4265654353013	-1.95502419554094	659.2037882973748	6.7840853933983	0.513	502	64	KIRC	OBATOCLAX	Clinical trials in cancer	VHL | AKT3 | MTOR
684.7025659912993	16.4790077211292	704.7464655146847	-4.68636966695976	0.56	343	58	HNSC	SELUMETINIB	Clinical trials in cancer	RAC1 | PIK3CA | FGFR3
734.8902887872166	2.91755224541058	738.1472664170732	13.3854768981516	0.574	512	82	UCEC	ZSTK474	Clinical trials in cancer	PIK3CA | SOS1 | BRAF
761.2671733243319	15.814503081675	728.4606306512186	-1.13121860815431	0.586	292	33	STAD	RIDAFOROLIMUS	Clinical trials in cancer	KRAS | PIK3CA | ERBB4
158.16156819016044	-33.3766438710971	165.43017565042928	-7.46982359085587	0.0006	264	35	SKCM	3-(2-(4-PYRIDYL)ETHYL)INDOLE	Experimental	CYBB | AKT3 | GNAS
196.5226588556389	94.440731877763	227.17233282098803	1.24546882372454	0.0006	169	47	READ	OLOMOUCINE	Experimental	KRAS | SMAD4 | NRAS
148.0996984020101	12.5802162488325	221.33284077674287	-36.7720692259898	0.0006	512	99	UCEC	CHEMBL291678	Experimental	ZAP70 | PTEN | SOS1
1051.2641779351945	2.71303477465233	1091.400454439393	-4.01063449885351	0.997	512	71	UCEC	NILOTINIB	Approved in cancer	KRAS | RB1 | SOS1
236.8266287379087	-54.3963053271819	182.7255386317653	-4.41005224458127	0.0004	543	60	LUAD	AURORA KINASE INHIBITOR II	Experimental	KRAS
674.5070877598351	-36.8787677107731	674.2744412973059	-4.65114799200524	0.527	202	31	LAML	391210-10-9	Clinical trials in cancer	KRAS | NF1 | KIT
956.7108745655543	-24.0187145229055	951.5674802827376	0.983590562502286	0.833	343	46	HNSC	CARBOPLATIN	Approved in cancer	PIK3CA | EGFR
533.4275273485575	55.848881446273	630.374352559467	-12.447525005245	0.433	57	24	PAAD	1224844-38-5	Clinical trials in cancer	KRAS
222.20302302695802	45.9689444808653	186.6305060477031	2.10316923119854	0.0006	502	63	KIRC	AMP-PNP	Experimental	VHL | AKT3 | MTOR
1027.2153353961583	-33.4659395853139	1059.3172017254194	-4.16435007416521	0.95	423	67	COAD	NILOTINIB	Approved in cancer	KRAS | SMAD4 | ABL1
359.89479077468036	3.29603995095371	354.99323505861776	-3.03623130552751	0.182	264	35	SKCM	209410-46-8	Clinical trials	CYBB | AKT3 | GNAS
104.14207845695594	108.066916735319	173.95075001543924	11.9105902436113	0.0004	435	183	THCA	1166227-08-2	Experimental	BRAF | PIK3CA
373.238540351889	2.38636941530203	371.3845639971607	0.633319191475721	0.192	512	64	UCEC	FASUDIL	Clinical trials	KRAS | AR | ITK
551.800673827849	-38.9522863090255	567.3108038700822	-8.80198569883851	0.412	543	60	LUAD	DANUSERTIB	Clinical trials in cancer	KRAS
140.32738909627756	-47.7440701099713	210.4285294115306	-9.92903340823887	0.0004	264	68	SKCM	BETA-ALLOLACTOSE	Experimental	NRAS
695.1023766772587	-31.475486568973	673.1144331660593	-19.642265097764	0.528	934	225	BRCA	TAK-733	Clinical trials in cancer	KRAS | NF1 | MAP2K1
610.9764858426912	-13.7049819525173	592.2289959950662	-0.951965561723227	0.432	264	36	SKCM	FAMITINIB	Clinical trials in cancer	KIT | KDR | FLT3
791.5633576568716	17.4822986623622	727.3101021529015	-27.5966178840886	0.599	512	170	UCEC	ALPELISIB	Clinical trials in cancer	KRAS | NRAS | TSC2
591.7228011310546	-32.1218386018421	580.8634528171272	-11.6696012882589	0.422	423	57	COAD	DANUSERTIB	Clinical trials in cancer	KRAS
216.28220875448125	65.9812430496539	183.71645826771862	-26.5090610516627	0.0004	169	38	READ	TYRPHOSTIN B42	Experimental	KRAS
209.0493674246552	51.6342109280952	227.6200580238916	-10.1393563201532	0.0004	512	80	UCEC	KU-0060648	Experimental	PIK3CA | BRAF
837.7769565548606	-55.5499937203017	809.1246027476506	50.9962501739874	0.6	264	197	SKCM	BINIMETINIB	Clinical trials in cancer	NF1 | NRAS | KIT
230.64212800855304	-6.78782602677649	181.32420098395858	-9.50288869666747	0.0006	502	62	KIRC	S-ISOPROPYL-ISOTHIOUREA	Experimental	VHL | AKT3 | MTOR
508.1282408568838	-21.1503377136949	484.000173163538	-0.000153546318415465	0.316	512	56	UCEC	NECITUMUMAB	Approved in other pathologies	KRAS | ERBB2 | EGF
177.6781279694307	-46.305508272784	217.29291786528256	11.7288979650903	0.0004	343	46	HNSC	WORTMANNIN	Experimental	AKT1 | PIK3CA
517.6418683793241	-73.3926928117171	530.6971115751986	3.66277496411701	0.412	57	24	PAAD	SAR245409	Clinical trials in cancer	KRAS
245.95318663724572	20.9301724097344	208.56066098561323	7.40593351743235	0.0004	202	21	LAML	FQI1	Experimental	IDH1 | SOS1 | MYC
616.7104384873724	5.95328353990331	605.1285362158238	-2.31514992063518	0.432	169	40	READ	LINSITINIB	Clinical trials in cancer	KRAS | PIK3CA
825.5036745259823	10.7962584045101	707.1987395796741	-44.8653757357471	0.525	435	209	THCA	GSK2126458	Clinical trials in cancer	NRAS | BRAF | SOS1
800.8926601412992	-10.3121260122285	760.9999071541913	-0.000253781186074775	0.623	934	219	BRCA	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | ERBB2 | PIK3CA
1004.8137541346563	-18.1866023891632	1030.8313722113191	-0.122732454503762	0.922	202	32	LAML	SORAFENIB TOSYLATE	Approved in cancer	FLT3 | NF1 | KIT
780.2688974635543	80.1263115946848	731.5554406203648	-10.6600818859847	0.563	57	24	PAAD	BUPARLISIB	Clinical trials in cancer	KRAS
194.28222523036393	1.00808397422301	199.92506023075558	1.02196067783893	0.0008	292	41	STAD	A-443654	Experimental	KRAS | PTPN11 | AKT1
951.0292141469762	-14.630758608839	962.0486922086179	-2.99544558436128	0.842	423	80	COAD	IRINOTECAN	Approved in same tumor type	KRAS | BRAF | PIK3CA
983.4194423012198	73.0637108491509	1000.8481439359149	7.56042782312898	0.92	435	185	THCA	TEMSIROLIMUS	Approved in cancer	KRAS | BRAF | PIK3CA
546.3489624854051	56.650657373098	646.5926271146399	-0.430947954576027	0.523	202	52	LAML	XL147	Clinical trials in cancer	KRAS | FLT3 | KIT
762.4041299986449	-43.2579074669959	727.0909466570185	-10.5261172275293	0.588	543	95	LUAD	PIMASERTIB	Clinical trials in cancer	KRAS | NF1 | NRAS
242.28905260610642	-22.0265907440665	242.1560907642294	5.85634130862582	0.0006	512	95	UCEC	RO 31-7549	Experimental	PTEN | SOS1 | PTPN11
1065.1739328737085	-62.5413852856256	1042.4014362628182	13.9396011944909	0.932	343	130	HNSC	BORTEZOMIB	Approved in cancer	TP53 | RAC1 | PIK3CA
190.75295913391605	-47.8474223259897	184.55409224808463	24.234854573006	0.0004	264	31	SKCM	NSC632839	Experimental	KRAS | CTNNB1 | TRIO
537.8629420511255	124.778612359514	585.0935157281898	24.3220667391747	0.412	57	24	PAAD	P7170	Clinical trials in cancer	KRAS
665.229827310702	43.3452281833671	710.1241115297415	5.96903738207504	0.583	169	47	READ	1032350-13-2	Clinical trials in cancer	KRAS | PTPN11 | NRAS
594.1700453803788	137.721000277932	672.7680884451205	30.5961326727681	0.54	435	211	THCA	PIMASERTIB	Clinical trials in cancer	KRAS | NRAS | BRAF
559.6522215157352	-15.1828538592011	570.0621979620984	2.52350120455321	0.423	343	45	HNSC	LY3023414	Clinical trials in cancer	PIK3CA
739.6540160396454	88.7061408442479	689.9744465914351	0.160545472705905	0.542	389	53	LUSC	AT-101	Clinical trials in cancer	BRAF | TP53 | MAPK14
1061.0054341834493	-15.1467314233607	1050.4207624108021	6.29807344286291	0.944	343	60	HNSC	REGORAFENIB	Approved in cancer	SMAD4 | RAC1 | PIK3CA
682.8257523958604	28.9272410005108	730.9331869770785	-16.2454982838929	0.583	543	92	LUAD	BAY869766	Clinical trials in cancer	KRAS | NF1 | NRAS
292.8029982958911	51.7550386579738	189.62175785133726	58.4561868723001	0.0008	435	183	THCA	CHEMBL526479	Experimental	BRAF
733.4374888807413	31.5548192445273	717.4069892989398	-5.89483186542247	0.582	169	29	READ	GOSSYPOL	Clinical trials in cancer	BRAF | TP53 | AR
201.1190817888723	21.5661096275055	247.11934726842594	-9.03675604453974	0.0006	512	94	UCEC	RU85493	Experimental	PTEN | KDR | GNAS
152.90532738467016	-47.4466626359979	188.20993593235033	-14.6695525790924	0.0006	264	35	SKCM	2-CHLOROPHENOL	Experimental	CYBB | AKT3 | GNAS
768.2005223640292	30.9278293532891	729.8386207797462	27.839115800218	0.6	512	125	UCEC	PIMASERTIB	Clinical trials in cancer	KRAS | NF1 | NRAS
322.73557987740713	90.8247967316703	219.93798191874146	14.4448971828963	0.0004	435	212	THCA	LY2183240	Experimental	KRAS | NRAS | TSHR
1084.7217077623266	72.1809518839518	1038.012855632101	-27.0589668109332	0.945	435	211	THCA	REGORAFENIB	Approved in cancer	KRAS | NRAS | BRAF
895.5019223932931	44.5364904259712	955.5368783831168	15.0876272422379	0.824	435	183	THCA	IDELALISIB	Approved in cancer	BRAF | PIK3CA
556.2828808267816	57.7813217200535	674.7164685095748	5.08023466116401	0.525	934	242	BRCA	1032350-13-2	Clinical trials in cancer	KRAS | AKT1 | PTEN
272.38928081638755	-32.0487946785962	171.48176348316608	-5.85781782122945	0.0004	934	220	BRCA	GW843682X	Experimental	PIK3CA | IDH1 | ARNT
789.4294826335703	29.3981321489339	714.6472906703565	-4.32790947299077	0.582	222	58	LGG	AT-101	Clinical trials in cancer	TP53 | BRAF | MTOR
1038.790713069316	118.741460686519	1023.1178136590553	-16.5302997074245	0.912	435	186	THCA	BORTEZOMIB	Approved in cancer	KRAS | BRAF | TP53
620.508811450959	35.0184276546916	690.520842395729	-17.002503328162	0.522	435	184	THCA	GOSSYPOL	Clinical trials in cancer	BRAF | TP53
737.9768523602578	-19.3283516197928	721.4004143363674	-13.013421610571	0.586	543	74	LUAD	DINACICLIB	Clinical trials in cancer	KRAS | RB1 | SMAD4
997.5616543473591	46.5488934666077	1046.9664417478407	0.00737695178213471	0.941	389	52	LUSC	ERIBULIN	Approved in cancer	BRAF | TP53 | MAPK14
174.45359080071722	27.4935004658436	192.00444223847276	-16.6211480927543	0.0006	502	59	KIRC	SIRNA-027	Experimental	VHL | MTOR
1009.7451802014474	35.6434009424694	1039.1479367325235	-9.25058754721999	0.926	202	43	LAML	CABOZANTINIB	Approved in cancer	KRAS | FLT3 | KIT
1049.8727769921693	-56.7277631543636	1075.9287080808747	-2.73837167609281	0.977	292	35	STAD	BEVACIZUMAB	Approved in cancer	KRAS | CTNNB1 | CREBBP
166.83683557939293	-10.7115206919075	206.55356027437404	8.30707895802652	0.0006	153	28	BLCA	OBLIMERSON	Experimental	CREBBP | TP53 | CHUK
508.0678864616668	8.00363822025201	541.2862815841767	16.6504602900206	0.422	57	24	PAAD	CAMPTOTHECIN	Clinical trials in cancer	KRAS
278.41186820193434	113.494423969304	238.06370015910852	13.0126800659089	0.0004	435	183	THCA	VX-11E	Experimental	BRAF
764.4102095223482	-37.0228322512674	782.1134431684644	1.15465216263556	0.644	343	53	HNSC	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	STK11 | AKT1 | PIK3CA
1056.9173953717755	-10.7169740718446	1019.9997596682881	0.000528327019765129	0.911	502	64	KIRC	ERIBULIN	Approved in cancer	VHL | AKT3 | MTOR
557.0660578066572	19.7056243460656	583.3880103887536	0.546860365741622	0.422	543	64	LUAD	SAR245409	Clinical trials in cancer	KRAS | PIK3CA
598.0345278882381	3.48388766013144	600.1608517909814	-0.691435457283887	0.422	934	234	BRCA	AFURESERTIB	Clinical trials in cancer	AKT1 | PIK3CA | AKT2
677.5578496068414	27.9735514637004	680.2071472432849	7.29982455767959	0.535	502	63	KIRC	LINIFANIB	Clinical trials in cancer	VHL | MTOR | KDR
246.83872340511704	-87.6321016612813	215.790293297851	63.1362506795458	0.0004	264	104	SKCM	KU-0060648	Experimental	BRAF | PIK3CA
741.5862853158425	24.0586040150202	723.5912946831991	-2.99003520850169	0.596	512	165	UCEC	XL765	Clinical trials in cancer	KRAS | NRAS | TSC2
945.1632031060516	24.5519459470271	923.495917858288	-2.79015739248484	0.812	169	38	READ	IXABEPILONE	Approved in cancer	KRAS
255.61738527107704	40.1695638586217	209.0116675160896	8.82129370081213	0.0004	169	42	READ	TW-37	Experimental	KRAS | BRAF | PIK3CA
694.0342240665773	-44.4452110524915	696.8515153632034	3.38287740360693	0.552	153	29	BLCA	GOSSYPOL	Clinical trials in cancer	CREBBP | TP53 | TRIO
392.6249924800019	7.77794530978588	390.9998845219525	1.83931931587722e-05	0.212	512	55	UCEC	CAPSAICIN	Approved in other pathologies	KRAS | ABCB1
148.49169382050275	-68.7947553389912	173.34776528371495	22.5532881453751	0.0006	264	35	SKCM	CHEMBL305178	Experimental	CYBB | AKT3 | GNAS
624.4653843857316	-26.5271412635661	568.1375504800269	-4.52370062755233	0.412	202	27	LAML	VE-822	Clinical trials in cancer	KRAS | IDH1
511.24209704315143	-18.1840094953614	483.057388076044	-4.28325351169354	0.311	57	6	PAAD	EDARAVONE	Approved in other pathologies	TP53
534.9176274070594	-69.4964731245063	546.8353185903235	14.0002461103027	0.381	264	123	SKCM	HEPARIN	Approved in other pathologies	AKT3 | BRAF | CTNNB1
936.9351622317273	25.5233175862128	938.5962330243359	6.49878916932255	0.823	202	43	LAML	OLAPARIB	Approved in cancer	KRAS | IDH1 | IDH2
946.8052301366529	-4.43099814435996	948.2493989773576	0.243014540124022	0.834	543	67	LUAD	GEMCITABINE	Approved in same tumor type	KRAS | PIK3CA | KDR
724.4176699716628	110.286260793895	558.4447003150023	-2.46666813191382	0.412	435	185	THCA	CH5132799	Clinical trials in cancer	KRAS | BRAF | PIK3CA
622.52176353932	-21.2620714779927	599.5541875716958	4.96189104078508	0.432	512	77	UCEC	PERIFOSINE	Clinical trials in cancer	PIK3CA
177.1886154922779	-25.6028771785688	209.11701787907379	6.54798458886899	0.0006	543	64	LUAD	LAX-101	Experimental	KRAS | NLRP3 | HRAS
684.0754408581547	7.10084975046612	715.5880943885052	5.40200540844353	0.588	292	42	STAD	DACTOLISIB	Clinical trials in cancer	KRAS | PTPN11 | NGF
932.6554702934359	-11.8817705006969	957.4420329382721	-4.90459704985051	0.844	264	31	SKCM	GEMCITABINE	Approved in cancer	KRAS | AKT1 | PIK3CA
531.9548446583507	-52.3023993032162	588.0110570233635	-0.656433312948593	0.423	343	45	HNSC	DS-7423	Clinical trials in cancer	PIK3CA
413.929704205218	-5.02460225936207	409.7045892153435	-2.97676645714273	0.233	543	83	LUAD	PEMBROLIZUMAB	Approved in other pathologies	KRAS | NRAS | BRAF
1082.644972880601	58.3458835239686	1024.4073915731128	5.13015586767847	0.93	169	42	READ	IMATINIB	Approved in cancer	KRAS | SMAD4 | BRAF
492.46622887730877	-25.7435067750091	491.52170602687266	5.52870676903922	0.321	502	63	KIRC	MICONAZOLE	Approved in other pathologies	VHL | AKT3 | MTOR
233.65207671033576	15.9251415003914	216.88626821584913	2.74721371828605	0.0006	502	59	KIRC	N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE	Experimental	VHL | MTOR
1027.5822746672914	-93.4845589951737	1039.2807400192876	14.2973153906546	0.94	264	176	SKCM	AFATINIB	Approved in cancer	NRAS | KRAS | BRAF
136.18566646203308	-68.9567710661546	236.72595936297796	2.9371593450569	0.013	934	217	BRCA	1173900-33-8	Clinical trials	PIK3CA | FOXP1 | BRAF
703.7428627874397	-38.7519371367349	679.9566591958829	-2.36586696327322	0.535	343	53	HNSC	GSK2126458	Clinical trials in cancer	AKT1 | RAC1 | PIK3CA
709.7634776465712	-21.274694153622	739.9394673005777	-4.51880026596541	0.584	512	96	UCEC	PF-562271	Clinical trials in cancer	PTEN | KDR | FLT3
273.38217084204615	-19.7348373086623	186.7996743787543	6.28641940762282	0.0006	202	37	LAML	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | FLT3 | KIT
1004.8347385139111	-4.84563548498349	1018.1022573696499	5.42231589921221	0.91	343	47	HNSC	FULVESTRANT	Approved in cancer	PIK3CA | MAP2K1 | PRKACA
754.2026802428314	17.1024246941202	661.7865122018137	-6.27965278818419	0.524	202	52	LAML	PX-866	Clinical trials in cancer	KRAS | FLT3 | KIT
240.10537240378846	-77.1021377182597	194.81078856213182	28.8386580498432	0.0004	934	218	BRCA	ELCPK	Experimental	PIK3CA | MAP3K4 | MTOR
1109.8573328648142	74.4470121379179	1063.544122871945	-12.7516475006482	0.944	934	330	BRCA	PACLITAXEL	Approved in cancer	KRAS | TP53 | AKT1
216.9926354348968	-48.0211582099519	215.22703204850015	-10.185609653506	0.0006	169	42	READ	AT7867	Experimental	KRAS | PTPN11 | PIK3CA
594.6995126927358	117.378384026497	613.729358335586	-9.71874787314991	0.44	57	24	PAAD	SELUMETINIB	Clinical trials in cancer	KRAS
287.9336127760766	67.8684411585887	219.20132705915447	54.7741870852049	0.0004	435	183	THCA	303727-31-3	Experimental	BRAF
341.44595201032496	-6.27592097431895	354.99995670907276	0.000167180304742942	0.172	423	62	COAD	FASUDIL	Clinical trials	KRAS | GATA2 | GNAS
1069.6711140391833	21.4470775182024	1061.3532110558665	2.12573618398665	0.956	543	65	LUAD	PAZOPANIB	Approved in cancer	KRAS | KDR | FGFR1
403.40175770981085	12.2954236174706	388.7083230429958	-7.93283115865393	0.212	57	24	PAAD	NIVOLUMAB	Approved in other pathologies	KRAS
1024.4614954308445	-43.4381745405502	1038.4758033971186	4.39453756912462	0.942	343	47	HNSC	MIDOSTAURIN	Approved in cancer	PIK3CA | PLCE1 | PDGFRB
1082.5613935474323	-23.9872763682754	1060.2032701048472	6.80596863939809	0.93	934	222	BRCA	DABRAFENIB	Approved in cancer	KRAS | NF1 | MAP2K1
653.2788433268166	14.6912165088061	590.2897205692668	10.1582049380781	0.422	169	42	READ	MK-1775	Clinical trials in cancer	KRAS | NRAS | TRRAP
954.8407011458436	-72.7771361066243	969.5376348278244	24.5755360511025	0.842	435	185	THCA	BEVACIZUMAB	Approved in cancer	KRAS | BRAF | PIK3CA
671.0908845474787	69.3118832172282	731.1918526120367	4.79097459544431	0.6	169	44	READ	BINIMETINIB	Clinical trials in cancer	KRAS | NRAS | BRAF
195.96632077836256	-10.3220403463986	209.06546378381202	30.9030931910736	0.0004	512	81	UCEC	109511-58-2	Experimental	PIK3CA | PTPN11 | RAF1
503.3201087506683	-20.3290784627968	594.0186559481557	6.21128448282752	0.423	343	45	HNSC	VS-5584	Clinical trials in cancer	PIK3CA
1086.3654361971949	-15.48606843315	1096.1082184714285	17.7917582863947	0.995	423	104	COAD	PACLITAXEL	Approved in cancer	KRAS | TP53 | MTOR
676.7036035071658	7.80394940323447	653.3934906139613	3.04814742270048	0.506	202	25	LAML	DINACICLIB	Clinical trials in cancer	KRAS | NRAS | MYC
643.9517695632312	-94.6229778602832	791.7193237661099	26.9359911701013	0.6	264	196	SKCM	REFAMETINIB	Clinical trials in cancer	NF1 | NRAS | KIT
658.9598462560475	99.0677119701581	548.1760654182975	-16.6542568033144	0.413	435	183	THCA	PLX8394	Clinical trials in cancer	BRAF
149.6072141520563	-155.187510981875	239.06649885667144	29.1437011738321	0.0008	264	189	SKCM	OLOMOUCINE	Experimental	RB1 | NRAS | KRAS
170.8187568044497	124.140975853445	171.40522477055399	48.8970143748652	0.0004	435	183	THCA	CEP-32496	Experimental	BRAF
124.86965846006858	-45.5313842114229	201.80789148912993	-0.1636813309442	0.0004	343	45	HNSC	IPI549	Experimental	PIK3CA
672.4357201862825	8.54186787927188	633.2637671128633	-2.31028929158268	0.511	57	6	PAAD	DHA-PACLITAXEL	Clinical trials in cancer	TP53
204.52455917825586	14.3112890881027	233.3392073549611	-14.2002616780983	0.021	512	100	UCEC	TRIPTOLIDE	Clinical trials	CTNNB1 | PIK3CA
657.1455457797553	-64.5040615805256	729.382578858881	-6.28647323899668	0.592	264	36	SKCM	AT9283	Clinical trials in cancer	RB1 | PTPN11 | AKT3
121.44674444980677	-35.3417019093778	192.36803211774125	-29.0148933377691	0.0006	264	107	SKCM	PF-3644022	Experimental	KRAS | BRAF | MAPK14
180.31062010995035	-22.3448071561282	216.35892932693145	-5.13906863318016	0.0006	264	35	SKCM	CHEMBL203567	Experimental	CYBB | AKT3 | GNAS
1028.7658098365805	4.36271983179577	1032.5185456126305	-6.12768000843278	0.927	202	31	LAML	NILOTINIB	Approved in same tumor type	KRAS | FLT3 | KIT
707.698544538821	107.650637768982	656.6973410633439	20.3420236929617	0.522	435	183	THCA	RO5212054	Clinical trials in cancer	BRAF
1103.710048449046	19.5694787053504	1059.6274282122015	-1.03575985200996	0.957	599	71	GBM	REGORAFENIB	Approved in cancer	RB1 | NF1 | NRAS
359.79712895790317	-3.38716218584042	366.2372270345796	0.936903204406008	0.181	543	91	LUAD	ADENOSINE TRIPHOSPHATE	Clinical trials	KRAS | RB1 | SMAD4
211.6324237027448	27.5155098664212	191.7204965218182	-11.6931562180739	0.0008	423	94	COAD	OLOMOUCINE	Experimental	KRAS | NRAS | SMAD4
818.6310641742559	90.6406372314347	693.3930578492673	-80.860469681928	0.583	264	195	SKCM	BAY869766	Clinical trials in cancer	NF1 | NRAS | KIT
764.2627142411962	19.2823315298317	740.8519701379505	-5.17073137897364	0.586	292	34	STAD	1224844-38-5	Clinical trials in cancer	KRAS | PIK3CA | BRAF
685.4866490421822	-50.0976465698695	736.1888995446383	-8.11382240966896	0.589	153	20	BLCA	391210-10-9	Clinical trials in cancer	NRAS | PIK3CA | SOS1
271.48869185569697	-44.9255562886796	291.0002299803973	-0.000266727637949771	0.101	169	39	READ	FASUDIL	Clinical trials	KRAS | AR
748.9356639773318	8.76525716406172	711.7331138197694	6.57181320577865	0.55	934	231	BRCA	SELUMETINIB	Clinical trials in cancer	KRAS | NF1 | MAP2K1
135.55259075460373	13.8847484939294	230.68881603764302	32.8558601331381	0.0004	512	122	UCEC	PIPERLONGUMINE	Experimental	TRIO | CTNNB1 | MTOR
1133.0404825890867	-66.3776382164435	1071.1717515219816	-0.210683622339957	0.985	512	119	UCEC	ARSENIC TRIOXIDE	Approved in cancer	KRAS | RB1 | NRAS
1097.4267072673497	48.1021928606369	1014.9443037570445	-10.8765978380441	0.92	169	45	READ	VEMURAFENIB	Approved in cancer	KRAS | NRAS | BRAF
756.2509748539266	106.366273100964	681.5002767205601	19.3242790384575	0.544	57	24	PAAD	NAVITOCLAX	Clinical trials in cancer	KRAS | TP53
1105.7841445344277	-16.4475697633306	1077.6128474067923	-14.0648131402404	0.99	423	100	COAD	PALBOCICLIB	Approved in cancer	KRAS | NRAS | SMAD4
992.8324976925135	-49.8229545650718	988.2154129161695	-0.833360173761776	0.874	423	65	COAD	GEMCITABINE	Approved in cancer	KRAS | PIK3CA | IDH1
235.80413134996945	12.0637891006909	198.02459097602247	-2.57552462128183	0.0006	512	54	UCEC	ZALTRAP	Experimental	VHL | CTNNB1 | MTOR
567.0955484386169	66.0353879638357	568.5057348468574	27.0081276730958	0.422	57	24	PAAD	MK-1775	Clinical trials in cancer	KRAS
722.6763488561627	-19.4356390030375	718.5125287854202	-11.0440866393747	0.596	512	79	UCEC	212631-79-3	Clinical trials in cancer	KRAS | NF1 | NRAS
162.18031718120227	-37.152501985662	193.89756342055836	14.189346302483	0.0004	343	45	HNSC	GDC-0077	Experimental	PIK3CA
959.8057197559175	10.8377894542768	971.3124843107656	3.36240653070581	0.854	512	63	UCEC	ERLOTINIB	Approved in cancer	KRAS | ERBB2 | BRAF
553.0431461204755	-33.0508083517996	539.2204412301526	-7.26106302538369	0.381	512	55	UCEC	GLYCEROL	Approved in other pathologies	CTNNB1 | CHD8 | PLCE1
136.14903408789237	118.779507160662	167.7240718811823	-57.2808088686357	0.0006	435	211	THCA	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	KRAS | NRAS | BRAF
671.1156331211778	-49.9892408980056	677.0353886037512	4.84850824774276	0.531	153	28	BLCA	DHA-PACLITAXEL	Clinical trials in cancer	CREBBP | TP53 | CHUK
767.1522009304173	-46.5597823377728	778.8918099372132	-5.48430451116656	0.641	264	30	SKCM	NINTEDANIB ESYLATE	Approved in other pathologies and in clinical trials in cancer	FGFR3 | KDR | FGFR1
590.5016345416293	-51.8713839971936	561.2756385241845	-8.29121431435249	0.412	169	38	READ	DANUSERTIB	Clinical trials in cancer	KRAS
760.7266805668341	-56.8706464570717	740.9493699202272	0.946799422187951	0.582	543	93	LUAD	RO4987655	Clinical trials in cancer	KRAS | NF1 | NRAS
512.224936730662	18.4098642676833	561.5350554024609	1.43113968827242	0.412	512	77	UCEC	INDOLE-3-CARBINOL	Clinical trials in cancer	PIK3CA
702.4303941102705	22.8617590386713	662.4177837519243	8.29750745756542	0.512	202	31	LAML	RO4987655	Clinical trials in cancer	KRAS | NF1 | KIT
272.28897122893056	97.8298649767153	177.73953181983723	3.50275771595079	0.0004	57	24	PAAD	A-443654	Experimental	KRAS
701.9845981120025	-8.90720663056476	680.6919651963185	-11.8384438198344	0.53	202	31	LAML	BINIMETINIB	Clinical trials in cancer	KRAS | NF1 | KIT
201.63596654937095	-24.1331140807317	202.86486864729304	-2.89028403854286	0.0004	543	71	LUAD	KINETIN RIBOSIDE	Experimental	KRAS | CTNNB1 | SOS1
660.3131889039886	18.4480116608639	656.293797366073	8.17618538481304	0.513	202	31	LAML	BAY869766	Clinical trials in cancer	KRAS | NF1 | KIT
804.4061023895146	137.353916335809	749.1148328782223	-76.4142610984354	0.599	264	198	SKCM	ALPELISIB	Clinical trials in cancer	NRAS | KIT | KRAS
192.75740053552863	-52.4890705114519	206.9692155993991	12.2614114067255	0.0006	264	35	SKCM	CHEMBL197277	Experimental	CYBB | AKT3 | GNAS
811.7050423341551	-25.5664942838919	747.3785504125717	-11.4096372645197	0.594	512	165	UCEC	APITOLISIB	Clinical trials in cancer	KRAS | NRAS | TSC2
415.12785262422915	7.66217097941478	413.2796277531814	0.618753997631757	0.233	423	87	COAD	PEMBROLIZUMAB	Approved in other pathologies	KRAS | NRAS | BRAF
844.3486483592309	-8.92080304511211	839.9997815054006	0.000213400043548972	0.711	543	69	LUAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | STK11
750.296287863885	-47.7697757429466	752.4079888465008	-10.9584879628919	0.598	423	98	COAD	DACTOLISIB	Clinical trials in cancer	KRAS | NRAS | ESR1
301.5606928433347	84.4187711654285	177.70933221833053	-23.8435863521365	0.0004	435	183	THCA	5Z-7-OXOZEAENOL	Experimental	BRAF
795.9883407416585	-96.3607960420955	769.1210741635658	8.18496371318952	0.594	264	192	SKCM	1032350-13-2	Clinical trials in cancer	NRAS | KIT | KRAS
570.4790379233651	-41.2266704446497	567.5058998736694	7.81423830023368	0.412	543	60	LUAD	GDC-0994	Clinical trials in cancer	KRAS
464.55964706806054	44.0734080432712	535.2996539596916	32.3729971282133	0.422	57	24	PAAD	VE-822	Clinical trials in cancer	KRAS
643.3257850197195	-15.9608445317637	672.0982327468137	1.89795142505773	0.532	153	16	BLCA	1260612-13-2	Clinical trials in cancer	PIK3CA | SOS1 | HRAS
1017.4943071660495	18.0463927143804	1007.1287115621074	2.84092775745546	0.902	202	33	LAML	BORTEZOMIB	Approved in cancer	KRAS | FLT3 | KIT
685.6643941497277	99.1142288118713	669.4169741917352	-9.90319314673684	0.526	169	45	READ	REFAMETINIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
155.09608470546826	10.9491396339487	196.40486594454677	-5.81327909956872	0.0004	423	65	COAD	AT13148	Experimental	KRAS | PIK3CA | ERBB2
1043.7925744944994	-13.7571315995762	1037.7008817283506	1.48822084860331	0.93	543	81	LUAD	NILOTINIB	Approved in cancer	KRAS | RB1 | SMAD4
1046.9922955196087	-38.6485685272662	1066.4362127842844	-2.4131803569544	0.961	153	21	BLCA	DABRAFENIB	Approved in cancer	NRAS | PIK3CA | SOS1
142.80902787357124	26.5510684150561	186.9508192275186	-14.5003887384159	0.0004	343	46	HNSC	NAKITERPIOSIN	Experimental	PIK3CA | MYC
1108.6660165563894	2.86034674581691	1097.8799940033073	-0.649656291555175	1.0	292	36	STAD	DABRAFENIB	Approved in cancer	KRAS | NF1 | PTPN11
235.0613064984187	-69.4789999586707	214.31735129315402	-12.9916763841834	0.0008	423	94	COAD	SB220025	Experimental	KRAS | NRAS | BRAF
226.77195363921936	-1.84133659788233	207.51297983417774	4.99317496733215	0.0006	502	59	KIRC	CHEMBL245549	Experimental	VHL | MTOR
220.04142361644438	-18.7706344626096	215.31524852318307	-12.1609913624302	0.0004	512	54	UCEC	MERCK60	Experimental	KRAS | FLT4 | STAT6
733.8015870601847	-51.3656168118615	717.0923554401037	17.4153511652817	0.598	423	95	COAD	TAK-733	Clinical trials in cancer	KRAS | NRAS | NF1
567.6620396471491	-37.2885259377106	583.0468004602733	-2.53022418158343	0.422	343	46	HNSC	UPROSERTIB	Clinical trials in cancer	AKT1 | PIK3CA
701.876951397557	-63.3346528278012	664.5834762808296	12.8155742018657	0.517	264	105	SKCM	CAPMATINIB	Clinical trials in cancer	BRAF | MET
259.3264424264839	-87.0991737456386	185.29200605935355	6.59525348481543	0.0004	934	216	BRCA	17-ALLYL-AMINOGELDANAMYCIN	Experimental	PIK3CA
889.0491087821755	61.4320888349102	941.6871729635515	-30.9612692374322	0.833	435	211	THCA	PALBOCICLIB	Approved in cancer	KRAS | NRAS | BRAF
555.0972070246831	-2.10525161168795	583.9676185670905	2.69815512476544	0.412	343	45	HNSC	ACALISIB	Clinical trials in cancer	PIK3CA
256.1001184580893	18.430579705148	194.80605669493264	-30.7337858171749	0.0006	169	43	READ	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | CYBB
167.04191824986154	-22.8071684635709	210.08016692973618	-5.97241442198629	0.0004	343	52	HNSC	FQI1	Experimental	RAC1 | PIK3CA | FGFR3
1171.5769764040986	-13.512650210511	1113.222788740476	50.3096218324877	0.97	264	182	SKCM	PALBOCICLIB	Approved in cancer	RB1 | NRAS | KRAS
155.76232545257474	71.9928203626532	208.37886858640695	37.4882194566698	0.0006	57	24	PAAD	LAX-101	Experimental	KRAS
234.70039920341162	-89.6572906965989	184.8759754782684	-26.8891127692618	0.0008	934	216	BRCA	PILARALISIB	Experimental	PIK3CA
1044.4500443779636	49.5443422328863	1041.8775508052736	10.2294986202003	0.94	169	44	READ	AFATINIB	Approved in cancer	KRAS | NRAS | BRAF
156.18620661110975	-44.0313807018431	207.57160355925095	-1.05112662849115	0.0008	153	16	BLCA	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE	Experimental	PIK3CA | SOS1 | HRAS
1070.8348513109152	36.3770410887393	1039.0373670745332	20.7267033589108	0.927	934	227	BRCA	RIBOCICLIB	Approved in same tumor type	KRAS | RB1 | STK11
310.97876291248343	-26.2303407582945	298.1692286156128	0.00300177752910713	0.111	502	62	KIRC	L-ARGININE	Clinical trials	VHL | AKT3 | MTOR
635.3774916449598	59.3701717834794	695.4754276151472	0.190795506126051	0.552	389	54	LUSC	GOSSYPOL	Clinical trials in cancer	BRAF | TP53 | MAPK14
271.2774938722759	24.0601610504874	220.73242630715754	-18.5652785958389	0.0006	169	43	READ	HYPOTHEMYCIN	Experimental	KRAS | NRAS | BRAF
1035.7643993979825	47.8660687771397	1048.645275066793	0.888004959366526	0.934	202	39	LAML	REGORAFENIB	Approved in cancer	KRAS | NF1 | KIT
175.19767979294804	-4.4566515833842	204.581161185278	15.0039736668739	0.0006	502	62	KIRC	6-NITRO-1H-INDAZOLE	Experimental	VHL | AKT3 | MTOR
671.8206606520672	-21.3231832245254	712.0941675557174	-4.14555118037697	0.582	423	66	COAD	GOSSYPOL	Clinical trials in cancer	TP53 | MTOR | BRAF
223.27046515451846	-31.7300378597661	188.33541537231628	5.35707535627762	0.0004	343	45	HNSC	TORIN 1	Experimental	PIK3CA
1061.03320307129	80.1721649154917	1100.7859356922727	-20.9085378011559	0.99	512	153	UCEC	TRAMETINIB	Approved in cancer	KRAS | NF1 | NRAS
987.7933098055464	-26.1044719583348	1030.0001586684348	9.78683522134816e-05	0.922	292	66	STAD	BORTEZOMIB	Approved in cancer	KRAS | MAP2K1 | CTSD
147.8955426395374	2.63160201478777	215.34042950024144	-8.03264482983741	0.0004	343	45	HNSC	AMG319	Experimental	PIK3CA
294.0982662477255	-38.765318017125	300.55705298546167	4.19079456615236	0.112	502	59	KIRC	AMINOGUANIDINE	Clinical trials	VHL | MTOR
1055.048293983854	32.8638517538798	1046.9772252400082	-4.12757463132516	0.93	934	219	BRCA	ADO-TRASTUZUMAB EMTANSINE	Approved in same tumor type	ERBB2 | PIK3CA | ERBB3
884.5441093260986	-10.5331989940497	956.9456190052555	-2.22381155090875	0.822	435	183	THCA	DABRAFENIB MESYLATE	Approved in cancer	BRAF
690.1468380053446	-7.69097302532276	710.691924273309	2.58666801031359	0.586	423	79	COAD	RAF265	Clinical trials in cancer	KRAS | BRAF | RAF1
127.66552758134242	-6.24426017977331	219.32855001249393	-7.47058820350981	0.0006	543	82	LUAD	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | GNRHR
625.8348032240687	-52.1924145447516	585.1503388072588	3.95417950631872	0.422	512	58	UCEC	FOLFIRI REGIMEN	Clinical trials in cancer	KRAS | NRAS
1074.5810453408774	-41.6292517207183	1096.2281026279063	-17.718001652931	1.0	264	45	SKCM	SUNITINIB	Approved in cancer	KIT | KRAS | VHL
131.54313195982087	-26.8693953304565	213.1811541476241	-0.693876014654052	0.0004	153	27	BLCA	LY2183240	Experimental	NRAS | CTNNB1 | FGFR3
523.8460768708627	4.55370152162902	557.8811158917897	14.0023804130508	0.412	57	24	PAAD	1375469-38-7	Clinical trials in cancer	KRAS
726.2725099756398	4.26321927397828	714.1624262474974	-4.21047585897315	0.574	599	74	GBM	SF1126	Clinical trials in cancer	NRAS | KRAS | PTPN11
388.61547989048825	-10.4945161501938	390.9999628300857	0.000273272213007658	0.212	934	216	BRCA	MILTEFOSINE	Approved in other pathologies	PIK3CA
679.214782444865	-8.23271860500896	740.6676448697682	6.15208089908992	0.594	343	62	HNSC	APITOLISIB	Clinical trials in cancer	STK11 | PTEN | AKT1
247.09775222530288	-17.9109020615938	221.54427128788942	-29.9003211122304	0.0004	512	77	UCEC	CCT128930	Experimental	PIK3CA
691.9162658332899	-59.5768796190567	720.1950631496991	38.5374500932908	0.584	264	33	SKCM	BMS-690514	Clinical trials in cancer	HSPG2 | ERBB4 | KDR
1029.135495429417	-48.2643578750878	1021.8859568431836	0.983443149855475	0.916	543	63	LUAD	RAMUCIRUMAB	Approved in same tumor type	KRAS | KDR | PDGFRA
198.16097967365826	10.8985052259	187.29700231938187	-11.2990185641984	0.0006	512	95	UCEC	VITAXIN	Experimental	PTEN | FLNA | EGF
1137.96698404007	18.0943584367795	1097.081750088824	-3.49754113932886	0.995	169	39	READ	PAZOPANIB	Approved in cancer	KRAS | FGFR1 | PDGFRB
639.0038189440631	125.01810554211	606.3511784737849	50.4151021400125	0.432	57	24	PAAD	RIDAFOROLIMUS	Clinical trials in cancer	KRAS
495.68357315791945	-41.7480327472279	595.7010176404397	37.3706221561737	0.412	57	24	PAAD	CH5132799	Clinical trials in cancer	KRAS
619.7479279304883	-16.9393551229067	641.999985558377	0.00028208987259859	0.491	153	17	BLCA	141400-58-0	Clinical trials in cancer	PIK3CA | TRIO | RET
1064.6960994532992	-10.4347554812721	1029.4207182025991	0.441254274910307	0.922	502	68	KIRC	DOCETAXEL	Approved in cancer	VHL | AKT3 | MTOR
994.8509316656481	-43.5918679543467	986.0343338957856	3.92597452325481	0.873	512	89	UCEC	DOXORUBICIN	Approved in cancer	KMT2A | PIK3CA | ERBB2
201.2369970468799	-73.5909498733048	184.96015693857342	0.116578151573322	0.0004	343	45	HNSC	WX-037	Experimental	PIK3CA
155.0710296898048	54.5959544874092	213.20151306210008	23.9371016952005	0.0004	934	220	BRCA	PARBENDAZOLE	Experimental	PIK3CA | IDH1 | AFF4
260.69977426200296	-17.5718956651889	230.5062705018564	11.5398856917889	0.0006	512	112	UCEC	154447-36-6	Experimental	KRAS | MTOR | PIK3CA
579.8683608011559	-23.9062008254179	565.263729409188	-3.47815710164059	0.413	512	54	UCEC	AMG-337	Clinical trials in cancer	KRAS | ERBB2 | EGFR
231.79704546409363	-1.80319540723343	193.68842714959132	-13.0716731612674	0.0006	264	40	SKCM	DB07268	Experimental	KRAS | AKT3 | MAP2K1
585.6885120841357	30.165200518242	573.0182188415215	-3.70179401950861	0.412	202	23	LAML	BGB-283	Clinical trials in cancer	KRAS | NRAS
784.5818876550017	116.9055386001	753.9838127234536	2.5026129967664	0.623	222	134	LGG	DECITABINE	Approved in other pathologies and in clinical trials in cancer	KRAS | IDH1 | EGFR
470.4097076046897	-1.75404305300975	481.1790586589492	-4.57177665701306	0.311	502	59	KIRC	TENECTEPLASE	Approved in other pathologies	VHL | MTOR
1058.6635674446306	-48.2335123950589	1061.6276847342667	-3.07792164349848	0.957	153	16	BLCA	BEVACIZUMAB	Approved in cancer	CREBBP | CTNNB1 | IDH1
1104.60010032519	55.7222808568214	1080.1376974195941	-15.3614715172738	0.982	169	44	READ	CABOZANTINIB	Approved in cancer	KRAS | NRAS | PIK3CA
1089.789507366422	-44.7258028188847	1016.0724227227352	9.07236456276382	0.93	934	231	BRCA	REGORAFENIB	Approved in cancer	KRAS | RB1 | NF1
174.92320988809252	70.9184856490284	198.28800838012833	23.0158307934894	0.0006	512	71	UCEC	6-CHLORO-9-HYDROXY-1,3-DIMETHYLPYRAZOLO[3,4-B]QUINOLIN-4-ONE	Experimental	KRAS | SOS1 | MAP3K8
510.51568348109345	-35.6819784515577	507.00005091602503	0.000245781369187625	0.341	389	52	LUSC	EDARAVONE	Approved in other pathologies	BRAF | TP53 | MAPK14
637.5043575798072	1.30494639435807	670.6439226646739	-2.28369551076548	0.536	502	63	KIRC	MOTESANIB	Clinical trials in cancer	VHL | MTOR | KDR
245.493067478277	-50.027049572407	224.01954229629766	4.18776055119315	0.0004	264	52	SKCM	FQI1	Experimental	TRIO | GNAS | PIK3CA
762.2448802004129	27.9991179126451	719.6332472497892	-0.398213136280731	0.575	389	39	LUSC	GDC-0068	Clinical trials in cancer	KRAS | PTEN | AKT1
744.5430173948358	79.1286149956016	659.7126264967046	16.033586437317	0.522	202	52	LAML	GSK2636771	Clinical trials in cancer	KRAS | FLT3 | KIT
691.1260250953983	-64.9647486922669	745.7833393233656	-5.54325494161685	0.595	153	23	BLCA	XL765	Clinical trials in cancer	NRAS | PTEN | PIK3CA
557.239385317585	2.38352581269993	592.4360764228913	4.04839742655827	0.422	543	64	LUAD	P7170	Clinical trials in cancer	KRAS | PIK3CA
1066.8880182710348	-17.1696864526691	1042.0870866477167	5.80054806193198	0.93	543	86	LUAD	NERATINIB	Approved in cancer	KRAS | BRAF | EGFR
969.8020329343879	-19.7008348412086	941.3291101750318	2.538072763488	0.822	169	41	READ	OXALIPLATIN	Approved in same tumor type	KRAS | BRAF | ERBB2
1087.9595708461113	10.1316709703124	1071.9886868694978	6.6877741466958	0.981	512	59	UCEC	VINBLASTINE	Approved in cancer	CTNNB1 | CHD8 | MAPK7
576.9416276360485	4.55814457515905	621.9384118479368	2.5823511410465	0.471	512	80	UCEC	LEXIBULIN	Clinical trials in cancer	PIK3CA | TRRAP | EGFR
203.42114782884323	58.4643404729613	192.85680043233128	11.7148309275435	0.0004	202	24	LAML	167869-21-8	Experimental	FLT3 | PTPN11 | MYC
443.43214059677865	39.5157359579399	617.1896457547688	18.565440387139	0.433	264	174	SKCM	UNII-CZP9GB25HO	Clinical trials in cancer	NRAS | BRAF | MAP2K1
713.9201977569627	-44.7002748783605	685.5870164256734	-0.654903024778605	0.543	512	107	UCEC	LINSITINIB	Clinical trials in cancer	KRAS | PIK3CA | PTPN1
1101.9224595834926	24.4711914970479	1092.1424321856198	-0.75513968295121	0.992	389	53	LUSC	REGORAFENIB	Approved in cancer	KRAS | FGFR2 | BRAF
1063.8416342151813	68.4828399011236	1095.0076379848363	-4.98857376071555	0.997	292	40	STAD	COPANLISIB	Approved in cancer	KRAS | PTPN11 | NGF
163.43854490640476	61.7423891409178	188.7899682572404	10.3703762824605	0.0006	502	62	KIRC	L-CANAVANINE	Experimental	VHL | AKT3 | MTOR
460.31852978665023	-23.8096291351142	480.0000408104058	-0.000292122512746573	0.311	934	219	BRCA	DEHYDROEPIANDROSTERONE	Approved in other pathologies	MAP2K1 | PIK3CA | MAPK1
206.97627722019448	95.3512120440824	196.30050410499925	32.5447134789367	0.0006	169	43	READ	TURPENTINE	Experimental	KRAS | NRAS | BRAF
758.9209484167081	-33.9108420593827	742.0423429064983	-1.0060520363063	0.599	343	63	HNSC	ALPELISIB	Clinical trials in cancer	STK11 | PTEN | AKT1
166.94428261916764	-0.824457043639484	182.82980509936493	1.77843929874234	0.0004	543	64	LUAD	DEGUELIN	Experimental	KRAS | PIK3CA
201.24469060545155	77.8655436152916	197.97317862388974	21.4959758053574	0.0004	169	40	READ	NSC632839	Experimental	KRAS | ERBB2 | FGFR1
714.5037482330869	-52.0264917525651	739.8554915905884	17.7840898994123	0.595	423	67	COAD	AZD5363	Clinical trials in cancer	KRAS | PTEN | MTOR
151.02078999208624	-15.9722587697957	188.1413046624827	2.21663953162943	0.0004	153	21	BLCA	TIPIFARNIB-P2	Experimental	FGFR3 | PIK3CA | SOS1
1001.5153591965142	22.0541222541248	999.7305742909824	0.273854765694523	0.891	512	59	UCEC	IDARUBICIN	Approved in cancer	CTNNB1 | FGFR2 | ARNT
1060.0673614054774	96.7927921108851	1022.220743501672	6.59877687900814	0.92	57	25	PAAD	NILOTINIB	Approved in cancer	KRAS | SMAD4
1072.0959680881092	8.49564803084189	1043.2600851496727	-3.30683104231946	0.936	202	30	LAML	SUNITINIB	Approved in cancer	KRAS | FLT3 | KIT
609.5082054602273	-0.283312797973565	581.0312189389942	8.370778868054	0.423	512	56	UCEC	1096708-71-2	Clinical trials in cancer	KRAS | BRAF | RAF1
683.984391908345	-24.8159382348616	731.2689314218056	-19.6052230259913	0.596	512	59	UCEC	RAF265	Clinical trials in cancer	KRAS | BRAF | FGFR1
985.967999206734	92.8674751546624	1009.8885200646256	-5.88080434263355	0.93	57	25	PAAD	RIBOCICLIB	Approved in cancer	KRAS | SMAD4
222.57316590120305	-39.5362358396827	201.30488738743955	5.95418090222756	0.0008	153	16	BLCA	PILARALISIB	Experimental	PIK3CA | SOS1 | HRAS
1069.9488888282956	73.3956035290045	1033.9759106492556	-10.2132399882504	0.92	169	43	READ	LAPATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
190.17208217547852	62.4776234684547	192.88888421822327	4.82232325194781	0.0004	169	38	READ	AURORA KINASE INHIBITOR II	Experimental	KRAS
1078.0346713359231	21.8427041540031	1031.3843459727696	-20.2544818237425	0.933	934	310	BRCA	ABT-199	Approved in cancer	KRAS | TP53 | MAP2K1
479.8338609118234	17.271371666366	643.0821937467496	1.46553362634364	0.422	57	24	PAAD	BI 2536	Clinical trials in cancer	KRAS
1030.9444085847945	-15.9329661343786	1028.284595661036	-1.56215786231439	0.922	599	72	GBM	BORTEZOMIB	Approved in cancer	TP53 | KRAS | FGFR3
976.6184500979432	-23.6939052729571	947.5797611607114	-3.25148975469847	0.832	423	65	COAD	CAPECITABINE	Approved in same tumor type	KRAS | PIK3CA | ERBB2
660.8502670433893	-53.147557468559	660.9482007884092	-4.73380369820006	0.513	343	46	HNSC	1224844-38-5	Clinical trials in cancer	STK11 | PIK3CA
493.2932224878969	-7.73415090600602	542.4103269807308	-5.26543696987574	0.381	169	43	READ	ISOPRENALINE	Approved in other pathologies	KRAS | NRAS | BRAF
977.1026420145791	-0.810060580349841	1034.923578162822	5.18884227043191	0.923	599	121	OV	ABT-199	Approved in cancer	KRAS | TP53 | PIK3CA
108.35633927947305	35.1152810214874	203.1368539193342	2.16714531637012	0.0006	599	67	GBM	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | PTPN11 | PTEN
147.72613447472213	28.4056940721204	210.19713186677612	-4.27956332908525	0.0006	502	62	KIRC	N-{(3R,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N&#39;-(3-CHLOROBENZYL)ETHANE-1,2-DIAMINE	Experimental	VHL | AKT3 | MTOR
179.51099240272762	-8.88447847791235	202.86676797627908	-13.5485248251484	0.0006	512	95	UCEC	3H9O	Experimental	PTEN | SOS1 | PTPN11
142.13162526468153	10.3627711602612	197.86693716826628	16.700981451924	0.0004	512	80	UCEC	VOXTALISIB	Experimental	MTOR | PIK3CA
177.13016499361413	-51.7105627058238	185.848343652312	31.156606043292	0.0006	264	35	SKCM	3-FLUORO-N-1H-INDOL-5-YL-5-MORPHOLIN-4-YLBENZAMIDE	Experimental	CYBB | AKT3 | GNAS
1000.3813572942124	5.75851058831654	967.3998013018751	-2.7018070942114	0.853	169	43	READ	IRINOTECAN	Approved in same tumor type	KRAS | BRAF | PIK3CA
189.615116268937	23.0419435590081	211.40521261721733	-11.7816714826517	0.0004	343	49	HNSC	SB 225002	Experimental	RAC1 | PIK3CA | AFF4
175.138983891019	50.7336575696408	187.52818100094646	-1.53287871426733	0.0008	543	92	LUAD	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	KRAS | NF1 | NRAS
760.1790521841673	-114.621453537577	738.9896920968856	-15.2581847545339	0.584	264	124	SKCM	SF1126	Clinical trials in cancer	NRAS | KIT | KRAS
935.9682778280215	102.833912730465	943.977681037483	-5.90003600593866	0.834	57	24	PAAD	GEMCITABINE	Approved in same tumor type	KRAS
213.31243891213992	-11.6174491589339	198.66936874834434	-9.48574358668384	0.0006	502	54	KIRC	HYALURONIDASE (HUMAN RECOMBINANT)	Experimental	VHL
897.2507007182734	1.47244485384692	940.0236966429869	-4.15508187925207	0.822	423	96	COAD	CETUXIMAB	Approved in cancer	KRAS | NRAS | BRAF
544.0159977647323	5.60281614751105	588.498412988908	-2.82103521721683	0.424	543	71	LUAD	CH5132799	Clinical trials in cancer	KRAS | BRAF | PIK3CA
224.55114987849618	49.9069456280718	202.85220099031312	6.27774837004768	0.0006	512	59	UCEC	T-5224	Experimental	CTNNB1 | CHD8 | MAPK7
766.8071587979816	93.3633560106459	562.5208690981585	42.7206828988744	0.412	57	24	PAAD	1096708-71-2	Clinical trials in cancer	KRAS
202.30168819280905	52.5207324413862	219.58934870970532	-2.9591784964	0.0006	512	94	UCEC	833481-69-9	Experimental	PTEN | KDR | GNAS
1102.5046730937213	-23.0584898863344	1093.7015608177583	-12.2279313439867	0.997	264	35	SKCM	NILOTINIB	Approved in cancer	RB1 | KIT | KRAS
594.0921484250872	-45.9034901120408	657.897246951746	-0.320017192230353	0.513	343	46	HNSC	CC-223	Clinical trials in cancer	STK11 | PIK3CA
654.4190453613884	62.6906661184172	671.1903282636007	-6.85275318259778	0.511	435	184	THCA	DHA-PACLITAXEL	Clinical trials in cancer	BRAF | TP53
733.158386390994	13.3776393582248	719.2372645169855	-4.16097791844049	0.572	599	78	GBM	BUPARLISIB	Clinical trials in cancer	NRAS | KRAS | PTPN11
745.8770295966042	51.3510860237757	761.0679730593773	1.84962579495809	0.612	57	24	PAAD	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS
616.1024734006687	-96.7865869997172	578.2195525459585	-28.243697932041	0.422	264	172	SKCM	XL888	Clinical trials in cancer	NRAS | BRAF
1016.30810441936	32.026406175742	1028.06628070543	10.3405196268881	0.929	202	33	LAML	IMATINIB	Approved in same tumor type	KRAS | FLT3 | KIT
969.5130159933487	2.65340870937388	947.9931202401243	-0.92236305845779	0.824	202	28	LAML	GEMCITABINE	Approved in cancer	KRAS | IDH1 | MYC
1057.389044161938	-24.3952938426576	1075.5283589790922	1.30670592226625	0.97	153	18	BLCA	PALBOCICLIB	Approved in cancer	RB1 | NRAS | PIK3CA
1133.0744833682736	-1.53523786943018	1046.875318020409	-22.1284392098516	0.93	934	227	BRCA	TRAMETINIB	Approved in cancer	KRAS | NF1 | MAP2K1
609.7459006307076	109.727257597787	594.1640885570246	-4.49147266721934	0.422	435	183	THCA	TIVOZANIB	Clinical trials in cancer	BRAF
787.1139254107313	-27.8405036413926	787.0000814844116	0.000620136916495539	0.652	423	77	COAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | MTOR
1022.5614584386338	67.9339255652262	1045.8222982925029	9.13039856677801	0.93	202	49	LAML	DASATINIB	Approved in same tumor type	KRAS | KIT | IDH1
714.7658837186392	-33.7433172841104	725.2586881530282	-10.2755398389977	0.565	423	65	COAD	GDC-0032	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
678.5461903092834	60.436915853252	715.7675808132963	7.48165261846498	0.595	512	170	UCEC	PICTILISIB	Clinical trials in cancer	KRAS | NRAS | ZAP70
163.3328410514496	-32.2018811763575	197.6128993147308	-8.96295364342677	0.0006	264	35	SKCM	SD-06	Experimental	CYBB | AKT3 | GNAS
468.819588505362	-16.7431513437571	487.03344835125876	3.28034224262433	0.321	502	63	KIRC	SEMAXANIB	Approved in other pathologies	VHL | MTOR | KDR
130.0893548290421	-14.3839160768643	215.76219349783904	14.9694906571381	0.0004	934	216	BRCA	AZD8186	Experimental	KRAS | PIK3CA
699.1982755228604	-53.1516408662987	715.1647733814827	-2.89151713683077	0.581	543	68	LUAD	CC-401	Clinical trials in cancer	KRAS | SOS1 | MAP2K1
1083.0242118061328	-0.19714121407435	1012.8894571047641	-1.68420573991773	0.91	202	41	LAML	PALBOCICLIB	Approved in cancer	KRAS | FLT3 | NRAS
724.6451620792989	-1.49659135729786	711.4900725149523	-2.92969146803762	0.575	292	30	STAD	GDC-0032	Clinical trials in cancer	KRAS | PIK3CA | IRS1
699.2960224783315	54.5771475634306	669.5200468480089	19.1579654098458	0.533	202	52	LAML	BUPARLISIB	Clinical trials in cancer	KRAS | FLT3 | KIT
735.9987715033334	82.3518009019231	579.9838460925924	-2.89317411945734	0.423	169	40	READ	1096708-71-2	Clinical trials in cancer	KRAS | BRAF | RAF1
725.3851679735747	-23.7688488225669	672.7643965641875	2.35414093042004	0.532	502	65	KIRC	GOSSYPOL	Clinical trials in cancer	VHL | AKT3 | MTOR
601.1461253018542	34.9655696705791	698.339567487825	-4.14331704922546	0.545	169	40	READ	MLN1117	Clinical trials in cancer	KRAS | PIK3CA
100.19906450821854	-20.8563455926034	181.37587704594205	-5.2735918450212	0.0006	423	64	COAD	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	Experimental	KRAS | MAP2K1 | MAP4K1
144.37813607168846	-29.4440854491344	209.0927425005859	-6.4565140299328	0.0008	153	27	BLCA	PI-103	Experimental	NRAS | PTEN | PIK3CA
194.2000540542079	-27.6870607009196	198.70041239483126	7.71103635819964	0.0006	512	52	UCEC	CIS-VACCENIC ACID	Experimental	CTNNB1 | CHD8 | GSK3B
346.191801976996	-3.34418556070068	370.2126985952916	-0.865360826098822	0.183	264	35	SKCM	DILMAPIMOD	Clinical trials	CYBB | AKT3 | GNAS
886.7944832271963	-32.3268965817062	923.5455159696696	-4.4147684884756	0.822	435	211	THCA	AFATINIB	Approved in cancer	KRAS | NRAS | BRAF
226.85664879297528	-68.1246617413726	203.615807960904	-20.9717672083889	0.0006	512	96	UCEC	BISINDOLYLMALEIMIDE I	Experimental	PTEN | SOS1 | STAT1
574.4476404874705	-44.5572255611234	578.0446300403908	-4.28503900866781	0.424	343	45	HNSC	CH5132799	Clinical trials in cancer	PIK3CA
166.91044096615556	28.3651784984285	176.0151082531608	-23.9481186266246	0.0004	934	220	BRCA	TIPIFARNIB-P2	Experimental	MAP2K1 | PIK3CA | AFF4
609.1777258563463	37.6269527354345	583.3797982902689	16.6226145437095	0.422	169	38	READ	BMS-754807	Clinical trials in cancer	KRAS
296.84260494793324	130.616213661125	182.92777651806279	8.59165358594026	0.0008	169	48	READ	PI-103	Experimental	KRAS | PTPN11 | NRAS
279.9317714110721	-17.0612226185286	213.4748714059989	-4.45049774969652	0.0004	543	97	LUAD	LY2183240	Experimental	KRAS | NRAS | CTNNB1
226.4884117571538	-6.48226278403189	192.69051015663203	7.06362094954045	0.0004	202	23	LAML	GDC-0879	Experimental	KRAS | NRAS
361.33072651652225	-23.0722250314429	364.51122413216694	-4.98742189782558	0.181	169	44	READ	ADENOSINE TRIPHOSPHATE	Clinical trials	KRAS | SMAD4 | NRAS
211.33476424361095	-36.074967952308	214.05820226761256	4.42986058887868	0.0006	543	82	LUAD	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | BRAF
688.7542457721647	20.5795567586393	715.7193793691379	-6.54067000623104	0.581	512	57	UCEC	SKF-86002	Clinical trials in cancer	VHL | CTNNB1 | MTOR
1045.2533507645314	18.6405221745873	1073.3156046252882	9.75785011361177	0.99	423	100	COAD	RIBOCICLIB	Approved in cancer	KRAS | NRAS | SMAD4
174.89827631790084	42.9110191912427	187.33046795483818	-12.3003382885964	0.0004	202	54	LAML	LY2183240	Experimental	KRAS | FLT3 | NRAS
818.6001461070812	-115.034836784839	798.793785811222	-50.8403250254096	0.593	264	195	SKCM	RO4987655	Clinical trials in cancer	NF1 | NRAS | KIT
653.5079880184759	87.7889843337548	557.0671103844775	6.99055965687364	0.422	169	38	READ	PHENFORMIN	Clinical trials in cancer	KRAS
517.0038807119457	-26.672420569025	497.99992451069403	0.000206156078093045	0.331	57	24	PAAD	ISOPRENALINE	Approved in other pathologies	KRAS
653.1386407895474	-22.9026843225939	682.6897926239299	-6.23932669340206	0.533	502	63	KIRC	OSI-930	Clinical trials in cancer	VHL | MTOR | KDR
171.97085398851377	-33.6232909159924	201.89885506358738	0.899604037596873	0.0004	423	57	COAD	LY-411575	Experimental	KRAS | ERBB2
543.2370640149644	-18.0157368927531	568.1207869233489	8.59273198696019	0.422	423	58	COAD	VE-822	Clinical trials in cancer	KRAS | IDH1 | ATR
448.4159113621611	-29.1534627387545	492.98089346727943	-0.0263281433726661	0.321	435	183	THCA	HEPARIN	Approved in other pathologies	BRAF | SOS1 | ESR1
926.0074331420673	0.633180052475069	936.0605501754487	0.0486094113005038	0.823	202	27	LAML	PEMETREXED	Approved in cancer	KRAS | IDH1
965.5332818505378	-7.01980338998712	941.315978682939	3.59520528167559	0.822	512	79	UCEC	FLOXURIDINE	Approved in cancer	PIK3CA | ERBB2
510.361208159252	84.3380855562821	573.1693555247004	55.7940808546307	0.422	57	24	PAAD	SALIRASIB	Clinical trials in cancer	KRAS
543.5208958208724	-37.9475247690164	568.9969986029821	-2.67077545876009	0.422	343	46	HNSC	LY2780301	Clinical trials in cancer	AKT1 | PIK3CA
259.47046593005	-9.40697046063292	172.45884146206166	-9.28856048363446	0.0004	512	106	UCEC	PKI-402	Experimental	KRAS | PIK3CA
977.6412634372318	43.1048096672751	1036.0268804187508	19.0589464256317	0.923	57	24	PAAD	ABT-199	Approved in cancer	KRAS | TP53
680.5451348838334	11.7195946828812	716.4890132712204	9.86553372053118	0.586	543	91	LUAD	XL765	Clinical trials in cancer	KRAS | NRAS | STK11
556.908074045796	-51.123409365317	599.4367378770178	15.8518224275886	0.424	934	220	BRCA	CH5132799	Clinical trials in cancer	KRAS | ERBB2 | PIK3CA
999.4729206943996	-83.3313404865352	1039.992785179201	4.36959202812523	0.932	153	42	BLCA	BORTEZOMIB	Approved in cancer	CREBBP | FGFR3 | TP53
369.46819549384605	-19.602787754285	363.01601494903736	-4.01917707066013	0.181	423	78	COAD	ADENOSINE TRIPHOSPHATE	Clinical trials	KRAS | NRAS | SMAD4
1116.4807210298986	40.885186644972	1112.249056341387	-16.8941741727233	1.0	512	158	UCEC	DASATINIB	Approved in cancer	KRAS | RB1 | PTEN
1009.0832589430194	13.1456678485343	974.9906620612555	3.72036835418737	0.853	169	41	READ	OLAPARIB	Approved in cancer	KRAS | PIK3CA | ERBB2
1076.1162401298361	-30.3986491636154	1071.0233073798229	2.26118565009756	0.981	423	66	COAD	ERIBULIN	Approved in cancer	TP53 | MTOR | BRAF
218.60949329978547	-84.1027956059928	183.1598370415186	-10.9728939502584	0.0006	264	35	SKCM	BMS-640994	Experimental	CYBB | AKT3 | GNAS
1104.5362857090342	-28.4004037713423	1075.8284917588921	-6.53049234603645	0.97	512	82	UCEC	ADO-TRASTUZUMAB EMTANSINE	Approved in cancer	PIK3CA | ERBB2 | ERBB4
1003.5934828416625	17.7755029510839	1041.3191540868804	7.52677216928282	0.936	502	67	KIRC	PAZOPANIB	Approved in same tumor type	VHL | MTOR | FGFR3
611.0080569301956	-52.4854257549992	582.5660700492734	-10.2611063140894	0.423	543	73	LUAD	POZIOTINIB	Clinical trials in cancer	KRAS | EGFR | ERBB3
709.4319535985994	15.9123370586811	683.1838222089275	2.87284349508491	0.534	502	71	KIRC	NAVITOCLAX	Clinical trials in cancer	VHL | AKT3 | MTOR
272.54419162633695	73.752866371416	187.11013295267233	22.5192618040126	0.0006	435	184	THCA	OBLIMERSON	Experimental	BRAF | TP53
173.17970084162758	-67.6881912559729	203.57702276166566	-10.411518444555	0.0004	153	25	BLCA	PARBENDAZOLE	Experimental	CTNNB1 | FGFR3 | IDH1
774.3155397591728	17.8295312518966	740.1121885300767	-1.64903766174245	0.597	389	50	LUSC	PKI-587	Clinical trials in cancer	KRAS | PTEN | BRAF
481.5710468842618	87.6044006191826	532.1082454729498	-40.8561764517235	0.412	57	24	PAAD	RIGOSERTIB	Clinical trials in cancer	KRAS
692.5157037637343	4.07916707333732	668.5457818451777	5.21516606714817	0.521	502	63	KIRC	SKF-86002	Clinical trials in cancer	VHL | MTOR | KDR
688.6360483426402	-97.1949847211883	731.1966537995806	34.0996130277194	0.566	264	124	SKCM	RAF265	Clinical trials in cancer	KRAS | BRAF | RAF1
190.12801563283688	-20.7485141576366	213.70948836036013	-38.9045655243908	0.0006	264	40	SKCM	6-CHLORO-9-HYDROXY-1,3-DIMETHYLPYRAZOLO[3,4-B]QUINOLIN-4-ONE	Experimental	KRAS | AKT3 | MAP2K1
547.5315708075647	-19.7947640879489	545.8106978995537	3.11406567682457	0.384	512	54	UCEC	RANIBIZUMAB	Approved in other pathologies	VHL | CTNNB1 | MTOR
928.2538330245404	-4.67307382868159	952.4950322942263	-1.77812452647686	0.832	512	80	UCEC	IDELALISIB	Approved in cancer	PIK3CA | BRAF
783.3904200896582	-122.831029101304	761.7043196623501	77.9533658704004	0.594	264	200	SKCM	AZD8330	Clinical trials in cancer	NF1 | NRAS | KIT
235.99538557697755	39.9278640824501	231.00280538158137	19.0508667454724	0.0004	512	80	UCEC	NVP-AEW541	Experimental	PIK3CA | BRAF
1044.9852382136069	31.7525647271389	1024.7743738244437	-15.5526440509288	0.92	169	47	READ	DABRAFENIB	Approved in cancer	KRAS | PTPN11 | NRAS
598.5883855764733	81.7201776633032	586.5310455920226	-20.110948424744	0.412	57	24	PAAD	NVP-AUY922	Clinical trials in cancer	KRAS
661.6841696184641	77.9281247690166	706.2516612624752	-24.9352835587097	0.552	57	24	PAAD	GSK2636771	Clinical trials in cancer	KRAS
935.2809396886205	-28.5918729615046	940.0654653885506	-2.43027048510521	0.822	543	68	LUAD	OXALIPLATIN	Approved in cancer	KRAS | BRAF
637.958375790083	156.015248770173	666.5375129861709	-57.9440929303223	0.598	264	197	SKCM	DACTOLISIB	Clinical trials in cancer	NRAS | KIT | KRAS
209.30855437675154	-45.8758396144141	203.90282622622007	-5.5965582269946	0.0008	343	55	HNSC	A-443654	Experimental	AKT1 | PIK3CA | AR
707.1402543108082	-9.94092355439443	723.496647581996	-10.8658630796567	0.588	292	34	STAD	PIMASERTIB	Clinical trials in cancer	KRAS | NF1 | NRAS
535.8295936940282	5.26936323605662	541.6180526724283	7.09794908472031	0.381	512	94	UCEC	CITRIC ACID	Approved in other pathologies	PTEN | KDR | NFKB2
246.0651342094783	26.1959912580679	219.4274168483512	-3.06111712817108	0.0006	169	28	READ	OBLIMERSEN	Experimental	BRAF | TP53 | RAF1
173.2908980814766	-83.1723115479342	221.57578785441655	1.65228657364219	0.0006	502	62	KIRC	CHEMBL44833	Experimental	VHL | AKT3 | MTOR
897.0775478099501	-66.0155401446316	916.0904771327401	-20.0327586145073	0.812	222	131	LGG	AZACITIDINE	Approved in cancer	IDH1
117.37885417532475	-11.4022980108726	186.45277209908963	43.3815340741812	0.0004	264	110	SKCM	CEP-32496	Experimental	BRAF | RAF1 | RET
609.2758606543767	-31.9212771160543	576.6962895800209	11.295355594558	0.423	543	68	LUAD	1096708-71-2	Clinical trials in cancer	KRAS | BRAF
648.4507206915553	-48.4111197994771	639.0322673272645	3.61579019358169	0.491	264	27	SKCM	SERDEMETAN	Clinical trials in cancer	KIT | GNAS | ERBB4
741.4799411644684	4.45061950202259	742.6839268625298	-5.90279890282523	0.595	543	99	LUAD	ALPELISIB	Clinical trials in cancer	KRAS | NRAS | STK11
85.51954868888419	-21.5345792247432	238.49690231683212	-25.121430106192	0.0008	222	131	LGG	NADP+	Experimental	IDH1
300.4876224696935	-12.3191929768563	305.2960071834163	4.30045167478852	0.111	502	60	KIRC	TRIFLUSAL	Clinical trials	VHL | AKT3 | MTOR
595.7449117479916	-27.9437217544822	651.9994816964315	-0.000441502461399068	0.502	423	76	COAD	952021-60-2	Clinical trials in cancer	KRAS | BRAF | ATR
1013.4213178709969	7.7624652484551	1016.8442521099671	3.13455374703221	0.915	202	22	LAML	LENVATINIB	Approved in cancer	KIT | NRAS | KDR
752.8321824348747	-59.3477711664207	704.179922834373	0.347937058778825	0.545	934	226	BRCA	PX-866	Clinical trials in cancer	KRAS | PTEN | MAP2K1
603.2801108473233	53.0022158064888	657.2920091894346	-14.7245242192232	0.524	934	217	BRCA	ZSTK474	Clinical trials in cancer	PIK3CA | BRAF
220.85028416039378	-61.9783205927123	201.77559838742792	35.7433068588812	0.0008	934	240	BRCA	A-443654	Experimental	KRAS | AKT1 | ERBB2
778.5040228902742	26.1578731069837	753.6691934408278	6.86122219100298	0.592	512	165	UCEC	GSK2636771	Clinical trials in cancer	KRAS | NRAS | ZAP70
245.24419523561355	50.7914886093216	210.63793685350856	8.48708445493526	0.0006	502	59	KIRC	ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE	Experimental	VHL | MTOR
233.84953029576175	80.3317233904796	203.6613188794485	-0.348500888291824	0.0006	389	52	LUSC	OBLIMERSEN	Experimental	BRAF | TP53 | MAPK14
736.3985699989624	37.0314511241919	716.5266427555856	0.129818925160521	0.576	599	74	GBM	XL765	Clinical trials in cancer	NRAS | KRAS | PTPN11
723.0161747418039	171.303040105723	701.9125711904633	74.3962680495683	0.598	264	197	SKCM	TAK-733	Clinical trials in cancer	NF1 | NRAS | KIT
671.258905760393	-69.723080772919	659.3524461618614	-5.53181038304206	0.517	934	224	BRCA	1224844-38-5	Clinical trials in cancer	KRAS | STK11 | ERBB2
726.4167130455207	19.5172788858129	730.189119263913	-2.60628518195244	0.593	389	48	LUSC	SF1126	Clinical trials in cancer	KRAS | PTEN | EGFR
266.69236882292194	-123.12265669348	173.09747618179327	33.6110619626215	0.0008	264	111	SKCM	CHEMBL526479	Experimental	BRAF | FGFR1 | PDGFRA
646.0010169772524	9.02647256508487	565.7821536540768	9.59699177236439	0.412	169	38	READ	GDC-0994	Clinical trials in cancer	KRAS
277.7992773988119	44.2758990536583	141.56188131469852	27.7057557225082	0.0004	435	185	THCA	TW-37	Experimental	KRAS | BRAF | PIK3CA
205.52356036799637	-69.8385507267958	218.3356262217555	8.48189523857945	0.0006	543	78	LUAD	TURPENTINE	Experimental	KRAS | NRAS | BRAF
913.6606878051882	-54.3449198419762	933.0724712449111	-18.7166344228329	0.822	57	24	PAAD	DABRAFENIB	Approved in cancer	KRAS
256.95960261262275	-59.2798350584764	300.4480384017225	-4.3806676374038	0.111	502	62	KIRC	L-CITRULLINE	Clinical trials	VHL | AKT3 | MTOR
251.3231790800829	-66.116007828203	230.1113180659662	-3.87278204583708	0.0006	934	218	BRCA	PP121	Experimental	PTEN | PIK3CA | PDGFRA
504.2838091069782	67.7071921055193	601.2639367503214	23.12731071449	0.432	169	43	READ	BAY1125976	Clinical trials in cancer	KRAS | NRAS | PIK3CA
1042.5578261155579	-27.0383455999625	1021.8416223075184	0.929460500027517	0.92	934	235	BRCA	VEMURAFENIB	Approved in cancer	KRAS | AKT1 | MAP2K1
215.2596852899613	-37.2570646740772	177.01575053203877	-4.90109007176693	0.0008	512	55	UCEC	UNII-414MEG73VU	Experimental	CTNNB1 | CHD8 | RAC1
581.4535891473722	-10.4432642675044	675.5618357632507	-1.81797737982038	0.521	502	61	KIRC	JUGLONE	Clinical trials in cancer	VHL | MTOR | HSPG2
242.65473962372843	-30.8749825519678	201.2967292126901	-23.3389864344515	0.0006	934	240	BRCA	NUTLIN-3	Experimental	AKT1 | LMNA | PIK3CA
694.6042382106308	-25.0549037629967	711.6936853795008	1.82718915414171	0.574	264	33	SKCM	PF-562271	Clinical trials in cancer	PTEN | HSPG2 | AURKA
819.5052400716369	-11.4590563913355	716.3503622659796	-24.3917138714448	0.597	512	123	UCEC	SARACATINIB	Clinical trials in cancer	KRAS | RB1 | PTEN
1063.9202663889669	30.5751986692932	1101.7478581499665	17.3454747886774	0.985	512	111	UCEC	OLAPARIB	Approved in cancer	KRAS | PIK3CA | ERBB2
177.33413945847983	14.431795817837	196.17188773814684	4.5044147868557	0.0004	423	87	COAD	GDC-0879	Experimental	KRAS | NRAS | BRAF
971.0524562041389	-4.02046685746024	946.2195512444184	-2.6070181134487	0.832	512	82	UCEC	VINCRISTINE	Approved in cancer	PIK3CA | MYCN | ABCB1
1041.5842756266322	24.7974259724277	1027.6166782705966	5.29586379484476	0.922	502	62	KIRC	LENALIDOMIDE	Approved in cancer	VHL | MTOR | MAPK14
310.26353406906486	-55.3871123113779	154.96941339182712	-1.49427247124436	0.0006	435	211	THCA	TURPENTINE	Experimental	KRAS | NRAS | BRAF
241.61243174690455	57.0466750148906	181.70255280840885	18.759665584763	0.0006	169	39	READ	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	Experimental	KRAS | MAP4K1 | RRAS2
205.9898775601845	20.2235393272393	190.56970065398903	3.29784411648234	0.0004	543	64	LUAD	AZD-8835	Experimental	KRAS | PIK3CA
566.5465196537243	47.6873946657088	639.3327453435438	-26.6301286983644	0.513	435	211	THCA	BAY869766	Clinical trials in cancer	KRAS | NRAS | BRAF
574.2652770721191	-49.6347835023228	595.7306298007967	-4.76371323022249	0.451	264	32	SKCM	FEDRATINIB	Clinical trials in cancer	TRIO | GNAS | FGFR3
178.1602024219603	-15.8907033665022	203.4006921554228	-5.58778780419971	0.0006	423	84	COAD	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | ESR1 | PTEN
1088.0222698898997	-3.44783413213085	1038.9031508458418	-3.1816547967278	0.937	502	64	KIRC	AXITINIB	Approved in same tumor type	VHL | MTOR | KDR
1057.7790574670082	-19.7891145402884	1062.874606758441	1.05016350459255	0.96	153	17	BLCA	RIBOCICLIB	Approved in cancer	RB1 | NRAS | PIK3CA
1068.351162465469	-29.733346784078	1037.6703768811076	-5.24211988170327	0.93	934	220	BRCA	NERATINIB	Approved in same tumor type	KRAS | ERBB2 | PIK3CA
177.75868655958004	30.1790849602547	203.11757042387788	5.97865673629781	0.0006	502	54	KIRC	RINUCUMAB	Experimental	VHL
702.679445714157	6.75596114373133	724.0983622871415	13.5794995557026	0.585	512	94	UCEC	KX2-391	Clinical trials in cancer	PTEN | KDR | GNAS
673.9739494100975	23.9316942140383	661.3416559007987	-5.90663864180624	0.511	502	60	KIRC	2-METHOXYESTRADIOL	Clinical trials in cancer	VHL | AKT3 | MTOR
552.6910973221673	35.2747621132269	626.2101341810567	23.6396425081803	0.524	435	210	THCA	OBATOCLAX	Clinical trials in cancer	NRAS | BRAF | TP53
622.2813203191312	-5.43968750276196	666.0038547906904	-0.418824219423186	0.522	599	119	OV	AT-101	Clinical trials in cancer	TP53 | MAPK14 | MAP3K5
728.8362287402068	-27.9580407394872	709.9253619403117	-3.95301533943211	0.581	264	35	SKCM	OZAGREL	Clinical trials in cancer	CYBB | AKT3 | GNAS
82.25590269391654	50.2757808804208	235.62394378301494	23.2390281781893	0.0006	57	24	PAAD	FR 180204	Experimental	KRAS
192.83581228279937	125.403688740728	240.59412453256968	-18.1663600398047	0.0008	435	209	THCA	PLX-4720	Experimental	NRAS | BRAF
379.0459406470947	-16.0678327999628	380.3429193862633	-0.434268087830333	0.193	512	167	UCEC	QUERCETIN	Clinical trials	KRAS | NRAS | TSC2
520.2398532793995	-45.819956794712	532.650666440723	0.140547558394019	0.37	512	82	UCEC	PERTUZUMAB	Approved in other pathologies	PIK3CA | ERBB2 | ERBB4
612.0986998148222	46.3970489590377	624.9982626730383	0.00105351546864085	0.472	169	41	READ	ABT-737	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
697.529195252301	-38.6067117234243	676.0317721602592	2.33049441823459	0.534	343	52	HNSC	ZSTK474	Clinical trials in cancer	RAC1 | PIK3CA | SOS1
475.2181262413228	-28.8079438343144	482.19898723975496	3.77572909549599	0.311	502	59	KIRC	SUCRALFATE	Approved in other pathologies	VHL | MTOR
369.02445930738935	-6.49603052464445	367.3838054350678	-1.80707196194885	0.184	512	56	UCEC	BEZAFIBRATE	Clinical trials	TSC2 | TSC1 | CTNNB1
670.8906251925071	30.0547543209409	652.2799632033748	0.729194964146473	0.525	934	217	BRCA	MLN1117	Clinical trials in cancer	KRAS | PIK3CA | MTOR
284.9600860511951	-9.0872760857508	250.47742112538086	1.85156635997168	0.0008	512	141	UCEC	PP121	Experimental	PTEN | MTOR | PIK3CA
239.95632536913655	35.6587068910072	191.4433395007284	0.830597509532936	0.0006	502	62	KIRC	S-ETHYLISOTHIOUREA	Experimental	VHL | AKT3 | MTOR
1049.2577292826252	-47.7836177742203	1069.3008254732194	-13.355543563865	0.935	264	88	SKCM	ABEMACICLIB	Approved in cancer	RB1 | NRAS | KRAS
670.4060257565317	-42.298783346289	747.6368726728033	-2.97840070056054	0.594	423	83	COAD	APITOLISIB	Clinical trials in cancer	KRAS | NRAS | ESR1
139.4262760633428	-0.528696481421974	212.2255942003544	16.8777279735223	0.0006	502	59	KIRC	AMP-PCP	Experimental	VHL | MTOR
680.3995861198445	-70.6547917774254	732.5340667021692	-8.42184522774278	0.588	423	94	COAD	ENCORAFENIB	Clinical trials in cancer	KRAS | NRAS | ESR1
206.21831993442433	-2.54274076945094	208.72930579238886	-16.2879370769188	0.0006	543	72	LUAD	154447-36-6	Experimental	KRAS | BRAF | PIK3CA
1016.4033111964161	11.870058965162	1035.8621865424932	-9.01384588623023	0.93	543	84	LUAD	TRASTUZUMAB	Approved in cancer	KRAS | BRAF | EGFR
82.71051104085913	2.2970818750658	178.67311998027392	0.867911571778791	0.0004	222	137	LGG	PNU-74654	Experimental	IDH1 | PIK3CA | EGFR
872.4002150961458	9.95886777760154	873.999871194558	5.2896009037795e-05	0.749	423	67	COAD	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | MTOR | PIK3CA
758.0301965592289	-138.715592272871	810.4283921467876	-21.3469938163767	0.596	264	195	SKCM	212631-79-3	Clinical trials in cancer	NF1 | NRAS | KIT
601.204890963122	12.4767247378962	611.7909514611963	4.71841093572493	0.452	512	114	UCEC	AZD2014	Clinical trials in cancer	KRAS | MTOR | PIK3CA
1071.8187925150369	-90.4208518665649	1087.9881463003323	50.1816830569037	0.967	264	127	SKCM	BEVACIZUMAB	Approved in cancer	KIT | KRAS | VHL
804.6450603334525	75.6036826096456	699.7513523832533	5.33794881355669	0.557	169	41	READ	NVP-BGJ398	Clinical trials in cancer	KRAS | PIK3CA | FGFR1
574.9061333565737	-39.6134694880197	582.0261247040894	-7.71504141732566	0.423	343	45	HNSC	CUDC-907	Clinical trials in cancer	PIK3CA
194.2773212100907	84.4002423653049	202.0460118133222	-23.7496800266312	0.0004	169	42	READ	154447-36-6	Experimental	KRAS | BRAF | PIK3CA
770.8991570987143	-26.231114646029	726.7229648298095	20.1402816260079	0.593	512	88	UCEC	RO4987655	Clinical trials in cancer	KRAS | NF1 | NRAS
733.7526754295109	-16.7532215566967	739.1618216126709	-11.0733087570466	0.623	423	57	COAD	DECITABINE	Approved in other pathologies and in clinical trials in cancer	KRAS | IDH1
816.8907925113597	-94.0023781395929	718.749488408154	26.1910069220755	0.595	512	162	UCEC	1032350-13-2	Clinical trials in cancer	KRAS | NRAS | TSC2
731.118112971783	64.0256340399022	694.4913456919448	-9.73255236655609	0.54	202	48	LAML	SELUMETINIB	Clinical trials in cancer	KRAS | NF1 | KIT
1033.6695086105278	32.6194666718266	1034.8995277530703	1.11710682304374	0.922	169	53	READ	BORTEZOMIB	Approved in cancer	KRAS | BRAF | TP53
595.6038542200008	-59.364713161349	615.0005288050386	0.000509769762174983	0.461	934	219	BRCA	141400-58-0	Clinical trials in cancer	PIK3CA | AFF4 | STAT3
243.80933968005596	105.264533807	217.76273432136742	38.0929342428412	0.0004	435	183	THCA	SB590885	Experimental	BRAF
720.0763176909716	-49.2455939848589	722.7858514227669	0.527159636892975	0.595	343	60	HNSC	PX-866	Clinical trials in cancer	PTEN | RAC1 | CD247
1076.7831998259835	11.9147184681094	1065.229785076094	-2.3008895229018	0.954	543	95	LUAD	ABT-199	Approved in cancer	KRAS | TP53 | BRAF
1016.8643832264783	-42.5652099623915	1041.2027502061592	-14.1914822286406	0.93	934	229	BRCA	PALBOCICLIB	Approved in same tumor type	KRAS | RB1 | STK11
209.75206664097072	22.1327622794834	204.62883883049165	2.26857225699064	0.0008	292	30	STAD	O-PHOSPHO-L-SERINE	Experimental	SMAD4 | PTPN11 | PTEN
526.6028238916116	19.6701380549138	571.3952651704794	16.2066933873782	0.421	934	217	BRCA	LEXIBULIN	Clinical trials in cancer	PIK3CA | IDH1
87.79745503303089	83.0047492022628	247.07834013098014	-20.1454844661614	0.0006	57	24	PAAD	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS
714.4817165328391	12.1943395417194	727.4044997706459	6.70146818720718	0.593	512	102	UCEC	XL-228	Clinical trials in cancer	RB1 | PTEN | SOS1
666.9550819911766	-56.7601079207619	576.0115089970669	-9.48152365426972	0.423	934	216	BRCA	RIGOSERTIB	Clinical trials in cancer	KRAS | PIK3CA
1055.99948012705	-5.78103543920142	1030.0704116688426	-7.77382010104679	0.929	543	77	LUAD	SUNITINIB	Approved in cancer	KRAS | EGFR | KDR
737.8607672271423	-12.4088994629943	724.5573680655652	13.5896184128451	0.595	423	83	COAD	PF-04691502	Clinical trials in cancer	KRAS | NRAS | ESR1
187.89120262628705	-1.44993281553269	183.0814193820315	-17.7642342936103	0.0004	934	218	BRCA	AT13148	Experimental	KRAS | ERBB2 | PIK3CA
691.7724830184509	111.582988743099	706.5390762936336	4.32535396327643	0.565	57	24	PAAD	PKI-587	Clinical trials in cancer	KRAS
315.8066906072028	51.3808261973055	223.8023528483532	-23.6159591010264	0.0006	512	95	UCEC	INOSITOL 1,3,4,5-TETRAKISPHOSPHATE	Experimental	PTEN | SOS1 | PTPN11
217.65016962416	17.2456272760546	180.192893147872	-34.2096314286759	0.0006	512	94	UCEC	RU78299	Experimental	PTEN | KDR | GNAS
300.7334328924712	-70.7139990614234	141.2671868358476	-13.3433285614149	0.0006	435	183	THCA	GOSURANEMAB	Experimental	BRAF
252.46711113567997	2.24824063429	218.86198032609073	4.30921860885769	0.0006	512	94	UCEC	1-(1-METHYLETHYL)-3-QUINOLIN-6-YL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE	Experimental	PTEN | KDR | GNAS
737.1527969570366	16.7861981033801	724.8146053812263	2.36501690106752	0.597	292	41	STAD	PKI-587	Clinical trials in cancer	KRAS | PTPN11 | NGF
847.5894704169359	12.8033187148392	857.0002194590842	5.71517871321703e-05	0.73	934	241	BRCA	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | STK11 | AKT1
681.1448778168851	-81.7433876928398	769.0000292202161	-0.000110480769308197	0.632	153	16	BLCA	METFORMIN	Approved in other pathologies and in clinical trials in cancer	NRAS | IDH1 | PIK3CA
656.4046794260745	-75.282364957731	632.3313978651969	-4.02868815744569	0.524	264	107	SKCM	BI 2536	Clinical trials in cancer	KRAS | BRAF | BRD4
123.87853249523442	-22.7575285746329	208.0785624577614	-16.2032196454877	0.0004	934	220	BRCA	PNU-74654	Experimental	PIK3CA | IDH1 | ARNT
264.4598336671465	4.31858634972204	208.89089881015758	0.360190921253889	0.0006	502	61	KIRC	BEVACIZUMAB+TRASTUZUMAB	Experimental	VHL | MTOR | HSPG2
187.84044531494155	15.9141949321454	206.78394242569664	17.1563051597786	0.0004	934	216	BRCA	RG-7666	Experimental	PIK3CA
997.4148992087908	-38.701641034326	1006.717081311211	-2.59092320485377	0.901	202	22	LAML	VINBLASTINE	Approved in cancer	IDH2 | MYC | MAPK1
179.99325456026466	37.3007314506305	197.03981089618784	12.3684073997176	0.0006	502	62	KIRC	5-NITROINDAZOLE	Experimental	VHL | AKT3 | MTOR
233.7589076571936	62.7268576256984	211.2900198879926	-0.96766552252069	0.0004	169	43	READ	LY3009120	Experimental	KRAS | NRAS | BRAF
873.7023382208679	-12.1166343830271	863.1293348300596	-0.0012869069989847	0.737	502	69	KIRC	NINTEDANIB	Approved in other pathologies and in clinical trials in cancer	VHL | PTEN | MTOR
867.1605826943012	-15.8686810415319	907.233348157568	4.46604572650654	0.784	512	123	UCEC	CELECOXIB	Approved in other pathologies and in clinical trials in cancer	PTEN | CTNNB1 | SOS1
656.9957263511963	-17.4621544665833	690.1437446174746	24.5664070342536	0.542	934	227	BRCA	GSK2636771	Clinical trials in cancer	KRAS | PTEN | MAP2K1
673.1936151680386	-9.61931421865094	730.412974815218	-4.87329400714157	0.585	543	83	LUAD	GDC-0068	Clinical trials in cancer	KRAS | EGFR | PTEN
986.330616876618	115.298125560183	983.6388248081987	1.51405926781536	0.91	264	180	SKCM	GEFITINIB	Approved in cancer	NRAS | KRAS | BRAF
714.2115836016844	-69.7813390243072	682.7619457683128	8.87596958664881	0.556	264	82	SKCM	DINACICLIB	Clinical trials in cancer	RB1 | NRAS | KRAS
810.1849009284165	-14.1394597833408	720.4236584767111	4.37858373880226	0.581	222	58	LGG	DHA-PACLITAXEL	Clinical trials in cancer	TP53 | BRAF | MTOR
1110.5677346218883	34.8678797470365	1097.6092822132955	-2.07366333818982	0.997	389	46	LUSC	COPANLISIB	Approved in cancer	KRAS | PTEN | EGFR
689.9347278489496	8.59019626841229	724.2253269577029	-2.67342612953212	0.587	292	33	STAD	OSI-027	Clinical trials in cancer	KRAS | PIK3CA | ERBB4
186.22550484650347	36.3896663921059	208.9406099205711	0.630150367587248	0.0008	423	92	COAD	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	KRAS | NRAS | NF1
531.2109062181275	-9.84291543873243	572.9340021728888	4.25208383149334	0.412	202	23	LAML	BAY1125976	Clinical trials in cancer	KRAS | NRAS
757.2912291355242	25.3692461356474	680.3108463966519	4.92360718664327	0.526	202	39	LAML	REFAMETINIB	Clinical trials in cancer	KRAS | NF1 | KIT
169.04288036638144	3.30320113641008	187.16111926682066	7.47939414156349	0.0004	512	58	UCEC	CHAETOCIN	Experimental	CTNNB1 | ACVR1 | ERBB2
170.2676725212266	54.1360018578328	190.83330251479578	-12.0681635511669	0.0006	502	59	KIRC	AEBSF	Experimental	VHL | MTOR
118.2236106232247	121.268585073539	180.20453598596995	-25.61530050151	0.0004	57	24	PAAD	LY3009120	Experimental	KRAS
564.6850271162178	-19.2087681425544	597.0010220940042	-0.000458984558463271	0.441	153	17	BLCA	LEXIBULIN	Clinical trials in cancer	FGFR3 | IDH1 | PIK3CA
1120.5815751823811	-24.9016939478421	1091.263426570343	-8.18336452336666	0.99	292	32	STAD	LAPATINIB	Approved in cancer	KRAS | PIK3CA | BRAF
212.7845724775014	-0.546376914468055	167.7040232376027	12.3881746208872	0.0004	934	217	BRCA	UNII-S9WA04F921	Experimental	PIK3CA | MTOR
778.6374277486254	-29.9061595456895	717.2486591363288	8.57444221707419	0.583	423	92	COAD	BAY869766	Clinical trials in cancer	KRAS | NRAS | NF1
588.810344427325	-8.52133280749715	589.6640263491943	6.67869618907889	0.423	423	77	COAD	1096708-71-2	Clinical trials in cancer	KRAS | BRAF | RAF1
403.3502271766206	1.32314251822962	402.1010029308819	-2.33541060015864	0.223	512	64	UCEC	PEMBROLIZUMAB	Approved in other pathologies	KRAS | NRAS | BRAF
563.6994237253766	-52.6589799280709	574.9156885710468	0.206665972121755	0.432	423	57	COAD	BMS-754807	Clinical trials in cancer	KRAS
586.4647871906653	-34.0942134691844	578.9569674317934	0.94728453033531	0.432	343	46	HNSC	ABT-737	Clinical trials in cancer	PIK3CA | EGFR
506.3240277687861	-25.2308460355923	490.68085695693156	-4.2378690860528	0.322	502	61	KIRC	ZIV-AFLIBERCEPT	Approved in other pathologies	VHL | MTOR | HSPG2
720.4836901969562	43.9974064089731	718.2273731646129	12.6938484631496	0.585	169	42	READ	SARACATINIB	Clinical trials in cancer	KRAS | SMAD4 | PTEN
249.36890812977876	-43.7963490117056	193.27109263311962	-35.4351550140686	0.0004	512	87	UCEC	TIPIFARNIB-P2	Experimental	TRIO | PIK3CA | SOS1
476.11287891482493	-39.6315748736811	478.76024370675935	9.06292060881469	0.311	435	184	THCA	EDARAVONE	Approved in other pathologies	BRAF | TP53
159.16608564656485	-24.1711134561737	202.3834089928037	-3.52777049450469	0.0006	153	28	BLCA	OBLIMERSEN	Experimental	CREBBP | TP53 | CHUK
570.4609749830221	-60.8790921845285	579.0956614317663	16.6823976189467	0.423	264	105	SKCM	PLX8394	Clinical trials in cancer	BRAF | RAF1
198.0029177586844	44.6691027279306	242.03977267894027	-19.6967425251937	0.0004	512	148	UCEC	LY2183240	Experimental	KRAS | TRIO | NRAS
273.34077328251425	-9.64753547754597	201.79947833524278	37.1537108639811	0.0008	512	165	UCEC	PI-103	Experimental	KRAS | NRAS | TSC2
688.2423515416917	4.82613768840181	671.8952257413634	0.0148041496391897	0.525	202	22	LAML	ENMD-2076	Clinical trials in cancer	FLT3 | KIT | KDR
177.8631773043848	60.5980286792342	202.60003160479587	-41.3789905080298	0.0004	264	105	SKCM	LGX-806	Experimental	BRAF | RAF1
760.1477793339192	-0.224572995684014	719.6602525952587	-0.174840764238752	0.582	292	43	STAD	GOSSYPOL	Clinical trials in cancer	MAP2K1 | CREBBP | TP53
127.07561775373382	53.2904394752465	173.01218186933565	-40.7995900419461	0.0006	57	24	PAAD	SB220025	Experimental	KRAS
170.68676319226276	49.41217296015	207.67090230116872	-16.7078167470663	0.0006	512	54	UCEC	TROMETAMOL	Experimental	VHL | CTNNB1 | MTOR
125.3929435389632	21.3615514862446	190.0961380766322	5.61424965276842	0.0006	502	62	KIRC	5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE	Experimental	VHL | AKT3 | MTOR
189.84036166998968	-13.9088463536953	199.9994567353881	-3.81055777299412	0.0006	599	118	OV	OBLIMERSEN	Experimental	TP53 | MAPK14 | MAP3K5
615.1531430682638	-2.81858873448647	570.5152847892728	15.5319000679037	0.422	512	106	UCEC	P7170	Clinical trials in cancer	KRAS | PIK3CA
703.3953191599026	-48.471831094098	714.2350915573901	-6.93335128518538	0.565	264	35	SKCM	MOTESANIB	Clinical trials in cancer	KIT | VHL | ARNT
153.0574102002134	61.5745137224678	214.1112483550723	12.4411051508694	0.0006	502	62	KIRC	130974-86-6	Experimental	VHL | AKT3 | MTOR
677.0757377874346	-41.3893750571185	730.2245487756178	3.53467931132673	0.593	292	40	STAD	SF1126	Clinical trials in cancer	KRAS | PTPN11 | NGF
211.33999262836295	-70.3847646539866	199.49759625356705	2.15836937434938	0.0004	512	77	UCEC	AMG319	Experimental	PIK3CA
951.6809696402389	-39.7780090891794	960.4993326660656	4.74743584372573	0.844	423	87	COAD	ATEZOLIZUMAB	Approved in cancer	KRAS | NRAS | BRAF
667.2471764848684	36.0868925653002	734.6387975802065	12.8147539414188	0.59	292	31	STAD	REFAMETINIB	Clinical trials in cancer	KRAS | NF1 | PTPN11
1106.1631495702213	-38.4721661023862	1098.8423408303756	-11.4292031051759	1.0	423	60	COAD	SUNITINIB	Approved in cancer	KRAS | MTOR | ERBB2
1022.0693279001938	-51.507767530908	1007.8260398419876	-1.96299191012804	0.909	264	72	SKCM	OSIMERTINIB	Approved in cancer	NRAS | KRAS | MET
159.2865136337819	-5.83246190909011	201.01772236122073	-22.7355763658306	0.0004	264	35	SKCM	GW843682X	Experimental	CTNNB1 | TRIO | GNAS
973.8549981551356	-51.661503283311	974.3990693545562	2.05148994331557	0.863	423	82	COAD	LAPATINIB	Approved in cancer	KRAS | ESR1 | BRAF
383.12853020487563	-4.50923023283252	374.00020963100155	0.000216898346934613	0.193	343	60	HNSC	QUERCETIN	Clinical trials	PTEN | RAC1 | CD247
310.53637739917804	-91.5655360506158	209.3643667539282	-37.0976356083529	0.0004	222	137	LGG	NUTLIN-3	Experimental	IDH1 | PIK3CA | EGFR
842.1732255805775	73.0954456977839	769.3727104594764	-54.5848792738302	0.592	264	196	SKCM	GSK2636771	Clinical trials in cancer	NRAS | KIT | KRAS
679.7028025462732	3.06568991166037	675.0002547706171	0.000216571234432195	0.528	423	65	COAD	NVP-BGJ398	Clinical trials in cancer	KRAS | PIK3CA | KDR
154.33822930903463	39.0693329939389	164.2062223509064	12.9045298057404	0.0004	512	93	UCEC	TELOMERASE INHIBITOR IX	Experimental	TRIO | PIK3CA | FGFR2
732.8886831146833	144.334087669002	674.1355516134798	-24.734597698076	0.524	435	211	THCA	AZD8330	Clinical trials in cancer	KRAS | NRAS | BRAF
650.0848057913236	-42.618448781543	669.2874131299618	6.82006676771994	0.522	599	119	OV	GOSSYPOL	Clinical trials in cancer	TP53 | MAPK14 | JAK3
156.26550727932073	31.2001577162375	212.97178826847377	-13.7877908358496	0.0006	502	59	KIRC	ALPHA-D-GLUCOSE 6-PHOSPHATE	Experimental	VHL | MTOR
835.5268285855001	-27.4740632832333	829.6939496155662	1.37916016194004	0.701	343	49	HNSC	METFORMIN	Approved in other pathologies and in clinical trials in cancer	STK11 | PIK3CA | HRAS
595.4139200921327	16.4187111522222	574.6740515390075	1.87421567750789	0.422	543	75	LUAD	NVP-AUY922	Clinical trials in cancer	KRAS | EGFR | KDR
1057.4431582612888	7.22022658170209	1045.0971912951659	12.7301033661502	0.93	934	242	BRCA	EVEROLIMUS	Approved in same tumor type	KRAS | STK11 | AKT1
889.636052727281	-20.1565892018377	884.0000157401641	-0.000306602763885166	0.76	264	32	SKCM	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | TSC1 | AKT3
1132.837326233073	-9.57423189373452	1073.3485854558728	-0.219002851762355	0.981	169	28	READ	ERIBULIN	Approved in cancer	BRAF | TP53 | RAF1
1182.1604132532857	35.1370752254721	1158.3358139644822	12.5421009319043	0.991	264	195	SKCM	ARSENIC TRIOXIDE	Approved in cancer	RB1 | NRAS | KRAS
667.6525784833127	173.775483193747	741.2814152359744	-48.6761021142297	0.594	264	183	SKCM	OBATOCLAX	Clinical trials in cancer	NRAS | VHL | AKT3
952.7404802075785	-7.97508934948803	948.2630712580457	5.73102697520972	0.833	543	82	LUAD	IRINOTECAN	Approved in cancer	KRAS | BRAF | EGFR
158.3031497256919	61.3464373442482	193.01182092096107	9.05578444606931	0.0006	512	71	UCEC	DB07268	Experimental	KRAS | SOS1 | MAP3K8
115.12623874432379	-24.1150534290313	180.44040623656508	-8.76008376510754	0.0004	934	221	BRCA	ISOEVODIAMINE	Experimental	PIK3CA | IDH1 | ARNT
1010.6220074762053	-8.16291378519273	1099.449315895749	9.34288832910397	0.982	512	103	UCEC	LENALIDOMIDE	Approved in cancer	KRAS | VHL | CTNNB1
253.43953956424642	-14.3011745928402	242.1446500042254	-3.01230777839191	0.0004	512	106	UCEC	DEGUELIN	Experimental	KRAS | PIK3CA
377.81896443679665	12.1523989795401	373.99991162015044	-5.72952258153236e-05	0.193	543	93	LUAD	QUERCETIN	Clinical trials	KRAS | NRAS | GNRHR
1020.6592327918996	25.4110341558068	1020.2115709112222	17.8310072310969	0.92	934	221	BRCA	FULVESTRANT	Approved in same tumor type	MAP2K1 | ERBB2 | PIK3CA
569.0051609034924	-16.9806874363944	584.9521188120523	9.94895359659745	0.422	543	67	LUAD	LONAFARNIB	Clinical trials in cancer	KRAS | NRAS | ABCB1
923.8836264703692	-7.67216621561354	931.4225417947824	-1.67172270329161	0.813	202	23	LAML	AFATINIB	Approved in cancer	KRAS | NRAS
106.78503654214987	13.5447831423479	201.86975948323877	10.8287655302206	0.0006	264	35	SKCM	N-(3-CYANOPHENYL)-2&#39;-METHYL-5&#39;-(5-METHYL-1,3,4-OXADIAZOL-2-YL)-4-BIPHENYLCARBOXAMIDE	Experimental	CYBB | AKT3 | GNAS
196.73864037241202	-58.2258336510075	223.17184643537647	-24.1247565714666	0.0006	264	35	SKCM	2-AMINO-3-BENZYLOXYPYRIDINE	Experimental	CYBB | AKT3 | GNAS
157.5661763690944	26.7690730135104	193.53329941927973	13.975162130208	0.0008	512	55	UCEC	BMS 275291	Experimental	CTNNB1 | CHD8 | RAC1
979.1743045584533	-80.9468403798868	1001.2149471562881	21.9767967440084	0.91	264	176	SKCM	PANITUMUMAB	Approved in cancer	NRAS | KRAS | BRAF
1133.0136710911818	34.9191944749374	1043.1367267521023	-6.35982138649115	0.93	169	41	READ	NILOTINIB	Approved in cancer	KRAS | SMAD4 | RB1
1050.530809565544	-26.420048982299	1061.9055823847964	-7.90481283546774	0.963	543	82	LUAD	MIDOSTAURIN	Approved in cancer	KRAS | GNRHR | EGFR
230.96495681184203	33.0612076253249	199.65209991990704	2.90626626809262	0.0006	502	62	KIRC	6S-5,6,7,8-TETRAHYDROBIOPTERIN	Experimental	VHL | AKT3 | MTOR
769.1719890772132	21.9773474619086	754.2393587327921	-3.57140474837752	0.596	512	102	UCEC	MASITINIB	Clinical trials in cancer	PTEN | FGFR2 | KIT
675.1975957296512	-46.1067986462656	718.025819207474	-10.094704544832	0.552	264	30	SKCM	XL-820	Clinical trials in cancer	KIT | HSPG2 | KDR
156.04276114676028	88.2311201548674	244.24117565763362	-29.0375426119012	0.0004	264	105	SKCM	303727-31-3	Experimental	BRAF | RAF1
194.49587163114845	-42.693247035172	185.45335997261938	15.701743463786	0.0004	423	65	COAD	DEGUELIN	Experimental	KRAS | PIK3CA
1123.0638799090298	61.5513236441741	1069.4587728556119	-13.8670375936676	0.996	512	167	UCEC	PONATINIB	Approved in cancer	KRAS | RB1 | VHL
859.9940713572178	-22.2743405382442	874.9997475642206	0.00098164053764549	0.75	169	42	READ	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | PIK3CA | ERBB2
217.1630007210274	23.3089440607868	202.1202334393933	-6.40751780054688	0.0006	502	62	KIRC	PIBTU	Experimental	VHL | AKT3 | MTOR
159.40688198023446	48.6758380180744	209.17547407239257	13.113952151411	0.0008	502	63	KIRC	CEP-7055	Experimental	VHL | MTOR | KDR
604.368138184286	-9.81837622578959	691.9784725517266	-15.232220109021	0.525	934	234	BRCA	PERIFOSINE	Clinical trials in cancer	AKT1 | PIK3CA | AKT2
1070.23917555535	-45.9645083171581	1067.0927865913197	3.75407391069871	0.966	543	77	LUAD	PANOBINOSTAT	Approved in cancer	KRAS | RB1 | SMAD4
768.9329694143383	-9.55735563495571	734.0996591393542	2.59510077629875	0.596	543	98	LUAD	DACTOLISIB	Clinical trials in cancer	KRAS | NRAS | STK11
1003.5723732896694	-11.3081895049565	1096.2904477212548	5.4462973854761	0.996	543	105	LUAD	REGORAFENIB	Approved in cancer	KRAS | RB1 | SMAD4
660.170559350423	120.356879259643	597.157221395029	-7.07554523095223	0.422	57	24	PAAD	AZD8055	Clinical trials in cancer	KRAS
142.07186622024636	3.43484695693971	176.50920825615663	-27.8616632330516	0.0006	512	94	UCEC	RU85053	Experimental	PTEN | KDR | GNAS
1040.2278231945033	-4.57669535361904	1009.5224044457533	-0.604192158393744	0.912	934	315	BRCA	BORTEZOMIB	Approved in cancer	KRAS | TP53 | MAP2K1
952.1411226890194	2.64227064775037	957.7834077796775	-2.59873263468671	0.842	512	57	UCEC	OXALIPLATIN	Approved in cancer	KRAS | ERBB2 | BRAF
261.2080478583046	-74.4174458363118	219.41078713541035	-53.0668329247222	0.0004	435	183	THCA	UNC0638	Experimental	BRAF | SOS1
1002.5439275662641	-46.7584995546292	1001.999796249276	0.00013854068930641	0.891	169	41	READ	PEMETREXED	Approved in cancer	KRAS | PIK3CA | TPR
933.9347615448788	17.2222626871554	969.4779935547165	-1.16178183257921	0.852	512	62	UCEC	ATEZOLIZUMAB	Approved in cancer	KRAS | NRAS | BRAF
652.8473914979218	-34.7378602539154	580.5113154458166	-18.0159888014484	0.422	934	234	BRCA	BAY1125976	Clinical trials in cancer	KRAS | AKT1 | PIK3CA
1129.8009116760375	14.6990918765451	1105.4902380411481	0.576308507378087	0.996	169	40	READ	SUNITINIB	Approved in cancer	KRAS | ERBB2 | FGFR1
750.8832412536626	90.8019692544295	777.9977165486871	-0.00132885712554298	0.642	57	24	PAAD	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS
577.8700018823831	57.7802415100431	667.029916369045	-18.5511873761092	0.522	202	52	LAML	SF1126	Clinical trials in cancer	KRAS | FLT3 | KIT
218.74594813959695	50.7385138935078	202.69906637381075	12.0949448936231	0.0006	512	94	UCEC	RU78783	Experimental	PTEN | KDR | GNAS
273.2906981031019	-25.2625912654008	181.74818066576688	-11.5536499537925	0.0006	512	52	UCEC	KD3010	Experimental	CTNNB1 | CHD8 | GSK3B
737.645784998241	-37.3541612205413	726.3313280281843	3.09450555733429	0.596	153	27	BLCA	BUPARLISIB	Clinical trials in cancer	NRAS | PTEN | FGFR3
164.66074797726466	12.3413090045499	183.0451122016301	5.06468737676823	0.0004	343	46	HNSC	PF 750	Experimental	PIK3CA | MYC
813.6154979416968	-73.0530493546472	720.2960657862818	-68.3828794656861	0.595	264	197	SKCM	PICTILISIB	Clinical trials in cancer	NRAS | KIT | KRAS
626.2080742638933	25.7232909686703	673.9988296352442	0.00013197972521084	0.527	512	66	UCEC	AZD4547	Clinical trials in cancer	KRAS | ERBB2 | FGFR2
342.95797300634905	6.01124983117143	361.44437686068073	4.964966463888	0.181	169	44	READ	ANTIBIOTIC K 252A	Clinical trials	KRAS | NRAS | BRAF
154.33659411042308	-19.8597447899135	179.80614086385972	22.6673860237088	0.0006	264	35	SKCM	3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE	Experimental	CYBB | AKT3 | GNAS
216.47449149774482	97.2752966036838	190.47846730999765	15.6758203928671	0.0004	169	40	READ	DEGUELIN	Experimental	KRAS | PIK3CA
228.37528886340235	28.35504246649	227.51356148382285	24.2438245929882	0.0004	512	80	UCEC	PWT-33587	Experimental	MTOR | PIK3CA
687.0039017644815	-43.8924480397386	677.5076735626274	-6.29806502555539	0.533	153	30	BLCA	OBATOCLAX	Clinical trials in cancer	NRAS | CREBBP | TP53
668.8603110732471	-5.2937905294813	739.7774000337917	13.2096932343375	0.592	343	60	HNSC	GSK2636771	Clinical trials in cancer	PTEN | RAC1 | CD247
694.803125385343	-55.9369439827215	689.6957474465665	3.98321110511961	0.544	264	30	SKCM	TELATINIB	Clinical trials in cancer	KIT | HSPG2 | KDR
231.41993810940727	37.862408907654	201.39774227560451	4.26793542944375	0.0008	389	48	LUSC	PI-103	Experimental	KRAS | PTEN | EGFR
472.2320210453165	-20.1591038082289	479.2702266870083	0.0931059848087443	0.311	502	59	KIRC	ALTEPLASE	Approved in other pathologies	VHL | MTOR
919.330456704043	-38.5297571164341	954.8946184068703	6.9351613471047	0.822	57	24	PAAD	PAZOPANIB	Approved in cancer	KRAS
688.7011866449765	-0.849408251577472	734.1013889004828	9.03627782513604	0.595	343	61	HNSC	PF-04691502	Clinical trials in cancer	STK11 | PTEN | RAC1
552.2419509299357	49.2474778391411	552.6741065471247	-10.9272395395877	0.412	169	38	READ	NRX 194204	Clinical trials in cancer	KRAS
518.7440064634958	15.396821428975	585.9986891731667	-17.6136329235764	0.422	169	38	READ	VE-822	Clinical trials in cancer	KRAS
1082.1366400482627	-31.7143865275047	1059.042472760465	2.16557506061145	0.947	423	67	COAD	ROMIDEPSIN	Approved in cancer	KRAS | SMAD4 | ERBB2
187.5166135981222	-34.9915046382762	194.03021800882624	13.2424519249503	0.0004	264	29	SKCM	AST 487	Experimental	KIT | KDR | FLT3
150.19149996950574	-28.8109290730407	186.69263415979503	7.31365483871514	0.0006	264	35	SKCM	CHEMBL257341	Experimental	CYBB | AKT3 | GNAS
144.15662741432826	-3.34869544751479	205.21531378722	15.2762330351288	0.0008	343	62	HNSC	PI-103	Experimental	STK11 | PTEN | RAC1
131.77778468649416	-43.057705741729	178.4299211004822	0.376310772964189	0.0004	934	217	BRCA	KU-0060648	Experimental	PIK3CA | BRAF
608.5009014530157	126.593497622153	714.7116636490183	-10.371156051244	0.573	57	24	PAAD	APITOLISIB	Clinical trials in cancer	KRAS
110.62917607950331	-122.392162461696	230.45640753787706	-66.9150347948748	0.0008	264	185	SKCM	PLX-4720	Experimental	NRAS | PTPN11 | GNAQ
194.46833647788327	55.8917377330692	208.34098990473666	-10.5916286893271	0.0008	543	83	LUAD	761437-28-9	Experimental	KRAS | BRAF | EGFR
840.5563836928378	-85.7598051122356	779.5824392862228	53.9702963934819	0.6	264	195	SKCM	PIMASERTIB	Clinical trials in cancer	NF1 | NRAS | KIT
631.9189093732755	-59.3938230009866	567.3642355242849	6.77280310194601	0.412	264	71	SKCM	FOLFIRI REGIMEN	Clinical trials in cancer	NRAS | KRAS
243.05353837938907	1.11030967409937	210.17453200922756	-1.25683892246525	0.0008	202	24	LAML	FR 180204	Experimental	KRAS | NRAS | MAPK1
1031.2214888107196	-53.0656609010441	1033.7461195374542	1.29964791936891	0.92	343	50	HNSC	PANITUMUMAB	Approved in cancer	PIK3CA | MAP2K1 | HRAS
1009.8435974990448	24.357448557788	1055.9982884160866	17.4788948867033	0.942	934	314	BRCA	DOCETAXEL	Approved in same tumor type	KRAS | TP53 | MAP2K1
543.90866133755	-6.35454217147415	557.0742427526421	7.73781084329516	0.412	934	216	BRCA	DUVELISIB	Clinical trials in cancer	PIK3CA
794.8773849248515	47.1072101149934	751.0747455282925	-20.9919082704002	0.6	169	46	READ	PIMASERTIB	Clinical trials in cancer	KRAS | NRAS | BRAF
523.0241532019979	-18.2494568461159	541.9846680217258	1.32837705186193	0.382	512	54	UCEC	PEGAPTANIB	Approved in other pathologies	VHL | CTNNB1 | MTOR
697.225352036032	5.19553237329438	685.2002585160789	7.81607143381939	0.535	502	63	KIRC	FORETINIB	Clinical trials in cancer	VHL | MTOR | KDR
307.9626704469661	-22.4370933941531	307.76677728115936	0.157769624037883	0.121	502	61	KIRC	VEGF TRAP	Clinical trials	VHL | MTOR | HSPG2
686.4128821341486	-67.6627278843681	741.0348313949679	12.6217576436034	0.583	264	32	SKCM	MARIMASTAT	Clinical trials in cancer	CYBB | CTNNB1 | MAP2K1
650.5316882868264	21.1347962718758	658.4679842745701	5.03298334442096	0.513	57	6	PAAD	OBATOCLAX	Clinical trials in cancer	TP53
759.1498462494817	48.1322549856963	737.5291870172058	-32.9046767316388	0.598	512	125	UCEC	TAK-733	Clinical trials in cancer	KRAS | NF1 | NRAS
764.8076384566104	40.3044383464078	768.838083143848	-0.0280173751119719	0.633	169	46	READ	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | BRAF
708.2104464097578	10.5144721714573	726.4646181543343	11.8490156695762	0.581	169	28	READ	DHA-PACLITAXEL	Clinical trials in cancer	BRAF | TP53 | RAF1
998.4635400769608	-16.8770963943805	1027.0204031025705	-2.06083642236013	0.922	543	99	LUAD	BORTEZOMIB	Approved in cancer	KRAS | TP53 | BRAF
704.0758385786781	-90.7542224915832	712.7657352120209	12.0744418346117	0.585	264	96	SKCM	FORETINIB	Clinical trials in cancer	NRAS | KIT | VHL
815.393538700873	3.85647362416381	746.1268192865432	5.54326462424388	0.6	292	37	STAD	SELUMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
1035.7328738227327	-41.7024484968677	1077.9552503016735	-9.88746750814062	0.961	264	35	SKCM	PAZOPANIB HYDROCHLORIDE	Approved in cancer	KIT | HSPG2 | FGFR3
730.9093535198671	-21.3029274951859	727.8710641893556	-22.6833040987317	0.593	423	92	COAD	BMS-908662	Clinical trials in cancer	KRAS | NRAS | ESR1
1054.7350339005172	16.9556381117793	1054.776501132664	-1.41682712557622	0.951	343	92	HNSC	ERIBULIN	Approved in cancer	TP53 | MAP2K1
976.7905331573198	-16.3027230677162	946.5037674155652	-4.87715796025918	0.833	543	80	LUAD	CRIZOTINIB	Approved in same tumor type	KRAS | BRAF | EGFR
262.4559151181473	27.1707549110739	216.43848075161281	15.0590267003411	0.0004	169	40	READ	PKI-402	Experimental	KRAS | PIK3CA
201.44321236365755	35.1635009245017	175.93308333026255	8.35771540112501	0.0008	512	102	UCEC	O-PHOSPHO-L-SERINE	Experimental	TGFBR2 | ZAP70 | PTEN
567.898028632499	-46.9946914465293	567.7653154233832	18.3829393072107	0.412	169	38	READ	RILOTUMUMAB	Clinical trials in cancer	KRAS
241.03317128708267	13.2895618640887	214.93818360473736	-5.53321759185428	0.0006	502	62	KIRC	7-NITROINDAZOLE-2-CARBOXAMIDINE	Experimental	VHL | AKT3 | MTOR
197.91487753299518	-66.9432945918505	193.72302591090948	32.0302779151975	0.022	264	68	SKCM	TPA	Clinical trials	NRAS
1064.1801756119553	-46.5940653407629	1062.3423735830359	7.93850454838866	0.956	543	95	LUAD	PONATINIB	Approved in cancer	KRAS | RB1 | SMAD4
577.7342561776317	-14.3019317048741	586.1621879725101	13.1691479472374	0.422	343	45	HNSC	GSK1059615	Clinical trials in cancer	PIK3CA
548.5255181757195	22.9973162448142	595.2654839927342	-5.12436500191961	0.432	423	70	COAD	MK-1775	Clinical trials in cancer	KRAS | NRAS | TRRAP
526.4815851822901	86.5950554866903	554.6653865116996	-59.1757854162929	0.412	57	24	PAAD	GDC-0994	Clinical trials in cancer	KRAS
129.80744833876292	6.48012713961344	219.92800020455243	-27.1478595024796	0.0004	934	217	BRCA	NVP-AEW541	Experimental	PIK3CA | BRAF
551.0050782250654	14.8455557553095	711.8749511696494	0.383377014881262	0.563	343	92	HNSC	OBATOCLAX	Clinical trials in cancer	TP53 | MAP2K1
78.72931513245605	33.5396736216872	160.97552874878744	2.08643079401884	0.0004	57	24	PAAD	LY-411575	Experimental	KRAS
104.07043749344713	0.894787295863892	187.42598647887664	40.6541089523405	0.0004	435	209	THCA	TUBASTATIN A	Experimental	NRAS | BRAF
629.8345322888515	-3.14765383811812	615.9996579427102	-0.000328828579995388	0.462	292	31	STAD	ABT-737	Clinical trials in cancer	KRAS | PIK3CA | EGFR
143.23152980385788	-67.9147031275306	202.92744028798907	0.966840593442612	0.0006	264	35	SKCM	4-{4-[(5-HYDROXY-2-METHYLPHENYL)AMINO]QUINOLIN-7-YL}-1,3-THIAZOLE-2-CARBALDEHYDE	Experimental	CYBB | AKT3 | GNAS
286.3370737248498	-28.7156638141289	187.67079254801095	15.0431102152086	0.0006	502	59	KIRC	CHEMBL390674	Experimental	VHL | MTOR
251.53275007498	9.85728226682488	217.1603527107809	-18.334266992671	0.0004	934	216	BRCA	DEGUELIN	Experimental	KRAS | PIK3CA
95.50226245688766	9.62913643718593	213.9731366326042	7.58815883707848	0.0004	343	45	HNSC	AS 604850	Experimental	PIK3CA
839.8253664027027	12.1933053081725	846.9998840817433	4.02929460960877e-05	0.719	292	39	STAD	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | AKT1 | PIK3CA
585.1045584243706	-39.5382304164036	600.9109354914872	-2.04625484049438	0.442	423	66	COAD	AZD2014	Clinical trials in cancer	KRAS | MTOR | PIK3CA
594.7913458262307	40.6297781264525	577.7659186824375	-21.7479906775346	0.422	169	40	READ	DEMCIZUMAB	Clinical trials in cancer	KRAS | PIK3CA
1029.9864773667211	75.6547479865675	1052.4294569099586	11.6189903422298	0.93	169	46	READ	TRAMETINIB	Approved in cancer	KRAS | NRAS | BRAF
654.9934254675151	-5.33263140287286	659.5655574588153	-14.1661632532225	0.514	202	31	LAML	AZD8330	Clinical trials in cancer	KRAS | NF1 | KIT
695.7683836931558	-9.87397086610295	706.9448745752716	8.18958437480342	0.581	423	64	COAD	CC-401	Clinical trials in cancer	KRAS | MAP2K1 | MAP4K1
231.6067142981764	-22.1919196030209	210.03375922486964	-26.8810217800665	0.0006	512	81	UCEC	SB220025	Experimental	KRAS | NRAS | ZAP70
128.47951558610757	13.0166010504802	193.31413537128654	-0.667399192518587	0.0006	543	68	LUAD	6-CHLORO-9-HYDROXY-1,3-DIMETHYLPYRAZOLO[3,4-B]QUINOLIN-4-ONE	Experimental	KRAS | SOS1 | MAP2K1
1130.4556162674578	-26.2791751062135	1083.4449157570793	-1.80616667331765	0.98	389	49	LUSC	SORAFENIB	Approved in cancer	KRAS | BRAF | AKT1
965.7970613255114	-50.0526376658004	931.1121641109274	-3.5019508413402	0.813	423	93	COAD	PANITUMUMAB	Approved in same tumor type	KRAS | NRAS | BRAF
927.9482481531677	-10.4075847005953	935.2620708734521	2.12499767475128	0.822	343	45	HNSC	VINCRISTINE	Approved in cancer	PIK3CA
1148.53244310413	-68.5916226496688	1106.5702167839177	-7.71704375419176	1.0	264	145	SKCM	DASATINIB	Approved in cancer	RB1 | KIT | KRAS
319.5142146761703	-42.7444968219239	311.7107845599175	-2.67856523340993	0.121	502	61	KIRC	GLICLAZIDE	Clinical trials	VHL | MTOR | HSPG2
788.7503110137595	-1.5599332283677	739.9846865019387	19.44136502427	0.585	512	81	UCEC	AZD8330	Clinical trials in cancer	KRAS | NF1 | NRAS
230.65687765072295	-120.670520406705	212.0309851365753	-23.4736721911199	0.0008	264	112	SKCM	841290-80-0	Experimental	BRAF | BCR | RET
1093.4322778086541	-12.1923661529277	1096.4950430077067	-6.00570147653639	0.993	512	69	UCEC	ABEMACICLIB	Approved in cancer	KRAS | RB1 | NRAS
205.87323597799943	24.8565733958537	205.28144235901078	-12.6424666585614	0.0004	202	23	LAML	LY3009120	Experimental	KRAS | NRAS
1000.4444754786293	-24.5536814910864	1041.329908362475	3.49724511397062	0.929	934	223	BRCA	TAMOXIFEN	Approved in same tumor type	MAP2K1 | ERBB2 | PIK3CA
1091.4643990593468	-85.1621680605552	1097.0464501464605	32.5577537237496	0.995	264	135	SKCM	PACLITAXEL	Approved in cancer	KRAS | VHL | AKT3
1021.2924381844173	-19.4742586634395	1029.6245918668426	18.9290559956996	0.93	934	221	BRCA	TRASTUZUMAB	Approved in same tumor type	KRAS | ERBB2 | PIK3CA
1120.088870222754	12.8035765786772	1093.101363953142	-12.9738282228598	1.0	512	130	UCEC	SORAFENIB	Approved in cancer	KRAS | NF1 | VHL
286.54155709434815	-17.1726815526231	200.297176654771	-10.7075893322793	0.0006	202	31	LAML	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	KRAS | NF1 | KIT
653.2107833723817	5.80449844580696	731.6190404383124	19.4844911517994	0.585	543	95	LUAD	BMS-908662	Clinical trials in cancer	KRAS | NF1 | NRAS
142.64318005348815	68.8415825753718	215.02079616317104	24.7536177116634	0.0004	169	43	READ	GDC-0879	Experimental	KRAS | NRAS | BRAF
1105.4069797942268	-9.4289427518228	1102.7349939964931	-0.758803421264474	1.0	292	35	STAD	MIDOSTAURIN	Approved in cancer	KRAS | PIK3CA | KIT
700.4986159743772	-43.7071008919294	722.8171069646627	-8.2326230030535	0.587	264	38	SKCM	ENZASTAURIN	Clinical trials in cancer	PTPN11 | GNAQ | GNA11
201.7532333231744	68.5203747759746	223.5054499283356	-11.6421754395321	0.0004	934	216	BRCA	WX-037	Experimental	PIK3CA
674.0094148217831	108.459306588113	657.0439484233987	-36.6398023352752	0.535	435	211	THCA	PICTILISIB	Clinical trials in cancer	KRAS | NRAS | BRAF
683.6153223820119	50.4195566762386	750.7138731430846	4.92017300595171	0.593	423	97	COAD	XL147	Clinical trials in cancer	KRAS | NRAS | ESR1
920.0954966647753	-13.4679226898849	956.1731119087254	-7.49630736428139	0.831	934	217	BRCA	PEMETREXED	Approved in cancer	KRAS | PIK3CA | IDH1
724.1866884998502	-7.5288648721648	668.4615387181606	-2.83408197304675	0.512	202	24	LAML	AT9283	Clinical trials in cancer	FLT3 | PTPN11 | SOS1
941.3079614156239	-25.3008173283818	948.7551123569872	-1.86834385718021	0.823	934	218	BRCA	LETROZOLE	Approved in same tumor type	ERBB2 | PIK3CA
509.17512565590806	40.820328370542	575.02729354127	12.692886180366	0.432	169	40	READ	952021-60-2	Clinical trials in cancer	KRAS | BRAF
669.8900468779086	23.7199220232383	674.00008245877	8.39854956211639e-05	0.527	292	30	STAD	NVP-BGJ398	Clinical trials in cancer	KRAS | PIK3CA | KIT
699.4536392632147	-15.8813451922995	721.6329977876464	-16.6633110027069	0.583	423	92	COAD	RO4987655	Clinical trials in cancer	KRAS | NRAS | NF1
688.4525756204874	158.282869109752	777.7906716284635	-1.51723999281035	0.632	222	134	LGG	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | IDH1
235.50672800998402	34.4384585189421	210.04945320285609	12.3293801050273	0.0006	202	31	LAML	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	KRAS | NF1 | KIT
754.1030933407177	3.37804284377984	738.2963069010649	-10.7740869872064	0.586	512	69	UCEC	DINACICLIB	Clinical trials in cancer	KRAS | RB1 | NRAS
187.5833071062824	-104.246160736249	259.6179947992235	-25.2285847976332	0.0004	264	104	SKCM	VORUCICLIB	Experimental	BRAF | CDK4
1036.8225176378808	24.8580059909374	1061.4343601535961	-1.60885371652125	0.956	512	61	UCEC	PANOBINOSTAT	Approved in cancer	KRAS | RB1 | KMT2A
950.41903151711	31.7997561719185	985.9652863485768	-3.92528436482371	0.873	512	112	UCEC	CARBOPLATIN	Approved in cancer	KRAS | PIK3CA | ABCB1
991.6449744184079	-34.2584453497099	1004.8023950889851	-4.19579090352067	0.893	512	114	UCEC	PEMETREXED	Approved in cancer	KRAS | PIK3CA | PDGFRA
233.42613622076067	-26.7531346131619	195.51263911319242	-0.97359273227994	0.0004	292	30	STAD	GW843682X	Experimental	CTNNB1 | PIK3CA | GNAS
1092.3533567692787	-66.911327578628	1057.8342180447314	25.6381300204462	0.96	264	111	SKCM	LAPATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
170.8019777561641	-75.336076508929	187.03149880050213	34.0154650723641	0.0004	934	219	BRCA	NAKITERPIOSIN	Experimental	PIK3CA | PAX8 | MTOR
1062.7795481497922	-22.401834910911	1066.5979950915757	17.6369888923973	1.0	264	46	SKCM	VANDETANIB	Approved in cancer	KRAS | VHL | CTNNB1
227.65202838866955	-33.7504645231419	224.07066127695333	11.879317151825	0.0006	512	54	UCEC	L-PYROGLUTAMIC ACID	Experimental	VHL | CTNNB1 | MTOR
556.6634704985227	-7.06340927040668	558.3725850269801	2.08143048416468	0.394	264	34	SKCM	MESALAZINE	Approved in other pathologies	TSC1 | AKT3 | BTK
992.5049574143015	4.46896984640028	1020.5611581355917	-4.4210222385891	0.92	543	88	LUAD	TEMSIROLIMUS	Approved in cancer	KRAS | STK11 | CTNNB1
568.9876069713246	-27.1177090605524	609.1975923727895	-4.24747292171924	0.444	264	35	SKCM	LUCITANIB	Clinical trials in cancer	KIT | PIK3CA | KDR
228.53214463507777	-62.7586515766937	193.75659261315093	12.7648621231572	0.0004	543	65	LUAD	NUTLIN-3A	Experimental	KRAS | CTNNB1
862.3929931979952	-9.60770670846372	855.999892518142	-0.00032456121971336	0.729	543	84	LUAD	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	KRAS | STK11 | EGFR
203.5445165843458	-44.4805736460504	210.37163441990072	18.76988506917	0.0004	343	45	HNSC	154447-36-6	Experimental	PIK3CA
234.74115335996765	5.28681951597213	204.46578508167624	-32.5952294704909	0.0004	934	217	BRCA	NVP-BGT226	Experimental	PIK3CA | MTOR
786.4388163570171	-39.319610664991	721.7270650543545	-10.6760077839681	0.584	343	133	HNSC	NAVITOCLAX	Clinical trials in cancer	TP53 | CTNNB1 | PIK3CA
156.44424565847007	-12.2736934427031	202.12263011846164	-22.2289142190166	0.0004	423	80	COAD	TW-37	Experimental	KRAS | BRAF | PIK3CA
218.4618829254615	-14.2305811337058	190.70716584728711	0.132509417172969	0.0008	343	54	HNSC	AT7867	Experimental	PIK3CA | AR | HRAS
1120.5250687963996	-6.01234257011623	1079.8639845392956	-5.82584725823313	0.98	292	38	STAD	TEMSIROLIMUS	Approved in cancer	KRAS | CTNNB1 | AKT1
1068.1985391659455	-52.1523875886276	1044.360005683504	-8.71481067895866	0.934	343	58	HNSC	PONATINIB	Approved in cancer	SMAD4 | PTEN | COL1A1
1041.6574871957998	-41.1055348761064	1068.2584527913418	-8.44311848656389	0.96	543	91	LUAD	PALBOCICLIB	Approved in cancer	KRAS | RB1 | SMAD4
214.57757809461057	11.1717040177185	171.12267875894065	-16.5965987717391	0.0004	512	88	UCEC	NUTLIN-3A	Experimental	KRAS | CTNNB1
1016.4192756640953	79.9654763382931	1087.6479330705902	1.65093822807816	0.972	57	25	PAAD	ARSENIC TRIOXIDE	Approved in cancer	KRAS | SMAD4
661.0332248509349	12.6199851662709	727.1987895138355	-18.3976426605209	0.584	264	37	SKCM	XL-228	Clinical trials in cancer	RB1 | PTEN | GPC3
892.0138170054436	26.9195987638365	972.0441917970056	-12.2171173596864	0.814	435	211	THCA	ATEZOLIZUMAB	Approved in cancer	KRAS | NRAS | BRAF
360.9627360175099	16.7703197701538	360.29242567433914	-3.23799654809363	0.182	264	35	SKCM	LOSMAPIMOD	Clinical trials	CYBB | AKT3 | GNAS
1119.7528218968641	22.9505236713177	1090.2776039573926	8.96031452253669	1.0	512	132	UCEC	BOSUTINIB	Approved in cancer	KRAS | RB1 | NF1
600.8543250414717	-30.8650677712544	576.1739659877995	6.60787237698787	0.422	543	60	LUAD	VE-822	Clinical trials in cancer	KRAS
1098.0960312165655	108.195341031121	1065.5353999452846	57.7609452365759	0.96	264	186	SKCM	EVEROLIMUS	Approved in cancer	NRAS | KRAS | GNAQ
742.5383181501952	-41.8500231502633	730.5713474102405	-8.3246611444024	0.593	153	23	BLCA	SF1126	Clinical trials in cancer	NRAS | PTEN | PIK3CA
467.73839420623403	-29.5363672862168	494.0903260274748	-1.14878939563755	0.33	934	219	BRCA	PERTUZUMAB	Approved in other pathologies	ERBB2 | PIK3CA | ERBB3
899.2314355198114	10.3285269174291	940.2497038244774	-5.74262385124803	0.822	934	218	BRCA	FLOXURIDINE	Approved in cancer	ERBB2 | PIK3CA
1071.9038312982418	119.310046285056	1019.8373418212205	23.6257567100519	0.912	57	24	PAAD	BORTEZOMIB	Approved in cancer	KRAS | TP53
671.803839837561	-62.5358956426073	683.4115709057053	-7.35012599425181	0.535	343	51	HNSC	GDC-0032	Clinical trials in cancer	RAC1 | PIK3CA | SOS1
1090.407856801794	-22.688177559519	1074.6299034458314	-4.62639495705162	1.0	264	47	SKCM	MIDOSTAURIN	Approved in cancer	KIT | KRAS | GNA11
760.584765694463	-93.3740122561556	733.8074412509267	1.03272503418111	0.597	512	116	UCEC	1224844-38-5	Clinical trials in cancer	KRAS | TSC2 | TSC1
733.1975053420568	26.538013809263	713.67312577641	4.16426210467898	0.574	599	74	GBM	APITOLISIB	Clinical trials in cancer	NRAS | KRAS | PTPN11
167.28402905943398	-17.0516138907719	198.9890089489983	4.53693623843083	0.0004	343	49	HNSC	KINETIN RIBOSIDE	Experimental	CTNNB1 | PIK3CA | AR
170.0402521003543	80.2350342573723	258.5256240324601	-16.3162890087181	0.022	435	183	THCA	LEUCOVORIN	Clinical trials	BRAF
250.59846206310445	55.9626271348043	204.32298475170955	-7.44038791925681	0.0004	169	38	READ	GA201	Experimental	KRAS
585.339430596309	-12.645791312036	584.0732869014236	5.20494796334128	0.412	543	64	LUAD	FOLFIRI REGIMEN	Clinical trials in cancer	KRAS | NRAS
1056.8094180112232	-35.7900520915919	1044.8689928795604	3.64580184738702	0.939	502	65	KIRC	SUNITINIB	Approved in same tumor type	VHL | MTOR | FGFR1
168.06647513569598	60.3353058700589	210.61546859273219	3.45718506656249	0.0008	202	24	LAML	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | MAPK1
625.1209981398742	51.4500110563699	655.3152153780891	2.01690800821052	0.536	435	211	THCA	BUPARLISIB	Clinical trials in cancer	KRAS | NRAS | BRAF
962.6924084631046	4.77182434157439	976.836280042314	-0.598046787003568	0.862	512	111	UCEC	GEMCITABINE	Approved in cancer	KRAS | PIK3CA | ERBB2
592.8380044271953	-17.6321678714347	573.2052094805432	-9.91370442634752	0.422	543	65	LUAD	MK-1775	Clinical trials in cancer	KRAS | NRAS | TRRAP
742.3583474338866	-23.1546813495349	744.7421420409132	-9.45295205869252	0.593	423	67	COAD	CC-223	Clinical trials in cancer	KRAS | MTOR | PIK3CA
533.7075071929753	30.5570254894847	567.745171597522	11.6342681133644	0.422	435	183	THCA	PEXIDARTINIB	Clinical trials in cancer	BRAF
551.2048358179272	-44.9204404854886	553.5333203435775	-8.95547983982033	0.381	264	50	SKCM	PEGADEMASE BOVINE	Approved in other pathologies	KIT | PTPN11 | PTEN
524.9412268964488	-12.4984618475163	605.2101519932042	-1.05186217814548	0.442	512	110	UCEC	CAMPTOTHECIN	Clinical trials in cancer	KRAS | PIK3CA | ABCB1
218.18007952869735	57.992901985054	176.98986607765255	26.2207200945411	0.0006	512	95	UCEC	BISINDOLYLMALEIMIDE III	Experimental	PTEN | SOS1 | PTPN11
1022.403605170925	13.4554702738124	1035.5623509359075	3.93979169527086	0.93	202	31	LAML	TRAMETINIB	Approved in cancer	KRAS | NF1 | KIT
713.917911965187	39.1478965865499	714.0991483684887	-11.750855049874	0.582	169	28	READ	AT-101	Clinical trials in cancer	BRAF | TP53 | RAF1
795.6502911442773	37.1895964206894	748.2866704844976	-1.39647891662685	0.583	169	44	READ	BAY869766	Clinical trials in cancer	KRAS | NRAS | BRAF
721.7389290451266	68.1425310880514	755.4542356268524	19.5695709952429	0.593	169	48	READ	XL147	Clinical trials in cancer	KRAS | PTPN11 | NRAS
283.3582550114233	-1.38241825136177	302.9883687245527	0.160847223871542	0.111	502	59	KIRC	PLASMIN	Clinical trials	VHL | MTOR
507.1914450418217	-47.8066802887459	552.6802170389758	-0.407499645400321	0.412	934	216	BRCA	1312445-63-8	Clinical trials in cancer	PIK3CA
273.53459720065365	54.8920014153989	188.34245417186312	12.6688723641178	0.0004	512	80	UCEC	PWT-33579	Experimental	MTOR | PIK3CA
192.52650178345027	-61.5183566258289	196.99100275841502	9.47686585220845	0.0006	264	35	SKCM	PYRIDINYLIMIDAZOLE	Experimental	CYBB | AKT3 | GNAS
1198.614455544321	-13.4330433600183	1090.5538317321939	18.8494011372147	0.99	222	147	LGG	DASATINIB	Approved in cancer	KRAS | IDH1 | IDH2
288.7612416838391	40.041641513172	215.5934330138085	0.642778380749292	0.0004	202	34	LAML	CYTOCHALASIN B	Experimental	NRAS | IDH1 | SOS1
210.72675841271644	-30.7808890872235	229.25864754747812	8.09849403556063	0.0006	264	35	SKCM	CHEMBL492265	Experimental	CYBB | AKT3 | GNAS
830.9658301592542	-17.2674435303242	670.716641062522	-24.0175336667994	0.523	57	24	PAAD	BMS-908662	Clinical trials in cancer	KRAS
861.4424639118823	-40.4767413284959	698.5922562042779	46.3364797175068	0.642	264	176	SKCM	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	NRAS | KRAS | BRAF
658.9209852340956	-26.6831703496292	650.2430179442495	-8.47058877129325	0.513	934	223	BRCA	CC-223	Clinical trials in cancer	KRAS | STK11 | ERBB2
805.835142081345	65.3768357277466	708.59154370423	-4.92725982705741	0.586	169	46	READ	DINACICLIB	Clinical trials in cancer	KRAS | SMAD4 | NRAS
692.0935987041061	48.7537166997826	746.7664283815317	-0.976965749560122	0.594	512	103	UCEC	XL-999	Clinical trials in cancer	PTEN | FGFR2 | KIT
747.7189072604675	-28.8405375488999	735.407649198632	-15.4999632674135	0.585	423	67	COAD	GDC-0068	Clinical trials in cancer	KRAS | PTEN | MTOR
771.0727013674934	72.8262956494996	743.0288559901188	-5.88117859673764	0.595	389	50	LUSC	PICTILISIB	Clinical trials in cancer	KRAS | FGFR2 | PTEN
202.61723910361687	-29.2718608386123	197.04767626599235	11.6628697163737	0.0006	512	52	UCEC	CHEMBL281795	Experimental	CTNNB1 | CHD8 | GSK3B
722.6470553787492	7.71107409295558	711.3094642130052	-0.194466680806499	0.581	512	58	UCEC	ABT-510	Clinical trials in cancer	VHL | CTNNB1 | MTOR
952.8448607573147	94.0558586910801	965.779893645172	19.7695227357694	0.84	57	24	PAAD	COBIMETINIB	Approved in cancer	KRAS
706.2523453848241	-108.011981453472	721.5914368018258	51.1571890971395	0.585	264	134	SKCM	SARACATINIB	Clinical trials in cancer	RB1 | KRAS | PTEN
222.30379113541542	-9.34149094794344	196.45794510346494	-1.65223333292863	0.0006	202	31	LAML	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	KRAS | NF1 | KIT
553.5576603144425	96.8213251990764	607.7227759251134	5.88225561438054	0.433	57	24	PAAD	RO4987655	Clinical trials in cancer	KRAS
984.5577003542601	-17.2337317228637	1046.5791402061784	-3.75837682917791	0.943	153	38	BLCA	ABT-199	Approved in cancer	CREBBP | TP53 | IDH1
816.092252042227	26.6808556433635	689.6982682986934	4.61483662929589	0.552	57	24	PAAD	XL765	Clinical trials in cancer	KRAS
755.2411657233056	75.5981314191692	750.3335112022721	24.0441477976572	0.595	512	158	UCEC	AZD5363	Clinical trials in cancer	KRAS | TSC2 | PTEN
853.4065786106455	-15.3268881955417	844.9406533166025	-4.0041886979966	0.714	934	219	BRCA	RALOXIFENE	Approved in other pathologies and in clinical trials in cancer	MAP2K1 | PIK3CA | MAPK1
106.87600495162712	24.6097174632482	198.91332154369405	-46.0729327537459	0.0004	435	183	THCA	UNII-Y2H4S74Y8U	Experimental	BRAF
112.35702613809052	45.0459372075929	248.23305322626493	29.145219095419	0.0008	435	183	THCA	PLX3603	Experimental	BRAF
1009.2713549391276	-14.7633638087234	1023.1577751925753	-3.76059926036669	0.92	343	46	HNSC	LAPATINIB	Approved in cancer	PIK3CA | EGFR
147.46304690301145	50.9172053884317	209.88100388837236	15.1455966767935	0.0004	512	106	UCEC	AZD-8835	Experimental	KRAS | PIK3CA
164.94167516132902	108.444706483005	237.46733269363034	-6.32690273907724	0.0006	57	24	PAAD	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	Experimental	KRAS
613.9703412625257	-29.9436997811917	561.56546365665	-3.91462028477622	0.413	543	74	LUAD	ERDAFITINIB	Clinical trials in cancer	KRAS | EGFR | KDR
64.48625464380947	-31.6211418479687	217.49378316381376	-14.3641312304908	0.0004	222	131	LGG	GSK429286A	Experimental	IDH1
690.1633432227957	-49.0466581197512	717.2475512994231	4.35570817757616	0.573	153	17	BLCA	XL-228	Clinical trials in cancer	RB1 | PTEN | FGFR3
1099.6714281939578	-56.2869734068443	1099.1739432501377	8.91743802542669	1.0	423	95	COAD	EVEROLIMUS	Approved in cancer	KRAS | NRAS | ESR1
184.83375066310668	21.4470681673114	197.4362515364336	-4.96223980215541	0.0006	502	62	KIRC	CACODYLIC ACID	Experimental	VHL | AKT3 | MTOR
175.64327639321326	96.0642542711604	213.51874404020876	-22.9323238048903	0.0004	57	24	PAAD	KINETIN RIBOSIDE	Experimental	KRAS
240.46083120416452	-13.5400010123634	246.18270861991107	13.8441422805429	0.0008	512	134	UCEC	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | TSC2 | TSC1
162.04116529418934	57.2656755201852	207.53300250721273	-6.76838698805136	0.0006	292	39	STAD	OBLIMERSEN	Experimental	MAP2K1 | CREBBP | TP53
1052.5282629772357	-38.6834008681717	1029.997378762163	8.88602876673826	0.929	543	75	LUAD	OSIMERTINIB	Approved in cancer	KRAS | NRAS | EGFR
1089.5452006226544	-8.4502293781083	1049.6972761416707	1.10545300162335	0.939	502	72	KIRC	REGORAFENIB	Approved in cancer	VHL | AKT3 | MTOR
255.1065323739017	-36.0301295349367	196.17105591825035	15.6551928955245	0.0004	202	28	LAML	MERCK60	Experimental	KRAS | IDH1 | MYC
706.7320183447706	20.0764576163221	716.3591406147895	2.09248240113988	0.574	389	41	LUSC	AZD5363	Clinical trials in cancer	KRAS | PTEN | AKT1
589.8468395534877	-14.2740020686312	550.0465959807289	-2.32667908803455	0.383	512	56	UCEC	TREPROSTINIL	Approved in other pathologies	TSC2 | TSC1 | CTNNB1
573.4416261568983	-29.9700034680295	574.9601909147057	4.41553039234077	0.422	343	45	HNSC	PKI-179	Clinical trials in cancer	PIK3CA
579.4076312215176	-47.2069810140549	588.7489984682327	-4.51274977181311	0.432	423	69	COAD	LONAFARNIB	Clinical trials in cancer	KRAS | NRAS | ABCB1
210.2308070193614	104.195281428012	207.58094086682542	-15.9590152532046	0.0004	169	39	READ	LY-411575	Experimental	KRAS | ERBB2
219.5035632027774	-35.7390471032887	184.44621742386607	-9.57012608008836	0.0004	343	49	HNSC	GW843682X	Experimental	CTNNB1 | PIK3CA | FGFR3
640.4674378729833	5.20758809036423	653.9890901720701	0.607756151243848	0.511	502	59	KIRC	DICHLOROACETIC ACID	Clinical trials in cancer	VHL | MTOR
270.0999571831387	61.8286289781391	176.37686174112835	0.651872767379302	0.0006	169	39	READ	1,9-PYRAZOLOANTHRONE	Experimental	KRAS | MAP4K1 | RRAS2
389.24622456459224	-3.13191656306225	392.0000632475864	0.000286309421426267	0.213	202	28	LAML	PEMBROLIZUMAB	Approved in other pathologies	KRAS | KIT | NRAS
191.3501516370954	28.1376627104149	195.46420478220858	4.16249661218308	0.0004	543	71	LUAD	GA201	Experimental	KRAS | EGFR
984.0579750413558	-59.9592642246263	950.4525093619466	-16.766951635746	0.832	264	108	SKCM	OXALIPLATIN	Approved in cancer	KRAS | BRAF | MET
573.2522876235826	-12.67117984858	576.530820231426	14.184946289688	0.412	512	52	UCEC	SAR125844	Clinical trials in cancer	KRAS | MET
197.66277664900485	-0.60001029148404	190.6137247891391	-6.6766027438664	0.0004	512	55	UCEC	CHM-1	Experimental	CTNNB1 | MTOR | SOS1
371.5373438315979	22.5544755027986	346.00023074973336	-0.000233083698191194	0.162	57	24	PAAD	QUERCETIN	Clinical trials	KRAS
1060.467104743864	-8.32460295949417	1064.52074780823	2.02231591404529	0.96	512	61	UCEC	CRIZOTINIB	Approved in cancer	KRAS | ERBB2 | BRAF
1072.303181253509	-18.8323278188126	1078.399660085761	-0.160085506972109	0.977	543	69	LUAD	ROMIDEPSIN	Approved in cancer	KRAS | RB1 | SMAD4
238.5236989931225	-103.9115568565	128.99069852488998	-16.5073907454325	0.0006	264	134	SKCM	GUANOSINE TRIPHOSPHATE	Experimental	KIT | PTPN11 | GNAQ
159.2263349089658	14.9024574142817	172.64585485261367	-2.20215734111048	0.0004	512	77	UCEC	AS 604850	Experimental	PIK3CA
633.853969646308	-5.86329600409698	684.214344029138	0.294807585425588	0.535	153	16	BLCA	MLN1117	Clinical trials in cancer	PIK3CA | SOS1 | HRAS
194.75471782466335	-82.0269987374632	216.22937079424173	-49.7756419363495	0.022	264	106	SKCM	LEUCOVORIN	Clinical trials	BRAF | MET | ERBB2
563.3763615563637	19.0941987239046	561.6544562713136	-16.554592049999	0.422	934	216	BRCA	P7170	Clinical trials in cancer	KRAS | PIK3CA
1030.6357551893948	89.7666804925112	1043.8044391865456	-14.766496914265	0.927	57	25	PAAD	ABEMACICLIB	Approved in cancer	KRAS | SMAD4
780.9619635233715	-6.83311941269335	717.068897226467	21.254874957312	0.594	169	31	READ	OBATOCLAX	Clinical trials in cancer	NRAS | BRAF | TP53
1168.846140575239	19.51626621619	1109.0701477288503	10.4721909472586	0.998	169	49	READ	REGORAFENIB	Approved in same tumor type	KRAS | SMAD4 | PTPN11
754.1714754188395	62.9289996322059	739.737635884302	-21.7850552564062	0.595	512	165	UCEC	PF-04691502	Clinical trials in cancer	KRAS | NRAS | TSC2
153.14687751367308	-33.1695411694479	179.79686302958336	9.26041070870724	0.0004	343	45	HNSC	VOXTALISIB	Experimental	PIK3CA
676.0445014636581	-32.4760911597799	696.5413482181233	12.4231646980088	0.544	264	29	SKCM	AMUVATINIB	Clinical trials in cancer	KIT | FLT3 | PDGFRA
361.0491934516535	37.4209589072224	360.33351398668196	13.6216237539347	0.191	264	129	SKCM	QUERCETIN	Clinical trials	NRAS | KIT | KRAS
210.46760841922244	6.25441918483273	186.96559646451323	-33.9877295170991	0.0004	512	80	UCEC	1166227-08-2	Experimental	PIK3CA | BRAF
612.9960337583016	-25.4160468321147	579.6458861756643	0.349831955187597	0.426	202	22	LAML	CRENOLANIB	Clinical trials in cancer	FLT3 | KIT | PDGFRB
226.81333484807183	126.208060086167	248.515724440028	-11.7012202031774	0.0006	264	127	SKCM	OBLIMERSEN	Experimental	VHL | AKT3 | BRAF
346.86140910436785	-20.1204574507316	299.9997524387064	0.000422782046143766	0.111	435	211	THCA	ANTIBIOTIC K 252A	Clinical trials	KRAS | NRAS | BRAF
180.92281468705565	-90.0729774434191	182.93822474959308	-57.5809737714408	0.0004	264	105	SKCM	2,6-DICHLORO-3-FLUOROPYRIDINE	Experimental	BRAF | ERBB4
504.25750878100126	-31.9458637051968	592.0675819726114	19.6872014942994	0.422	169	40	READ	AZD4547	Clinical trials in cancer	KRAS | ERBB2 | FGFR1
413.2718552977211	0.888611017505895	409.29583692733485	2.97606735368663	0.232	543	79	LUAD	NIVOLUMAB	Approved in other pathologies	KRAS | BRAF | EGFR
571.3345515870144	-9.13273661070883	588.6709367273276	6.44293410242653	0.432	512	53	UCEC	VE-822	Clinical trials in cancer	KRAS | ATR
539.3145207498051	-55.4876736613649	515.9999697337993	-0.000204915030735719	0.351	343	92	HNSC	EDARAVONE	Approved in other pathologies	TP53 | MAP2K1
180.52864802296332	-63.7579910152936	168.02174453013882	-14.8396109878804	0.0004	264	68	SKCM	TL-1-85	Experimental	NRAS
971.1620487454103	59.8234675978989	1070.345909914312	-16.8046806717464	0.94	435	211	THCA	TRAMETINIB	Approved in cancer	KRAS | NRAS | BRAF
231.26535491760862	24.2601809643878	218.75706313758727	11.1880714979002	0.0006	502	59	KIRC	1-[4-(AMINOMETHYL)BENZOYL]-5&#39;-FLUORO-1&#39;H-SPIRO[PIPERIDINE-4,2&#39;-QUINAZOLIN]-4&#39;-AMINE	Experimental	VHL | MTOR
629.5635021035207	11.5597394822262	554.5861407705404	-1.8966678123823	0.422	169	40	READ	SAR245409	Clinical trials in cancer	KRAS | PIK3CA
1029.9688607814867	22.3056099726179	1031.7409432159814	12.0249154021471	0.92	169	43	READ	TEMSIROLIMUS	Approved in cancer	KRAS | BRAF | PIK3CA
680.3383572038068	74.1938613029032	689.2923199468645	6.52532973102416	0.537	222	64	LGG	NAVITOCLAX	Clinical trials in cancer	TP53 | KRAS | PTPN11
579.987107116809	109.623960144643	592.5176579964166	-35.7803170136306	0.412	57	24	PAAD	DS-7423	Clinical trials in cancer	KRAS
537.249022780318	19.1335105564121	587.0757005537668	-11.1224677181458	0.422	423	75	COAD	BI 2536	Clinical trials in cancer	KRAS | BRAF
1010.3991074262818	-0.494097593479438	1010.8096941902141	-7.87941791975538	0.905	202	25	LAML	ABEMACICLIB	Approved in cancer	KRAS | NRAS | MYC
229.08011745347684	-37.5337523926858	199.95854680392196	5.90457061795064	0.0004	543	60	LUAD	LY-411575	Experimental	KRAS
245.1756277128895	-62.034559803945	191.28595784983963	-18.7987957855144	0.0004	423	57	COAD	TYRPHOSTIN B42	Experimental	KRAS
112.90865915056986	-50.8008055077751	237.39163271920012	-50.9272799752921	0.0006	435	211	THCA	HYPOTHEMYCIN	Experimental	KRAS | NRAS | BRAF
569.9801218192065	96.3357377800221	591.0712678534027	8.61368525692197	0.422	57	24	PAAD	952021-60-2	Clinical trials in cancer	KRAS
555.3267777459259	-17.3729662393713	565.7733737318569	6.21833942414787	0.412	343	45	HNSC	P7170	Clinical trials in cancer	PIK3CA
868.0388101005078	65.6330116206685	961.9812684244012	-3.16359164555206	0.822	222	134	LGG	TEMOZOLOMIDE	Approved in cancer	IDH1 | EGFR
1044.0548499737843	-76.6046057005917	1099.6853523041536	12.35174679478	0.994	264	135	SKCM	ABT-199	Approved in cancer	KRAS | VHL | AKT3
680.0972883489987	-77.2776218973198	690.4923968895257	2.44808963609898	0.546	599	74	GBM	NAVITOCLAX	Clinical trials in cancer	TP53 | KRAS | PTPN11
203.91375031729618	7.02699021416396	208.70222145981805	0.719650991460412	0.0008	543	95	LUAD	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | STK11 | BRAF
788.772443516584	55.952918444743	746.7468485052339	26.6676747339257	0.595	169	47	READ	XL765	Clinical trials in cancer	KRAS | PTPN11 | NRAS
1032.1101975598956	8.48237074893353	1040.952489105582	-2.43493645074841	0.934	599	72	GBM	ABT-199	Approved in cancer	TP53 | KRAS | IDH1
570.8869868316408	17.3785066149861	593.4946450641908	4.82942314851994	0.422	512	78	UCEC	GM-CSF	Clinical trials in cancer	PIK3CA | TSHR
945.7061336873672	15.4243567240864	925.0565326067963	4.90691924878865	0.814	934	217	BRCA	IDELALISIB	Approved in cancer	PIK3CA | BRAF
670.9423784002049	-82.7242328373125	655.7853004286288	-17.7118548335002	0.534	264	108	SKCM	ARQ-092	Clinical trials in cancer	BRAF | AKT1 | PIK3CA
1002.8068594255709	90.4057877717099	1031.474652621772	-27.238871982627	0.91	57	25	PAAD	IMATINIB	Approved in cancer	KRAS | SMAD4 | ETV6
554.1779377424184	23.2135190001639	550.605594156686	2.12926635717736	0.391	512	59	UCEC	ICOSAPENT	Approved in other pathologies	TSC2 | TSC1 | CTNNB1
1080.2564325499873	-11.3711701709415	1042.915015152915	-6.51709636805026	0.936	502	67	KIRC	CABOZANTINIB	Approved in cancer	VHL | MTOR | PIK3CA
705.9319396511719	-17.7043147384578	685.6121922462038	-2.01157374928744	0.535	502	66	KIRC	DOVITINIB	Clinical trials in cancer	VHL | MTOR | FGFR3
1030.3321648192593	-43.2861409808123	1033.818259630249	-3.17549208314995	0.93	543	84	LUAD	LAPATINIB	Approved in cancer	KRAS | BRAF | EGFR
248.8878392680481	-37.1451870275052	203.4693652748843	7.03756454696668	0.0006	423	77	COAD	761437-28-9	Experimental	KRAS | PTEN | BRAF
98.68594035008398	-12.0950038967971	192.4500398267619	18.5985705783928	0.0004	423	95	COAD	LY2183240	Experimental	KRAS | NRAS | MTOR
363.65381986695957	-7.38211872111967	364.42251923050054	-5.02845136030965	0.181	512	56	UCEC	ELAFIBRANOR	Clinical trials	TSC2 | TSC1 | CTNNB1
1082.1704950251835	-50.9616682649922	1105.2110676867778	-6.96398808551612	0.994	423	105	COAD	ABT-199	Approved in cancer	KRAS | TP53 | IDH2
734.8088767838119	-30.7093088622906	745.5895230023273	21.9578369556525	0.595	423	83	COAD	PX-866	Clinical trials in cancer	KRAS | NRAS | ESR1
151.72443322417672	-42.3220142196517	185.76325634038577	18.3815883672282	0.0004	264	35	SKCM	32703-82-5	Experimental	KIT | GNAQ | IDH1
548.5310819891569	-94.663507075021	604.4020460225341	7.95655665580193	0.432	934	216	BRCA	LUCITANIB	Clinical trials in cancer	PIK3CA | PDGFRA
777.4283053159892	63.7676253836011	640.5649831538001	-8.35733268229683	0.522	435	183	THCA	1260612-13-2	Clinical trials in cancer	BRAF | SOS1 | PIK3CA
260.71864452147435	-103.611795748806	188.0791123961867	69.9122992866896	0.0008	264	159	SKCM	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KIT | KRAS | PTPN11
375.5575295900246	-36.9947868465854	384.3951452948029	9.11083011511619	0.181	264	194	SKCM	ANTIBIOTIC K 252A	Clinical trials	NF1 | NRAS | KIT
1036.3512135625501	4.82519337543366	1051.0588657805818	-1.1871477247596	0.942	543	97	LUAD	DOCETAXEL	Approved in cancer	KRAS | TP53 | BRAF
185.35559106049644	-76.9924913953668	202.6865000474096	-8.73160221034095	0.0006	264	35	SKCM	CHEMBL85860	Experimental	CYBB | AKT3 | GNAS
582.9295720542917	164.651880535262	610.8851933569312	-6.33796069253162	0.422	435	183	THCA	GANETESPIB	Clinical trials in cancer	BRAF
562.169703341788	106.461952391936	570.4782506013536	-16.0721764174031	0.422	169	38	READ	2-[(E)-2-(3-NITROPHENYL)VINYL]QUINOLINE	Clinical trials in cancer	KRAS
139.67097780369582	90.3008324830028	193.14244641059435	-30.3597715776098	0.0004	435	183	THCA	LGX-806	Experimental	BRAF
758.8879890891817	-84.8168247119893	742.0127720791551	3.00596935715384	0.583	423	92	COAD	1032350-13-2	Clinical trials in cancer	KRAS | NRAS | PTEN
779.0274018105523	17.5291183865035	756.6830507392212	-0.0270866691997753	0.622	202	27	LAML	DECITABINE	Approved in other pathologies and in clinical trials in cancer	KRAS | IDH1
197.47733138571743	4.21238250990453	176.85268573698406	-19.4886650143465	0.0004	512	77	UCEC	17-ALLYL-AMINOGELDANAMYCIN	Experimental	PIK3CA
931.3155142916165	0.173518557161941	942.9630016176851	-2.82789315833224	0.823	343	46	HNSC	LETROZOLE	Approved in cancer	CTNNB1 | PIK3CA
606.6306883634112	19.3175833995953	563.6909409193104	0.588602635632753	0.422	169	40	READ	1375469-38-7	Clinical trials in cancer	KRAS | PIK3CA
128.68718705601708	64.881092391254	178.66337100334638	0.58773522220622	0.0006	512	94	UCEC	ISO24	Experimental	PTEN | KDR | GNAS
605.2166775591572	-2.66551891006145	577.5712509258441	-3.58793777427002	0.421	202	23	LAML	INDISULAM	Clinical trials in cancer	KIT | IDH1 | SOS1
1133.464871537146	-39.0668649752627	1101.9114341935087	-4.13146149301315	0.997	512	78	UCEC	PAZOPANIB	Approved in cancer	KRAS | VHL | ZAP70
506.8982479119113	-16.6475693796467	680.4771605468854	-1.72892777776178	0.534	502	63	KIRC	MGCD-265	Clinical trials in cancer	VHL | MTOR | KDR
853.5556019051122	1.90651869829276	857.8703713670283	0.00138822746293954	0.731	502	63	KIRC	AFLIBERCEPT	Approved in other pathologies and in clinical trials in cancer	VHL | MTOR | KDR
1076.5449829962608	31.0183830469897	1063.856949847665	1.38765801558384	0.96	599	75	GBM	BOSUTINIB	Approved in cancer	RB1 | NF1 | NRAS
719.3752783576997	-30.4343919594484	704.7557238288572	-3.08856217285324	0.581	512	71	UCEC	CC-401	Clinical trials in cancer	KRAS | SOS1 | MAP3K8
793.5348674612853	-30.9717258559616	739.0829608669595	7.45580428721678	0.594	543	91	LUAD	PX-866	Clinical trials in cancer	KRAS | NRAS | EGFR
609.5668531232917	-27.4084676427015	579.9997099686157	-6.5770445871749e-05	0.422	292	30	STAD	BAY1125976	Clinical trials in cancer	KRAS | NRAS | AKT1
249.44923687699915	20.9706011751786	201.13959559921287	-5.44891166177763	0.0004	202	23	LAML	PLX-4720	Experimental	PTPN11 | NRAS | KDR
280.92391184910014	-53.9499618424879	186.59569402454912	33.5951340776278	0.0004	512	80	UCEC	TORIN 1	Experimental	MTOR | PIK3CA
937.1720280187895	-84.1327883639163	939.2053049673815	-12.4550621591594	0.833	222	139	LGG	OLAPARIB	Approved in cancer	KRAS | IDH1 | IDH2
615.342610558767	-16.4885093790005	568.1823365770362	4.24993536405998	0.412	202	25	LAML	CAMPTOTHECIN	Clinical trials in cancer	KRAS | IDH2
1052.348935385035	68.375271733044	1005.2573460386327	11.0395269110286	0.93	57	25	PAAD	DASATINIB	Approved in cancer	KRAS | SMAD4
584.8851580202358	17.2776016041485	543.0001130262613	-0.000201678822577378	0.381	292	39	STAD	EDARAVONE	Approved in other pathologies	MAP2K1 | CREBBP | TP53
651.9738360265821	-11.4833214352738	668.1345297348918	2.18441295321122	0.518	543	75	LUAD	AZD4547	Clinical trials in cancer	KRAS | EGFR | KDR
577.7127023386856	-27.5131742252624	583.620870410356	-0.714799248237114	0.422	512	60	UCEC	NVP-AUY922	Clinical trials in cancer	KRAS | ITK | FGFR1
259.2432605539548	129.579290156585	210.88848636543509	8.18589776870661	0.0006	57	24	PAAD	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	Experimental	KRAS
1083.1050664231434	6.76965232297334	1089.5021226268361	8.20188316158442	0.99	543	94	LUAD	EVEROLIMUS	Approved in same tumor type	KRAS | NRAS | STK11
533.7810979578255	71.3347380978602	559.3489525167172	-30.4786037070737	0.412	57	24	PAAD	NRX 194204	Clinical trials in cancer	KRAS
939.545964027452	-38.2102404337228	931.5482189985971	-6.8840479989758	0.824	264	106	SKCM	IDELALISIB	Approved in cancer	BRAF | PIK3CA | MYC
1143.353065639403	52.4731800834298	1116.355303779759	1.00256294529021	0.994	169	52	READ	ABT-199	Approved in cancer	KRAS | BRAF | TP53
641.2376485368502	63.2523082967838	603.1401882812323	-11.5714552544239	0.433	169	40	READ	DS-7423	Clinical trials in cancer	KRAS | PIK3CA
138.24114615522558	-40.0050881089252	178.7890634115183	-13.8239322200634	0.0006	264	35	SKCM	CHEMBL379760	Experimental	CYBB | AKT3 | GNAS
180.95993704463396	85.2027618221348	208.44088690065408	7.60000505260405	0.0006	512	94	UCEC	CHEMBL87580	Experimental	PTEN | KDR | GNAS
734.2607537441312	-67.1739157610766	728.6783936776978	-29.5367590151873	0.542	264	111	SKCM	RO5212054	Clinical trials in cancer	BRAF | FGFR1 | PDGFRA
102.59992280592824	91.232519845644	154.55125127653298	38.7616859832021	0.0006	435	186	THCA	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | BRAF | SOS1
244.37112621638283	9.87311529241947	204.20838255367028	-2.5035161834935	0.0008	292	40	STAD	AT7867	Experimental	KRAS | PTPN11 | PIK3CA
1030.6046971178669	-10.6257665872752	1003.9998513037823	-7.95724054114544e-06	0.893	423	68	COAD	PEMETREXED	Approved in cancer	KRAS | PIK3CA | IDH1
786.8418928697326	-72.5618572623768	713.1742801887186	28.8359523341437	0.596	264	126	SKCM	APITOLISIB	Clinical trials in cancer	NRAS | KIT | KRAS
187.24212565512443	-152.510416578835	147.1200685515554	37.0604330987167	0.0008	264	190	SKCM	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	NRAS | KRAS | CYBB
922.7384026002148	52.4752918146672	949.6541430950324	-21.7415935186382	0.833	57	24	PAAD	AFATINIB	Approved in cancer	KRAS
571.5906319119435	-2.29153181047568	580.8252200300936	-1.10934825198342	0.422	934	235	BRCA	937174-76-0	Clinical trials in cancer	AKT1 | PIK3CA | PRKACA
710.6121122293463	-32.4458672142612	674.0287273060907	13.372025448999	0.524	202	22	LAML	AMUVATINIB	Clinical trials in cancer	FLT3 | KIT | PDGFRB
596.2410654621656	-2.83296061665553	578.7967169766598	-11.9345348966317	0.422	512	53	UCEC	BMS-754807	Clinical trials in cancer	KRAS | AKAP9 | PTPN1
1098.5944941153937	73.2608554237215	1115.2518415324382	-0.0254636855647732	0.999	512	108	UCEC	IMATINIB	Approved in cancer	KRAS | RB1 | CTNNB1
150.81797407383016	7.24933050387978	187.61440132249072	-4.78076833933028	0.0004	343	45	HNSC	1166227-08-2	Experimental	PIK3CA
776.9816154681498	10.1690726330408	682.4711418417879	13.6492511914613	0.522	202	52	LAML	XL765	Clinical trials in cancer	KRAS | FLT3 | KIT
175.73855185014085	-36.4304116384639	217.46706671230857	4.04997452273938	0.0006	264	35	SKCM	CHEMBL371491	Experimental	CYBB | AKT3 | GNAS
645.7182311763123	-11.3303065733408	663.0008474077163	-3.13676264340756e-06	0.514	423	66	COAD	AZD8055	Clinical trials in cancer	KRAS | MTOR | PIK3CA
226.37298071500734	78.3106895973173	185.8910766446102	-1.86638171801184	0.0006	169	44	READ	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	KRAS | NRAS | BRAF
946.2855530260149	-19.4103219128559	953.341373386536	2.39146084635604	0.834	543	83	LUAD	ATEZOLIZUMAB	Approved in same tumor type	KRAS | NRAS | BRAF
224.87345300601413	-21.6570095378791	208.50355892888328	-18.5403899511821	0.0006	423	76	COAD	PF-3644022	Experimental	KRAS | BRAF | MAPK14
1017.204158082262	40.1741676676297	1045.3199188867527	-15.9305253840526	0.947	169	42	READ	ROMIDEPSIN	Approved in cancer	KRAS | SMAD4 | ERBB2
684.7556258315132	-60.7089679621783	663.7253826305247	-21.5894693823429	0.518	934	223	BRCA	OSI-027	Clinical trials in cancer	KRAS | STK11 | ERBB2
252.02402202738998	-29.7958233214049	179.08711528224342	11.9002728094433	0.0008	423	92	COAD	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	KRAS | NRAS | NF1
585.4840267855641	-45.9174289283686	592.4591584792495	0.584499771674473	0.433	423	65	COAD	CUDC-907	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
680.9571579929102	-51.1920689279081	714.1919539795949	-1.97310657037269	0.563	264	27	SKCM	OSI-930	Clinical trials in cancer	KIT | VHL | RAF1
218.5221060878513	73.9908175938555	239.98222237436735	-10.5095780347888	0.0006	512	94	UCEC	RU82197	Experimental	PTEN | KDR | GNAS
242.98552959919354	-38.7707732408942	224.8527939535028	6.91136795241482	0.0006	512	76	UCEC	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
1065.685002590922	8.17496703777908	1090.7921507993874	-4.6224742152508	0.99	153	26	BLCA	SORAFENIB	Approved in cancer	NRAS | CREBBP | FGFR3
870.5279471163964	-1.47217563606515	921.7402837011093	12.9996209373844	0.812	57	24	PAAD	IRINOTECAN	Approved in cancer	KRAS
1017.0632545179667	-3.0696757995168	1018.1812065149884	-8.09687099031567	0.93	934	220	BRCA	LAPATINIB	Approved in same tumor type	KRAS | ERBB2 | PIK3CA
588.3671816651048	11.5465500829104	583.3107761611107	-4.72169902727524	0.422	543	79	LUAD	952021-60-2	Clinical trials in cancer	KRAS | BRAF | EGFR
697.1936038407808	20.6488661997101	705.7279384585825	-2.24173737701494	0.565	543	66	LUAD	GDC-0032	Clinical trials in cancer	KRAS | SOS1 | PIK3CA
572.6925871180633	145.876645750323	732.0633601011244	-9.61134746794346	0.585	222	144	LGG	SARACATINIB	Clinical trials in cancer	KRAS | IDH1 | IDH2
691.7726848019272	84.1819338060504	721.4504748427354	-1.06512266619393	0.53	435	211	THCA	BINIMETINIB	Clinical trials in cancer	KRAS | NRAS | BRAF
928.7000721187607	12.5041861334759	933.0771964903417	9.54799582045689	0.822	934	216	BRCA	VINCRISTINE	Approved in cancer	PIK3CA
848.1723665310841	-6.01255181280231	837.9996864142548	-0.000280688581369759	0.709	153	18	BLCA	RAPAMYCIN	Approved in other pathologies and in clinical trials in cancer	PIK3CA | ERBB4 | HRAS
212.77534190757888	35.5098354265719	215.722088935977	-32.3078446103439	0.0004	512	84	UCEC	BISTRAMIDE A	Experimental	PIK3CA | LZTR1 | IL6ST
751.673855242432	-34.4490534940201	724.5983284745153	3.02305262014124	0.595	264	47	SKCM	DOVITINIB	Clinical trials in cancer	KIT | VHL | ARNT
636.9856414583621	-34.7560424110481	679.8385064512358	-0.472750467773949	0.535	153	18	BLCA	GSK2126458	Clinical trials in cancer	NRAS | PIK3CA | SOS1
518.8678488636505	-37.4200731148668	547.1402156807804	-5.95447797213478	0.381	512	63	UCEC	SEMAXANIB	Approved in other pathologies	VHL | CTNNB1 | MTOR
1093.475556797165	59.0908176116053	1054.1177854256837	-8.73069749348832	0.925	169	54	READ	PACLITAXEL	Approved in cancer	KRAS | BRAF | TP53
1001.9382512763517	40.5610749755888	1031.6613349519444	2.13460452115464	0.93	934	227	BRCA	COBIMETINIB	Approved in cancer	KRAS | NF1 | MAP2K1
258.7542560508151	-25.2020284655934	202.000618308497	3.81089846163354	0.0006	599	118	OV	OBLIMERSON	Experimental	TP53 | MAPK14 | MAP3K5
463.81907255615243	-16.6972793738042	476.3357830945248	-3.83407888432021	0.311	502	64	KIRC	EDARAVONE	Approved in other pathologies	VHL | AKT3 | MTOR
711.4254275656526	20.900790174963	735.8418393888494	-5.9105953154608	0.595	292	40	STAD	XL765	Clinical trials in cancer	KRAS | PTPN11 | NGF
667.4268873559504	5.3427667787231	685.7599719712665	1.28011609474731	0.54	599	72	GBM	SELUMETINIB	Clinical trials in cancer	NF1 | NRAS | KRAS
644.4068872014643	17.7799491171749	612.1517804177528	-8.65507277859149	0.453	169	40	READ	CAMPTOTHECIN	Clinical trials in cancer	KRAS | PIK3CA
244.4458118239291	81.4037208179006	234.79401161349418	-0.947167501019521	0.0006	264	105	SKCM	NVP-AEW541	Experimental	BRAF | GPC3 | PIK3CA
1076.8951284010561	5.44540204797389	1083.9161566607427	-7.7658046389538	0.987	543	79	LUAD	ABEMACICLIB	Approved in cancer	KRAS | RB1 | SMAD4
1061.4964517522492	-1.59403579638072	1090.1903606919298	-22.3321132862995	0.99	512	121	UCEC	PALBOCICLIB	Approved in cancer	KRAS | RB1 | NRAS
180.04612247256924	20.8261575872748	203.26894340982753	-8.06824504028759	0.0004	543	71	LUAD	TYRPHOSTIN B42	Experimental	KRAS | EGFR
563.353214576863	-23.793696207867	579.920087731164	6.15453385597766	0.412	343	45	HNSC	DEMCIZUMAB	Clinical trials in cancer	PIK3CA
1101.4819718344158	-34.2925764360351	1096.999831398446	0.000198062667550403	0.997	343	60	HNSC	COPANLISIB	Approved in cancer	PTEN | RAC1 | CD247
234.99530890913596	-60.6303006303446	211.01131484239312	23.5954134849815	0.0004	512	114	UCEC	ISOEVODIAMINE	Experimental	TRIO | CTNNB1 | MTOR
215.16221870903647	-32.8246656113015	189.09510211735395	22.3392398229339	0.0004	264	34	SKCM	ENMD-981693	Experimental	FGFR3 | AURKA | KDR
960.2612531067907	-42.5235123499174	957.6318409267852	2.09359690392216	0.834	934	236	BRCA	GEMCITABINE	Approved in cancer	KRAS | AKT1 | ERBB2
1124.9001901049007	-29.2004299126082	1101.8959061540195	-11.0746634780289	1.0	512	100	UCEC	VANDETANIB	Approved in cancer	KRAS | VHL | CTNNB1
631.0475621672589	-16.2115869765211	573.9556588851386	1.0877157613254	0.423	512	80	UCEC	LY3023414	Clinical trials in cancer	MTOR | PIK3CA
145.13456887174482	-39.5365458510999	203.053581031783	-28.9397602400661	0.0004	512	109	UCEC	TW-37	Experimental	KRAS | PIK3CA | BRAF
580.9879455147542	-2.90883172610413	549.8582041750577	-0.465122816772237	0.422	264	72	SKCM	MK-1775	Clinical trials in cancer	NRAS | KRAS | TRRAP
748.3941295777666	19.4996811686669	714.4102601457384	0.331529807246625	0.586	292	34	STAD	TAK-733	Clinical trials in cancer	KRAS | NF1 | NRAS
957.2701193201976	21.5624459793896	1013.7092365343701	18.5533919492868	0.912	435	183	THCA	SORAFENIB TOSYLATE	Approved in cancer	BRAF | SOS1 | ESR1
714.5738712961601	34.2332753911029	672.2255375963373	-2.98432470766605	0.522	57	6	PAAD	GOSSYPOL	Clinical trials in cancer	TP53
607.5796069088393	-41.1067300485276	581.5211639185515	13.5335198431526	0.412	512	77	UCEC	GSK1059615	Clinical trials in cancer	PIK3CA
101.76045859294176	124.788098771218	201.79346551663883	14.1080474586722	0.0004	435	185	THCA	761437-28-9	Experimental	KRAS | BRAF
168.83565786224474	-63.5940166759663	186.84210679174467	-19.7059879285894	0.0006	264	35	SKCM	3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE	Experimental	CYBB | AKT3 | GNAS
508.51757377537115	54.5536241702871	619.7619217736348	-25.4611655960305	0.412	57	24	PAAD	FOLFIRI REGIMEN	Clinical trials in cancer	KRAS
927.7898637886487	-28.1717790839286	940.9701682577615	3.9430832256644	0.823	934	236	BRCA	IRINOTECAN	Approved in cancer	KRAS | AKT1 | ERBB2
548.3072686119018	-52.305922740533	590.4957514396207	-12.784781496616	0.433	512	109	UCEC	DS-7423	Clinical trials in cancer	KRAS | MTOR | PIK3CA
738.6267553883135	-133.064458728649	696.0713616198466	-2.86486584723889	0.552	343	94	HNSC	AT-101	Clinical trials in cancer	TP53 | MAP2K1 | CSNK2A1
1049.7542923180833	-2.42870771590381	1039.5521874731692	2.23636138392612	0.94	502	73	KIRC	SORAFENIB	Approved in same tumor type	VHL | AKT3 | MTOR
233.43061649669417	-42.400464959739	213.63472069679278	17.3532170890517	0.0008	423	92	COAD	TURPENTINE	Experimental	KRAS | NRAS | BRAF
604.6137022842339	-35.0952598904819	549.0888882434443	8.11187817714062	0.381	512	99	UCEC	PEGADEMASE BOVINE	Approved in other pathologies	ZAP70 | PTEN | SOS1
264.4446427110801	-42.2155881738289	198.64282043734391	-7.65265871634551	0.0008	512	79	UCEC	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE	Experimental	PIK3CA | SOS1 | RAC1
398.2949922395959	-8.5303165138676	398.8982542523924	2.33620634757358	0.222	512	81	UCEC	MILTEFOSINE	Approved in other pathologies	PIK3CA | ABCB1
546.8273785548755	9.05566277855252	581.9168656295533	-3.25132428601432	0.422	202	21	LAML	AKN-028	Clinical trials in cancer	FLT3 | KIT
705.0693507530793	50.7676620028363	693.601303763072	-1.08723437708738	0.545	599	67	GBM	GDC-0068	Clinical trials in cancer	KRAS | PTPN11 | PTEN
1027.1426343541561	10.4344761248083	1029.2317989392682	-11.3101095739798	0.915	202	31	LAML	BOSUTINIB	Approved in same tumor type	KRAS | NF1 | KIT
672.56192647249	38.1950023397494	649.5685073489057	7.8609656050329	0.515	202	37	LAML	FORETINIB	Clinical trials in cancer	FLT3 | KIT | NRAS
1131.1412326610712	-14.6746397271555	1083.535359934117	1.55701017258866	0.985	292	30	STAD	ABEMACICLIB	Approved in cancer	RB1 | SMAD4 | KRAS
677.3930331891021	-23.4487547256912	745.3540465351064	-25.9134050150865	0.592	264	40	SKCM	AFURESERTIB HYDROCHLORIDE	Clinical trials in cancer	PTPN11 | PTEN | AKT1
151.51503390986502	33.2281507851898	208.89028420217508	-10.6340455816992	0.0008	512	79	UCEC	PILARALISIB	Experimental	PIK3CA | SOS1 | RAC1
1123.4767456892973	-0.992689199727522	1093.2162172999806	-10.7798835916265	0.997	423	60	COAD	PAZOPANIB	Approved in cancer	KRAS | MTOR | ABL1
686.4577147318425	11.2380289369995	737.0544887123484	2.48351349292085	0.596	389	50	LUSC	BUPARLISIB	Clinical trials in cancer	KRAS | FGFR2 | PTEN
705.7194951000688	-80.3924116858728	736.3782061840134	13.7177014650895	0.59	543	94	LUAD	REFAMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
566.7916286129821	3.17705372370799	581.0641446832117	11.7031532800743	0.422	343	46	HNSC	BAY1125976	Clinical trials in cancer	AKT1 | PIK3CA
205.80843973142416	-27.3749921847843	211.07342485768578	-20.73033393527	0.0004	512	80	UCEC	UNII-S9WA04F921	Experimental	MTOR | PIK3CA
135.17183904894446	30.0578382414802	210.90241337928973	-25.1242654795865	0.0008	934	216	BRCA	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE	Experimental	PIK3CA
659.5019403935875	-33.4927129402229	720.7701934521394	7.1476606499109	0.538	264	28	SKCM	QUIZARTINIB	Clinical trials in cancer	KIT | FLT3 | PDGFRA
1085.6072050736407	93.3062543000053	1025.278676513958	-4.90554641596009	0.92	169	43	READ	TRASTUZUMAB	Approved in cancer	KRAS | BRAF | PIK3CA
294.14972938253413	-44.7078942228333	183.02276289204536	-16.9977842703424	0.0006	512	94	UCEC	RU78262	Experimental	PTEN | KDR | GNAS
188.19881071360777	-62.3605742758579	202.66717846182567	-15.0149756184414	0.023	343	45	HNSC	1173900-33-8	Clinical trials	PIK3CA
1026.9056079768254	-15.5742896352331	1003.9999258157668	0.000448450841304293	0.893	292	31	STAD	PEMETREXED	Approved in cancer	KRAS | PIK3CA | GNAS
679.7335168713058	-29.2321364669331	717.5826989585424	2.48185069183455	0.596	264	46	SKCM	ENMD-2076	Clinical trials in cancer	KIT | VHL | ARNT
488.624895661846	-33.3973834531862	495.11765812623264	-2.25928091180776	0.322	502	61	KIRC	PEGAPTANIB	Approved in other pathologies	VHL | MTOR | HSPG2
204.96259303925672	-49.08761124838	188.39033896164744	27.0238644572919	0.0004	264	29	SKCM	BMS-536924	Experimental	GPC3 | GNAS | ARNT
664.1282298155833	-15.6904455559599	697.6112869095239	-3.10876027088398	0.553	153	21	BLCA	1032350-13-2	Clinical trials in cancer	NRAS | PTEN | PIK3CA
1085.9021805904006	-37.4143295079283	1082.580560222941	2.35854077744489	0.984	153	27	BLCA	REGORAFENIB	Approved in cancer	RB1 | NRAS | CREBBP
167.6409661234933	-50.22454679886	203.01035531483083	-29.5912520992229	0.0006	264	34	SKCM	HERBIMYCIN A	Experimental	PTEN | GNAS | PIK3CA
681.7356911641484	-36.9494203502614	701.7707862249592	-16.3611131745301	0.543	934	227	BRCA	XL147	Clinical trials in cancer	KRAS | PTEN | MAP2K1
605.6561886572838	-57.3789423602243	585.2745745480316	-9.67324298163226	0.422	934	216	BRCA	GM-CSF	Clinical trials in cancer	PIK3CA
760.0509846997303	20.6318468386264	750.9994546002082	0.000371492469980694	0.612	202	23	LAML	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS
232.92977332311452	-16.4990259235016	181.96255380555792	-4.4461633438259	0.0004	343	49	HNSC	PNU-74654	Experimental	CTNNB1 | PIK3CA | FGFR3
142.96451587689086	-23.7808147770769	199.3413672274365	1.8156187325194	0.0004	153	19	BLCA	NUTLIN-3	Experimental	CTNNB1 | IDH1 | PIK3CA
899.7960718562656	-20.917105078485	902.1363347760883	-0.00145674590885392	0.781	264	27	SKCM	VITAMIN E	Approved in other pathologies and in clinical trials in cancer	GNA11 | BTK | KDR
183.5596795600573	-12.5989526035337	193.4887584457156	9.09493189283717	0.0006	502	60	KIRC	BETA-D-GLUCOSE	Experimental	VHL | MTOR | IKBKE
542.8946413343784	-45.2163916457163	566.7806175245869	-8.84641131143167	0.422	934	216	BRCA	DEMCIZUMAB	Clinical trials in cancer	KRAS | PIK3CA
778.0944036539021	-85.979547635194	753.1863427123673	-22.9090812299828	0.594	512	165	UCEC	SF1126	Clinical trials in cancer	KRAS | NRAS | TSC2
1057.4916185175523	52.3498163607503	949.2181144166042	22.7943189990557	0.823	57	24	PAAD	CARBOPLATIN	Approved in cancer	KRAS
299.8799987154277	-48.2586050242367	296.9933789317397	-0.322114126418796	0.111	202	31	LAML	ANTIBIOTIC K 252A	Clinical trials	KRAS | NF1 | KIT
163.39772610296723	139.28326919393	158.61408343143847	31.1591646931232	0.0006	57	24	PAAD	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS
239.70493729694456	-51.445595118068	181.22536891572662	5.73324710359725	0.0006	512	52	UCEC	79558-09-1	Experimental	CTNNB1 | CHD8 | GSK3B
661.5009344614831	-11.7016086685899	662.489642301079	0.49797692410516	0.512	512	52	UCEC	YM155	Clinical trials in cancer	CTNNB1 | DEK | PER1
1006.7542928606856	-35.3602556203912	1042.0786215716612	-10.5688419419157	0.93	543	90	LUAD	VEMURAFENIB	Approved in cancer	KRAS | NRAS | BRAF
984.7984453709126	-32.6535546422679	1031.5271990442313	-4.55144914136918	0.923	502	68	KIRC	ABT-199	Approved in cancer	VHL | AKT3 | MTOR
306.7534660085375	101.719337033787	156.74320456424414	17.649989949887	0.0006	435	211	THCA	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | BRAF
801.145097906633	-28.673935768965	712.6974306017165	-16.2651293089384	0.599	423	97	COAD	ALPELISIB	Clinical trials in cancer	KRAS | NRAS | ESR1
211.70528615075926	136.548399989174	153.81589692978028	-13.1219243014269	0.0004	57	24	PAAD	761437-28-9	Experimental	KRAS
160.31710742549953	8.83197299615017	184.3471923431708	-40.2550319098366	0.0006	512	94	UCEC	RU84687	Experimental	PTEN | KDR | GNAS
243.62257570565728	-43.8123705902567	203.1385615780919	15.5857056003267	0.0006	543	68	LUAD	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	Experimental	KRAS | SOS1 | MAP2K1
1185.838005103391	-39.3831095417449	1097.9106148977676	-63.6614993639496	1.0	264	207	SKCM	REGORAFENIB	Approved in cancer	RB1 | NF1 | NRAS
1147.5577832434776	72.9090688370841	1061.6635760946112	3.33915610843087	0.993	264	154	SKCM	SORAFENIB TOSYLATE	Approved in cancer	NF1 | KIT | PTPN11
505.86632351434935	-60.6975481644652	569.9821306221882	-17.4318527431245	0.412	57	24	PAAD	BGB-283	Clinical trials in cancer	KRAS
654.2660758836229	-123.080352989579	749.9293410919707	50.0774261798142	0.593	264	201	SKCM	BMS-908662	Clinical trials in cancer	NF1 | NRAS | KIT
719.2588403204497	-62.8939544286947	718.9458420194319	-3.75657808969072	0.581	264	40	SKCM	CC-401	Clinical trials in cancer	KRAS | AKT3 | MAP2K1
541.6683115502295	23.133607829838	588.778297860323	7.0228934179122	0.423	543	64	LUAD	DS-7423	Clinical trials in cancer	KRAS | PIK3CA
246.17556800881792	14.0204135473499	220.9618491461462	-0.268226835743008	0.022	202	21	LAML	JNJ-40346527	Clinical trials	FLT3 | KIT
1039.5552806877902	74.6818239820674	1017.4095547307978	-8.54824562755766	0.914	202	42	LAML	ARSENIC TRIOXIDE	Approved in same tumor type	KRAS | FLT3 | NRAS
1074.417759570564	-52.8694751318665	1099.6882297062568	2.48837826952195	0.997	153	23	BLCA	COPANLISIB	Approved in cancer	NRAS | PTEN | PIK3CA
600.007899653049	25.5714786808438	595.0372794725256	7.54894742490137	0.422	934	219	BRCA	PKI-179	Clinical trials in cancer	ERBB2 | PIK3CA | MTOR
664.8394250312875	0.14888960753089	710.7650634983167	-3.8771731887673	0.57	153	26	BLCA	SELUMETINIB	Clinical trials in cancer	NRAS | FGFR3 | IDH1
164.9654157619863	-59.3923410440731	204.46204949159278	4.36974069459393	0.0004	343	45	HNSC	NVP-AEW541	Experimental	PIK3CA
632.9456559062938	39.9460014943733	599.3733282235568	13.4903717328893	0.422	169	40	READ	BI 2536	Clinical trials in cancer	KRAS | BRAF
649.1248648654271	-5.75412329838124	727.1843723286607	0.84501879936056	0.589	543	96	LUAD	391210-10-9	Clinical trials in cancer	KRAS | NF1 | NRAS
582.010747123651	-84.28899110157	601.9504528839254	3.70136342512524	0.423	264	107	SKCM	1096708-71-2	Clinical trials in cancer	KRAS | BRAF | RAF1
207.30802301873413	-132.399817152809	270.97483159307353	-4.45297333854387	0.0008	264	185	SKCM	FR 180204	Experimental	NRAS | KRAS | AKT3
299.27677666123947	-38.1846336455387	186.20783295185373	-4.17043649018353	0.0006	202	29	LAML	GUANOSINE TRIPHOSPHATE	Experimental	FLT3 | KIT | PTPN11
166.59976532012251	-105.82793935666	212.08896544107216	32.9217678096211	0.0004	264	174	SKCM	LY3009120	Experimental	NRAS | KRAS | BRAF
793.7363832346895	-23.2431193135411	733.4252567526856	0.562158213287148	0.595	423	97	COAD	PICTILISIB	Clinical trials in cancer	KRAS | NRAS | ESR1
772.5300140604292	-100.667068354125	718.5329257858556	-44.1154345214654	0.593	264	124	SKCM	PF-04691502	Clinical trials in cancer	NRAS | KIT | KRAS
581.5874975950672	-19.7035660075888	568.1270589230636	-7.89946280160302	0.422	343	45	HNSC	INDOLE-3-CARBINOL	Clinical trials in cancer	PIK3CA
1042.9202906711046	-34.7516853728694	1044.6019077417707	0.145793096729903	0.939	543	82	LUAD	VANDETANIB	Approved in cancer	KRAS | CTNNB1 | EGFR
213.0461027963098	-41.518524606533	209.8431578959879	-10.4772295803699	0.0006	202	28	LAML	CHEMBL291678	Experimental	FLT3 | KIT | PTPN11
130.01365129197586	41.0200584663891	183.71779851453675	-4.74360312082058	0.0006	512	94	UCEC	PAS219	Experimental	PTEN | KDR | GNAS
609.3374518404471	-75.002934923263	563.3145363113126	19.6300901193863	0.412	264	107	SKCM	CH5132799	Clinical trials in cancer	KRAS | BRAF | PIK3CA
550.3165949076944	-3.4133690134019	581.0793575222909	-12.8607627693304	0.422	343	45	HNSC	AZD2014	Clinical trials in cancer	PIK3CA
633.9878196325222	17.0114989018913	677.8546676646928	2.5546505563143	0.532	502	63	KIRC	X-82	Clinical trials in cancer	VHL | MTOR | KDR
691.1486735775914	32.6336177503462	720.6937736129601	2.46744104277741	0.594	169	47	READ	APITOLISIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
188.2197642651171	-43.1682581897147	203.081371848098	16.4048072141168	0.0006	264	40	SKCM	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	Experimental	KRAS | AKT3 | MAP2K1
1157.3028349582198	30.8899439410081	1074.7753336175604	35.052337097603	0.999	264	138	SKCM	IMATINIB	Approved in cancer	RB1 | KIT | KRAS
1096.6957429686627	85.7029645076186	1052.2169488194893	14.4326619254559	0.949	57	24	PAAD	SORAFENIB	Approved in cancer	KRAS
148.67137245818708	63.6994494897941	192.66877667095474	-3.88777842605487	0.0006	502	62	KIRC	CHEMBL444422	Experimental	VHL | AKT3 | MTOR
187.0151343790101	-52.5268027918436	205.15260069276778	13.8717084622899	0.0006	423	72	COAD	A-443654	Experimental	KRAS | PIK3CA | ERBB2
933.4778819833668	5.09683009323717	930.7791895531211	3.58242694814453	0.812	423	57	COAD	IXABEPILONE	Approved in cancer	KRAS
279.32474198536545	134.040082486438	213.12503626445107	33.7134724392408	0.0004	222	135	LGG	ISOEVODIAMINE	Experimental	IDH1 | MTOR | PIK3CA
693.0334505664742	41.384914233898	747.7713451932744	-0.729067471505005	0.593	543	98	LUAD	XL147	Clinical trials in cancer	KRAS | NRAS | BRAF
1125.7382094885581	-20.2197189568588	1119.972247583535	-8.34186870264011	1.0	512	137	UCEC	EVEROLIMUS	Approved in cancer	KRAS | NRAS | TSC2
491.63282318550256	5.61473681338532	589.7430552652256	53.0778605233018	0.412	57	24	PAAD	PHENFORMIN	Clinical trials in cancer	KRAS
1049.9528183534576	41.3851775632032	1015.3288759130438	9.73295430168406	0.92	169	44	READ	GEFITINIB	Approved in cancer	KRAS | NRAS | BRAF
294.9711769838675	-31.4641923632834	199.44293849738833	11.8174580939273	0.0006	169	43	READ	SB220025	Experimental	KRAS | NRAS | CYBB
1026.786947553334	15.6547655465205	1030.4007598224414	5.30663880540192	0.921	202	23	LAML	SUNITINIB MALATE	Approved in cancer	FLT3 | KIT | KDR
582.3340769440829	-14.9342108083443	574.3271208006828	-3.08642151363301	0.412	543	60	LUAD	PHENFORMIN	Clinical trials in cancer	KRAS
153.03675326497546	3.17567768775538	192.86357742329417	-5.22218378485422	0.0004	343	45	HNSC	RG-7666	Experimental	PIK3CA
614.0424531060504	76.1537561216953	643.057696457096	30.3732495091383	0.522	435	185	THCA	SARACATINIB	Clinical trials in cancer	KRAS | BRAF | SOS1
196.26594608652348	143.104649908182	194.5000578207559	4.86337085900146	0.0004	57	24	PAAD	AT13148	Experimental	KRAS
710.0425221117763	-6.48265328957041	674.7471505205622	12.7439971805845	0.532	934	118	BRCA	GOSSYPOL	Clinical trials in cancer	TP53 | MAP2K1 | STAT3
667.533803593508	60.931178642729	597.9410254012327	4.01928905247411	0.432	169	41	READ	LONAFARNIB	Clinical trials in cancer	KRAS | NRAS
522.0340799575742	-57.2857625314984	551.0066919794632	12.7465059638148	0.412	435	183	THCA	PF-04217903	Clinical trials in cancer	BRAF
709.0823472933108	56.2008370046074	743.9853043522246	16.747092534326	0.596	169	40	READ	RAF265	Clinical trials in cancer	KRAS | BRAF | FGFR1
207.42029715747245	-77.7995092769791	216.06678656256844	-0.0736519585257156	0.0006	343	92	HNSC	OBLIMERSON	Experimental	TP53 | MAP2K1
213.57492884996532	-64.9655994518977	185.16409855389045	2.43895844261351	0.0004	512	80	UCEC	NVP-BGT226	Experimental	MTOR | PIK3CA
568.2729117575146	-21.9365958200194	578.845039199166	-1.48389607457966	0.422	543	71	LUAD	BMS-754807	Clinical trials in cancer	KRAS | EGFR
350.19526461472856	-38.2397225814562	308.9999600300652	0.000352904884806549	0.121	57	25	PAAD	ADENOSINE TRIPHOSPHATE	Clinical trials	KRAS | SMAD4
632.6572613223317	2.74645247592949	666.6751956788215	0.644951698750674	0.521	502	61	KIRC	ABT-510	Clinical trials in cancer	VHL | MTOR | MAPK14
628.8733472861176	-9.51193181673028	583.598710960123	-7.99434324822596	0.422	512	106	UCEC	SAR245409	Clinical trials in cancer	KRAS | PIK3CA
1011.3828587681156	-60.2739321032876	1054.3813442568883	-15.3692682427072	0.936	264	111	SKCM	PANOBINOSTAT	Approved in cancer	RB1 | KRAS | KMT2A
1009.8426356697003	43.8487047234268	1017.0909069110061	9.0706606124669	0.911	202	38	LAML	DABRAFENIB	Approved in cancer	KRAS | NF1 | KIT
131.95913267986563	75.9489810397645	226.91917267058173	47.8754991556707	0.0004	264	104	SKCM	RG-7256	Experimental	BRAF
1099.5048174424417	-41.8092223064017	1109.4771124031802	1.51875724910906	1.0	423	96	COAD	COBIMETINIB	Approved in cancer	KRAS | NRAS | NF1
652.8567394893703	-60.4455980037762	679.2902974080469	7.3757362190745	0.532	343	51	HNSC	1260612-13-2	Clinical trials in cancer	RAC1 | PIK3CA | SOS1
999.1586632250703	26.2428013217472	1052.1786441461932	-0.928914322142077	0.948	389	51	LUSC	PONATINIB	Approved in cancer	KRAS | FGFR2 | PTEN
102.27166985019431	74.2726102130071	205.40201861641702	64.5861640905002	0.0004	435	185	THCA	154447-36-6	Experimental	KRAS | BRAF | PIK3CA
561.9584282597586	81.5808710110587	556.5233995899619	58.4587535936433	0.422	57	24	PAAD	RAF265	Clinical trials in cancer	KRAS
768.0612328697803	4.62314619370432	666.8266283124586	3.06432396716764	0.522	202	38	LAML	ENCORAFENIB	Clinical trials in cancer	KRAS | NF1 | KIT
938.0753615032031	11.0283945899531	949.614754418754	-2.51523968020001	0.833	169	41	READ	CAPECITABINE	Approved in same tumor type	KRAS | PIK3CA | ERBB2
1130.4153638519288	24.8856651428048	1097.1357175919445	6.79241916175295	0.987	169	48	READ	BOSUTINIB	Approved in cancer	KRAS | SMAD4 | NRAS
561.5837387404873	5.26245209038129	597.9557225209289	-12.9225645465106	0.432	512	82	UCEC	ARQ-092	Clinical trials in cancer	PIK3CA | ERBB2 | BRAF
731.7440146820862	-35.8913114345858	728.4559466027426	12.764219690778	0.582	292	40	STAD	AT-101	Clinical trials in cancer	MAP2K1 | CREBBP | TP53
740.9384111363586	62.4620347254716	670.3519858085344	0.230747409161836	0.536	169	41	READ	RIDAFOROLIMUS	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
555.1787904101994	-22.3081989213455	572.1566058245569	-11.3456540437719	0.422	343	46	HNSC	AFURESERTIB	Clinical trials in cancer	AKT1 | PIK3CA
125.47238350081973	16.3330292874973	198.39744901924462	-0.170485591400393	0.0004	543	71	LUAD	TW-37	Experimental	KRAS | BRAF | PIK3CA
1025.910187188625	-2.18333916234536	1025.2657795105645	-5.09158836495112	0.922	599	125	OV	BORTEZOMIB	Approved in cancer	KRAS | TP53 | PIK3CA
166.18723347351457	-40.728894238081	191.71728545260336	9.00332781455563	0.0006	264	35	SKCM	1-(2,6-DICHLOROPHENYL)-5-(2,4-DIFLUOROPHENYL)-7-PIPERIDIN-4-YL-3,4-DIHYDROQUINOLIN-2(1H)-ONE	Experimental	CYBB | AKT3 | GNAS
719.9794316144579	-3.76496010753718	711.0208382597699	-7.13550382857125	0.583	543	93	LUAD	1032350-13-2	Clinical trials in cancer	KRAS | NRAS | BRAF
1097.1444510412603	-18.2345889660086	1105.296379604515	15.5419942880035	1.0	423	96	COAD	TRAMETINIB	Approved in cancer	KRAS | NRAS | NF1
1072.3357548541655	-12.1027872212088	1055.5609910419112	0.785235787181136	0.954	153	39	BLCA	PACLITAXEL	Approved in cancer	CREBBP | TP53 | PIK3CA
907.1272398822723	-13.4470483276062	966.2026772025624	-24.7732671408426	0.822	57	24	PAAD	RAMUCIRUMAB	Approved in cancer	KRAS
764.7447057278525	-22.6727451493713	678.438621024452	22.1464019773935	0.525	202	43	LAML	SARACATINIB	Clinical trials in cancer	KRAS | IDH1 | IDH2
648.4474134147455	2.21890868017289	677.5565856006294	-6.45855522431134	0.534	502	66	KIRC	ORANTINIB	Clinical trials in cancer	VHL | MTOR | FGFR3
939.3782321206751	2.44127585718974	969.5610136341974	-3.88675397124507	0.852	423	80	COAD	NERATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
166.14823153744135	90.637980204118	215.4473523050949	7.67266004546377	0.0008	502	63	KIRC	IMC-1C11	Experimental	VHL | MTOR | KDR
73.53770705910674	-87.1917626458405	190.5749686240555	-78.8737965160331	0.0008	264	194	SKCM	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	NF1 | NRAS | KIT
1112.465169546245	-97.3152884860275	1070.6192428253485	-51.9305599541212	0.97	264	185	SKCM	VEMURAFENIB	Approved in same tumor type	NRAS | KRAS | BRAF
202.41587958664232	-16.0373963783517	216.02576546879493	-10.2220733569898	0.0006	502	59	KIRC	BILIVERDIN	Experimental	VHL | MTOR
476.69791807082953	-21.9407085433719	484.0256604184595	-0.687104962790499	0.313	502	62	KIRC	SAPROPTERIN	Approved in other pathologies	VHL | AKT3 | MTOR
264.2161548880162	19.2365537275177	198.61380230580733	9.594263710409	0.0008	202	38	LAML	ISOCITRIC ACID	Experimental	IDH1 | IDH2
965.2129776523303	-13.0406709754209	967.0758825654227	-0.0402476536000904	0.852	343	49	HNSC	CABOZANTINIB	Approved in cancer	PIK3CA | HRAS | EGFR
229.05536915659812	19.4755097535055	203.8373735441338	19.8011280885676	0.0006	512	94	UCEC	RU79072	Experimental	PTEN | KDR | GNAS
1101.202634230872	12.6972524535337	1089.0102315322206	-9.4945927991547	0.985	169	46	READ	ABEMACICLIB	Approved in cancer	KRAS | SMAD4 | NRAS
135.2658458725803	-6.95277936166252	198.95554412850504	-54.0472505430607	0.0004	264	70	SKCM	N-METHYL-N-NITROSOUREA	Experimental	NRAS | MYC
228.462242936115	-28.2512694470506	185.12424590219226	-16.663126568631	0.0004	423	81	COAD	154447-36-6	Experimental	KRAS | MTOR | BRAF
577.7960897589502	20.576968718696	575.9117925309558	7.62111664996155	0.423	934	235	BRCA	UPROSERTIB	Clinical trials in cancer	AKT1 | PIK3CA | BRAF
162.93824207339145	-85.3338383035563	241.20775995514862	-47.7563739973561	0.0004	264	106	SKCM	UNC0638	Experimental	BRAF | GMDS
611.6366692310676	-20.6136853867572	597.9528312204675	3.44516055174927	0.433	423	66	COAD	CAMPTOTHECIN	Clinical trials in cancer	KRAS | IDH2 | PIK3CA
704.0788391043994	0.859265748206639	660.3697198761722	-1.87372908944872	0.514	543	68	LUAD	BI 2536	Clinical trials in cancer	KRAS | BRAF | CHEK1
163.9116411030535	96.2966048631576	171.18109651214303	-5.32946161489212	0.0006	169	28	READ	OBLIMERSON	Experimental	BRAF | TP53 | RAF1
195.58430536708966	-32.0976148931954	208.61250741040217	17.518092691028	0.0006	264	35	SKCM	1-(5-TERT-BUTYL-2-METHYL-2H-PYRAZOL-3-YL)-3-(4-CHLORO-PHENYL)-UREA	Experimental	CYBB | AKT3 | GNAS
1013.3749164678171	-30.1755279594435	1047.3106368659476	-0.146133092618129	0.951	264	42	SKCM	SUNITINIB MALATE	Approved in cancer	KIT | HSPG2 | KDR
369.14998718907117	4.52935243743607	370.4656949016616	0.00887189515719911	0.191	292	32	STAD	ADENOSINE TRIPHOSPHATE	Clinical trials	RB1 | SMAD4 | KRAS
107.56253552940957	-19.2704336281443	170.316818164997	21.3064983123918	0.0004	934	217	BRCA	VOXTALISIB	Experimental	PIK3CA | MTOR
87.46745686927268	66.123497042164	168.1772320526864	17.3111468576406	0.0006	57	24	PAAD	PI-103	Experimental	KRAS
794.3154040379758	-14.976272510812	724.2615741570169	17.4271089024044	0.593	543	99	LUAD	BUPARLISIB	Clinical trials in cancer	KRAS | NRAS | BRAF
646.8685913198801	111.009927346073	663.4358647440681	-8.8225152222754	0.552	57	24	PAAD	SF1126	Clinical trials in cancer	KRAS
219.16915188295212	2.43405264991168	226.07160623768831	-4.37859495649195	0.0004	512	77	UCEC	RECILISIB	Experimental	PIK3CA
247.14657100676743	-0.355073543362124	193.76325116133543	-9.76015778254759	0.0004	512	60	UCEC	ZEBULARINE	Experimental	CTNNB1 | MTOR | SOS1
1129.4697711751903	47.9013734156978	1044.7763455449524	23.5732058080437	0.922	435	186	THCA	DOCETAXEL	Approved in cancer	KRAS | BRAF | TP53
917.9886326785387	-5.58086244573269	946.18261457489	5.0471497649911	0.822	202	35	LAML	CYTARABINE	Approved in same tumor type	FLT3 | KIT | NRAS
716.381848661478	-19.9926702943059	690.0373530214262	3.38055572242683	0.544	343	55	HNSC	AZD5363	Clinical trials in cancer	PTEN | AKT1 | PIK3CA
727.7503719943765	10.0986767677952	734.6292268401891	-10.190475343996	0.593	543	101	LUAD	PICTILISIB	Clinical trials in cancer	KRAS | NRAS | BRAF
495.05530602706415	77.4490303124841	548.7403500736684	-43.4706356045609	0.412	57	24	PAAD	2-[(E)-2-(3-NITROPHENYL)VINYL]QUINOLINE	Clinical trials in cancer	KRAS
775.2662048783333	-9.80619341896931	739.0483448848429	7.38945201214671	0.599	389	53	LUSC	ALPELISIB	Clinical trials in cancer	KRAS | FGFR2 | PTEN
809.6239324253413	55.8067897405746	734.4117467032385	14.5598890898207	0.584	169	43	READ	AZD5363	Clinical trials in cancer	KRAS | PTPN11 | PTEN
1022.2758313121092	-36.9641806460292	1032.916909636227	-4.40649093309594	0.93	343	49	HNSC	TEMSIROLIMUS	Approved in cancer	CTNNB1 | STK11 | AKT1
202.1297436843193	-56.6088301250911	182.01950631086765	3.64131441371774	0.0006	502	59	KIRC	10041-02-8	Experimental	VHL | MTOR
1118.714786950984	-42.5196436857078	1071.7950813917857	0.387294066933464	0.962	543	80	LUAD	LENALIDOMIDE	Approved in cancer	KRAS | CTNNB1 | EGFR
467.51034284248914	-21.820645421543	480.59923654334904	-2.5033476028691	0.311	202	28	LAML	PEGADEMASE BOVINE	Approved in other pathologies	FLT3 | KIT | PTPN11
1032.425415796581	14.4395321995192	1070.2081522417882	0.0741132028741731	0.965	389	71	LUSC	PACLITAXEL	Approved in same tumor type	KRAS | BRAF | AKT1
600.2586044165362	-18.8610099102767	667.4743801312487	11.9164337904965	0.53	934	225	BRCA	PIMASERTIB	Clinical trials in cancer	KRAS | NF1 | MAP2K1
547.5875248019709	-29.109137151927	580.8690394504837	-0.111485188389452	0.422	423	69	COAD	FOLFIRI REGIMEN	Clinical trials in cancer	KRAS | NRAS
295.3159379412293	116.265684927966	218.47549019557482	23.5858188604103	0.0006	57	25	PAAD	OLOMOUCINE	Experimental	KRAS | SMAD4
1005.51532437319	0.283397660076076	1012.511492041305	4.83714491971114	0.907	202	25	LAML	RIBOCICLIB	Approved in cancer	KRAS | NRAS | MYC
711.4085625972951	30.606413209518	684.5858969348699	-0.164908523850727	0.541	389	52	LUSC	DHA-PACLITAXEL	Clinical trials in cancer	BRAF | TP53 | MAPK14
280.2568161076653	-125.046051046266	196.6849175321046	21.6826432167654	0.0006	343	92	HNSC	OBLIMERSEN	Experimental	TP53 | MAP2K1
956.4502278364555	3.25601487374593	950.000052677785	-0.000254700341201897	0.833	292	32	STAD	IRINOTECAN	Approved in cancer	KRAS | AKT1 | PIK3CA
101.56022895891579	-92.7389072312901	156.3589338568404	-31.4333230971524	0.0008	264	185	SKCM	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	NRAS | KRAS | AKT3
179.3833921688263	-73.1444089598464	192.0161085500587	-20.3143782543477	0.0004	934	217	BRCA	TW-37	Experimental	KRAS | PIK3CA | BRAF
106.20891873451306	-11.4969546536215	219.60025115675447	14.6402491017398	0.013	512	80	UCEC	1173900-33-8	Clinical trials	PIK3CA | BRAF
736.7615147581757	-44.2450283433265	688.9734563213389	32.7836514189735	0.595	264	44	SKCM	TRICIRIBINE	Clinical trials in cancer	PTPN11 | PTEN | AKT1
605.275332213237	2.16681335793479	586.7048324188979	1.07710112310951	0.422	423	57	COAD	ULIXERTINIB	Clinical trials in cancer	KRAS | MAPK1
204.9379915173962	-64.7515303760459	190.73610843361976	1.89995934933472	0.0004	292	30	STAD	TW-37	Experimental	KRAS | PIK3CA | BRAF
929.3477649723856	36.021063255876	985.7797979283351	-0.270237233967464	0.832	435	185	THCA	NERATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
466.208223931226	8.14813918021383	639.5477953415992	44.9206408335208	0.412	57	24	PAAD	DANUSERTIB	Clinical trials in cancer	KRAS
190.44603632044112	-56.9427062257781	223.7186484497336	22.2077236278751	0.0006	264	35	SKCM	CHEMBL522579	Experimental	CYBB | AKT3 | GNAS
536.4811638243084	-11.1582765879097	590.141283427503	13.3756599265444	0.422	423	65	COAD	1375469-38-7	Clinical trials in cancer	KRAS | PIK3CA
291.74920337448924	-84.3335559923344	255.3957101021478	-40.3931239194467	0.0004	264	105	SKCM	SB590885	Experimental	BRAF | RAF1
265.7187973939408	-12.6388309301603	178.39452540432703	14.7978064055501	0.0006	512	76	UCEC	HYPOTHEMYCIN	Experimental	KRAS | NRAS | BRAF
158.84791051843175	-17.3614820556077	222.28017369278865	12.0378121485994	0.0006	934	117	BRCA	OBLIMERSEN	Experimental	TP53 | MAP2K1 | STAT3
783.0955053302597	96.4635963615507	625.2240263292205	-15.2101885807276	0.512	435	184	THCA	AT-101	Clinical trials in cancer	BRAF | TP53
200.8958260262014	28.2269937046594	172.00709183029298	-22.993288573799	0.0004	512	77	UCEC	RG-7666	Experimental	PIK3CA
211.07268022441085	16.7365456392531	167.33922636832946	1.9452566359605	0.0006	512	94	UCEC	PURVALANOL A	Experimental	PTEN | KDR | GNAS
692.7998529489452	22.2165166181117	741.2472178197689	4.48247593403426	0.587	292	36	STAD	FLAVOPIRIDOL	Clinical trials in cancer	RB1 | SMAD4 | MAP2K1
705.0405804736864	-12.6744900164599	736.8539855699058	9.27704491943132	0.585	292	30	STAD	MLN1117	Clinical trials in cancer	KRAS | PIK3CA | IRS1
712.330503099566	25.686541856979	726.093979645552	-6.92730700109973	0.589	292	35	STAD	391210-10-9	Clinical trials in cancer	KRAS | NF1 | NRAS
129.10355986162816	-100.581377370324	119.31372727877137	44.5696147865524	0.0004	264	192	SKCM	LY2183240	Experimental	NRAS | KRAS | BRAF
695.282395003641	-19.7989143422387	728.5339039137186	6.95031232476822	0.583	543	74	LUAD	1224844-38-5	Clinical trials in cancer	KRAS | STK11 | BRAF
218.0921464481286	-41.0801451921176	184.73152851611604	-10.1599922849005	0.0004	423	57	COAD	AURORA KINASE INHIBITOR II	Experimental	KRAS
155.5693764955125	-51.97248398153	191.98194996076558	-18.391067434558	0.0006	264	35	SKCM	1BMK	Experimental	CYBB | AKT3 | GNAS
1115.320154871591	52.5616571604203	1109.85466023945	-8.74452559226023	0.997	169	47	READ	COPANLISIB	Approved in cancer	KRAS | PTPN11 | NRAS
501.3202956408666	-3.16222455074984	571.1787244700071	-0.758393430444812	0.412	934	216	BRCA	INDOLE-3-CARBINOL	Clinical trials in cancer	PIK3CA
774.5365892519416	142.299400613193	815.3726694557165	8.26524003129816	0.6	264	202	SKCM	391210-10-9	Clinical trials in cancer	NF1 | NRAS | KIT
223.42384970380107	54.5577095667418	205.02446333702326	-7.99544875359527	0.0008	202	24	LAML	HYPOTHEMYCIN	Experimental	KRAS | NRAS | MAPK1
539.9659740757193	-34.7685470340438	553.3132310947136	-5.17694853286412	0.392	512	55	UCEC	DALTEPARIN	Approved in other pathologies	VHL | CTNNB1 | MTOR
1012.6595451399035	66.4527255551408	1028.0067552204648	-7.18723049405594	0.93	934	241	BRCA	TEMSIROLIMUS	Approved in cancer	KRAS | STK11 | AKT1
782.7237831504107	34.3447623505286	732.9809152171495	-6.67165730747786	0.593	389	48	LUSC	XL147	Clinical trials in cancer	KRAS | PTEN | BRAF
1040.068208921169	-58.4516462927283	1071.5859239382928	6.14658209588242	0.962	343	129	HNSC	DOCETAXEL	Approved in cancer	TP53 | PIK3CA | MAP2K1
560.8216199592155	-37.8526662034901	591.899765559975	-4.16620129482044	0.422	343	45	HNSC	DUVELISIB	Clinical trials in cancer	PIK3CA
120.90027819009035	-75.2316021780975	235.08288549425052	23.4714452218473	0.0004	222	134	LGG	CYTOCHALASIN B	Experimental	NRAS | IDH1 | RAF1
527.5371250802822	-6.23951266135171	543.0000484593427	-1.39575815865101e-05	0.381	543	78	LUAD	ISOPRENALINE	Approved in other pathologies	KRAS | NRAS | BRAF
1203.9491628117685	14.5154750771395	1132.9669356839854	-48.2888207568067	1.0	264	201	SKCM	DABRAFENIB	Approved in same tumor type	NF1 | NRAS | KIT
130.4800736640283	-21.2775543015196	183.3966979511731	-15.98532736885	0.0006	264	32	SKCM	BMS 275291	Experimental	CYBB | CTNNB1 | MAP2K1
1020.9023015900273	5.54110711342122	1065.7664350614227	-1.03564977926658	0.94	934	227	BRCA	DASATINIB	Approved in cancer	KRAS | RB1 | PTEN
751.0390786445946	23.4374590782197	744.5911434103941	0.497822461473334	0.595	292	40	STAD	PX-866	Clinical trials in cancer	KRAS | PTPN11 | NGF
83.49032160084316	-114.395967011772	164.35538067657902	81.5838932300439	0.0008	264	190	SKCM	SB220025	Experimental	NRAS | KRAS | CYBB
321.8237906563838	-8.64456336212749	302.59772451034326	0.338633968466297	0.111	202	26	LAML	ADENOSINE TRIPHOSPHATE	Clinical trials	KRAS | NRAS | SOS1
551.1775653231889	-19.2159758472703	554.3706171073304	-0.730032339749641	0.391	512	62	UCEC	UREA	Approved in other pathologies	CTNNB1 | KRIT1 | CDH1
1095.2351023904757	28.8465505688873	1100.1816287397053	17.7374425164767	1.0	169	48	READ	SORAFENIB	Approved in cancer	KRAS | PTPN11 | NRAS
664.9646204570915	-49.6859381895553	651.0001143599004	-0.00093760708841728	0.501	343	46	HNSC	RESVERATROL	Clinical trials in cancer	PIK3CA | MAP2K1
60.65498389573058	50.5661848309825	281.3459866247444	20.7116734322376	0.0004	264	174	SKCM	GDC-0879	Experimental	NRAS | KRAS | BRAF
646.447577289194	-27.2227559548948	577.6414695080841	3.36015368889184	0.422	264	72	SKCM	LONAFARNIB	Clinical trials in cancer	NRAS | KRAS | ABCB1
164.32876138884126	-5.19873218334445	196.5080256726002	-0.416842904186979	0.0004	343	46	HNSC	BISTRAMIDE A	Experimental	PIK3CA | MYC
623.8314417143973	-13.4905318413169	654.5591694701952	-2.36419981906772	0.524	202	31	LAML	212631-79-3	Clinical trials in cancer	KRAS | NF1 | KIT
719.2852785979621	-12.4805271518786	668.4553533932	-2.67474503862809	0.516	934	223	BRCA	RIDAFOROLIMUS	Clinical trials in cancer	KRAS | STK11 | ERBB2
1052.7460551671566	-64.0473937124461	1069.0474883638958	4.9842160819685	0.962	153	39	BLCA	DOCETAXEL	Approved in cancer	CREBBP | TP53 | PIK3CA
176.2517227024978	0.130184214421973	205.98456252818391	-11.0059783200709	0.0004	343	45	HNSC	RECILISIB	Experimental	PIK3CA
1083.9910855583994	-7.32031421634122	1106.2540528541467	11.4121405900473	1.0	512	80	UCEC	SUNITINIB	Approved in cancer	KRAS | VHL | MTOR
122.01481057767107	10.0242434155463	205.48139662154114	-7.25102902436242	0.0004	934	216	BRCA	PUQUITINIB	Experimental	PIK3CA
172.87180815228203	4.38985504698144	201.32884939207918	10.7508555051575	0.0004	543	72	LUAD	GDC-0879	Experimental	KRAS | NRAS | BRAF
579.738036282048	-41.5213047738595	577.088878244444	-4.72396136512407	0.412	423	57	COAD	BBI608	Clinical trials in cancer	KRAS
232.27053605059646	-54.7518052769187	191.7089854299666	8.15825409605145	0.0004	543	72	LUAD	LY3009120	Experimental	KRAS | NRAS | BRAF
222.22699172756904	109.047106731596	220.74515248191574	-7.72219839152746	0.022	57	24	PAAD	FASUDIL	Clinical trials	KRAS
483.43066649581647	-60.8542346684261	536.7492453913421	-14.8920374255226	0.381	264	185	SKCM	ISOPRENALINE	Approved in other pathologies	NRAS | KRAS | AKT3
631.9068767066428	-49.4287539707498	725.4843762170867	5.11696168509843	0.596	423	97	COAD	BUPARLISIB	Clinical trials in cancer	KRAS | NRAS | ESR1
325.27129666058426	41.969849565391	170.8866836336401	30.7386266030833	0.0004	435	211	THCA	GDC-0879	Experimental	KRAS | NRAS | BRAF
697.969933878776	9.5673672958452	728.3089631393374	-11.3244761903461	0.591	512	63	UCEC	TAK-593	Clinical trials in cancer	VHL | CTNNB1 | MTOR
187.77265186539813	99.83908416405	195.34247352566535	-5.04558254529917	0.0004	169	41	READ	KINETIN RIBOSIDE	Experimental	KRAS | PIK3CA | ERBB2
466.47253764356503	60.6650500779103	598.521818766294	-51.5336978747629	0.422	57	24	PAAD	GDC-0032	Clinical trials in cancer	KRAS
1120.2395999196863	-62.1733318661998	1018.173566621697	7.82349560298826	0.93	264	116	SKCM	TRASTUZUMAB	Approved in cancer	KRAS | BRAF | PIK3CA
181.7949362002956	-79.8829572518709	198.34601607994188	14.2808359156079	0.0004	264	30	SKCM	ZEBULARINE	Experimental	KIT | LMNA | CTNNB1
544.0875409252146	-23.8166074918598	600.8697356166648	-8.28659929723062	0.433	423	66	COAD	DS-7423	Clinical trials in cancer	KRAS | MTOR | PIK3CA
716.3868456977772	78.8877231312225	688.5909934383698	4.22994961895216	0.534	169	54	READ	NAVITOCLAX	Clinical trials in cancer	KRAS | PTPN11 | BRAF
240.72998508814214	63.6390639329514	206.82156057709076	-7.86960282275004	0.0006	502	62	KIRC	L-NIO	Experimental	VHL | AKT3 | MTOR
609.2481881276527	28.3877095086838	607.0744336774989	7.61168248483193	0.442	169	42	READ	AZD8055	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
952.8502608352557	9.23174497954415	932.4590164086532	-0.657681903722732	0.822	934	216	BRCA	STREPTOZOCIN	Approved in cancer	PIK3CA
637.5352124800008	-39.5432543487784	721.4076189372993	-13.2860035804806	0.582	264	32	SKCM	PRINOMASTAT	Clinical trials in cancer	CYBB | CTNNB1 | MAP2K1
652.1508476025748	35.3859853022827	661.0036456366183	-55.5909564194112	0.538	435	211	THCA	DACTOLISIB	Clinical trials in cancer	KRAS | NRAS | BRAF
159.84362887306744	-28.7802913154588	209.0555004632748	3.12252478441451	0.0006	153	16	BLCA	AT7867	Experimental	PIK3CA | ERBB4 | HRAS
206.01215099312938	-33.9534194079959	196.4058384103572	8.11620818173833	0.0004	153	25	BLCA	ISOEVODIAMINE	Experimental	CTNNB1 | FGFR3 | IDH1
233.50668407784005	28.9000823711605	192.8065340857789	-14.6659923011548	0.0006	512	71	UCEC	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	Experimental	KRAS | SOS1 | MAP3K8
748.5979362326203	-40.3141567969984	743.138327963654	12.7917495568752	0.582	543	91	LUAD	SARACATINIB	Clinical trials in cancer	KRAS | RB1 | SMAD4
477.72041393324076	34.164050328885	576.8634591643048	-33.450688180169	0.422	435	185	THCA	BI 2536	Clinical trials in cancer	KRAS | BRAF
1050.7431451152343	24.9741676215471	1056.546930058489	3.42801431043068	0.952	389	69	LUSC	DOCETAXEL	Approved in cancer	KRAS | BRAF | TP53
617.2987257751878	-11.0222032758048	574.6481952492809	8.31602468093524	0.422	512	106	UCEC	1375469-38-7	Clinical trials in cancer	KRAS | PIK3CA
618.3969410861895	18.7901980941966	577.1494704380804	27.2526976886602	0.412	435	183	THCA	CAPMATINIB	Clinical trials in cancer	BRAF
181.24368721946524	-27.8422910667896	214.40751825045402	-10.9772000676469	0.0006	543	82	LUAD	SB220025	Experimental	KRAS | NRAS | BRAF
618.4657289296197	-25.8385914405923	625.8785827140487	-2.6656446474276	0.471	512	88	UCEC	ABT-751	Clinical trials in cancer	PIK3CA | BRAF | ITK
492.99436849600255	60.7539299746593	526.0973895099595	-25.1153448912315	0.412	57	24	PAAD	BBI608	Clinical trials in cancer	KRAS
840.8950400295381	-22.9725580874122	833.0348649903594	-3.25671577287085	0.703	343	49	HNSC	SULINDAC	Approved in other pathologies and in clinical trials in cancer	CTNNB1 | PIK3CA | MAP2K1
710.471675713656	46.202101686632	696.0702927980989	-24.2668389230339	0.547	934	229	BRCA	PKI-587	Clinical trials in cancer	KRAS | STK11 | PTEN
732.660094538617	-2.08359101959948	733.8211423374032	6.34649228581191	0.595	389	48	LUSC	PF-04691502	Clinical trials in cancer	KRAS | PTEN | EGFR
710.3390485852306	-38.2627382018972	688.0006185060404	-0.00187415629329735	0.542	543	97	LUAD	ENCORAFENIB	Clinical trials in cancer	KRAS | NF1 | NRAS
540.8735193753147	39.3035728319022	564.6342749939743	-8.55711774209885	0.412	512	77	UCEC	DUVELISIB	Clinical trials in cancer	PIK3CA
765.2756569899419	-30.3715749787106	714.512906736031	3.19557084741768	0.583	543	98	LUAD	GSK2636771	Clinical trials in cancer	KRAS | NRAS | BRAF
571.7054057738245	6.04606320865747	569.1976938386816	-12.4794516996712	0.412	512	77	UCEC	ACALISIB	Clinical trials in cancer	PIK3CA
728.0442961500713	-4.43295679371357	732.0928543290619	8.66547182456407	0.595	292	40	STAD	PF-04691502	Clinical trials in cancer	KRAS | PTPN11 | NGF
195.89999190074028	-23.027713322644	237.8643176306695	11.0023269304916	0.012	512	77	UCEC	TG100-115	Clinical trials	PIK3CA
561.1158486533095	-45.1087333862097	566.4177675280516	-5.57317880440633	0.422	423	57	COAD	2-[(E)-2-(3-NITROPHENYL)VINYL]QUINOLINE	Clinical trials in cancer	KRAS
561.4661416720795	-9.73639985906266	575.2903376936688	-10.2015075238137	0.422	423	65	COAD	DEMCIZUMAB	Clinical trials in cancer	KRAS | PIK3CA
1029.3694168650043	50.5748983505046	1046.2703901685359	-5.76972182373152	0.939	543	83	LUAD	CABOZANTINIB	Approved in cancer	KRAS | NRAS | EGFR
331.60837276390004	25.0721070281936	201.34728106599687	22.0948132431864	0.0006	57	24	PAAD	DB07268	Experimental	KRAS
564.9955196261127	-14.2337946208922	569.8877178827404	-0.846740107647292	0.422	543	75	LUAD	LINSITINIB	Clinical trials in cancer	KRAS | EGFR | PIK3CA
920.7121492758242	0.805511541046855	940.5034839126889	1.87476912374404	0.822	343	45	HNSC	CAPECITABINE	Approved in cancer	PIK3CA
700.5238690369201	-34.0490818634331	704.3554378764367	3.13962412418459	0.565	423	56	COAD	GSK2126458	Clinical trials in cancer	NRAS | MTOR | BRAF
198.53224230906866	-27.8971506347256	205.19930971036447	-20.6265801193003	0.0004	343	46	HNSC	GSK2334470	Experimental	PIK3CA | EGFR
750.8047980624469	-85.1235994749929	725.8831616445409	-3.36689986708643	0.596	423	83	COAD	XL765	Clinical trials in cancer	KRAS | NRAS | ESR1
200.5223041401019	-48.7093604708588	196.6841536432871	-2.061204673867	0.0004	153	17	BLCA	109511-58-2	Experimental	FGFR3 | PIK3CA | RAF1
1054.3723931718723	-15.8791489827952	1025.9255639129083	4.63255014574725	0.93	543	85	LUAD	AFATINIB	Approved in same tumor type	KRAS | NRAS | BRAF
155.47449243706725	-28.7518931777338	191.18638195034146	9.72926002309805	0.0004	343	45	HNSC	CCT128930	Experimental	PIK3CA
747.9273575575053	-0.809113185802886	747.2860635367892	13.5213753948697	0.6	423	99	COAD	SELUMETINIB	Clinical trials in cancer	KRAS | NRAS | NF1
159.34455105376205	-69.2434678232357	168.28881849783738	-50.3157413748158	0.0006	264	111	SKCM	GOSURANEMAB	Experimental	BRAF | MAP2K1 | RAF1
812.553633044163	114.052495076721	689.7900494980196	39.9014770748329	0.523	435	211	THCA	RO4987655	Clinical trials in cancer	KRAS | NRAS | BRAF
249.32084475608454	72.8340110268549	196.19033816793285	-15.9444561326496	0.0006	57	6	PAAD	O-PHOSPHO-L-SERINE	Experimental	SMAD4 | TGFBR1
553.6411639307928	-63.4151998924703	568.5326625764283	-6.57622202305311	0.422	264	106	SKCM	952021-60-2	Clinical trials in cancer	KRAS | BRAF
911.753897357371	38.0615881976289	940.4148663986776	5.12179358481626	0.823	435	211	THCA	GEFITINIB	Approved in cancer	KRAS | NRAS | BRAF
918.7811423782312	21.1492767420925	926.7552844390132	32.9594286292484	0.822	435	185	THCA	PANOBINOSTAT	Approved in cancer	KRAS | BRAF
292.2138415029962	-56.5776712900018	222.68222731813515	-19.6116806356322	0.0004	435	183	THCA	P-0850	Experimental	BRAF | PIK3CA
532.2702097287581	13.0129262661325	559.1717376673711	15.7288956963383	0.412	169	38	READ	BBI608	Clinical trials in cancer	KRAS
1071.9126303379323	-4.67804920544319	1066.7750714764804	-2.22286783452023	0.963	599	64	GBM	SORAFENIB	Approved in cancer	NF1 | NRAS | KRAS
719.1712992023239	20.0025112944291	652.3112428963665	-10.273405874546	0.523	202	52	LAML	PF-04691502	Clinical trials in cancer	KRAS | FLT3 | KIT
162.12465577440958	52.5285520780862	191.05851650528624	-2.16859106850393	0.0008	202	24	LAML	TURPENTINE	Experimental	KRAS | NRAS | MAPK1
1049.3718396681058	-32.970964057571	1036.875715968798	-4.23345162145051	0.931	153	28	BLCA	ERIBULIN	Approved in cancer	CREBBP | TP53 | CHUK
652.0491316062884	-1.06155895342994	658.4960427917622	1.93533775050128	0.511	502	59	KIRC	DIHYDROXYACETONE PHOSPHATE	Clinical trials in cancer	VHL | MTOR
937.985028798064	86.1159781752353	982.3473580029121	16.7403917629819	0.841	57	24	PAAD	ETOPOSIDE	Approved in cancer	KRAS
207.21339252872758	-40.1194010353224	221.15628647162976	-7.61402006037179	0.0004	343	55	HNSC	PARBENDAZOLE	Experimental	CTNNB1 | RAC1 | PIK3CA
621.6012839264456	-49.6224851464768	595.7819273423818	-11.1035911893841	0.442	423	57	COAD	AZD4547	Clinical trials in cancer	KRAS | ERBB2 | KDR
935.7498254877651	-18.570629734516	931.0003108743772	-0.00044132872199043	0.812	153	18	BLCA	CETUXIMAB	Approved in cancer	NRAS | PIK3CA | ERBB4
1078.420675055898	42.8002537856748	1032.9692479028765	-2.54811193313094	0.921	599	118	OV	ERIBULIN	Approved in cancer	TP53 | MAPK14 | MAP3K5
869.801739809159	-24.7302979089742	885.000002237513	0.000105503633903936	0.761	512	116	UCEC	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | MTOR
160.46010752361957	28.8190323418451	183.1871124592781	-1.34343438479482	0.0006	502	61	KIRC	CAND 5	Experimental	VHL | MTOR | HSPG2
687.7091349581744	67.1661641197055	704.2859002432193	-10.9242383168457	0.567	512	117	UCEC	NVP-BGJ398	Clinical trials in cancer	KRAS | PIK3CA | FGFR2
718.556106924551	36.509032022254	746.0425377894179	-4.9239067422327	0.599	292	42	STAD	ALPELISIB	Clinical trials in cancer	KRAS | PTPN11 | NGF
209.86604642192432	119.831586155752	191.54091086242582	37.1144690309656	0.0004	57	24	PAAD	GA201	Experimental	KRAS
1051.68424667086	130.257385948386	1039.1896336696059	2.15370666162045	0.928	57	25	PAAD	PONATINIB	Approved in cancer	KRAS | SMAD4
907.0619769166259	15.474388551253	938.3558849090113	-3.63479766411047	0.822	512	121	UCEC	CETUXIMAB	Approved in cancer	KRAS | NRAS | PIK3CA
284.9662008345575	3.85589171984424	181.5393986749346	20.4821836617994	0.0006	512	94	UCEC	RU79073	Experimental	PTEN | KDR | GNAS
207.22530147606787	40.329512369046	239.15433582768327	-6.01530506207291	0.021	934	216	BRCA	TRIPTOLIDE	Clinical trials	PIK3CA
1046.3778029484852	2.6431102756122	1037.0701686863429	-0.189678721898417	0.93	512	64	UCEC	AFATINIB	Approved in cancer	KRAS | NRAS | ERBB2
251.63310849884252	-6.02840195585458	169.6029017923844	3.269884410842	0.0004	934	217	BRCA	1166227-08-2	Experimental	PIK3CA | BRAF
657.5335669599746	0.302642049774647	632.4549024155164	0.330217588321148	0.482	512	97	UCEC	LUCITANIB	Clinical trials in cancer	PIK3CA | FGFR2 | KIT
200.41766129236768	-33.6647427306712	190.88060643911234	-2.99088162191674	0.0004	153	24	BLCA	FQI1	Experimental	FGFR3 | IDH1 | PIK3CA
187.2691671581595	90.6087111186152	191.38545358108348	-21.6494867606855	0.0006	169	39	READ	6-CHLORO-9-HYDROXY-1,3-DIMETHYLPYRAZOLO[3,4-B]QUINOLIN-4-ONE	Experimental	KRAS | MAP4K1 | RRAS2
137.63919299709133	-14.3792344838588	206.89046502683593	-11.6421865934467	0.0006	423	64	COAD	6-CHLORO-9-HYDROXY-1,3-DIMETHYLPYRAZOLO[3,4-B]QUINOLIN-4-ONE	Experimental	KRAS | MAP2K1 | MAP4K1
501.4398872293983	-12.3151331804802	546.8650315072076	3.35591430192318	0.381	169	39	READ	CHOLINE	Approved in other pathologies	KRAS | RRAS2 | RAF1
969.9334948152342	-33.1323334553352	959.3709600666485	-35.3249264626421	0.823	435	185	THCA	LAPATINIB	Approved in cancer	KRAS | BRAF | PIK3CA
167.7275073147881	8.11462435305816	190.83762128452398	29.1593774298362	0.0004	512	77	UCEC	WORTMANNIN	Experimental	PIK3CA
170.0961370926353	-5.18469218879974	200.8016790629935	18.6071184769357	0.0006	423	64	COAD	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	Experimental	KRAS | MAP2K1 | MAP4K1
623.8823497884399	-31.5989100149786	680.843565147041	9.6908959108589	0.533	934	117	BRCA	OBATOCLAX	Clinical trials in cancer	TP53 | MAP2K1 | STAT3
956.9674259386576	-18.7548152956099	1017.9258910067058	-5.38739729371218	0.909	343	48	HNSC	TAMOXIFEN	Approved in cancer	PIK3CA | MAP2K1 | PLCE1
321.1539322072509	11.7683101980861	204.0753603996469	-8.99007463091903	0.0006	57	24	PAAD	6-CHLORO-9-HYDROXY-1,3-DIMETHYLPYRAZOLO[3,4-B]QUINOLIN-4-ONE	Experimental	KRAS
1039.617465299768	11.8857218331642	1025.1746471633764	-5.08794563530148	0.924	202	44	LAML	PONATINIB	Approved in same tumor type	KRAS | FLT3 | KIT
564.838050566229	-96.6373258698169	580.0786280613629	11.130915896677	0.422	222	131	LGG	TALAZOPARIB	Clinical trials in cancer	IDH1
601.4488604954414	-26.1541659986963	597.419633365534	-2.10897170669705	0.432	343	46	HNSC	TANESPIMYCIN	Clinical trials in cancer	CTNNB1 | PIK3CA
844.0270039226721	-16.0739566850307	840.0591643138802	4.00436843083071	0.713	934	219	BRCA	SULINDAC	Approved in other pathologies and in clinical trials in cancer	MAP2K1 | PIK3CA | MAPK1
152.3554595444289	27.1079343815621	184.04282146751336	6.39312150332125	0.0004	423	65	COAD	PKI-402	Experimental	KRAS | PIK3CA
273.3216711253608	-38.6460514989017	310.00018714010804	-0.000246425406430717	0.122	543	64	LUAD	FASUDIL	Clinical trials	KRAS | GNRHR | DRD2
600.9994317618268	-2.98063387234816	595.1764366302962	-8.09079215856036	0.432	512	61	UCEC	LONAFARNIB	Clinical trials in cancer	KRAS | NRAS | ABCB1
1055.9609638789166	113.487664494291	1035.211235839183	-4.44028912771523	0.934	435	186	THCA	ABT-199	Approved in cancer	KRAS | BRAF | TP53
401.59363287127155	-3.7784650902282	399.99997244687796	-0.000122418843147898	0.222	343	45	HNSC	MILTEFOSINE	Approved in other pathologies	PIK3CA
284.79139364961355	84.5658796188139	252.41767001820034	23.8063941082597	0.0004	57	24	PAAD	NSC632839	Experimental	KRAS
202.78630186053365	86.5070459948306	212.52607510366704	-23.7328052862504	0.0006	169	39	READ	LAX-101	Experimental	KRAS | RRAS2 | NLRP3
247.7346673024861	-11.6702640470858	211.95625257390978	-15.2601690857016	0.0004	512	63	UCEC	LY3009120	Experimental	KRAS | NRAS | BRAF
472.89314997130924	-24.7858005026629	488.53220198085046	0.00888160990439246	0.321	543	63	LUAD	CHOLINE	Approved in other pathologies	KRAS | MAP2K1 | HRAS
205.2313172804226	-60.5969006672626	212.04675558021373	12.4696137061196	0.0004	343	45	HNSC	PKI-402	Experimental	PIK3CA
227.74774418045067	-79.7192577472826	275.3044127655601	-25.9243422750642	0.023	264	104	SKCM	1173900-33-8	Clinical trials	BRAF | PIK3CA
268.61266119845294	-0.624979929717369	166.6253512913269	30.5772628457728	0.0004	512	99	UCEC	NSC632839	Experimental	KRAS | TRIO | CTNNB1
457.0310673886502	-6.48560563046865	561.9361950732908	-0.951468045412639	0.422	934	217	BRCA	TANESPIMYCIN	Clinical trials in cancer	PIK3CA | PDGFRA | CDK4
559.9568637399793	-20.2675607855266	570.8447837208618	7.76873571242004	0.422	343	46	HNSC	MK-2206	Clinical trials in cancer	AKT1 | PIK3CA
1032.081561840432	-37.3795853748453	1039.1159191053262	-1.39989995754695	0.93	343	53	HNSC	PALBOCICLIB	Approved in cancer	SMAD4 | STK11 | PIK3CA
198.1156027764334	108.329326807747	175.360216904567	32.5392520262446	0.0004	57	24	PAAD	AURORA KINASE INHIBITOR II	Experimental	KRAS
241.95447213966125	-56.6703267404395	207.7900604300692	-3.95188193244121	0.0006	512	94	UCEC	PHENYLPHOSPHORIC ACID	Experimental	PTEN | KDR | GNAS
653.5964260919602	-52.6313548256112	590.4822839753988	-0.624271035475431	0.432	934	218	BRCA	ABT-737	Clinical trials in cancer	KRAS | ERBB2 | PIK3CA
723.7603398089768	-65.6619288610265	732.1645458225744	1.8046819915715	0.595	389	46	LUSC	PX-866	Clinical trials in cancer	KRAS | PTEN | EGFR
942.5558767868129	-49.6456229831633	964.8674412864086	3.29062745051988	0.852	512	102	UCEC	LETROZOLE	Approved in cancer	CTNNB1 | PIK3CA | ERBB2
1001.7920406592186	12.9442032028937	1032.8056907300238	4.72099342427896	0.924	502	69	KIRC	PACLITAXEL	Approved in cancer	VHL | AKT3 | MTOR
1035.5391979076023	61.7421039646352	1051.3175247149588	-13.0027849029814	0.927	435	211	THCA	BOSUTINIB	Approved in cancer	KRAS | NRAS | BRAF
605.5219686892251	-29.3525327459759	593.0692833160424	-0.697871163281661	0.432	543	66	LUAD	AZD8055	Clinical trials in cancer	KRAS | PIK3CA | FGFR1
253.3862276212303	26.7717735887063	173.8429484243136	13.6968084783297	0.0004	169	40	READ	PF-3644022	Experimental	KRAS | BRAF
827.3913954217136	-4.09975305602725	735.5909039463587	25.2598705648729	0.599	169	48	READ	ALPELISIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
1096.7941340696261	-49.1872937671405	1063.5214245400161	-1.19189283125479	0.96	343	58	HNSC	SORAFENIB	Approved in cancer	AKT1 | RAC1 | PIK3CA
218.10878087267744	36.1180925424557	224.45228238134467	1.15697186713692	0.0006	512	71	UCEC	1,9-PYRAZOLOANTHRONE	Experimental	KRAS | SOS1 | MAP3K8
1126.8585424752546	-78.9502330771567	1114.8768002581164	24.5871883346449	0.994	264	123	SKCM	COPANLISIB	Approved in cancer	NRAS | KIT | KRAS
920.0694472336347	-22.6791988159961	947.6941749435384	-11.3984450749301	0.823	934	219	BRCA	OLAPARIB	Approved in cancer	KRAS | ERBB2 | PIK3CA
546.7022898022365	0.633427776015196	582.6405844416431	-6.19446882166267	0.423	423	65	COAD	RIGOSERTIB	Clinical trials in cancer	KRAS | PIK3CA
753.6838495387791	-28.1137189147192	733.9307696058156	21.0069506042298	0.6	512	79	UCEC	REFAMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
123.32921995750289	0.109369414699813	193.73234292146276	-29.4252319624243	0.0004	934	216	BRCA	CCT128930	Experimental	PIK3CA
594.1468859558842	11.1681952316876	591.1444170284009	-9.54147439844974	0.433	343	48	HNSC	AZD8055	Clinical trials in cancer	PIK3CA | HRAS
742.2617899939003	-48.9425379806197	673.4729329520916	-11.8317307466596	0.528	202	42	LAML	QUIZARTINIB	Clinical trials in cancer	FLT3 | KIT | IDH2
647.2360085280924	24.2466813612227	702.1187447644362	3.7332147940233	0.562	599	77	GBM	XL147	Clinical trials in cancer	NRAS | KRAS | PTPN11
176.78156199140375	-79.9031724749077	202.08518141266111	9.39289040181939	0.0006	343	50	HNSC	HERBIMYCIN A	Experimental	PTEN | PIK3CA | FGA
172.88677506295733	9.29509818949583	197.08079113582957	-17.2450927106261	0.0004	423	70	COAD	KINETIN RIBOSIDE	Experimental	KRAS | ESR1 | PIK3CA
532.8291227446099	-32.4814505426315	592.1166462484355	-6.23006233655178	0.422	543	64	LUAD	DEMCIZUMAB	Clinical trials in cancer	KRAS | PIK3CA
68.22106614404305	18.8759970121777	139.0407993974898	9.67577371816515	0.0006	435	211	THCA	OLOMOUCINE	Experimental	KRAS | NRAS | BRAF
994.2076606559805	31.2610969720842	1023.6391326881372	3.78725868857384	0.903	202	47	LAML	ABT-199	Approved in cancer	KRAS | IDH1 | IDH2
761.1073969428495	122.486383960221	732.0103396257309	18.498583828192	0.563	57	24	PAAD	PF-04691502	Clinical trials in cancer	KRAS
200.7735783959632	-4.2417906514014	214.9644134207902	-3.09235832236618	0.0004	423	58	COAD	N-ISOPROPYLPHTHALIMIDE	Experimental	KRAS | ATR
953.6489349934329	114.481522299772	1024.5356761580738	-0.00465941028733141	0.919	222	135	LGG	VANDETANIB	Approved in cancer	KRAS | IDH1 | MTOR
215.7284101418065	32.5383068748191	198.86316924145368	2.19466418848219	0.0004	599	61	GBM	LY2183240	Experimental	NRAS | KRAS | COL1A1
643.4188855875234	-19.913841011857	682.1689050063264	2.84489870705681	0.538	222	25	LGG	DACTOLISIB	Clinical trials in cancer	KRAS | NRAS | PTPN11
492.76088143884675	27.7645492921286	600.9276774825655	-19.8993941407532	0.422	435	183	THCA	ARQ-092	Clinical trials in cancer	BRAF | PIK3CA
210.32952172735153	73.0862635095199	203.94399233426134	-4.04406702155984	0.0006	222	58	LGG	OBLIMERSON	Experimental	TP53 | BRAF | MTOR
116.76954557846389	65.7467356234214	203.92554450539305	47.7303313438724	0.0006	435	183	THCA	1,6-HEXANEDIOL	Experimental	BRAF | SOS1 | ESR1
772.8557831683734	-16.6952110897941	735.6035174175678	24.167493728617	0.6	423	95	COAD	PIMASERTIB	Clinical trials in cancer	KRAS | NRAS | NF1
750.4943582061505	-72.6969893088346	700.3553598670248	2.16068446646113	0.554	264	115	SKCM	ZSTK474	Clinical trials in cancer	BRAF | PIK3CA | RAC1
601.8687347836901	-64.1898054365898	643.000366375525	0.000645841596451646	0.492	423	67	COAD	ABT-737	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
1074.0176999394578	86.4817243652307	1006.4062756601516	-13.2282148909028	0.911	435	184	THCA	ERIBULIN	Approved in cancer	BRAF | TP53
992.1513664076774	-15.6986638339626	992.5622820655163	3.03005346637292	0.881	423	58	COAD	ETOPOSIDE	Approved in cancer	KRAS | GATA2 | CTNNB1
1040.465372042437	-46.3416361172394	1031.7161012204708	1.56262787900232	0.922	599	67	GBM	DOCETAXEL	Approved in cancer	TP53 | KRAS | MTOR
552.2837003254168	1.9366321911163	571.8230707210276	4.60633992708244	0.412	423	57	COAD	SALIRASIB	Clinical trials in cancer	KRAS
501.1276641926642	-25.0898330903151	569.0736215451973	-10.3161647453094	0.412	423	58	COAD	NVP-AUY922	Clinical trials in cancer	KRAS | FOXP1 | KDR
1103.280534015292	29.0415049106686	1064.4007079216947	0.235839675264629	0.961	389	42	LUSC	DABRAFENIB	Approved in cancer	KRAS | BRAF | EGFR
629.314069527522	18.9638306470201	675.2176056566083	6.8262516367738	0.535	502	63	KIRC	VATALANIB	Clinical trials in cancer	VHL | MTOR | KDR
592.3844504760416	31.3327548953758	568.9377053556741	-25.1734851660244	0.423	169	40	READ	RIGOSERTIB	Clinical trials in cancer	KRAS | PIK3CA
165.89681716992928	42.1961031427806	203.3368035032132	27.1020306567959	0.0006	512	95	UCEC	936833-38-4	Experimental	PTEN | SOS1 | PTPN11
259.8877964286616	-1.08324999339993	187.26221092373163	-2.46918625972171	0.0004	934	217	BRCA	PWT-33579	Experimental	PIK3CA | MTOR
1137.8778887971448	97.9193571109309	1129.4552814527483	4.92565414687533	1.0	264	200	SKCM	COBIMETINIB	Approved in same tumor type	NF1 | NRAS | KIT
1042.4614679204456	5.43449516472276	1040.8839892315718	2.4394565214202	0.934	599	74	GBM	PONATINIB	Approved in cancer	RB1 | NRAS | KRAS
182.4548997893066	-43.5144284588943	185.45029072464285	10.3722375897873	0.0006	343	54	HNSC	NUTLIN-3	Experimental	CTNNB1 | AKT1 | RAC1
161.6477549111282	-9.94521052497757	198.18485310103762	14.8421074932614	0.0006	543	68	LUAD	DB07268	Experimental	KRAS | SOS1 | MAP2K1
990.6347845498751	17.734147334648	1062.2489909025985	18.339707139037	0.93	435	211	THCA	VEMURAFENIB	Approved in cancer	KRAS | NRAS | BRAF
181.02901891544198	-37.8462786042142	196.4850974473589	9.47895263756482	0.0004	343	46	HNSC	MSC-2363318A	Experimental	AKT1 | PIK3CA
171.19456280997693	-38.9249266725625	227.65405242340057	-8.88176907416528	0.0006	264	35	SKCM	CHEMBL494072	Experimental	CYBB | AKT3 | GNAS
692.9140575522335	14.8992468254778	711.412981957916	-17.7842536444664	0.545	934	228	BRCA	XL765	Clinical trials in cancer	KRAS | STK11 | PTEN
674.6052732233182	-4.6761881578158	678.9990331428309	-0.000164265772355066	0.532	512	55	UCEC	952021-60-2	Clinical trials in cancer	KRAS | BRAF | ATR
606.6611000563172	-47.8823566088428	596.2641014534079	10.1820370461901	0.444	423	81	COAD	CH5132799	Clinical trials in cancer	KRAS | MTOR | BRAF
238.55782926066064	67.8656615320778	204.57336858212147	-15.7196139943749	0.0006	502	62	KIRC	CHEMBL1230023	Experimental	VHL | AKT3 | MTOR
1031.5508856214628	-5.30228913287752	1020.9999242165009	-0.000222068038965517	0.912	292	32	STAD	GEMCITABINE	Approved in cancer	KRAS | AKT1 | PIK3CA
679.801696253268	18.8757637394581	689.0733531336281	-2.25047921111388	0.543	599	73	GBM	1032350-13-2	Clinical trials in cancer	NRAS | KRAS | PTPN11
199.8038658337828	-112.939656807798	241.6412336471854	50.3019605316244	0.0004	264	93	SKCM	CYTOCHALASIN B	Experimental	NRAS | CTNNB1 | IDH1
1049.6997138845845	-10.0049718827235	1035.4230628404287	10.8764993468365	0.932	934	218	BRCA	MIDOSTAURIN	Approved in cancer	KRAS | PIK3CA | PDGFRA
180.89960596791195	5.80381726299649	196.9942568546814	21.9528765170503	0.0004	264	73	SKCM	WZ4002	Experimental	NRAS | BTK | ERBB4
288.04725223646915	-106.680517674653	161.9194256043201	-72.440841736046	0.0008	264	194	SKCM	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	NF1 | NRAS | KIT
305.0946395826118	14.6120475519062	151.14831360238614	-52.5681795454639	0.0004	264	105	SKCM	COMPOUND 44	Experimental	BRAF | PIK3CA | ERBB4
1068.9215107838183	-22.7242089591237	1088.3291960209715	5.02225070621716	0.99	153	20	BLCA	COBIMETINIB	Approved in cancer	NRAS | PIK3CA | SOS1
462.2933062539349	-1.83586191668408	479.40090593881536	2.50376822744681	0.311	202	24	LAML	ISOPRENALINE	Approved in other pathologies	KRAS | NRAS | MAPK1
455.9752521411791	-15.6321530366027	483.99998311562985	0.000297987874148475	0.316	169	39	READ	NECITUMUMAB	Approved in other pathologies	KRAS | ERBB2
244.25420771019057	69.8613003394432	220.8099801190614	-10.2675336574275	0.0008	512	96	UCEC	O-PHOSPHO-L-TYROSINE	Experimental	PTEN | KIT | KDR
884.2316636971091	84.8314073504781	947.7634123909471	20.4709053924239	0.832	264	174	SKCM	ATEZOLIZUMAB	Approved in cancer	NRAS | KRAS | BRAF
945.1408972810376	7.9682793155485	941.9942455313367	-0.222135790565403	0.823	202	33	LAML	AZACITIDINE	Approved in same tumor type	FLT3 | IDH1 | MYC
599.5044791285715	18.8178885539482	592.0546519274943	0.0217393578618612	0.434	292	30	STAD	CH5132799	Clinical trials in cancer	KRAS | PIK3CA | BRAF
240.39954103539625	-63.6168124820709	202.72807524815838	-2.52305788311116	0.0008	599	74	GBM	PI-103	Experimental	NRAS | KRAS | PTPN11
554.2549297782382	132.691309723994	724.0449817616573	37.6256342102279	0.53	435	211	THCA	REFAMETINIB	Clinical trials in cancer	KRAS | NRAS | BRAF
589.70886944841	17.1629040498615	589.178063710736	0.590607985184988	0.432	512	77	UCEC	AFURESERTIB	Clinical trials in cancer	PIK3CA
1016.7930515148133	94.1061674559124	1058.701623637602	2.43127535621051	0.938	169	48	READ	PONATINIB	Approved in cancer	KRAS | SMAD4 | NRAS
1014.2736373355929	127.976606783506	1047.5104966574902	-36.6349968326799	0.947	264	181	SKCM	RIBOCICLIB	Approved in cancer	RB1 | NRAS | KRAS
143.24794555561593	139.076855939456	191.09123772795508	43.1911145924076	0.0004	222	131	LGG	32703-82-5	Experimental	IDH1 | MTOR
750.0329750788584	-21.6705711675068	704.4627205916509	11.1091990055675	0.574	512	114	UCEC	AZD8055	Clinical trials in cancer	KRAS | TSC2 | TSC1
156.11737626735905	-38.7841918670732	235.95020503155382	10.5743413086029	0.0004	264	48	SKCM	ISOEVODIAMINE	Experimental	CTNNB1 | TRIO | GNAS
641.3464897983447	-0.922472222725418	658.5108452275755	-0.498009415804745	0.511	512	53	UCEC	PHENFORMIN	Clinical trials in cancer	KRAS | PRKCE
667.3133501453057	-19.4836268892048	679.6624858870923	-45.916581658777	0.531	264	27	SKCM	UNII-RFG3GJ6251	Clinical trials in cancer	HSPG2 | KDR | FLT3
668.7087867239023	-101.452038452287	748.758073987343	23.5973184419236	0.593	264	146	SKCM	ARQ736	Clinical trials in cancer	NF1 | KIT | PTPN11
662.8313569623008	25.5079151205142	702.4844596692245	9.90510289162626	0.543	934	228	BRCA	SF1126	Clinical trials in cancer	KRAS | STK11 | PTEN
330.27816589966466	-33.3783983367993	170.37403114852714	23.5543798293675	0.0004	222	131	LGG	PIK-75	Experimental	IDH1
116.68748155125719	54.9014240929164	218.35772848368057	-2.0151521716482	0.0006	502	61	KIRC	L-PYROGLUTAMIC ACID	Experimental	VHL | MTOR | HSPG2
1167.3659601544098	-31.5540131119774	1089.2172734194132	12.1794993608578	0.982	292	64	STAD	DOCETAXEL	Approved in cancer	KRAS | MAP2K1 | CREBBP
118.55205150320889	18.9043496216277	227.67322921770713	5.2025935704537	0.0004	934	221	BRCA	FQI1	Experimental	PIK3CA | IDH1 | AFF4
702.0040060339846	-24.0485891331961	698.017655664156	-7.30986448699787	0.543	934	232	BRCA	FLAVOPIRIDOL	Clinical trials in cancer	RB1 | STK11 | MAP2K1
202.57405479597531	-52.4303340401757	221.97804370698444	-19.6016173712055	0.0004	264	28	SKCM	882531-87-5	Experimental	AURKA | KDR | FGFR1
241.70673899475017	40.3250737447758	196.20640212844611	3.88726089864485	0.0008	202	25	LAML	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | MAPK1
1111.8439464451885	62.6221155046495	1048.0554065786891	2.14240211134961	0.946	169	42	READ	PANOBINOSTAT	Approved in cancer	KRAS | SMAD4 | BRAF
1027.5003886120446	42.4488255021824	1043.6005661298973	4.96565607536627	0.942	512	149	UCEC	BORTEZOMIB	Approved in cancer	KRAS | TP53 | VHL
568.5385403678135	-32.1008418362349	587.0116749834538	-6.04736798700833	0.422	343	45	HNSC	1375469-38-7	Clinical trials in cancer	PIK3CA
1173.9423022423005	78.4339622421906	1137.5111502445618	34.2768883820572	1.0	264	202	SKCM	TRAMETINIB	Approved in same tumor type	NF1 | NRAS | KIT
1147.9261561589653	-29.6027127465651	1084.2322403482378	-7.63738285837576	1.0	512	135	UCEC	TEMSIROLIMUS	Approved in cancer	KRAS | TSC2 | TSC1
228.74217031789073	-18.0324087116192	215.48323594977307	17.6077771170751	0.0006	512	52	UCEC	CHEMBL282146	Experimental	CTNNB1 | CHD8 | GSK3B
345.962233291461	-8.33892596515275	363.2474577174754	-0.9766515129445	0.182	512	52	UCEC	MBX-8025	Clinical trials	CTNNB1 | CHD8 | GSK3B
768.6295911390035	13.3552402118033	722.6996391027664	-12.7074512244323	0.585	169	44	READ	AZD8330	Clinical trials in cancer	KRAS | NRAS | BRAF
498.242508817449	15.9874183952354	576.0550828517804	21.8759464852238	0.412	169	38	READ	ULIXERTINIB	Clinical trials in cancer	KRAS
190.45129085307562	-7.37436868541133	199.2536309905147	-11.2424712641377	0.0004	423	65	COAD	AZD-8835	Experimental	KRAS | PIK3CA
1117.1333473527134	-2.92572037942261	1064.0008795219355	0.000386135131975607	0.96	292	33	STAD	NERATINIB	Approved in cancer	KRAS | PIK3CA | BRAF
1013.9679522843774	3.25908829878693	1043.6652780555523	-1.35077773399189	0.935	502	64	KIRC	LENVATINIB	Approved in cancer	VHL | MTOR | FGFR1
331.9182953852699	-0.940443969511165	175.34853364729412	-3.93238715241159	0.0004	264	104	SKCM	NVP-BHG712	Experimental	BRAF
685.0152260153243	-122.044751856465	780.8551013328585	-26.8216320866659	0.597	264	202	SKCM	ENCORAFENIB	Clinical trials in cancer	NF1 | NRAS | KIT
153.86904906554338	-6.45200013181025	192.75663132630325	-1.39741482966019	0.0004	423	58	COAD	NSC632839	Experimental	KRAS | ERBB2 | CTNNB1
633.8194504005329	-42.7643996391174	663.2443009455092	0.114953147726737	0.515	343	46	HNSC	PERIFOSINE	Clinical trials in cancer	AKT1 | PIK3CA
1078.459741740285	36.0453269096244	1085.7681976151962	5.87711875027685	0.994	292	41	STAD	PONATINIB	Approved in cancer	RB1 | SMAD4 | KRAS
656.1851945652538	49.5578749385595	674.6131744393741	2.44880266251732	0.532	222	59	LGG	GOSSYPOL	Clinical trials in cancer	TP53 | BRAF | MTOR
158.5762995124761	-57.8005269284385	185.85088172772961	0.93863695816799	0.0006	264	50	SKCM	CHEMBL291678	Experimental	KIT | PTPN11 | PTEN
259.6198285513746	33.5905683167393	204.27859761289412	1.58142935328738	0.0006	502	59	KIRC	AR-C102222	Experimental	VHL | MTOR
216.26959149776792	-7.72809124652187	169.99604240467565	23.8336803559312	0.0006	512	94	UCEC	CHEMBL94061	Experimental	PTEN | KDR | GNAS
966.5699319703004	12.5243357660087	942.5016543650023	13.5433222738664	0.823	934	218	BRCA	CAPECITABINE	Approved in same tumor type	KRAS | ERBB2 | PIK3CA
637.8730665388899	11.7202172956599	594.2852084616179	-14.1584963499211	0.432	169	38	READ	VOLASERTIB	Clinical trials in cancer	KRAS
495.5289302428279	44.3702692928074	524.6587375251901	19.3322680361138	0.412	57	24	PAAD	DEMCIZUMAB	Clinical trials in cancer	KRAS
725.5211354935932	91.9863503592172	690.5602592744408	-35.1531026426804	0.539	435	211	THCA	ALPELISIB	Clinical trials in cancer	KRAS | NRAS | BRAF
937.229447130945	-13.8447245674755	937.6646550817323	-2.54073566056741	0.822	343	45	HNSC	FLOXURIDINE	Approved in cancer	PIK3CA
895.2288008059461	-16.8731138252024	917.8668856001993	0.133980311849655	0.797	512	104	UCEC	NINTEDANIB	Approved in other pathologies and in clinical trials in cancer	VHL | PTEN | MTOR
1021.7726310729397	-31.4234868551835	1032.5303219251743	1.42241495967846	0.93	423	60	COAD	VANDETANIB	Approved in cancer	KRAS | MTOR | IDH1
317.4865609566342	-72.0146176310645	151.4016066907282	15.9380311284343	0.0004	57	24	PAAD	AT7867	Experimental	KRAS
293.68501886947945	-14.5606130264127	201.8488067056795	2.12351934174063	0.0004	169	41	READ	AT13148	Experimental	KRAS | PIK3CA | ERBB2
708.0628161076467	-28.0010659223012	732.8122166294717	3.94108422300587	0.593	153	23	BLCA	XL147	Clinical trials in cancer	NRAS | PTEN | PIK3CA
607.181761692967	-17.0148376090817	687.800044912548	-6.78630749127092	0.536	502	66	KIRC	ENMD-2076	Clinical trials in cancer	VHL | MTOR | FGFR3
1022.7123620580338	-10.629781115871	1009.668224483413	-12.0396418617686	0.912	934	219	BRCA	CABOZANTINIB	Approved in cancer	KRAS | PIK3CA | STAT3
180.25379283038365	33.622702351767	208.88712326902	-5.62035934702499	0.0004	202	22	LAML	AST 487	Experimental	FLT3 | KIT | KDR
731.4772524249609	-12.4328785682186	723.7306975711069	-11.5573922129424	0.592	512	55	UCEC	PRINOMASTAT	Clinical trials in cancer	CTNNB1 | CHD8 | RAC1
341.9609167671767	-1.2423210134717	359.8251289566243	1.3523794435639	0.181	512	54	UCEC	GLICLAZIDE	Clinical trials	VHL | CTNNB1 | MTOR
1140.922005170061	28.2347110899432	1022.7114536576042	17.4047954060845	0.92	169	46	READ	EVEROLIMUS	Approved in cancer	KRAS | NRAS | BRAF
590.4213650242555	-37.363176929653	577.0863258181926	-9.44522417241751	0.421	343	45	HNSC	ABT-751	Clinical trials in cancer	PIK3CA
260.34130830436385	-48.8954658126098	196.44328943453266	-30.3886929977402	0.0006	512	65	UCEC	CHEMBL1236441	Experimental	VHL | CTNNB1 | MTOR
1086.3702386377495	48.476538401767	1089.0504083663825	14.9239442673668	0.99	169	49	READ	PALBOCICLIB	Approved in cancer	KRAS | SMAD4 | NRAS
669.9865617751501	-15.3212236187663	691.100160748218	14.1109861200357	0.583	264	46	SKCM	TALMAPIMOD	Clinical trials in cancer	CYBB | AKT3 | MAP2K1
162.24016653038183	-14.3818382436156	198.0804711090378	-5.4891094843083	0.0004	343	45	HNSC	DEGUELIN	Experimental	PIK3CA
558.9718534510666	9.39490303278342	563.3991187179379	-1.11074113543737	0.412	423	57	COAD	NRX 194204	Clinical trials in cancer	KRAS
1085.146272358788	31.5149551611604	1099.7889270041246	-13.1793292379662	1.0	169	46	READ	COBIMETINIB	Approved in cancer	KRAS | NRAS | BRAF
642.8379481971523	-5.73450233948753	581.5664222921691	5.23250396861533	0.422	202	31	LAML	UNII-CZP9GB25HO	Clinical trials in cancer	FLT3 | NRAS
773.735455228414	3.87578995057797	769.999872871912	-0.000103980519270408	0.633	292	31	STAD	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | PIK3CA
226.8390452054986	-40.9361512034147	194.41616358603656	-4.5063789541905	0.0008	512	56	UCEC	INDEGLITAZAR	Experimental	TSC2 | TSC1 | CTNNB1
333.91856974029565	-13.4572651560172	329.00001474792543	5.60903472432983e-05	0.143	934	227	BRCA	QUERCETIN	Clinical trials	KRAS | PTEN | MAP2K1
666.966483034622	-34.0543742149734	700.9284151480615	-12.5599568713642	0.551	343	92	HNSC	DHA-PACLITAXEL	Clinical trials in cancer	TP53 | MAP2K1
694.0028637605794	8.18188948847546	752.3752598237057	15.4076183289101	0.594	512	56	UCEC	OBATOCLAX	Clinical trials in cancer	TP53 | VHL | NRAS
732.8080752475805	-7.86939996664776	724.0236991012445	20.5670339626586	0.581	423	66	COAD	DHA-PACLITAXEL	Clinical trials in cancer	TP53 | MTOR | BRAF
775.6339334209304	38.265487535278	708.6223808489026	17.0020580161758	0.593	169	47	READ	SF1126	Clinical trials in cancer	KRAS | PTPN11 | NRAS
1146.2505866834008	-2.70343643821425	1048.105330764585	6.78912715777301	0.945	435	186	THCA	PACLITAXEL	Approved in cancer	KRAS | BRAF | TP53
1078.3488938707703	-17.2830639155765	1090.0057547052388	-5.44823569214623	0.99	543	98	LUAD	DASATINIB	Approved in cancer	KRAS | RB1 | SMAD4
1077.0803501658866	0.336132246241789	1077.9025040712781	-11.5409336232699	0.983	512	57	UCEC	RAMUCIRUMAB	Approved in cancer	KRAS | ERBB2 | KDR
550.1579227243644	113.400969392646	580.5067853092372	-4.41562926457163	0.437	57	24	PAAD	PIMASERTIB	Clinical trials in cancer	KRAS
206.94100227186354	-20.8553137178453	223.06012459452623	-3.88145768723871	0.0006	264	55	SKCM	NUTLIN-3	Experimental	LMNA | AKT3 | CDKN2A
423.2676751860466	3.04059220707879	417.99989008348064	0.000165052616011963	0.242	169	40	READ	NIVOLUMAB	Approved in other pathologies	KRAS | BRAF
378.2621062925849	-0.0411653948716548	373.1322690066067	5.97992112167003	0.191	512	80	UCEC	ADENOSINE TRIPHOSPHATE	Clinical trials	KRAS | RB1 | NRAS
249.65833248656665	49.9921972000201	198.88163613209693	0.384627397839779	0.0008	389	42	LUSC	GUANOSINE 5&#39;-DIPHOSPHATE	Experimental	KRAS | PTEN | BRAF
244.80708626627927	-7.4950320891333	186.01095181952147	-11.2482592155757	0.0006	502	64	KIRC	OBLIMERSEN	Experimental	VHL | AKT3 | MTOR
687.5449185588454	-30.4107004834352	660.9303680350046	18.7828817182053	0.525	934	218	BRCA	GDC-0032	Clinical trials in cancer	KRAS | ERBB2 | PIK3CA
950.6014885293675	-29.9825801265898	934.7477784259148	6.60532680841243	0.832	264	77	SKCM	CYTARABINE	Approved in cancer	NRAS | KIT | KMT2A
727.3091647596066	77.2420436390635	677.4843908995474	7.14856474758454	0.533	169	43	READ	1224844-38-5	Clinical trials in cancer	KRAS | BRAF | PIK3CA
181.5325973235925	-54.7203384535456	213.22206457699752	-17.130042876377	0.0004	343	48	HNSC	ISOEVODIAMINE	Experimental	CTNNB1 | PIK3CA | FGFR3
148.12746193643486	-45.8416660363643	189.89934349887514	-9.49685507412732	0.0004	343	45	HNSC	KU-0060648	Experimental	PIK3CA
98.30583473085962	-66.6599120824898	215.33072771526005	9.47787108203818	0.0004	222	135	LGG	FQI1	Experimental	IDH1 | MTOR | PIK3CA
1091.1496792604285	18.821475728446	1079.6847766441792	7.13394294338502	0.982	169	54	READ	DOCETAXEL	Approved in cancer	KRAS | BRAF | TP53
736.4717916657336	72.5222313636561	752.5815647417513	8.58091343836657	0.595	169	48	READ	PICTILISIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
580.513889430041	125.936428579976	542.7430348159714	-27.796399833234	0.435	57	24	PAAD	212631-79-3	Clinical trials in cancer	KRAS
861.155667176189	12.4315841489948	899.9499938409956	-12.641317487886	0.812	57	24	PAAD	OXALIPLATIN	Approved in cancer	KRAS
195.9583537218205	-37.3568240258812	187.79969082658948	12.488983423897	0.0006	264	35	SKCM	4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE	Experimental	CYBB | AKT3 | GNAS
281.548708111374	-59.8142931873265	190.8363143338025	4.00562410806151	0.0004	512	71	UCEC	BIX-01294	Experimental	TRIO | CTNNB1 | SOS1
705.5419248869214	78.5622421718448	679.6360552618969	-2.56749231494291	0.533	169	41	READ	CC-223	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
324.22468011914606	-16.0631244980898	310.4114476066385	-0.0163418305787673	0.122	202	53	LAML	QUERCETIN	Clinical trials	KRAS | FLT3 | KIT
601.4806539872484	65.9454617580879	536.7227927666185	-12.0501243690643	0.412	57	24	PAAD	LINSITINIB	Clinical trials in cancer	KRAS
748.5486511068575	-100.172233877057	757.4489242597468	-12.5843613078232	0.594	264	123	SKCM	PX-866	Clinical trials in cancer	NRAS | KIT | KRAS
856.195275977163	31.8620463659623	920.5358832926456	3.13709916405401	0.822	222	131	LGG	RUCAPARIB	Approved in cancer	IDH1 | MET
282.9676878054302	29.2815105329087	188.65042159737192	3.77481824585539	0.0004	435	183	THCA	RG-7256	Experimental	BRAF
648.150156390773	-57.5096684096913	665.5404927695787	4.96449077433181	0.516	343	46	HNSC	RIDAFOROLIMUS	Clinical trials in cancer	STK11 | PIK3CA
754.6187558806681	-89.8870678722351	720.1466811266769	5.32960921780386	0.586	543	66	LUAD	RIDAFOROLIMUS	Clinical trials in cancer	KRAS | STK11 | PIK3CA
534.4667275367826	-3.32929298481696	594.892577090481	-9.21559714812247	0.422	934	234	BRCA	LY2780301	Clinical trials in cancer	AKT1 | PIK3CA | AKT2
590.0163106139184	-42.4611822926303	565.4012492524162	3.89369068715223	0.412	423	57	COAD	RALIMETINIB	Clinical trials in cancer	KRAS
306.9760405069019	43.1532319094642	254.8689017906324	13.7073570930838	0.0004	435	183	THCA	VORUCICLIB	Experimental	BRAF
123.36325626759516	42.4964555114237	197.99294239043886	-5.86310690323012	0.0006	543	84	LUAD	AT7867	Experimental	KRAS | GNRHR | EGFR
625.4980216252793	102.929681528685	618.2981342105322	18.8694493290093	0.452	57	24	PAAD	AZD5363	Clinical trials in cancer	KRAS
722.5561954946442	127.934330403684	689.296572592779	20.4650379589259	0.523	435	211	THCA	BMS-908662	Clinical trials in cancer	KRAS | NRAS | BRAF
246.6116500509096	62.9588007153564	209.0154421821186	-34.1362019401759	0.0006	512	96	UCEC	N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE	Experimental	PTEN | ERBB2 | KDR
723.5637371234494	-33.0362143411445	749.2432364612231	-20.5547076901212	0.595	264	28	SKCM	TESEVATINIB	Clinical trials in cancer	VHL | ARNT | HSPG2
829.2160741986108	56.4177054941734	700.5365054592146	21.19935595175	0.581	512	163	UCEC	NAVITOCLAX	Clinical trials in cancer	KRAS | TP53 | VHL
875.917409031734	43.1957134136362	958.8379865615823	-26.8260549513918	0.822	222	131	LGG	NIRAPARIB	Approved in cancer	IDH1
1125.9613854566655	76.5944835381233	1068.7877497023542	9.8630475552701	0.956	57	25	PAAD	REGORAFENIB	Approved in cancer	KRAS | SMAD4
575.9086219784562	-8.92226758345046	577.8164339168089	-7.04472930647194	0.423	543	83	LUAD	BGB-283	Clinical trials in cancer	KRAS | NRAS | BRAF
521.6504822975113	44.0616239148657	601.7213262532234	21.6610131739974	0.432	57	24	PAAD	ABT-737	Clinical trials in cancer	KRAS
1086.7053516410258	-109.310413578222	1041.86098117278	41.9118479371809	0.995	264	190	SKCM	LENVATINIB	Approved in cancer	NRAS | KIT | VHL
786.3559619780323	8.65935410351437	739.869879360131	-11.951023838471	0.584	292	66	STAD	NAVITOCLAX	Clinical trials in cancer	KRAS | CTNNB1 | PTPN11
1061.5384660330872	-27.9797512718774	1068.7412873574685	1.87085668336897	0.963	599	72	GBM	COPANLISIB	Approved in cancer	NRAS | KRAS | PTPN11
961.8188726109291	37.7765129869433	909.7374518391961	-16.252221012624	0.822	435	185	THCA	CRIZOTINIB	Approved in cancer	KRAS | BRAF
377.5300373814096	-6.62438750395083	373.99986918887714	-3.24866948631097e-06	0.193	389	49	LUSC	QUERCETIN	Clinical trials	KRAS | PTEN | EGFR
238.43046092581838	-1.94713551467819	215.1688476199099	9.9168833856213	0.0004	512	89	UCEC	ML214	Experimental	PIK3CA | PBX1 | ITK
643.2209713457049	-56.4808132816895	647.1364915102625	-11.7272933453773	0.514	264	31	SKCM	MK-2461	Clinical trials in cancer	FGFR3 | KDR | FGFR1
642.3191210064086	94.7059747604326	641.1837559703761	13.4970185065181	0.526	435	185	THCA	RAF265	Clinical trials in cancer	KRAS | BRAF
558.9843581880517	-25.9369442272031	587.9204405565481	2.23439187887539	0.422	543	68	LUAD	BAY1125976	Clinical trials in cancer	KRAS | NRAS | PIK3CA
759.1040627149878	32.7590541048834	706.9528781270482	4.08765975211963	0.571	543	109	LUAD	NAVITOCLAX	Clinical trials in cancer	KRAS | TP53 | CTNNB1
483.98121948117375	-26.064319381687	477.5156664096054	4.50154894588559	0.311	502	60	KIRC	HYDROCORTISONE	Approved in other pathologies	VHL | MTOR | ABCB1
289.1472225752943	9.01562285996152	198.2085292983979	8.24708561300622	0.0006	292	39	STAD	OBLIMERSON	Experimental	MAP2K1 | CREBBP | TP53
989.9987363500217	56.2945427345476	1027.7112781719648	30.024539635056	0.94	435	211	THCA	COBIMETINIB	Approved in cancer	KRAS | NRAS | BRAF
213.8815325302234	21.5398040140853	191.4687977548798	-2.2811588660677	0.0008	292	32	STAD	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | MAP2K1
162.62600544066572	-19.5407596192157	204.97355077641075	-4.20029843208476	0.0006	264	32	SKCM	BATIMASTAT	Experimental	CYBB | CTNNB1 | MAP2K1
173.4518374625305	-43.3083122431797	192.1380141749424	-39.5793466178347	0.0006	264	35	SKCM	CHEMBL29641	Experimental	CYBB | AKT3 | GNAS
496.09221364923593	-19.8063332582306	556.8380146565804	-8.66912964682365	0.412	934	216	BRCA	ACALISIB	Clinical trials in cancer	PIK3CA
185.95608586026782	74.9064318673285	205.00310538244707	-61.730634359002	0.0004	435	183	THCA	NVP-BHG712	Experimental	BRAF
756.4028384955684	-52.414925855012	688.9038988819725	9.63247446724927	0.545	343	54	HNSC	GDC-0068	Clinical trials in cancer	PTEN | AKT1 | PIK3CA
1026.8194516089475	-68.2319175825527	1022.4024247550195	28.9154462189877	0.926	264	119	SKCM	VORINOSTAT	Approved in cancer	RB1 | GNA11 | BRAF
78.48402722387003	-64.9316613920597	232.18064979206108	-18.4096033675501	0.0008	264	107	SKCM	154447-36-6	Experimental	KRAS | BRAF | PIK3CA
1061.6267355739797	-33.3335475892693	1082.125695345955	-7.81512069226937	0.982	423	63	COAD	LENALIDOMIDE	Approved in cancer	KRAS | MTOR | ERBB2
210.87619008329705	-25.7805995053052	199.38599080152954	-11.1375268441382	0.0004	543	64	LUAD	AZD8186	Experimental	KRAS | PIK3CA
488.2674740493705	-28.4368857766087	500.90867599865044	1.14819249352695	0.331	934	117	BRCA	EDARAVONE	Approved in other pathologies	TP53 | MAP2K1 | STAT3
755.1038446473723	-1.81048245137453	710.4885736777306	-1.30408376906689	0.575	543	66	LUAD	MLN1117	Clinical trials in cancer	KRAS | SOS1 | PIK3CA
643.9491385322688	2.63551892208562	712.2590966744505	0.594774609296167	0.57	389	43	LUSC	SELUMETINIB	Clinical trials in cancer	KRAS | FGFR2 | BRAF
1110.814150353864	-27.4728513318579	1060.7443161333376	4.97722650952574	0.96	343	58	HNSC	TRAMETINIB	Approved in cancer	CTNNB1 | RAC1 | PIK3CA
1054.712623148909	-0.735628005376782	1078.1434220664826	-1.40392208210778	0.967	512	62	UCEC	ROMIDEPSIN	Approved in cancer	KRAS | RB1 | KMT2A
1099.5509402942964	-10.7888937270016	1074.6360865570327	-5.5581583208866	0.97	543	99	LUAD	DABRAFENIB	Approved in cancer	KRAS | NF1 | NRAS
1036.5582482723894	-21.3802259401774	1040.1201674455767	-4.28074322756038	0.93	543	89	LUAD	PANITUMUMAB	Approved in cancer	KRAS | NRAS | BRAF
1024.5187825925916	-26.3904645100702	1031.690234196241	-1.6781152991714	0.93	512	79	UCEC	GEFITINIB	Approved in cancer	KRAS | NRAS | ERBB2
144.44476882545052	78.3602638005372	232.05401139115628	-22.581499402723	0.0008	512	119	UCEC	A-443654	Experimental	KRAS | PIK3CA | ERBB2
582.9826091689091	85.8512725449982	609.1071010485738	-38.5046047518706	0.452	57	24	PAAD	1032350-13-2	Clinical trials in cancer	KRAS
541.7121095918634	-13.202094743776	578.7616681537706	10.9683316830233	0.412	423	57	COAD	RILOTUMUMAB	Clinical trials in cancer	KRAS
265.12003203755324	-47.4354786779162	195.14534890706406	17.8546328600021	0.0006	502	62	KIRC	2-AMINOTHIAZOLINE	Experimental	VHL | AKT3 | MTOR
677.042314522061	-49.8413881099149	675.4014993091075	-0.669991397025569	0.527	153	16	BLCA	FLAVOPIRIDOL	Clinical trials in cancer	RB1 | PIK3CA | MOS
130.18797733585404	-57.1044541639307	147.0082149562337	60.5708398321708	0.0006	264	121	SKCM	761437-28-9	Experimental	KRAS | PTEN | BRAF
566.2731924756325	11.216956669672	580.7479441946683	16.0544835081546	0.423	934	219	BRCA	VS-5584	Clinical trials in cancer	ERBB2 | PIK3CA | MTOR
221.23580576147117	-54.4491201115072	190.65254502301124	6.95136939681652	0.0004	153	20	BLCA	GW843682X	Experimental	CTNNB1 | FGFR3 | IDH1
1093.117464691989	9.15599608827745	1084.228248908501	-1.43634036480557	0.984	543	93	LUAD	ARSENIC TRIOXIDE	Approved in cancer	KRAS | RB1 | SMAD4
1061.5731389546524	-52.5514411243563	1038.007836508815	-7.47683267279854	0.93	343	53	HNSC	RIBOCICLIB	Approved in cancer	SMAD4 | STK11 | PIK3CA
198.07256004160234	61.5621673284013	234.50936908327805	25.0861261104915	0.0004	512	100	UCEC	FQI1	Experimental	TRIO | MTOR | PIK3CA
929.6619186289311	19.3969860809995	939.934248912069	2.42983695490284	0.822	543	64	LUAD	CAPECITABINE	Approved in cancer	KRAS | PIK3CA
1123.6547979710851	32.8121524256014	1068.470526363126	6.33599230392019	0.982	169	41	READ	MIDOSTAURIN	Approved in cancer	KRAS | PIK3CA | FGFR1
600.253690942301	-41.9350999551732	585.5965226127746	7.30235735042015	0.423	934	217	BRCA	CAMPTOTHECIN	Clinical trials in cancer	KRAS | PIK3CA | CDK4
689.8939195578486	57.6972703513579	666.6216446966777	-12.2662451145588	0.524	934	234	BRCA	MK-2206	Clinical trials in cancer	AKT1 | PIK3CA | AKT2
929.6522482980196	-35.305523945048	931.5580126446353	2.22590095974147	0.812	292	34	STAD	CETUXIMAB	Approved in cancer	KRAS | NRAS | AKT1
143.77329851677018	33.8162531171281	218.3484187943111	6.0780606041078	0.0004	934	217	BRCA	BISTRAMIDE A	Experimental	PIK3CA | MAP3K4
1107.7971702768898	-74.8225625116204	1068.7942240530629	-28.940014231086	0.98	264	118	SKCM	TEMSIROLIMUS	Approved in cancer	KRAS | TSC1 | AKT3
1141.8128055562051	-37.9641677859711	1098.6735228284174	26.5412894369038	1.0	512	137	UCEC	REGORAFENIB	Approved in cancer	KRAS | RB1 | NF1
466.3071138831706	-6.23188793170257	498.00005913972046	-0.000165712406669627	0.331	153	28	BLCA	EDARAVONE	Approved in other pathologies	CREBBP | TP53 | CHUK
227.70132893626842	-57.5654974872379	188.15916032273577	12.8211604365599	0.0006	543	87	LUAD	OLOMOUCINE	Experimental	KRAS | RB1 | SMAD4
874.262708583851	22.8753279756148	970.7153938695045	7.60486074470145	0.822	435	185	THCA	OXALIPLATIN	Approved in cancer	KRAS | BRAF
702.2008175292118	15.0952242743857	653.1450265512158	10.0618835704017	0.514	934	221	BRCA	AZD8055	Clinical trials in cancer	KRAS | ERBB2 | PIK3CA
225.16860227539092	-35.9312434355652	201.201318426361	-19.164696200756	0.0006	502	59	KIRC	DROTRECOGIN ALFA	Experimental	VHL | MTOR
517.6494682575474	69.3381680832239	622.9694910240535	47.6786450004109	0.44	57	24	PAAD	BINIMETINIB	Clinical trials in cancer	KRAS
737.1381857633315	-24.6486658790525	720.9860045968558	-6.46012077643036	0.583	292	40	STAD	OBATOCLAX	Clinical trials in cancer	NRAS | MAP2K1 | CREBBP
756.271178482522	54.9351095270912	737.9472513564193	-6.25224337898675	0.594	389	49	LUSC	APITOLISIB	Clinical trials in cancer	KRAS | PTEN | AKT1
504.93169846952094	32.4734614750138	590.1271977222051	-17.5817746295909	0.422	934	216	BRCA	SAR245409	Clinical trials in cancer	KRAS | PIK3CA
1017.0504092894104	-34.9686739138805	1046.4756769915366	-2.66138805046921	0.94	343	52	HNSC	EVEROLIMUS	Approved in cancer	CTNNB1 | STK11 | AKT1
1157.968020907121	-46.0489172498796	1068.0432348015672	5.58447514318459	0.983	222	143	LGG	ABT-199	Approved in cancer	TP53 | KRAS | IDH1
715.7203105819667	-39.3574390915911	663.167831431528	1.92003717126022	0.514	543	60	LUAD	VOLASERTIB	Clinical trials in cancer	KRAS | CHEK1
278.0744662152096	-48.7194553422333	196.8028492836241	28.5898698447581	0.0004	512	77	UCEC	AS-605240	Experimental	PIK3CA
700.7981734322153	45.0668148529003	692.3699230026189	16.4843902402672	0.534	202	52	LAML	PKI-587	Clinical trials in cancer	KRAS | FLT3 | KIT
167.75671656561408	-31.1021356183956	194.99826918562863	-3.70573565719769	0.0008	264	31	SKCM	PP121	Experimental	PTEN | GNAS | PIK3CA
659.6849061635565	-37.5428164367333	712.1592659300923	3.37150641360267	0.572	153	17	BLCA	RO4987655	Clinical trials in cancer	NRAS | FGFR3 | SOS1
194.6329675474377	67.3321736052495	213.91955873302865	-5.36605637260379	0.0006	202	29	LAML	1,6-HEXANEDIOL	Experimental	FLT3 | KIT | PTPN11
181.8870578942927	-49.3666129780499	197.30498792162385	-18.0561216581059	0.0006	264	35	SKCM	CHEMBL478649	Experimental	CYBB | AKT3 | GNAS
247.43443051083563	43.8901753977316	178.50492779094745	-8.34141227819043	0.0006	169	39	READ	DB07268	Experimental	KRAS | MAP4K1 | RRAS2
1067.269663808513	25.3949708025447	1095.9770167893985	3.6736788796336	0.993	292	33	STAD	CABOZANTINIB	Approved in cancer	KRAS | NRAS | CREBBP
712.0407431488264	-10.8642266280811	721.6228902948068	0.506793365404292	0.576	599	79	GBM	PKI-587	Clinical trials in cancer	NRAS | KRAS | PTPN11
200.8345543065376	-60.3282478281131	187.56210150714443	0.597357903569787	0.0004	202	21	LAML	PARBENDAZOLE	Experimental	IDH1 | SOS1 | MYC
147.74121595628085	-33.751532753587	200.4146517162078	-10.2625276932554	0.0004	343	45	HNSC	NVP-BGT226	Experimental	PIK3CA
228.41132032409453	11.2462768437408	214.49346810293693	-9.46697572834182	0.0004	934	216	BRCA	RECILISIB	Experimental	PIK3CA
639.6791638524905	38.9841561108848	596.2267384542951	-5.37334558598059	0.412	169	38	READ	SALIRASIB	Clinical trials in cancer	KRAS
694.4441452706001	-50.9950219304542	666.2970106626035	-4.29673992630569	0.518	343	46	HNSC	NVP-BGJ398	Clinical trials in cancer	PIK3CA | FGFR3
730.8975159641773	-57.2011451025302	726.2574668278013	-2.07909532503595	0.584	599	80	GBM	ALPELISIB	Clinical trials in cancer	NRAS | KRAS | PTPN11
42.9692361971193	-21.5315265598675	193.94232966790983	-18.1529062202976	0.0004	222	134	LGG	GW843682X	Experimental	IDH1 | MTOR | PIK3CA
944.4409433326887	-13.905595170274	952.1397440671964	-3.41688992467516	0.833	543	78	LUAD	CARBOPLATIN	Approved in same tumor type	KRAS | EGFR | PIK3CA
334.4600028806493	11.9397311024823	188.87286633845795	25.4614408155741	0.0006	169	44	READ	2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE	Experimental	KRAS | NRAS | BRAF
689.415207854141	-54.3823186491109	689.512819183415	-8.65142431323147	0.546	343	56	HNSC	TAK-733	Clinical trials in cancer	RAC1 | PIK3CA | NF1
1077.6660149641768	-5.18786865039951	1087.1648679053017	0.775321395108449	0.981	512	93	UCEC	TAMOXIFEN	Approved in cancer	TSC2 | ZAP70 | MTOR
173.8265338354481	-9.27886047227165	203.62866846298104	-14.1741820194732	0.0006	543	78	LUAD	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
633.7306003407575	-1.47154372448057	676.2730536576443	9.54570106087806	0.533	202	23	LAML	CEDIRANIB	Clinical trials in cancer	FLT3 | KIT | KDR
407.6983727675737	-2.88340934162042	405.7205758136876	-0.618102828430438	0.232	423	75	COAD	NIVOLUMAB	Approved in other pathologies	KRAS | BRAF
587.8534871187708	-103.838566459614	603.8204263140392	6.74152958622017	0.431	222	137	LGG	LEXIBULIN	Clinical trials in cancer	IDH1 | PIK3CA | EGFR
975.1391930346239	8.10120502979663	931.6785010433548	-10.3077448780664	0.823	934	236	BRCA	DOXORUBICIN	Approved in cancer	AKT1 | ERBB2 | PIK3CA
198.7145560612184	16.2026581646154	208.39959428389963	1.81928657991716	0.0008	512	55	UCEC	PF-3644022	Experimental	KRAS | BRAF | MAPK14
113.27971780203416	11.5560535936636	217.7608711557652	3.39892715189262	0.0008	423	92	COAD	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
85.1895324906518	-45.6128717041343	154.25817468144103	5.34246599330947	0.0004	222	139	LGG	LY2183240	Experimental	KRAS | NRAS | IDH1
57.5949899310873	-1.30593527596582	168.31565956379615	54.4256861612271	0.0004	264	172	SKCM	TUBASTATIN A	Experimental	NRAS | BRAF
568.8951339594131	31.1104400437102	724.4767056895782	-19.1075884454499	0.546	435	187	THCA	NAVITOCLAX	Clinical trials in cancer	KRAS | TSHR | BRAF
1037.523445690104	19.0392875852495	1057.9625506594443	-2.71285858857027	0.943	543	95	LUAD	IMATINIB	Approved in cancer	KRAS | RB1 | SMAD4
549.752668007023	-23.9457368634705	573.0599996373859	-6.08927652820603	0.412	343	45	HNSC	SAR245409	Clinical trials in cancer	PIK3CA
478.7783364887807	-10.2123612259016	529.0600238612333	7.47413513317861	0.381	264	127	SKCM	EDARAVONE	Approved in other pathologies	VHL | AKT3 | BRAF
947.3143516208011	-9.51044111733486	949.7458361835475	5.96452517721809	0.833	343	45	HNSC	OLAPARIB	Approved in cancer	PIK3CA
255.99855688517286	93.9690593305119	144.7881801940277	-29.7592074763921	0.0006	435	183	THCA	2,2,2-TRIFLUOROETHANOL	Experimental	BRAF | SOS1 | ESR1
170.13208461375785	35.8465775025538	216.60380811972507	-25.4907163430846	0.0006	512	94	UCEC	1-CYCLOBUTYL-3-(3,4-DIMETHOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE	Experimental	PTEN | KDR | GNAS
550.1005379643393	-80.5865051586732	585.7401150063077	11.4094705041373	0.412	435	209	THCA	UNII-CZP9GB25HO	Clinical trials in cancer	NRAS | BRAF
551.939030531507	-8.13981339389025	545.5785909923889	-1.36754716093878	0.382	512	61	UCEC	CARVEDILOL	Approved in other pathologies	VHL | TSC2 | CTNNB1
160.98029385200013	25.3145992431595	212.91596261329062	7.50532792607044	0.0008	202	23	LAML	452105-23-6	Experimental	FLT3 | KIT | KDR
841.3803518592192	-34.6245189234624	766.0457472751007	-23.6189370741893	0.597	512	165	UCEC	PKI-587	Clinical trials in cancer	KRAS | NRAS | TSC2
740.4022441241957	120.654828079577	706.3122466447774	29.751670407823	0.527	435	211	THCA	ENCORAFENIB	Clinical trials in cancer	KRAS | NRAS | BRAF
943.0575921472737	-7.12808559377561	930.4421217529649	-2.22540061369273	0.812	292	33	STAD	VEMURAFENIB	Approved in cancer	KRAS | NRAS | AKT1
618.17355738277	-60.8158187659687	595.4402874847804	19.0490731705522	0.441	264	113	SKCM	ABT-751	Clinical trials in cancer	BRAF | PIK3CA | FGFR1
324.0896835372316	60.2106563018149	233.00369471198962	45.1480609315279	0.0006	435	183	THCA	GUANOSINE TRIPHOSPHATE	Experimental	BRAF | SOS1 | ESR1
795.2802396763046	-4.27535813575068	745.8219706846006	-30.1132185023632	0.582	512	99	UCEC	AFURESERTIB HYDROCHLORIDE	Clinical trials in cancer	TSC2 | PTEN | MTOR
619.2586859018625	-32.1334662859622	606.9997208785342	-6.74609250381764e-05	0.452	543	78	LUAD	ABT-737	Clinical trials in cancer	KRAS | EGFR | PIK3CA
983.1296509877649	-43.4582881512028	955.2154689413338	-18.9145869383281	0.822	435	183	THCA	VORINOSTAT	Approved in cancer	BRAF
906.6622915366507	57.1631350296779	943.5365150320231	38.6408954905374	0.812	57	24	PAAD	CAPECITABINE	Approved in cancer	KRAS
176.03054851072463	-21.6186418487121	198.7844152606479	-8.01090277271942	0.0004	153	16	BLCA	BISTRAMIDE A	Experimental	PIK3CA | ZNF521 | MAP3K4
461.74665497724305	25.6531039253472	605.0401230480898	10.80972769086	0.423	435	211	THCA	BGB-283	Clinical trials in cancer	KRAS | NRAS | BRAF
848.74545321124	-10.4050716805874	857.9995592696379	0.000509344345118734	0.731	292	30	STAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | PIK3CA
609.9231998683596	4.39871466286647	604.9487977277672	5.71299252716426	0.442	512	63	UCEC	BGB-283	Clinical trials in cancer	KRAS | NRAS | ERBB2
558.5760652412266	-32.3025899680119	603.2121422587898	7.61268468728622	0.442	423	76	COAD	BAY1125976	Clinical trials in cancer	KRAS | NRAS | PIK3CA
693.164673671371	71.9248983633202	726.5914483214107	7.62115336628926	0.585	292	40	STAD	GDC-0068	Clinical trials in cancer	KRAS | PTPN11 | AKT1
622.6649626668218	9.10703860093196	677.9532248431319	-16.4316028461028	0.534	202	23	LAML	LINIFANIB	Clinical trials in cancer	FLT3 | KIT | KDR
161.72592706223955	-1.02378675239913	193.9262309801358	-19.2734098996712	0.0004	343	47	HNSC	PUQUITINIB	Experimental	PIK3CA | PDGFRB | EGFR
792.9665453271432	69.3511017555405	698.3410077375154	19.0675598340728	0.566	57	24	PAAD	DACTOLISIB	Clinical trials in cancer	KRAS
194.20116437563857	36.8955478137884	207.04869273166534	11.5960063941557	0.0006	543	84	LUAD	A-443654	Experimental	KRAS | GNRHR | EGFR
224.41142921664076	-15.270685308991	218.74861434421064	0.0842755222472533	0.0008	543	92	LUAD	PI-103	Experimental	KRAS | NRAS | STK11
755.843247922646	-23.6667161168089	733.421671692103	8.58961381833501	0.583	543	66	LUAD	CC-223	Clinical trials in cancer	KRAS | STK11 | PIK3CA
408.4825273144445	2.88578656816586	408.9998658303557	0.000316592507147107	0.232	202	23	LAML	SEMAXANIB	Approved in other pathologies	FLT3 | KIT | KDR
537.3704660412019	-31.3920534064	554.8566944951946	5.52716211260986	0.381	264	31	SKCM	4-AMINOSALICYLIC ACID	Approved in other pathologies	AKT3 | BTK | MAP2K1
688.8353824178414	124.494507777228	584.6395276532074	26.1169469738582	0.434	169	43	READ	CH5132799	Clinical trials in cancer	KRAS | BRAF | PIK3CA
643.4324328981274	76.994999558819	672.344269765671	11.2868171486318	0.537	435	211	THCA	PKI-587	Clinical trials in cancer	KRAS | NRAS | BRAF
173.6640313686116	31.4085742609016	205.53525535497374	-3.0288370917192	0.0006	502	59	KIRC	CHEMBL258208	Experimental	VHL | MTOR
809.5108768332365	-38.30774082302	765.8872012887656	10.967201464621	0.598	512	165	UCEC	DACTOLISIB	Clinical trials in cancer	KRAS | NRAS | TSC2
237.11124806451406	-142.330146757691	126.90074395711054	16.8909815994057	0.0008	264	187	SKCM	D-O-PHOSPHO THREONINE	Experimental	NRAS | KRAS | AKT3
573.96744778732	76.3561564331109	585.744838306439	-26.8222490417278	0.422	169	40	READ	P7170	Clinical trials in cancer	KRAS | PIK3CA
101.80447086097035	57.5372147499529	227.7351765922899	7.608084274845	0.0006	57	24	PAAD	TURPENTINE	Experimental	KRAS
666.1123189736693	-10.3983353053708	668.5910599160309	0.551876440127671	0.514	343	46	HNSC	OSI-027	Clinical trials in cancer	STK11 | PIK3CA
65.46552188470638	33.1432110543276	211.45605913585794	33.2978796002474	0.0004	934	227	BRCA	LY2183240	Experimental	KRAS | PIK3CA | IDH1
168.3721598415796	47.0595952901483	202.89007549258574	9.57267744766818	0.0008	292	32	STAD	154447-36-6	Experimental	KRAS | CREBBP | PIK3CA
697.3269641332275	36.4658648337207	733.5256291231867	-0.877625422478786	0.594	292	41	STAD	APITOLISIB	Clinical trials in cancer	KRAS | PTPN11 | NGF
161.18805946087653	-42.7340357694873	210.34480185787532	-6.63141034285491	0.0004	423	65	COAD	AZD8186	Experimental	KRAS | PIK3CA
1107.5032758483678	-3.61586230183661	1091.2901349935837	5.36145817122951	0.987	292	40	STAD	RIBOCICLIB	Approved in cancer	RB1 | SMAD4 | KRAS
773.7831380826511	-3.06821438313435	796.0006797027079	0.000396145495415112	0.662	512	117	UCEC	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | PIK3CA
750.4501728165001	136.841850291709	675.9885688249808	44.0149911782046	0.525	264	124	SKCM	PEXIDARTINIB	Clinical trials in cancer	KIT | BRAF | KDR
1096.9689352986263	-27.7300513848582	1075.5135990173183	-4.04744228204254	0.987	423	98	COAD	BOSUTINIB	Approved in cancer	KRAS | NRAS | SMAD4
238.33089495162898	47.5781133933249	190.48593602104992	20.8401344123929	0.0004	512	137	UCEC	KINETIN RIBOSIDE	Experimental	KRAS | CTNNB1 | PIK3CA
172.80822022285193	-24.5619577708591	185.19947879843593	-5.108158596066	0.0008	264	30	SKCM	BISINDOLYLMALEIMIDE I	Experimental	PTPN11 | PTEN | INSR
311.04622639730985	3.54565878821359	206.85752668199393	18.2581624803761	0.0004	169	40	READ	AZD-8835	Experimental	KRAS | PIK3CA
244.50321770195345	121.808199070796	223.09310138659689	-36.7870449750079	0.0004	57	24	PAAD	DEGUELIN	Experimental	KRAS
663.933199624481	-64.8565717663124	717.0739818790377	-23.7376097872902	0.585	423	86	COAD	SARACATINIB	Clinical trials in cancer	KRAS | SMAD4 | ESR1
543.9782875433002	26.8495255875375	587.6452046304537	-7.7201749562837	0.422	543	64	LUAD	1375469-38-7	Clinical trials in cancer	KRAS | PIK3CA
247.53634161173338	34.0839483862593	196.15475189844815	2.89054392640242	0.0006	222	58	LGG	OBLIMERSEN	Experimental	TP53 | BRAF | MTOR
206.85871141843512	-12.7647156557148	198.01576522466672	12.3161596981058	0.0008	423	83	COAD	PI-103	Experimental	KRAS | NRAS | ESR1
136.0063535120109	62.0845275789777	224.39249998418845	9.03890124762029	0.0008	423	92	COAD	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	KRAS | NRAS | NF1
123.1396324670156	101.683022920763	170.3315393390847	-21.7762571258531	0.0004	222	131	LGG	MERCK60	Experimental	KRAS | IDH1
247.61092143850743	-24.8837044130172	184.0436760540342	11.3650627545026	0.0006	502	60	KIRC	CHEMBL1236441	Experimental	VHL | AKT3 | MTOR
1126.5743950574226	-6.45218386633181	1102.426582245503	-5.60713575515911	1.0	543	99	LUAD	SORAFENIB	Approved in cancer	KRAS | NF1 | NRAS
562.3378523208382	-2.30328620885052	562.1355033438566	15.499467401133	0.423	934	217	BRCA	DS-7423	Clinical trials in cancer	KRAS | PIK3CA | MTOR
642.929182082948	-66.7917059790136	696.3570484143513	24.2709499864231	0.513	264	105	SKCM	PF-04217903	Clinical trials in cancer	BRAF | MET
1083.1537346917492	13.1740158124857	1093.3339780212316	1.68644359062819	0.99	153	26	BLCA	TRAMETINIB	Approved in cancer	NRAS | CTNNB1 | FGFR3
1084.7888608614137	-58.3502594314218	1085.2906785594325	26.8374714295505	0.997	264	38	SKCM	AXITINIB	Approved in cancer	RB1 | KIT | VHL
753.8794326928682	39.9686464252654	694.6134516559652	1.9309531897984	0.545	934	228	BRCA	PF-04691502	Clinical trials in cancer	KRAS | STK11 | PTEN
779.5154651831651	49.8956690183698	755.9611566579036	-9.11039103659385	0.596	169	48	READ	BUPARLISIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
1112.1763305422464	-1.04085140137695	1105.755816683569	-5.16906126091294	1.0	292	43	STAD	DASATINIB	Approved in cancer	RB1 | SMAD4 | KRAS
358.6629755777185	10.1882232441399	362.98419133317583	4.01858498965248	0.181	423	92	COAD	ANTIBIOTIC K 252A	Clinical trials	KRAS | NRAS | NF1
365.10348768543776	7.36627155475014	365.5791240788921	-3.44553757324866	0.182	264	35	SKCM	DORAMAPIMOD	Clinical trials	CYBB | AKT3 | GNAS
587.3441414530796	-28.4062844085685	569.1494390460238	-0.492674432752665	0.422	423	65	COAD	SAR245409	Clinical trials in cancer	KRAS | PIK3CA
548.5588920520688	-35.231339377137	538.3546873999004	-2.22276279342691	0.381	512	76	UCEC	ISOPRENALINE	Approved in other pathologies	KRAS | NRAS | BRAF
95.79738110438456	38.5580698143308	213.83371390176805	-35.83176991451	0.0006	435	211	THCA	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
550.3594107505331	70.1213158111254	545.9038926770634	45.3854183387681	0.422	57	24	PAAD	BAY1125976	Clinical trials in cancer	KRAS
741.32543380211	-28.8211170177407	729.0619301300542	-15.2324251358077	0.582	423	68	COAD	AT-101	Clinical trials in cancer	TP53 | MTOR | BRAF
148.6138219808074	95.3718303580704	203.2464950352443	-11.1035199573084	0.0006	502	59	KIRC	FENOXAPROP-ETHYL	Experimental	VHL | MTOR
678.5525291763023	23.4031558117879	695.2579984828624	-2.98856319519655	0.545	502	63	KIRC	TESEVATINIB	Clinical trials in cancer	VHL | MTOR | KDR
129.75608673516882	17.5581488580559	188.69062376920047	-17.2196556165475	0.0004	512	53	UCEC	LY-411575	Experimental	KRAS | ERBB2
677.6757440851361	-63.97593075757	736.7484820112685	8.48184098217689	0.595	153	23	BLCA	PICTILISIB	Clinical trials in cancer	NRAS | PTEN | PIK3CA
1034.6721695161543	-27.1948842093197	1048.1623051205254	-4.50509488120042	0.934	502	74	KIRC	PONATINIB	Approved in cancer	VHL | PTEN | MTOR
243.77013533245076	17.288217520461	194.146168330282	-8.58305181597507	0.0006	502	62	KIRC	N-OMEGA-HYDROXY-L-ARGININE	Experimental	VHL | AKT3 | MTOR
764.491966497328	68.578339340851	737.935134304491	-3.22058063491676	0.593	169	45	READ	BMS-908662	Clinical trials in cancer	KRAS | PTPN11 | NRAS
629.401980433023	69.075285168554	520.0732935028017	-9.40592808017556	0.432	57	24	PAAD	CC-223	Clinical trials in cancer	KRAS
796.0829921471841	85.6228429976194	715.1783828325039	18.7759874081951	0.564	57	24	PAAD	PX-866	Clinical trials in cancer	KRAS
705.4859722524579	-33.4340125781707	744.2471825444081	0.270285801339014	0.595	153	23	BLCA	PX-866	Clinical trials in cancer	NRAS | PTEN | PIK3CA
122.23713325569072	31.4628403150114	184.91265133184112	18.6544195433004	0.0004	57	24	PAAD	PF-3644022	Experimental	KRAS
721.1939154362093	2.46249258531077	734.1551651848401	8.57656561267322	0.597	512	78	UCEC	ENCORAFENIB	Clinical trials in cancer	KRAS | NF1 | NRAS
594.0552007967901	-22.1996045368695	587.1574705706356	-12.4464566810236	0.423	543	65	LUAD	RIGOSERTIB	Clinical trials in cancer	KRAS | PIK3CA | HRAS
166.8455647992147	-132.812201172498	295.6014693759596	-17.785880940372	0.0008	264	185	SKCM	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	NRAS | KRAS | AKT3
565.8915477988372	118.797095315476	553.3087411435095	-14.701419844374	0.422	57	24	PAAD	NVP-BGJ398	Clinical trials in cancer	KRAS
549.2872925227038	5.97113301903352	559.1853220407733	6.66489964646826	0.4	512	70	UCEC	HEPARIN	Approved in other pathologies	CTNNB1 | SOS1 | BRAF
985.3826935753248	32.9077766093649	1039.5743402858739	-6.80167111812511	0.93	512	117	UCEC	VEMURAFENIB	Approved in cancer	KRAS | NRAS | PIK3CA
147.73686803488408	-24.4401426860073	204.40687326727294	2.41539405910771	0.0004	153	20	BLCA	PNU-74654	Experimental	CTNNB1 | FGFR3 | IDH1
667.281325246386	10.262469812126	659.4652795094315	2.24339017038108	0.513	202	37	LAML	1032350-13-2	Clinical trials in cancer	KRAS | KIT | PTPN11
646.298207094925	-52.501043365059	660.1946980513351	4.5275433924794	0.514	343	46	HNSC	ARQ-092	Clinical trials in cancer	AKT1 | PIK3CA
1007.11911688012	-28.8813434324302	1035.8720090844502	7.48270155561454	0.93	543	89	LUAD	GEFITINIB	Approved in same tumor type	KRAS | NRAS | BRAF
591.0110320853959	-24.9071656909348	562.8928506390857	3.59529837708305	0.412	543	60	LUAD	RILOTUMUMAB	Clinical trials in cancer	KRAS
254.868990400783	33.7279907346472	200.05979382972237	-4.30247341827226	0.0006	389	52	LUSC	OBLIMERSON	Experimental	BRAF | TP53 | MAPK14
130.20860346504475	-0.896028801598192	219.31114877485933	8.84024258990894	0.0006	264	35	SKCM	CHEMBL273158	Experimental	CYBB | AKT3 | GNAS
1037.7780406233314	-36.7304105317023	1027.5996662789098	4.88402508087074	0.92	343	46	HNSC	NERATINIB	Approved in cancer	PIK3CA | EGFR
166.27454399327198	56.0754499150281	204.0893196575086	6.60883124099507	0.0008	202	25	LAML	SB220025	Experimental	KRAS | NRAS | SOS1
1047.1529246217794	85.1188871530828	1060.772390707673	-19.2321515668382	0.947	57	25	PAAD	BOSUTINIB	Approved in cancer	KRAS | SMAD4
146.33440575672964	7.26744616100098	185.46439268069375	6.84037589910645	0.0006	502	59	KIRC	CHEMBL232827	Experimental	VHL | MTOR
164.41412790556834	-27.0189193659014	217.7804770402626	11.6041367746793	0.0006	423	58	COAD	LAX-101	Experimental	KRAS | NLRP3
800.8399380099044	-35.6810611979382	760.9998021768837	-0.000433313499343058	0.623	543	71	LUAD	DECITABINE	Approved in other pathologies and in clinical trials in cancer	KRAS | EGFR
237.97792073480187	16.835303491487	194.8541805367445	-5.37814165546979	0.0008	292	35	STAD	OLOMOUCINE	Experimental	RB1 | SMAD4 | KRAS
421.7756727810937	24.1201328752157	416.76086633308313	7.50315444926719	0.232	264	179	SKCM	PEMBROLIZUMAB	Approved in other pathologies	NRAS | KIT | KRAS
190.5124402375593	-26.2565507768217	197.44635613581224	-14.5808176148539	0.0004	343	45	HNSC	UNII-S9WA04F921	Experimental	PIK3CA
762.6325251247047	-50.3138972274474	702.2068809071183	14.4198726529426	0.598	264	47	SKCM	AZD5363	Clinical trials in cancer	KRAS | PTPN11 | PTEN
780.9107398037863	-147.262104428999	729.3427638433175	15.3133489903357	0.581	264	127	SKCM	DHA-PACLITAXEL	Clinical trials in cancer	VHL | AKT3 | BRAF
655.7593547213263	-45.7214695075417	715.4793674538316	-0.146095693417919	0.576	153	20	BLCA	TAK-733	Clinical trials in cancer	NRAS | PIK3CA | SOS1
141.97298283509653	-11.1100049606862	223.73128608597722	-2.39881106990333	0.0004	343	45	HNSC	AZD-8835	Experimental	PIK3CA
159.8286449881577	43.3005982915745	214.38794639284095	-38.7666386763531	0.0004	512	86	UCEC	NAKITERPIOSIN	Experimental	MTOR | PIK3CA | FGFR1
243.54444453394208	139.891571510926	160.03694328590146	-20.0246163823851	0.0006	435	211	THCA	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | BRAF
150.5171518380593	-37.4237199673162	194.91642884977426	4.88401269368433	0.0008	264	33	SKCM	A-443654	Experimental	KRAS | PTPN11 | AKT3
1137.283740914681	8.05832606767018	1111.2483193711332	20.1420945485254	0.995	512	143	UCEC	PACLITAXEL	Approved in cancer	KRAS | TP53 | VHL
611.739128302381	-8.37560709833448	666.0108149342369	-4.29413596516338	0.522	502	64	KIRC	AT-101	Clinical trials in cancer	VHL | AKT3 | MTOR
1024.7998649868844	107.143539225619	1037.689428449695	-8.60200522182822	0.981	264	127	SKCM	ERIBULIN	Approved in cancer	VHL | AKT3 | BRAF
771.4099803828897	-34.0450423265877	754.5215734205638	19.1874157066882	0.6	423	96	COAD	391210-10-9	Clinical trials in cancer	KRAS | NRAS | NF1
496.8925027195439	-27.9458935593667	499.70208797321453	-0.417828784429503	0.331	502	63	KIRC	APREMILAST	Approved in other pathologies	VHL | AKT3 | MTOR
725.2159427667295	57.4188156990723	761.969097892442	-18.7472334538706	0.596	169	48	READ	DACTOLISIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
1069.784207918632	14.8717990208805	1033.3553623883097	5.68081641967501	0.93	512	114	UCEC	NERATINIB	Approved in cancer	KRAS | PIK3CA | ERBB2
1058.3586581938946	-41.9741755041557	1038.8730449948898	4.26627299278243	0.93	423	87	COAD	AFATINIB	Approved in cancer	KRAS | NRAS | BRAF
591.2037005305242	6.6124260115555	593.052020657912	0.998049845967216	0.432	343	46	HNSC	LUCITANIB	Clinical trials in cancer	PIK3CA | PDGFRB
229.0558249244718	44.388423661174	205.36336072367925	27.9600503050912	0.0008	169	43	READ	FR 180204	Experimental	KRAS | NRAS | BRAF
951.4294495715844	-2.33247854586443	961.2088060415687	-3.04173260838525	0.843	343	48	HNSC	STREPTOZOCIN	Approved in cancer	PIK3CA | HRAS
218.76713514624896	-70.9000410987167	209.3484943419151	8.27704007581201	0.0004	934	217	BRCA	TORIN 1	Experimental	PIK3CA | MTOR
186.1008469514322	-121.022134587765	140.6734540026218	-1.592591356914	0.0006	264	117	SKCM	CHEMBL1236441	Experimental	VHL | AKT3 | BRAF
682.2187466975128	-21.3218140324269	682.7504934919265	4.21307786384841	0.535	153	16	BLCA	GDC-0032	Clinical trials in cancer	PIK3CA | SOS1 | HRAS
586.5459254063778	5.5667089882553	589.0001168565212	0.000208191532237834	0.432	153	16	BLCA	LUCITANIB	Clinical trials in cancer	PIK3CA | KDR | PDGFRA
230.5299148746397	92.5081764392446	227.6947173086271	-35.8608246139452	0.0006	264	132	SKCM	2,2,2-TRIFLUOROETHANOL	Experimental	KIT | PTPN11 | GNAQ
1008.8309593796957	-41.6496674080271	1044.375197109922	3.26730106236573	0.931	343	56	HNSC	DABRAFENIB	Approved in cancer	RAC1 | PIK3CA | NF1
594.0000600741718	-5.70827579559432	566.0912854680726	-0.0180033190891891	0.412	202	23	LAML	LONAFARNIB	Clinical trials in cancer	KRAS | NRAS
207.0793656751224	2.60576694489976	192.32662017040352	13.8026114184256	0.0006	502	62	KIRC	3-BROMO-7-NITRO-1H-INDAZOLE	Experimental	VHL | AKT3 | MTOR
763.2794230735352	24.0786860920569	735.098942962261	-2.15945720658277	0.595	389	48	LUSC	XL765	Clinical trials in cancer	KRAS | PTEN | EGFR
505.11682258490686	22.5429138092428	570.7261409021299	-6.39544693074669	0.433	169	44	READ	BGB-283	Clinical trials in cancer	KRAS | NRAS | BRAF
481.58256337378003	-21.931980385388	491.1823604494438	0.597052849527017	0.324	502	61	KIRC	RANIBIZUMAB	Approved in other pathologies	VHL | MTOR | HSPG2
662.5033290014356	-43.3028669882299	732.5507433685982	15.8250492169841	0.585	423	93	COAD	AZD8330	Clinical trials in cancer	KRAS | NRAS | NF1
895.7079464635623	-23.6452491667989	956.9691176388119	0.524469731417412	0.843	343	47	HNSC	IRINOTECAN	Approved in cancer	AKT1 | PIK3CA | EGFR
697.2065501962569	64.5753242269093	660.8878783893173	-3.51949305250264	0.524	169	45	READ	212631-79-3	Clinical trials in cancer	KRAS | NRAS | BRAF
703.5100896490467	125.27471188525	656.3334376123802	-17.2877917303601	0.54	435	211	THCA	391210-10-9	Clinical trials in cancer	KRAS | NRAS | BRAF
520.9709795636966	56.8543899463127	587.1599965481489	-8.72558282489445	0.412	169	38	READ	RALIMETINIB	Clinical trials in cancer	KRAS
772.0884177311914	-46.3678222294438	723.0548949769941	11.8125382121677	0.584	292	40	STAD	AZD5363	Clinical trials in cancer	KRAS | PTPN11 | AKT1
200.9787605484958	-40.0438458392656	229.89201721541178	14.1079455018235	0.0004	264	45	SKCM	PIPERLONGUMINE	Experimental	CTNNB1 | TRIO | GNAS
207.35543734326438	33.4781149352236	195.1363897575936	3.80388990336132	0.0008	292	40	STAD	PI-103	Experimental	KRAS | PTPN11 | NGF
262.5781548853843	10.8794419957656	203.8114093449173	26.0631320686764	0.0004	934	222	BRCA	PIPERLONGUMINE	Experimental	PIK3CA | AFF4 | ARNT
1102.8577948968803	-5.5675123679701	1100.2779546897477	-5.03706581614983	1.0	292	37	STAD	BOSUTINIB	Approved in cancer	RB1 | SMAD4 | KRAS
909.8918796050236	2.6512478975566	910.8579444099055	0.184917554831429	0.814	57	24	PAAD	ATEZOLIZUMAB	Approved in cancer	KRAS
138.10237978761168	-28.2696940114507	187.40283100307926	-22.2548859946837	0.0006	512	81	UCEC	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | ZAP70
442.04984542183206	-12.2686633237703	477.25894512615196	-9.03583904809489	0.311	435	211	THCA	ISOPRENALINE	Approved in other pathologies	KRAS | NRAS | BRAF
517.1798479510452	28.8053481675588	624.3353634511965	3.27466060126278	0.412	57	24	PAAD	ULIXERTINIB	Clinical trials in cancer	KRAS
153.64247508958326	46.4365840001703	163.6451162188385	20.1685904087872	0.0006	512	94	UCEC	RU81843	Experimental	PTEN | KDR | GNAS
641.3007947378857	-46.3239020443934	697.3825551623374	8.01958982300494	0.552	343	94	HNSC	GOSSYPOL	Clinical trials in cancer	TP53 | AR | MAP2K1
579.6722812748774	-69.0452151909115	599.1468029900448	12.4046834026392	0.442	512	114	UCEC	CH5132799	Clinical trials in cancer	KRAS | MTOR | PIK3CA
958.8839375382311	-3.25192821651135	923.9153438894233	-4.38453265442013	0.813	934	220	BRCA	PANITUMUMAB	Approved in cancer	KRAS | MAP2K1 | ERBB2
265.63300519158656	38.2352610000174	196.48943247303674	-18.0812080027831	0.0006	202	53	LAML	PI-103	Experimental	KRAS | FLT3 | KIT
708.0469220853855	91.1375192718381	745.1514675470244	7.36463768573381	0.613	57	24	PAAD	DECITABINE	Approved in other pathologies and in clinical trials in cancer	KRAS
226.06252456470037	23.9669639923851	192.4827030904076	-19.7888279416675	0.0004	512	64	UCEC	CYTOCHALASIN B	Experimental	NRAS | CTNNB1 | SOS1
767.4632649769256	-75.4513697866398	648.7927485122591	-0.804323941990788	0.542	264	115	SKCM	1260612-13-2	Clinical trials in cancer	BRAF | PIK3CA | RAC1
180.23584299307873	-2.73101693797813	205.52572119885005	6.50174310140619	0.0006	264	40	SKCM	5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE	Experimental	KRAS | AKT3 | MAP2K1
195.69592394062522	-48.1828108961685	210.46179999985412	-34.2599232038178	0.0006	264	35	SKCM	2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE	Experimental	CYBB | AKT3 | GNAS
675.6338758096769	126.508554048567	612.3017996670737	34.6316447283996	0.422	57	24	PAAD	BMS-754807	Clinical trials in cancer	KRAS | ETV6
720.7073887209972	-42.4876344755605	703.4140888627927	1.76451990198257	0.554	343	55	HNSC	1032350-13-2	Clinical trials in cancer	PTEN | AKT1 | PIK3CA
215.7763639078071	42.7969503677456	196.98504770733095	-38.0850423242525	0.0004	934	216	BRCA	IPI549	Experimental	PIK3CA
678.0564236114615	33.8345355035198	715.3150807189289	-12.4272319167505	0.585	543	92	LUAD	212631-79-3	Clinical trials in cancer	KRAS | NF1 | NRAS
973.6298218100108	25.0396511173391	1017.7937590512465	0.919018780887654	0.95	435	211	THCA	SORAFENIB	Approved in cancer	KRAS | NRAS | BRAF
752.6492234012499	-5.40128851972253	721.1433826907121	6.6032745449902	0.592	292	41	STAD	GSK2636771	Clinical trials in cancer	KRAS | PTPN11 | NGF
590.6519912368179	-0.0786882853675763	578.7037771319804	-12.1466210813423	0.412	169	39	READ	NVP-AUY922	Clinical trials in cancer	KRAS | FGFR1
377.30594488322816	5.88500943553564	375.53415928750223	-0.00820405299714366	0.193	292	42	STAD	QUERCETIN	Clinical trials	KRAS | PTPN11 | NGF
980.2670609358809	-33.6577655125537	958.9999177126248	0.00112118148831541	0.843	292	30	STAD	CARBOPLATIN	Approved in cancer	KRAS | PIK3CA | EGFR
209.90834495233497	-61.5557091015216	184.11421158896673	15.3933750366537	0.0004	512	52	UCEC	CERULENIN	Experimental	KRAS | PBX1 | CBFA2T3
130.71199800532932	23.1972998039472	191.71851186175206	38.0090458103687	0.0006	512	94	UCEC	MALONIC ACID	Experimental	PTEN | KDR | GNAS
178.56565864502184	25.5876253493977	194.55635210149606	-10.5785526772388	0.0006	543	68	LUAD	1,9-PYRAZOLOANTHRONE	Experimental	KRAS | SOS1 | MAP2K1
688.9065662092527	25.1319553081158	688.40857473402	3.95520274244382	0.536	502	63	KIRC	TIVOZANIB	Clinical trials in cancer	VHL | MTOR | KDR
928.433558170959	-17.9272914175131	927.1794638928162	6.06648043506351	0.812	169	43	READ	BEVACIZUMAB	Approved in same tumor type	KRAS | BRAF | PIK3CA
634.2239166310849	112.515177454273	561.4749337456589	-17.3784812909964	0.414	169	39	READ	POZIOTINIB	Clinical trials in cancer	KRAS | ERBB2
726.6879315458617	-15.2645324155754	724.4823412289918	-18.2785745980909	0.59	543	92	LUAD	BINIMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
346.7643286442802	67.4679765932011	187.30654987443592	-10.3438268194016	0.0006	57	24	PAAD	1,9-PYRAZOLOANTHRONE	Experimental	KRAS
1122.1546770392067	-48.805615211205	1085.1496134822594	-10.1849829798737	0.983	292	62	STAD	ABT-199	Approved in cancer	KRAS | MAP2K1 | CREBBP
674.7878345784155	143.014106641508	697.8708914250376	-10.1148358131474	0.553	57	24	PAAD	PICTILISIB	Clinical trials in cancer	KRAS
172.74684308867003	-48.3662287075382	190.76561989696378	16.7889640003814	0.0006	264	35	SKCM	CHEMBL559401	Experimental	CYBB | AKT3 | GNAS
958.3628856387778	-34.6202555406815	967.4305569708464	2.67994634525076	0.853	423	66	COAD	CARBOPLATIN	Approved in cancer	KRAS | PIK3CA | PDGFRA
148.55645302182546	57.9784393449115	213.50097635054664	-0.021991153149429	0.0004	512	83	UCEC	PUQUITINIB	Experimental	PIK3CA | KDR | PDGFRB
1136.7310348211595	-29.5871809862562	1118.6027166156068	1.52860043193914	1.0	423	97	COAD	DABRAFENIB	Approved in cancer	KRAS | NRAS | ESR1
100.16929462063109	14.1202096984853	237.95935415708843	17.9896786977988	0.0008	512	102	UCEC	STAUROSPORINE	Experimental	RB1 | ZAP70 | PTEN
188.7384417544497	-69.9830789915079	220.3134521095993	-12.6407984235589	0.0004	264	68	SKCM	1-ETHYL-1-NITROSOUREA	Experimental	NRAS | ERBB2
1061.564913206126	-76.8793543404753	1061.8814278641653	-11.9578264680845	0.953	343	126	HNSC	ABT-199	Approved in cancer	TP53 | PIK3CA | MAP2K1
252.8869409503702	-49.3809284712601	185.88257382405632	6.63205866845033	0.0008	543	92	LUAD	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	KRAS | NF1 | NRAS
627.8822133459727	-65.3433245022626	587.9452896347309	-0.0214304638857357	0.432	292	30	STAD	AZD2014	Clinical trials in cancer	KRAS | PIK3CA | FGFR1
274.1812641213992	-86.5554641830724	173.68845139153154	-6.20795463974059	0.0006	435	211	THCA	N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
527.9218946636112	-45.9177506527951	570.8870942077587	-17.170932541178	0.423	934	217	BRCA	LY3023414	Clinical trials in cancer	PIK3CA | MTOR
262.4236466254225	-34.1452402672696	163.26470463523933	-12.3023925908312	0.0006	512	141	UCEC	HERBIMYCIN A	Experimental	PTEN | PIK3CA | KDR
359.65016517708904	-12.6106762571048	358.60875936745856	-4.29603197994857	0.181	512	94	UCEC	172889-27-9	Clinical trials	PTEN | KDR | GNAS
141.72902019689474	55.2731088567295	197.0231095920494	-40.753328596453	0.0006	512	80	UCEC	OLOMOUCINE	Experimental	KRAS | RB1 | NRAS
625.5808867433295	3.17055432036608	685.0461746385357	-18.9457950381296	0.523	202	53	LAML	PICTILISIB	Clinical trials in cancer	KRAS | FLT3 | KIT
269.3425722952939	-58.7741708876875	228.98200045129113	-2.70224974349048	0.0006	435	211	THCA	SB220025	Experimental	KRAS | NRAS | BRAF
191.1600547236444	32.6136819029532	202.68989854484994	-7.18689531925861	0.0004	292	32	STAD	ISOEVODIAMINE	Experimental	CTNNB1 | PIK3CA | GNAS
244.19714989764776	93.0373535239019	184.2768569116749	27.2477569229059	0.0006	512	94	UCEC	RU83876	Experimental	PTEN | KDR | GNAS
352.5222476809248	-6.97586883594607	213.6479395225798	-33.9566746708413	0.0004	934	217	BRCA	P-0850	Experimental	PIK3CA | BRAF
1074.5067079340938	-24.442773565014	1097.6603398824293	-3.72501656437407	0.994	153	27	BLCA	PONATINIB	Approved in cancer	RB1 | NRAS | CREBBP
1018.5119474215743	-26.6501659609085	1022.7045947285067	1.93693734687849	0.918	343	52	HNSC	BEVACIZUMAB	Approved in cancer	CTNNB1 | CD247 | PIK3CA
1057.6445107216923	25.757829429317	1096.2398999710745	-1.95632618820673	0.99	543	96	LUAD	COBIMETINIB	Approved in cancer	KRAS | NF1 | NRAS
806.7612346909996	-49.2051930921386	711.406934009106	-16.5164288092801	0.596	512	115	UCEC	RIDAFOROLIMUS	Clinical trials in cancer	KRAS | TSC2 | TSC1
623.364645032226	119.436507559179	551.882317031143	29.6899444123956	0.412	57	24	PAAD	RILOTUMUMAB	Clinical trials in cancer	KRAS
239.56765660666971	-41.7207578644264	208.99825081049556	-2.27631115972963	0.0008	292	30	STAD	SB220025	Experimental	KRAS | NRAS | MAP2K1
997.428581147567	-2.71061254803357	958.3248398426733	-7.30907112763589	0.842	169	43	READ	ATEZOLIZUMAB	Approved in cancer	KRAS | NRAS | BRAF
269.8024077191555	6.70461605770828	212.18485436575776	36.9269229929982	0.0006	512	94	UCEC	RU90395	Experimental	PTEN | KDR | GNAS
148.3665562132945	-106.091319523516	144.2486303687508	-16.4868315867598	0.0004	264	68	SKCM	NADA	Experimental	NRAS
1003.6721956459893	49.6253271629867	957.7145397922245	2.37624916950222	0.841	169	39	READ	ETOPOSIDE	Approved in cancer	KRAS | FGFR1 | FBN2
228.23357258874384	-10.881533731244	173.33845998429678	31.811371487001	0.0008	512	76	UCEC	FR 180204	Experimental	KRAS | NRAS | BRAF
597.9747771757952	-86.361442671484	584.3987831835359	-8.22186925503956	0.432	264	105	SKCM	GANETESPIB	Clinical trials in cancer	BRAF | MET
331.7749892877605	75.1281905961852	176.83647353916763	12.1078197894149	0.0008	264	111	SKCM	PLX3603	Experimental	BRAF | FGFR1 | PDGFRA
369.30525499361556	0.0295324562177655	360.6007174452843	5.499536370447	0.181	512	54	UCEC	VEGF TRAP	Clinical trials	VHL | CTNNB1 | MTOR
1032.566588250849	-32.1313462982905	1019.307226281853	-2.33310469608341	0.91	153	18	BLCA	VEMURAFENIB	Approved in cancer	NRAS | PIK3CA | PDGFRA
574.5806223438561	9.30890326705668	566.4759088792214	-4.46211466838167	0.412	543	60	LUAD	RALIMETINIB	Clinical trials in cancer	KRAS
936.0678677160498	-5.54114368290502	941.1043299969931	-7.16896974064957	0.823	169	41	READ	CRIZOTINIB	Approved in cancer	KRAS | BRAF | ERBB2
712.9309238529609	-15.8648409189495	676.9283240236698	2.52631600642917	0.551	264	32	SKCM	TAK-593	Clinical trials in cancer	VHL | CTNNB1 | ARNT
1037.26790116692	-31.9240166455447	1048.5448056920002	3.29327325500344	0.942	153	18	BLCA	CABOZANTINIB	Approved in cancer	NRAS | CREBBP | PIK3CA
800.9966753156818	-0.62617834104995	757.5601234697716	15.4846248304787	0.6	512	77	UCEC	BINIMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
598.2409628418709	-6.42910096256722	581.1844906213804	12.7203902773083	0.422	543	60	LUAD	2-[(E)-2-(3-NITROPHENYL)VINYL]QUINOLINE	Clinical trials in cancer	KRAS
365.02655257594597	2.07867633476468	363.11444840022574	1.25020754025627	0.182	264	35	SKCM	KC-706	Clinical trials	CYBB | AKT3 | GNAS
479.1907593011332	-26.1480628927661	485.91755805824295	-5.20534282047788	0.321	502	61	KIRC	DALTEPARIN	Approved in other pathologies	VHL | MTOR | HSPG2
1040.3357759451478	40.74103753249	1053.833456374973	5.13935066957129	0.94	512	113	UCEC	TRASTUZUMAB	Approved in cancer	KRAS | PIK3CA | ERBB2
580.5698994814844	28.3310153024128	601.3427067135274	-7.48298010163262	0.442	512	82	UCEC	VS-5584	Clinical trials in cancer	MTOR | PIK3CA | ERBB2
645.5048228941134	-1.34105479380258	662.905059377302	3.56950752297371	0.511	502	59	KIRC	NICOTINAMIDE	Clinical trials in cancer	VHL | MTOR
617.4958857731189	-20.521611312377	611.5972253612249	-1.88021756308581	0.452	512	55	UCEC	BI 2536	Clinical trials in cancer	KRAS | BRAF | BRD4
586.8249206152805	23.8971681321469	581.6499607992386	6.29396815659737	0.422	169	38	READ	602306-29-6	Clinical trials in cancer	KRAS
1141.7047146107284	-22.9666393417783	1101.1564294966088	0.836044811052943	1.0	423	81	COAD	TEMSIROLIMUS	Approved in cancer	KRAS | MTOR | BRAF
199.71488916517342	-19.5589635826241	220.0484174812992	6.22719075127884	0.0006	502	59	KIRC	OXAMIC ACID	Experimental	VHL | MTOR
969.3063055364637	101.276880573112	960.5481704857237	-8.9125746598034	0.822	57	24	PAAD	OLAPARIB	Approved in cancer	KRAS
760.652943469185	-64.3044784600341	718.2830145529127	-0.0705296213600377	0.596	423	92	COAD	212631-79-3	Clinical trials in cancer	KRAS | NRAS | NF1
573.5057533106184	-16.375745756464	537.482048215523	2.8989474958064	0.381	512	57	UCEC	CHOLINE	Approved in other pathologies	KRAS | RRAS2 | RAF1
183.56477343917524	13.0624452881799	195.50366677517275	4.98303854405981	0.0006	512	54	UCEC	CAND 5	Experimental	VHL | CTNNB1 | MTOR
738.8847555348202	10.5153375045783	733.604386018376	-2.54108327126914	0.599	153	27	BLCA	ALPELISIB	Clinical trials in cancer	NRAS | PTEN | FGFR3
479.6819756547862	70.8870101927591	635.0525398857585	16.2348845613445	0.432	57	24	PAAD	OSI-027	Clinical trials in cancer	KRAS
243.71343302166815	-3.21381289913421	191.54065736263723	2.54477587236124	0.0008	202	24	LAML	OLOMOUCINE	Experimental	KRAS | NRAS | MAPK1
1010.8021039509576	-48.2069332577186	1004.4665857822955	3.92226656791559	0.892	512	94	UCEC	ETOPOSIDE	Approved in cancer	KRAS | CTNNB1 | MYCN
1067.3411338898954	-5.67203116392326	1088.1676222827903	1.02180007632865	0.99	292	38	STAD	EVEROLIMUS	Approved in cancer	KRAS | CTNNB1 | NRAS
673.9312951868465	89.3539137478447	705.7481666625077	10.3511125052587	0.55	435	211	THCA	SELUMETINIB	Clinical trials in cancer	KRAS | NRAS | BRAF
1098.9571974802109	20.2945765292684	1093.0664983036804	0.0381895384830386	0.99	292	35	STAD	COBIMETINIB	Approved in cancer	KRAS | NF1 | NRAS
1115.2023070762377	-20.0397923790557	1085.580959690699	1.06303357017805	0.981	222	58	LGG	ERIBULIN	Approved in cancer	TP53 | BRAF | MTOR
590.5025679884953	53.7270002452607	581.9089243833807	-48.8430735905687	0.422	57	24	PAAD	MLN1117	Clinical trials in cancer	KRAS
764.7121221322683	57.38268416991	762.6397111224644	23.1592984142819	0.596	512	158	UCEC	GDC-0068	Clinical trials in cancer	KRAS | TSC2 | PTEN
928.1551837493685	5.39825809633561	935.0765678406135	-5.20496792213908	0.822	202	27	LAML	VANDETANIB	Approved in cancer	KRAS | IDH1 | KDR
767.4201948119162	-88.254588962841	695.4394012906805	-9.93904807515173	0.565	512	111	UCEC	MLN1117	Clinical trials in cancer	KRAS | MTOR | PIK3CA
958.5302559340028	-11.9768993297926	954.4029072544351	-0.844638849883268	0.843	423	88	COAD	GEFITINIB	Approved in cancer	KRAS | NRAS | BRAF
672.9092026337989	16.1999172629228	681.7803103071641	-14.5647886325594	0.545	934	244	BRCA	PICTILISIB	Clinical trials in cancer	KRAS | AKT1 | PTEN
705.3143121111359	-73.9383358449739	735.9226619959576	-5.0635825256968	0.598	343	63	HNSC	DACTOLISIB	Clinical trials in cancer	STK11 | PTEN | RAC1
798.8208370634798	102.232567625377	689.4218422646079	-24.6738225757956	0.563	57	24	PAAD	XL147	Clinical trials in cancer	KRAS
300.33838131237513	-21.673727223718	178.83345908553414	-18.1429994918689	0.0006	169	44	READ	N-(5-{3,4-DIFLUORO-2-[(2-FLUORO-4-IODOPHENYL)AMINO]PHENYL}-1,3,4-OXADIAZOL-2-YL)ETHANE-1,2-DIAMINE	Experimental	KRAS | NRAS | BRAF
602.443599887379	43.7697619360127	682.4655771145385	-3.83230402512925	0.523	202	52	LAML	APITOLISIB	Clinical trials in cancer	KRAS | FLT3 | KIT
558.4419533199507	24.3666778851384	567.3078072114547	3.40635663850594	0.412	543	60	LUAD	SALIRASIB	Clinical trials in cancer	KRAS
608.9770662082848	10.8703384687461	582.9487643422203	-16.7018246513856	0.432	512	109	UCEC	BAY1125976	Clinical trials in cancer	KRAS | NRAS | PIK3CA
540.8371399188643	0.71129330019852	545.079549141172	-3.10356069241243	0.381	423	66	COAD	EDARAVONE	Approved in other pathologies	TP53 | MTOR | BRAF
690.7436954845349	137.917934953533	665.3886034365635	24.2120422349869	0.531	57	24	PAAD	CC-401	Clinical trials in cancer	KRAS
248.50363625509075	-75.5172996722287	211.18872054128883	9.03380943136972	0.0008	423	92	COAD	HYPOTHEMYCIN	Experimental	KRAS | NRAS | BRAF
896.0321675115501	106.852519429828	923.5825557358847	26.5432498535555	0.812	222	131	LGG	LOMUSTINE	Approved in same tumor type	IDH1
596.9912129659244	-34.5026612740883	577.5823479089103	5.31518576866483	0.422	423	65	COAD	P7170	Clinical trials in cancer	KRAS | PIK3CA
351.5026803761043	6.98105806790619	362.7363228649652	-8.87253488769511	0.183	264	46	SKCM	VX-702	Clinical trials	CYBB | AKT3 | MAP2K1
395.76809540243005	1.2721755232879	400.99998545773053	0.000227914904087356	0.223	169	43	READ	PEMBROLIZUMAB	Approved in other pathologies	KRAS | NRAS | BRAF
306.1848321249941	-26.8325467674552	318.0002803349489	-0.000433365394655993	0.131	502	64	KIRC	867331-82-6	Clinical trials	VHL | MTOR | FGFR1
1032.2578368383456	0.0957505508731913	1041.525152023046	2.47416627431176	0.93	202	31	LAML	COBIMETINIB	Approved in cancer	KRAS | NF1 | KIT
178.13362520756866	-32.0950423607496	199.13862997438386	14.0835543556154	0.0004	343	45	HNSC	PWT-33587	Experimental	PIK3CA
568.9480186171864	-12.5408559746101	564.9409022134314	-0.326361398924973	0.412	543	60	LUAD	BBI608	Clinical trials in cancer	KRAS
894.8181756910767	15.4708043705527	911.7320865583138	-0.835548101651739	0.791	512	55	UCEC	AFLIBERCEPT	Approved in other pathologies and in clinical trials in cancer	VHL | CTNNB1 | MTOR
704.5177274906182	-53.327282658627	720.6089999635705	0.870075302922487	0.578	153	20	BLCA	PIMASERTIB	Clinical trials in cancer	NRAS | PIK3CA | SOS1
225.13196122754044	60.1142950860914	226.17428625570346	-16.6568602219493	0.0006	512	94	UCEC	PHENYLMALONIC ACID	Experimental	PTEN | KDR | GNAS
561.1016403041832	-56.5482964534891	574.1233653243338	-11.0879889799919	0.414	512	54	UCEC	POZIOTINIB	Clinical trials in cancer	KRAS | ERBB2 | ERBB4
1110.5572324859	9.81928350720472	980.4195705833945	-4.17250670565096	0.863	169	40	READ	CARBOPLATIN	Approved in cancer	KRAS | PIK3CA
611.4407224298203	143.245198206526	595.7866838356962	26.3859988663444	0.432	435	183	THCA	CEDIRANIB	Clinical trials in cancer	BRAF
898.998402835748	-45.8871453402004	925.5560942483922	-22.5103109514775	0.823	435	185	THCA	IRINOTECAN	Approved in cancer	KRAS | BRAF | PIK3CA
265.0924231427475	-145.359659646886	263.0152032113773	44.4700931739399	0.0008	264	185	SKCM	HYPOTHEMYCIN	Experimental	NRAS | KRAS | AKT3
1094.8975674149494	4.09596235393283	1080.1881279435415	-1.04545697870503	0.982	292	32	STAD	TRASTUZUMAB	Approved in same tumor type	KRAS | PIK3CA | BRAF
591.9557626625202	-71.6292144152964	558.9426542920094	-19.553662930633	0.423	264	107	SKCM	UPROSERTIB	Clinical trials in cancer	BRAF | AKT1 | PIK3CA
804.7638276301062	47.3577094897032	728.0858696731583	-4.48940846037931	0.581	169	39	READ	CC-401	Clinical trials in cancer	KRAS | MAP4K1 | RRAS2
162.59254956305392	-52.5918235261016	214.3355346740876	16.3029377179882	0.0006	264	43	SKCM	1-[1-(3-AMINOPHENYL)-3-TERT-BUTYL-1H-PYRAZOL-5-YL]-3-NAPHTHALEN-1-YLUREA	Experimental	CYBB | PTEN | AKT3
209.372414723621	-54.5887724487344	210.69850654130025	0.26128322748491	0.0004	264	68	SKCM	NG25	Experimental	NRAS
1073.234357694827	-35.4832049527042	1071.9352295714932	-2.30984283378848	0.97	153	21	BLCA	DASATINIB	Approved in cancer	RB1 | PTEN | IDH1
235.40048227939798	24.901250936523	201.99618648520686	5.4243924158875	0.0008	292	30	STAD	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | MAP2K1
173.8039802248193	-29.28830211451	224.26024750130802	16.5780183281067	0.0006	264	35	SKCM	N-ETHYL-4-{[5-(METHOXYCARBAMOYL)-2-METHYLPHENYL]AMINO}-5-METHYLPYRROLO[2,1-F][1,2,4]TRIAZINE-6-CARBOXAMIDE	Experimental	CYBB | AKT3 | GNAS
555.3023961267097	-12.0822841927823	564.9470255991487	0.919963072336941	0.421	343	47	HNSC	937174-76-0	Clinical trials in cancer	AKT1 | PIK3CA | PRKACA
678.5616530308621	42.5924728595357	741.663366091754	6.11433618515002	0.583	512	124	UCEC	TRICIRIBINE	Clinical trials in cancer	TSC2 | PTEN | CTNNB1
724.1741074224034	-28.6083887913884	691.2664874466258	8.29585355875861	0.575	264	31	SKCM	VATALANIB	Clinical trials in cancer	KIT | VHL | ARNT
818.9409798634972	44.3987855892631	707.3837475684353	-25.5648588131039	0.533	435	211	THCA	XL147	Clinical trials in cancer	KRAS | NRAS | BRAF
257.59166695987534	-53.8336099178484	214.14580971903843	-6.88484473262952	0.0004	512	85	UCEC	SB 225002	Experimental	PIK3CA | ERBB2 | IL6ST
116.27987033793633	4.12950911651146	221.72776126879236	35.9427911764669	0.0006	512	94	UCEC	RU82209	Experimental	PTEN | KDR | GNAS
269.54516562445036	16.7508738757256	295.63385861671793	-4.09528565090932	0.111	502	59	KIRC	FORMIC ACID	Clinical trials	VHL | MTOR
222.21351878562774	21.8892983209236	198.16719546667588	-9.47468861804646	0.0004	292	42	STAD	LY2183240	Experimental	KRAS | CTNNB1 | NRAS
534.6927194928271	42.8210245964762	590.0655558525682	15.4685866854888	0.423	934	218	BRCA	CUDC-907	Clinical trials in cancer	KRAS | ERBB2 | PIK3CA
240.25182630400954	-6.29314600927319	179.97720088155293	-4.88649065224195	0.0006	502	59	KIRC	CHEMBL114500	Experimental	VHL | MTOR
725.4007073865337	-60.1770505009611	728.3892485358077	4.79644086180497	0.596	343	61	HNSC	BUPARLISIB	Clinical trials in cancer	PTEN | RAC1 | CD247
226.36726714200313	143.702374122493	148.6053288503549	13.15170011176	0.0004	264	104	SKCM	VX-11E	Experimental	BRAF
1071.3199523617104	28.828540651064	1037.2512847023397	-2.06453702427632	0.93	202	32	LAML	MIDOSTAURIN	Approved in same tumor type	KRAS | FLT3 | KIT
1175.1976203463744	-68.8734625879268	1146.7088050173504	-20.6117689508937	1.0	264	207	SKCM	SORAFENIB	Approved in cancer	NF1 | NRAS | KIT
208.52530365327846	-65.5554908194986	194.64271401254325	0.41745174251173	0.0004	512	61	UCEC	GDC-0879	Experimental	KRAS | NRAS | BRAF
265.1374503857543	-6.17455171473233	193.285023367948	10.8860437364071	0.0006	934	117	BRCA	OBLIMERSON	Experimental	TP53 | MAP2K1 | STAT3
1070.6133800259493	60.9192812490909	1085.9996984827794	-7.76341553319071e-05	0.984	343	127	HNSC	PACLITAXEL	Approved in cancer	TP53 | AKT1 | PIK3CA
319.05261928126083	-1.4801364771202	207.6426496842283	-32.111947554589	0.0006	169	43	READ	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | BRAF
223.9216509570941	1.70283701952459	209.0767824446081	2.17504742501842	0.0004	292	35	STAD	KINETIN RIBOSIDE	Experimental	KRAS | CTNNB1 | PIK3CA
585.4529756212095	-23.2363756096719	584.9620856688322	7.94417304702574	0.431	343	47	HNSC	LEXIBULIN	Clinical trials in cancer	PIK3CA | FGFR3 | EGFR
290.6131796685861	-23.1453688094323	223.98601056593654	20.7403713504047	0.0006	169	40	READ	761437-28-9	Experimental	KRAS | PTEN | BRAF
744.948275919832	-61.4828102987695	706.3928174498471	3.17630809173852	0.582	512	95	UCEC	PF-04605412	Clinical trials in cancer	PTEN | FLNA | EGF
1055.8475397424154	-55.7604293157388	1114.0002183105692	-5.63455836113872	0.997	423	83	COAD	COPANLISIB	Approved in cancer	KRAS | NRAS | ESR1
284.05564990762826	-38.8348369989628	205.99408300914777	-19.4968486611358	0.0004	435	183	THCA	KU-0060648	Experimental	BRAF | PIK3CA
1012.3626174069146	-77.9397246563456	1031.9855494097337	12.3180810557321	0.92	435	185	THCA	IMATINIB	Approved in cancer	KRAS | BRAF | SOS1
775.2655562719517	-41.0855516964873	747.4433890195363	3.80111460967009	0.595	343	61	HNSC	XL765	Clinical trials in cancer	STK11 | PTEN | RAC1
582.0005073333639	-27.5280012643115	579.6121282281041	3.50472439339524	0.432	543	66	LUAD	AZD2014	Clinical trials in cancer	KRAS | PIK3CA | FGFR1
838.5551724137838	43.7265941634875	761.0011952778332	-0.00105404159830869	0.623	435	211	THCA	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | BRAF
719.4166670312222	-55.9255386341448	673.9586014871484	0.432692197013921	0.521	599	118	OV	DHA-PACLITAXEL	Clinical trials in cancer	TP53 | MAPK14 | MAP3K5
736.7068850817991	43.2117145109417	726.7958271047046	5.10080662113762	0.584	389	73	LUSC	NAVITOCLAX	Clinical trials in cancer	KRAS | BRAF | TP53
912.6252106476303	-84.0545726639106	965.8221577381705	20.6730873541028	0.832	222	134	LGG	GEMCITABINE	Approved in cancer	KRAS | IDH1 | PIK3CA
579.5791089120161	-33.9876960548177	604.5798234791935	-9.32085853677404	0.422	934	219	BRCA	AZD2014	Clinical trials in cancer	KRAS | ERBB2 | PIK3CA
942.419364594385	-2.75756280569453	957.0305639440337	-1.57245066023324	0.842	543	64	LUAD	OLAPARIB	Approved in cancer	KRAS | PIK3CA
171.9246628059265	-53.9882459108121	197.18408070522938	39.4672068487921	0.0006	264	40	SKCM	1,9-PYRAZOLOANTHRONE	Experimental	KRAS | AKT3 | MAP2K1
563.6869366323059	-28.9823587466844	584.4894511042818	10.9584132143827	0.432	423	65	COAD	LINSITINIB	Clinical trials in cancer	KRAS | PIK3CA
643.844382058818	-36.35071046034	680.6180632050333	16.8319509579669	0.522	934	217	BRCA	1260612-13-2	Clinical trials in cancer	PIK3CA | BRAF
724.5179803305297	15.0755129922797	707.8247335295445	-3.13157620827837	0.565	599	68	GBM	AZD5363	Clinical trials in cancer	KRAS | PTPN11 | FGFR3
148.61502905019793	-9.21836413030539	221.0409267665511	-7.0563815024143	0.0008	423	96	COAD	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | BRAF
61.26585751469441	-54.9988525340738	193.66041926152562	19.7349083572047	0.0004	222	131	LGG	IVOSIDENIB	Experimental	IDH1
696.7032896310781	26.2474136061518	729.636132851642	12.9451071687108	0.593	543	91	LUAD	PF-04691502	Clinical trials in cancer	KRAS | NRAS | STK11
740.7846370566482	-117.770705097605	678.2458867132975	24.6002439903314	0.596	264	134	SKCM	CEDIRANIB	Clinical trials in cancer	KIT | VHL | BRAF
219.05071382157712	-22.835666192338	206.04002485580588	9.40473730775125	0.0006	502	59	KIRC	BBS-4	Experimental	VHL | MTOR
661.0442951822992	6.3651182758104	739.7777990207678	-4.71460598757039	0.586	423	78	COAD	DINACICLIB	Clinical trials in cancer	KRAS | NRAS | SMAD4
604.5877387886035	6.92073438696673	597.9999708465001	-0.000119116484938786	0.442	292	30	STAD	LINSITINIB	Clinical trials in cancer	KRAS | PIK3CA | EGFR
954.8091607258151	53.0685993568406	938.3209933624754	9.96079237299801	0.842	57	24	PAAD	MIDOSTAURIN	Approved in cancer	KRAS | ETV6
1107.5947579110125	-33.0623813166833	1107.730485541939	0.0919307886515526	0.994	292	39	STAD	ARSENIC TRIOXIDE	Approved in cancer	RB1 | SMAD4 | KRAS
1029.673700212086	-28.247164486712	1054.816258936914	-0.670723466184199	0.948	502	64	KIRC	VANDETANIB	Approved in cancer	VHL | MTOR | KDR
800.6720988543794	26.6769547376769	696.2731949996496	0.997297385737738	0.596	512	170	UCEC	BUPARLISIB	Clinical trials in cancer	KRAS | NRAS | ZAP70
766.6674808003735	-1.97900399294761	763.3164897033349	0.0274767549517492	0.622	202	40	LAML	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | IDH1
134.14358056991588	-34.2540354133189	220.89090097319828	-2.77970173610811	0.0004	934	216	BRCA	109511-58-2	Experimental	PIK3CA
239.76852110366983	29.8058254019725	230.4766559571906	3.44803630126034	0.0006	512	94	UCEC	RU82129	Experimental	PTEN | KDR | GNAS
723.3961254919901	33.4504463963714	735.8359507671781	4.3817813779624	0.595	292	43	STAD	PICTILISIB	Clinical trials in cancer	KRAS | PTPN11 | NGF
828.1148812155158	32.6922505210051	740.2141415091256	-21.8125132248729	0.598	169	46	READ	TAK-733	Clinical trials in cancer	KRAS | NRAS | BRAF
726.4287299792335	-102.503397838392	791.8363419425333	-3.08652076548742	0.596	264	143	SKCM	NAVITOCLAX	Clinical trials in cancer	KRAS | VHL | PTPN11
743.6398242134247	-16.8978721393821	736.5540813192563	-12.3248105960802	0.595	343	62	HNSC	PICTILISIB	Clinical trials in cancer	PTEN | AKT1 | RAC1
996.6273478871383	-10.8621553777314	1028.148682950542	-0.859963136265833	0.922	343	53	HNSC	CETUXIMAB	Approved in same tumor type	AKT1 | CD247 | PIK3CA
243.3478352495513	-69.2640092496423	160.3374795445816	-2.74649693034553	0.0006	512	101	UCEC	1-[1-(3-AMINOPHENYL)-3-TERT-BUTYL-1H-PYRAZOL-5-YL]-3-NAPHTHALEN-1-YLUREA	Experimental	ZAP70 | PTEN | SOS1
215.78152953204497	-110.865298685817	233.07711012909712	64.3912266068423	0.0006	264	126	SKCM	PI-103	Experimental	NRAS | KIT | KRAS
164.45319695001646	3.75236688608487	189.16432232454093	3.13451272399016	0.0006	423	64	COAD	DB07268	Experimental	KRAS | MAP2K1 | MAP4K1
1139.4362030661252	-14.3475761220708	1083.3671891598628	16.433776897092	1.0	512	129	UCEC	COBIMETINIB	Approved in cancer	KRAS | NF1 | NRAS
186.2396219415232	-47.4656641877845	204.04081642780704	-13.2455478553165	0.0008	264	28	SKCM	O-PHOSPHO-L-SERINE	Experimental	PTPN11 | PTEN | GNAS
665.4991314782552	16.0006493441084	644.0894043225541	-2.24406719491731	0.491	512	68	UCEC	INDISULAM	Clinical trials in cancer	CTNNB1 | SOS1 | BRAF
678.3556021468373	-15.573418727329	707.8098919249328	-8.68585049842682	0.538	934	229	BRCA	DACTOLISIB	Clinical trials in cancer	KRAS | STK11 | PTEN
571.740742457984	-20.2094049540175	572.2529828293868	9.71928594662563	0.422	543	60	LUAD	NRX 194204	Clinical trials in cancer	KRAS
523.1015184646067	-35.5555114315114	577.968091513248	-12.5110222735468	0.423	543	66	LUAD	CAMPTOTHECIN	Clinical trials in cancer	KRAS | PIK3CA | ABCB1
1161.8321224085998	53.4465020475048	1095.850777331642	-17.7518772904746	0.987	222	139	LGG	BEVACIZUMAB	Approved in cancer	KRAS | IDH1 | BRAF
636.9512299247475	-21.9134277616979	662.7277666569307	6.97263807039366	0.517	169	45	READ	ENCORAFENIB	Clinical trials in cancer	KRAS | PTPN11 | NRAS
288.69353500128136	100.26347358139	197.04434617874603	-26.3655383442921	0.0004	57	24	PAAD	TW-37	Experimental	KRAS
635.9405444871894	5.40277347432681	715.1155218745399	-2.25023461568412	0.581	512	54	UCEC	JUGLONE	Clinical trials in cancer	VHL | CTNNB1 | MTOR
172.3842139280572	21.1785932246423	176.49568516113135	9.44041542283276	0.0004	934	216	BRCA	AMG319	Experimental	PIK3CA
989.0678726061997	-8.53896582317492	1025.8721713049722	10.0344029953685	0.941	934	230	BRCA	PONATINIB	Approved in cancer	KRAS | RB1 | PTEN
1047.7688342425224	57.4625218930324	1059.6988178778886	-2.8140297622686	0.954	389	67	LUSC	ABT-199	Approved in cancer	KRAS | BRAF | TP53
185.29889599037554	-24.1539449454658	188.25345853564738	-9.28288717575469	0.0008	264	38	SKCM	452105-23-6	Experimental	KIT | HSPG2 | KDR
543.8657516101331	18.7092232705644	591.6617927459846	10.7931842945886	0.431	512	82	UCEC	PKI-179	Clinical trials in cancer	MTOR | PIK3CA | ERBB2
564.5268258518914	-41.2418859705384	585.5077657905196	9.73312459402723	0.432	512	64	UCEC	ERDAFITINIB	Clinical trials in cancer	KRAS | FGFR2 | FGFR1
1042.1683109347534	-19.3065720878697	1027.7634874971097	-6.7362498006396	0.922	343	48	HNSC	TRASTUZUMAB	Approved in cancer	CD247 | PIK3CA | FGA
150.55462439485646	-2.2365829903689	186.58781886361243	-7.76833965149467	0.0004	543	79	LUAD	PF-3644022	Experimental	KRAS | BRAF | EGFR
192.31763612543193	-34.603093503968	198.27312675444355	-1.83583102785724	0.0008	599	61	GBM	PP121	Experimental	PTEN | MTOR | PIK3CA
1026.895322535232	-39.0179265867718	1075.523261273488	1.21595634659661	0.951	264	31	SKCM	VINBLASTINE	Approved in cancer	AKT3 | CTNNB1 | MAP2K1
140.49092603423338	-80.7278443366291	155.30504610686071	-9.65585461046066	0.0004	264	104	SKCM	5Z-7-OXOZEAENOL	Experimental	BRAF
221.82528485042144	-27.0758039164386	195.177578538379	-9.84539242771871	0.0004	343	45	HNSC	AZD8186	Experimental	PIK3CA
611.987161106217	55.7209180748304	648.5540939700564	3.23825577980256	0.492	512	113	UCEC	ABT-737	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
268.14824428720567	30.9140470142086	211.51082400860597	-8.92327951761536	0.0006	502	59	KIRC	3-PHOSPHOGLYCERATE	Experimental	VHL | MTOR
663.2600996816833	-21.126518890498	739.1081068173761	-0.343828159091572	0.583	292	41	STAD	1032350-13-2	Clinical trials in cancer	KRAS | PTPN11 | NRAS
717.0147783116723	52.6702768068166	695.3384533426453	11.8960061531673	0.555	512	110	UCEC	GDC-0032	Clinical trials in cancer	KRAS | PIK3CA | SOS1
371.1666611709883	9.94182090895623	366.16333880105145	3.92470456518527	0.181	512	94	UCEC	OXALIC ACID	Clinical trials	PTEN | KDR | GNAS
185.25248336253304	-38.7771792807444	192.2272706992451	-14.2018391969495	0.0004	343	45	HNSC	17-ALLYL-AMINOGELDANAMYCIN	Experimental	PIK3CA
400.49481442501127	29.5175747638288	404.01854363367	-0.902609568695738	0.222	57	24	PAAD	NECITUMUMAB	Approved in other pathologies	KRAS
726.7918916515456	26.2898723542389	700.8791639210418	-2.17631066511956	0.534	202	52	LAML	ALPELISIB	Clinical trials in cancer	KRAS | FLT3 | KIT
951.7457981926948	-21.1778620555178	959.2854260947804	3.23091222245671	0.842	543	80	LUAD	ETOPOSIDE	Approved in cancer	KRAS | CTNNB1 | EGFR
116.99598732904188	82.4912054528646	189.83477604062975	-41.5896903364453	0.0006	57	24	PAAD	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS
878.0013288779752	-21.3701295812523	903.167626901698	-3.76459116050364	0.783	512	112	UCEC	SULINDAC	Approved in other pathologies and in clinical trials in cancer	CTNNB1 | PIK3CA | CHD8
999.8400468451395	-33.1639073725208	981.2658229800537	-1.65002831139782	0.865	423	83	COAD	TRASTUZUMAB	Approved in cancer	KRAS | ESR1 | BRAF
1027.624863066736	-56.8566698947359	1018.6903758958243	2.33217389377387	0.91	153	18	BLCA	EVEROLIMUS	Approved in cancer	NRAS | CTNNB1 | PIK3CA
242.11422056394397	5.44964991336647	184.68256508995566	-5.95404677589318	0.0006	502	61	KIRC	TROMETAMOL	Experimental	VHL | MTOR | HSPG2
446.5774014600511	64.3005821666196	564.4450288577962	-6.55285217514279	0.422	222	131	LGG	VE-822	Clinical trials in cancer	KRAS | IDH1
1006.7728369365975	107.07202512151	939.5262945160292	-12.9617841489539	0.832	435	183	THCA	DOXORUBICIN	Approved in cancer	BRAF | PIK3CA
633.1629065387338	-37.6388143695534	687.29527572953	-2.90948292903749	0.538	153	18	BLCA	NVP-BGJ398	Clinical trials in cancer	FGFR3 | PIK3CA | KDR
718.9772342268667	7.41425961943673	681.0738516073557	-0.390358586660113	0.537	599	77	GBM	SARACATINIB	Clinical trials in cancer	RB1 | KRAS | IDH1
1048.5873865671017	-17.2250825368913	1048.4409415097325	5.10144968335976	0.938	543	88	LUAD	BEVACIZUMAB	Approved in cancer	KRAS | CTNNB1 | BRAF
768.7263724745384	-41.4787431820945	732.5642522169287	8.2795552786697	0.596	423	67	COAD	RIDAFOROLIMUS	Clinical trials in cancer	KRAS | MTOR | PIK3CA
152.38686177354015	-79.4010593379738	212.8808137703582	9.10506407650428	0.0004	264	54	SKCM	PARBENDAZOLE	Experimental	CTNNB1 | TRIO | GNAS
673.4255865912562	50.2835426042832	684.1184900997721	14.5459429126439	0.534	169	41	READ	OSI-027	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
365.240392729118	13.032555696103	374.0001255644565	-0.00014473112696578	0.193	153	23	BLCA	QUERCETIN	Clinical trials	NRAS | CREBBP | PTEN
1090.8191433125376	-53.968651102517	1046.7877017357991	-6.16351713675476	0.94	423	95	COAD	VEMURAFENIB	Approved in cancer	KRAS | NRAS | BRAF
755.7147005317106	-40.6439255762269	736.0860096178568	-22.5183650707181	0.597	423	82	COAD	1224844-38-5	Clinical trials in cancer	KRAS | MTOR | BRAF
611.9494451444275	93.151952329684	680.5843083573506	-9.94761768718035	0.526	57	25	PAAD	DINACICLIB	Clinical trials in cancer	KRAS | SMAD4
143.44417556507182	61.1325590311081	182.60251095214323	10.5384599519891	0.0008	512	79	UCEC	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | ZAP70
802.1198710582361	-19.5211174792906	756.0963248613921	-2.50747665344034	0.592	423	97	COAD	GSK2636771	Clinical trials in cancer	KRAS | NRAS | ESR1
1053.0552266057705	-21.6777482829625	1082.6724583003947	-2.08068019419625	0.976	423	59	COAD	RAMUCIRUMAB	Approved in same tumor type	KRAS | ERBB2 | KDR
958.3985303363456	-90.5874630205223	906.8678128615334	5.4629461376685	0.823	435	211	THCA	EVEROLIMUS	Approved in cancer	KRAS | NRAS | BRAF
166.39944892411987	51.2017507825159	202.91938028141684	2.23227051648109	0.0006	543	68	LUAD	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	Experimental	KRAS | SOS1 | MAP2K1
186.90259083346504	42.690073111065	201.57783403965266	-1.11006872963367	0.0008	202	21	LAML	PLX108-01	Experimental	FLT3 | KIT
838.0276768453043	23.2225395368504	674.1182444483228	-42.9423294734643	0.513	435	185	THCA	1224844-38-5	Clinical trials in cancer	KRAS | BRAF | PIK3CA
599.076845056887	156.456976580255	657.083127629854	41.9826578688874	0.532	435	211	THCA	GSK2636771	Clinical trials in cancer	KRAS | NRAS | BRAF
216.72038538665674	-55.6952416261872	194.85425716876378	-10.6409789023278	0.0004	202	24	LAML	NUTLIN-3	Experimental	IDH1 | CSF3R | MAPK1
234.02373473164914	-33.5355470428992	189.78211838629105	-11.3381842871011	0.0004	934	216	BRCA	AS-605240	Experimental	PIK3CA
738.889636517456	32.8481062619394	732.4207370620945	-10.2660110623935	0.593	292	41	STAD	XL147	Clinical trials in cancer	KRAS | PTPN11 | NGF
156.82644786823226	21.4346820162554	190.57207651055228	-28.3166738744746	0.0006	512	94	UCEC	D-SULFOPHENYLACETIC ACID	Experimental	PTEN | KDR | GNAS
373.10356887727454	-3.30469170266508	371.88991882227623	-4.84952629917598	0.192	512	77	UCEC	ANTIBIOTIC K 252A	Clinical trials	KRAS | NF1 | NRAS
940.7741178802947	-17.9853772404444	962.0665412344672	2.37443932186034	0.841	343	46	HNSC	PEMETREXED	Approved in cancer	PIK3CA | EGFR
184.64758730063892	-17.9044459154287	187.7990815267757	-4.89537158548092	0.0006	423	72	COAD	AT7867	Experimental	KRAS | PIK3CA | ERBB2
613.86079152956	-37.3647847770361	585.9046274904044	23.8471837354232	0.421	934	219	BRCA	ABT-751	Clinical trials in cancer	PIK3CA | MAP3K4 | MOS
953.7098640739054	73.1934865210663	942.9444463229341	12.1245133785515	0.831	222	137	LGG	PEMETREXED	Approved in cancer	KRAS | IDH1 | PIK3CA
659.2446876161822	-48.8606164169872	722.4129843814729	-17.6411650384034	0.572	264	27	SKCM	X-82	Clinical trials in cancer	VHL | ARNT | HSPG2
467.14761228543887	-12.1907069171909	474.61377718874314	0.753099655351434	0.311	502	59	KIRC	RETEPLASE	Approved in other pathologies	VHL | MTOR
1115.4830755384578	31.0703182349251	1021.9999609387859	3.95616746686756e-05	0.913	389	76	LUSC	BORTEZOMIB	Approved in cancer	KRAS | BRAF | FGFR3
234.66177013530086	20.5024388080893	194.95014173765512	4.4012565294438	0.0006	502	64	KIRC	OBLIMERSON	Experimental	VHL | AKT3 | MTOR
236.89946675576726	-25.5143831400052	175.236778264073	19.7796525552099	0.0006	512	76	UCEC	TURPENTINE	Experimental	KRAS | NRAS | BRAF
219.40191956687298	-30.5498025933709	204.4698944866449	0.579075334711206	0.0008	512	55	UCEC	BATIMASTAT	Experimental	CTNNB1 | CHD8 | RAC1
1117.6226521853773	3.68205962638268	1109.2108202434624	-6.50775152418532	0.995	512	119	UCEC	RIBOCICLIB	Approved in cancer	KRAS | RB1 | NRAS
746.2072161255869	69.777145513716	796.0000154318699	-0.000391014925298805	0.662	423	92	COAD	5-FLUOROURACIL	Approved in other pathologies and in clinical trials in cancer	KRAS | NRAS | BRAF
1127.982616157862	-12.0381841718903	1072.3895989199148	0.073608771694353	0.97	292	31	STAD	IMATINIB	Approved in cancer	RB1 | SMAD4 | KRAS
1134.3691596965489	-21.5912367173636	1072.8004971122725	6.97981385558569	0.97	543	101	LUAD	TRAMETINIB	Approved in cancer	KRAS | NF1 | NRAS
205.88698413707533	47.561509692272	201.70548791277062	11.1564410196611	0.0006	502	59	KIRC	ANISTREPLASE	Experimental	VHL | MTOR
672.9033529159072	1.90091678829683	644.6503797428037	6.04922046055208	0.511	934	218	BRCA	RESVERATROL	Clinical trials in cancer	MAP2K1 | PIK3CA | MAPK1
459.4424058597233	-41.8000146793887	476.9423716501524	4.28470413355649	0.311	57	24	PAAD	CHOLINE	Approved in other pathologies	KRAS
153.49810472840986	16.0070047264842	202.88400547366845	-15.7261286467105	0.0004	423	57	COAD	GA201	Experimental	KRAS
190.8205541655848	7.58847153655148	222.23985654376625	21.5734504836562	0.0004	934	216	BRCA	AS 604850	Experimental	PIK3CA
490.33853856415317	-15.1825159225862	482.74010780946026	0.0363878741309236	0.312	343	48	HNSC	DEHYDROEPIANDROSTERONE	Approved in other pathologies	PIK3CA | AR | MAP2K1
657.1605939048933	-10.1734029423284	674.1069622697993	-11.2858100396654	0.532	934	118	BRCA	AT-101	Clinical trials in cancer	TP53 | MAP2K1 | STAT3
252.2547544594275	-21.9051827593257	204.3680618103671	-39.9229181243243	0.0006	512	94	UCEC	PASBN	Experimental	PTEN | KDR | GNAS
980.515855688825	-28.6163456371716	995.1941690185017	-2.26204654811499	0.882	423	67	COAD	OLAPARIB	Approved in cancer	KRAS | IDH2 | PIK3CA
68.69979355122648	74.6959827391736	185.0499737171183	-40.7954783645941	0.0008	222	136	LGG	ISOCITRIC ACID	Experimental	IDH1 | IDH2
171.32855865330015	-0.286753413914113	193.20793473411524	-7.74598235076564	0.0006	264	30	SKCM	T-5224	Experimental	AKT3 | CTNNB1 | MAP2K1
167.54311948197306	67.8394325943006	234.89072741661408	-5.90637530366456	0.0006	169	42	READ	A-443654	Experimental	KRAS | PTPN11 | PIK3CA
1076.9432170353107	-73.300890033952	1083.4755585358646	-19.5470555533302	0.95	264	112	SKCM	CRIZOTINIB	Approved in cancer	KRAS | BRAF | FGFR1
1012.0976446523102	-36.8926433677752	1034.2661252387588	-11.5944441225274	0.931	934	117	BRCA	ERIBULIN	Approved in same tumor type	TP53 | MAP2K1 | STAT3
783.2777424357847	14.6107040729567	715.9783334670739	-4.41609432289488	0.581	292	39	STAD	DHA-PACLITAXEL	Clinical trials in cancer	MAP2K1 | CREBBP | TP53
204.7881252316709	-84.9090201145714	189.31412706032066	-7.51438673134521	0.0006	502	62	KIRC	N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N&#39;-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE	Experimental	VHL | AKT3 | MTOR
997.6152210153159	-69.6535336338867	1019.6285549246408	-9.39303336132843	0.91	264	112	SKCM	ERLOTINIB	Approved in cancer	KRAS | BRAF | ERBB4
1034.9734381265819	-47.8266624246768	1053.2132152178526	-1.25650369623827	0.95	423	76	COAD	CRIZOTINIB	Approved in cancer	KRAS | BRAF | ERBB2
283.8677778083812	-21.2834955763728	312.0053541892642	1.89534271490425	0.122	502	54	KIRC	FRESOLIMUMAB	Clinical trials	VHL
576.5346911841605	-20.0820274743472	573.454387079536	9.78614428473929	0.432	423	58	COAD	602306-29-6	Clinical trials in cancer	KRAS | CDK13
984.1352986856008	4.53459573057367	1037.393008580096	-4.73834730603539	0.932	423	106	COAD	BORTEZOMIB	Approved in cancer	KRAS | TP53 | CTSD
210.26889664983898	46.8313046984205	196.10568961161303	-0.351375078315414	0.0006	502	59	KIRC	N-OMEGA-PROPYL-L-ARGININE	Experimental	VHL | MTOR
703.8809639457784	60.7320147628167	742.2277113285338	3.08955348885564	0.598	389	51	LUSC	DACTOLISIB	Clinical trials in cancer	KRAS | PTEN | BRAF
586.4074113169927	-17.5571408997034	590.055007231334	9.64384202058773	0.433	343	45	HNSC	CAMPTOTHECIN	Clinical trials in cancer	PIK3CA
555.4248868849231	-36.7658965498847	570.7632662057174	-5.88344572570486	0.412	543	63	LUAD	602306-29-6	Clinical trials in cancer	KRAS | CDK6
182.9527650887239	17.5550728873079	199.93152216772563	-14.4038919631657	0.0006	502	59	KIRC	CHEMBL293212	Experimental	VHL | MTOR
739.8722528990118	102.83484712042	603.1732214800194	-22.7333529381	0.422	57	24	PAAD	VOLASERTIB	Clinical trials in cancer	KRAS
221.15049979952383	-3.72406341080847	196.63276896240845	-24.2083357203653	0.0006	512	94	UCEC	RU78300	Experimental	PTEN | KDR | GNAS
1122.0209821199658	-12.2620842663247	1096.6920744087777	-5.22139611250896	0.999	423	79	COAD	CABOZANTINIB	Approved in cancer	KRAS | NRAS | MTOR
714.6234276892588	-26.9528693785483	638.1660904986561	-4.46947824738868	0.491	512	94	UCEC	141400-58-0	Clinical trials in cancer	TRIO | MTOR | PIK3CA
282.74124977188325	-70.6856817036811	264.940903621885	27.141374613401	0.023	435	183	THCA	1173900-33-8	Clinical trials	BRAF | PIK3CA
173.34894898539312	-61.753945715007	197.6815794106843	0.626073772122254	0.0006	264	35	SKCM	L09	Experimental	CYBB | AKT3 | GNAS
527.5484248905163	-37.973929479475	493.4677137169187	-0.00876358716527648	0.326	543	71	LUAD	NECITUMUMAB	Approved in other pathologies	KRAS | EGFR
205.46887730434563	29.6701270310772	204.56721640458787	11.5404944854236	0.0008	202	25	LAML	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | SOS1
239.3243239147798	-46.6880563916843	225.29913795641235	16.8040665942879	0.022	512	77	UCEC	SURAMIN	Clinical trials	PIK3CA
563.9452536880881	-34.1214404831114	575.1948196430711	0.299342408293001	0.412	202	23	LAML	MK-1775	Clinical trials in cancer	KRAS | NRAS
1055.9975419159327	-29.9835223265591	1033.1437422570816	7.74507031173562	0.93	343	61	HNSC	DASATINIB	Approved in cancer	SMAD4 | PTEN | COL1A1
195.9249612973132	30.9250388413724	199.6153426898941	-19.7227942362706	0.0008	343	51	HNSC	PILARALISIB	Experimental	RAC1 | PIK3CA | SOS1
1153.0229870360397	15.8082130841502	1084.7251860135	-3.15289857074026	0.99	292	41	STAD	PALBOCICLIB	Approved in cancer	RB1 | SMAD4 | KRAS
258.1603808708812	-64.0522072631971	213.61830265684594	-0.803834729794517	0.0006	502	62	KIRC	N,N-DIMETHYLARGININE	Experimental	VHL | AKT3 | MTOR
1063.8788635918474	20.526881801152	1079.1923158532038	8.93258904376626	0.984	292	65	STAD	PACLITAXEL	Approved in cancer	KRAS | AKT1 | MAP2K1
692.3150890625855	-78.3049829333839	767.609798334078	32.5525327830237	0.582	264	130	SKCM	GOSSYPOL	Clinical trials in cancer	VHL | AKT3 | BRAF
994.3597994934014	-28.0593066719858	1019.3227949200812	-1.76831655060937	0.91	202	24	LAML	EVEROLIMUS	Approved in cancer	KRAS | NRAS | MAPK1
257.5122838402049	66.6125435952312	162.5918923415739	20.7208529714326	0.0004	264	108	SKCM	NEOPELTOLIDE	Experimental	BRAF | STAT6 | FGFR3
709.9930437832222	-77.2192525073887	696.4654108047835	-7.92173362706399	0.574	264	30	SKCM	FLAVOPIRIDOL	Clinical trials in cancer	RB1 | AKT3 | CDKN2A
664.1643569253362	32.7902270594375	670.1081841372004	-7.26903320998099	0.521	502	63	KIRC	TAK-593	Clinical trials in cancer	VHL | MTOR | KDR
696.874697561334	-150.408989401725	705.7068715094289	-22.8721050798736	0.6	264	204	SKCM	SELUMETINIB	Clinical trials in cancer	NF1 | NRAS | KIT
849.456143954258	-25.2693140890313	840.0003168166267	0.000161895917699439	0.711	264	79	SKCM	METFORMIN	Approved in other pathologies and in clinical trials in cancer	NRAS | KRAS | PIK3CA
214.82447611372015	84.6853895366355	260.3797594805082	22.6320098094625	0.0004	264	105	SKCM	P-0850	Experimental	BRAF | PIK3CA | TRRAP
676.4994693191113	-56.2497164994911	686.3398952737357	-23.5609313329335	0.546	934	227	BRCA	BUPARLISIB	Clinical trials in cancer	KRAS | PTEN | MAP2K1
238.14824164724533	-38.2664377530364	202.12420423879337	-3.8056212715494	0.0008	512	56	UCEC	BEVACIZUMAB+TRASTUZUMAB	Experimental	VHL | CTNNB1 | MTOR
135.38454770791844	1.76438204801826	219.71532127062912	13.8252151723277	0.0006	264	35	SKCM	CHEMBL410668	Experimental	CYBB | AKT3 | GNAS
896.4905523972828	-7.12392809394677	918.4239959096723	-0.00957906334861036	0.797	264	54	SKCM	NINTEDANIB	Approved in other pathologies and in clinical trials in cancer	VHL | PTEN | GNAS
981.7002598849023	-23.6379525541798	986.7009527199131	16.8924007993928	0.881	264	27	SKCM	PEMETREXED	Approved in cancer	KRAS | GNAS | PIK3CA
682.9126485250744	-1.34634785057995	711.3762289541012	-9.50070334971451	0.589	423	49	COAD	FLAVOPIRIDOL	Clinical trials in cancer	SMAD4 | PIK3CA | ERBB2
195.2687988637044	-4.24339185191465	190.9235322023213	-41.3415012199471	0.0004	512	77	UCEC	MSC-2363318A	Experimental	PIK3CA
312.24744677542816	118.912318840299	170.57341364966857	-11.7273497406832	0.0006	57	24	PAAD	D-O-PHOSPHO THREONINE	Experimental	KRAS
283.9614747089971	-49.4629586070093	198.6728687507739	7.56416353781196	0.0006	502	59	KIRC	ICRUCUMAB	Experimental	VHL | MTOR
479.92068336249145	50.8058807209646	615.1462767914331	-54.1903963552518	0.412	57	24	PAAD	LONAFARNIB	Clinical trials in cancer	KRAS
256.952458814736	-42.9731056274736	226.04107202919857	0.403202584924202	0.0008	423	94	COAD	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS | NRAS | BRAF
158.5653593466096	3.83156146049774	183.96209127139858	-28.6949808864149	0.0006	512	77	UCEC	2-[(2-CHLORO-4-IODOPHENYL)AMINO]-N-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}-3,4-DIFLUOROBENZAMIDE	Experimental	KRAS | NF1 | NRAS
781.3348105766586	1.06182114105636	761.5542154633005	-9.87450397582779	0.597	423	97	COAD	PKI-587	Clinical trials in cancer	KRAS | NRAS | ESR1
1109.471671711778	24.5832922618633	1091.489405334094	-19.8546079708677	0.994	169	44	READ	DASATINIB	Approved in cancer	KRAS | SMAD4 | PTEN
235.2480272268444	-6.41600443737579	212.19566358698054	3.90069582077444	0.0006	502	62	KIRC	L-HOMOARGININE	Experimental	VHL | AKT3 | MTOR
268.39466602638265	-16.9299062401996	201.29159249694243	15.1191795353927	0.0008	202	24	LAML	(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE	Experimental	KRAS | NRAS | MAPK1
150.06401335915803	-20.4353194161624	195.09275246937386	-6.06588592520848	0.0006	153	16	BLCA	A-443654	Experimental	PIK3CA | ERBB4 | HRAS
323.29404890653825	-45.6786503259312	295.85507857030814	4.2295892305583	0.111	502	59	KIRC	NADH	Clinical trials	VHL | MTOR
180.10833919569362	138.212029605521	254.23950507664992	-4.79368936528815	0.0006	57	24	PAAD	4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE	Experimental	KRAS
185.5861476960889	-57.8453731738982	216.77633015643312	-13.0529802404235	0.0004	343	45	HNSC	PWT-33579	Experimental	PIK3CA
1178.8821531881017	54.1874122953533	1096.502784268833	1.2711165719661	1.0	512	117	UCEC	CABOZANTINIB	Approved in cancer	KRAS | VHL | NRAS
657.2202251832945	9.78537594211446	689.8440627646555	-4.45392985958699	0.532	202	23	LAML	XL-999	Clinical trials in cancer	FLT3 | KIT | KDR
840.4062392596394	1.33533035320252	748.3283361446942	-9.17516842290004	0.612	57	24	PAAD	METFORMIN	Approved in other pathologies and in clinical trials in cancer	KRAS
222.49175661364478	-94.5199334201067	208.2395215062429	-64.06618331445	0.0008	264	111	SKCM	R7204	Experimental	BRAF | FGFR1 | PDGFRA
667.2012143372143	-25.3632986365774	683.5868987378074	2.85189109188514	0.539	343	56	HNSC	FLAVOPIRIDOL	Clinical trials in cancer	SMAD4 | STK11 | PIK3CA
149.71192227621995	-93.1258907847524	180.52833069909914	-39.6044643066261	0.0004	264	104	SKCM	878739-06-1	Experimental	BRAF
225.45170215511507	68.7417007635425	225.3236852580283	-9.36414918982894	0.0006	169	44	READ	D-O-PHOSPHO THREONINE	Experimental	KRAS | NRAS | BRAF
302.1394292525283	-29.6634353652985	293.278232180243	0.19970809028996	0.111	502	61	KIRC	TELBERMIN	Clinical trials	VHL | MTOR | KDR
661.4911321222278	-5.86301593269499	670.7497826025734	-6.83475087308307	0.523	599	120	OV	OBATOCLAX	Clinical trials in cancer	TP53 | NRAS | MAPK14
769.8746518492253	106.715537192118	725.8853595125059	20.3511223884205	0.593	169	44	READ	RO4987655	Clinical trials in cancer	KRAS | NRAS | BRAF
710.6090629628513	34.9585631301881	715.7482403562936	-2.28670620802268	0.573	389	45	LUSC	1032350-13-2	Clinical trials in cancer	KRAS | PTEN | BRAF
1130.214857906486	-33.7902846999314	1085.8990171865428	5.63112576484218	1.0	423	67	COAD	MIDOSTAURIN	Approved in cancer	KRAS | MTOR | PIK3CA
153.02768396637737	-24.3627680928403	193.54395712797455	5.05791196734117	0.0004	343	45	HNSC	AS-605240	Experimental	PIK3CA
1081.6931848519819	-42.7738688770931	1102.2606842540465	1.38767154914603	0.994	543	91	LUAD	COPANLISIB	Approved in cancer	KRAS | NRAS | EGFR
391.23040375626874	-21.7129966384259	373.8067465594523	-9.70835362891467	0.191	264	91	SKCM	ADENOSINE TRIPHOSPHATE	Clinical trials	RB1 | NRAS | KRAS
652.8619388589121	136.405893553067	566.0254084347417	-18.9197044947966	0.422	435	209	THCA	XL888	Clinical trials in cancer	NRAS | BRAF
1143.0548946118017	39.8947152310062	1071.930386142414	15.4374509440265	0.997	512	165	UCEC	COPANLISIB	Approved in cancer	KRAS | NRAS | ZAP70
785.9485317345569	41.1043888653134	730.0922671222193	8.57632143270189	0.583	222	59	LGG	OBATOCLAX	Clinical trials in cancer	TP53 | NRAS | BRAF
707.0104377257259	39.151689407479	710.243575877412	-5.69207401233007	0.581	512	86	UCEC	RESVERATROL	Clinical trials in cancer	PIK3CA | MAPK7 | PPARG
462.1240128362756	-11.7178618556385	483.7103665028473	-0.00133032085022933	0.316	423	57	COAD	NECITUMUMAB	Approved in other pathologies	KRAS | ERBB2
1102.5939014147002	65.3121799051434	1092.8312271571522	18.4371068446678	1.0	512	119	UCEC	MIDOSTAURIN	Approved in cancer	KRAS | TSC2 | ZAP70
1113.2290864419033	-9.41155203625965	1080.2237654622204	-8.42634395094422	0.982	222	63	LGG	DOCETAXEL	Approved in cancer	TP53 | KRAS | BRAF
721.3475513289692	11.9827380165986	700.9638553875209	-0.185104822464837	0.554	389	53	LUSC	OBATOCLAX	Clinical trials in cancer	BRAF | TP53 | MAPK14
148.37696798469418	105.93896186736	231.4317260374952	28.3956178959033	0.0008	435	183	THCA	R7204	Experimental	BRAF
716.388799734009	60.3771208204807	732.9120340594023	-7.18897369185083	0.589	512	97	UCEC	FLAVOPIRIDOL	Clinical trials in cancer	RB1 | PIK3CA | ERBB2
806.1894560452431	37.3360845963551	688.6876793030555	-7.72376689360527	0.54	169	47	READ	SELUMETINIB	Clinical trials in cancer	KRAS | NRAS | BRAF
939.1756786159316	49.6289963133852	932.6503697227644	25.8303080855996	0.832	57	24	PAAD	LENALIDOMIDE	Approved in cancer	KRAS
726.2287565682474	-53.5863743961297	734.7137692281117	-3.34346550562168	0.597	264	44	SKCM	GDC-0068	Clinical trials in cancer	KRAS | PTPN11 | PTEN
1076.1577918435107	103.145383228791	1072.7213787548014	-6.87286910326205	0.964	57	24	PAAD	COPANLISIB	Approved in cancer	KRAS
224.5615071623411	36.0884828378141	222.64651227329082	-15.7939591466029	0.0008	423	92	COAD	FR 180204	Experimental	KRAS | NRAS | BRAF
759.552218304471	7.81064254101057	763.1134011575507	-0.567530419606783	0.59	512	139	UCEC	SELUMETINIB	Clinical trials in cancer	KRAS | NF1 | NRAS
696.5861888522714	98.6571448969183	727.3348231670302	-22.4077486216914	0.595	169	47	READ	PF-04691502	Clinical trials in cancer	KRAS | PTPN11 | NRAS
220.81380037360734	28.9974189414606	186.46726967702463	24.6311111219447	0.0004	934	219	BRCA	ML214	Experimental	MAP2K1 | PIK3CA | MOS
1062.579035077102	13.6379575524072	1051.452472199825	0.00087300009295177	0.945	599	84	GBM	PACLITAXEL	Approved in cancer	TP53 | KRAS | MTOR
1088.6952233439865	-30.2493033297269	1088.7972085925712	-5.35785654260508	0.988	423	88	COAD	PONATINIB	Approved in cancer	KRAS | NRAS | SMAD4
246.86211659600974	4.56340060067311	168.96458095499895	8.23755858474283	0.0004	512	77	UCEC	WX-037	Experimental	PIK3CA
616.3828240498757	63.7961261730256	614.3124278646885	0.805897843614844	0.442	169	42	READ	AZD2014	Clinical trials in cancer	KRAS | PIK3CA | ERBB2
1107.4097691205507	-23.2786651987592	1087.9123014529482	0.203167151951675	0.987	153	17	BLCA	BOSUTINIB	Approved in cancer	RB1 | NRAS | PTEN
772.9110846034436	-58.2637844797539	746.0535457330582	2.08881202415614	0.576	264	123	SKCM	TIVOZANIB	Clinical trials in cancer	VHL | BRAF | ARNT
979.9166434424739	-8.82328546472573	1054.805758390672	-3.83154968137842	0.95	512	118	UCEC	LAPATINIB	Approved in cancer	KRAS | PIK3CA | ERBB2
513.332452316166	-8.0496055180065	560.3343826442879	26.7346211729434	0.421	435	183	THCA	ABT-751	Clinical trials in cancer	BRAF | PIK3CA
248.61006348314592	16.8096202759993	200.84490944583044	3.15433982559	0.0004	202	23	LAML	4-(1-METHYL-1H-PYRAZOL-5-YL)BENZALDEHYDE	Experimental	FLT3 | KIT | KDR
176.60184844037872	-57.1158349786261	179.4570808529813	0.768187169384873	0.0004	343	50	HNSC	TIPIFARNIB-P2	Experimental	PIK3CA | FGFR3 | AFF4
230.50254004333988	53.4159528256438	232.78132946733206	-12.9323191878268	0.0008	934	223	BRCA	AT7867	Experimental	KRAS | ERBB2 | PIK3CA
183.2899794643416	-33.0852805693901	183.89662805529355	0.212450091100436	0.0006	423	64	COAD	1,9-PYRAZOLOANTHRONE	Experimental	KRAS | MAP2K1 | MAP4K1
354.4611096685432	0.789983328898984	359.7626914807349	-0.937252066689553	0.181	543	92	LUAD	ANTIBIOTIC K 252A	Clinical trials	KRAS | NF1 | NRAS
589.8434275381798	-20.8070192839535	570.6418506996456	0.18339297925138	0.412	202	23	LAML	FOLFIRI REGIMEN	Clinical trials in cancer	KRAS | NRAS
808.3412892079285	-4.02522694298023	715.4917797497507	-20.0309570962406	0.585	169	43	READ	GDC-0068	Clinical trials in cancer	KRAS | PTPN11 | PTEN
750.4476969995568	30.9208658757606	739.745680404591	27.6410074464159	0.6	512	129	UCEC	391210-10-9	Clinical trials in cancer	KRAS | NF1 | NRAS
213.56837051646255	49.3367674733803	192.66662160302639	-6.52665459648699	0.0004	202	23	LAML	32703-82-5	Experimental	KIT | IDH1
583.567552350437	-51.3362039311016	589.0587563310936	4.48087769975882	0.432	343	45	HNSC	1312445-63-8	Clinical trials in cancer	PIK3CA
615.0151402802389	-46.5761623474004	576.171165545041	24.1426335541369	0.422	934	216	BRCA	LINSITINIB	Clinical trials in cancer	KRAS | PIK3CA
691.0377425366378	-37.9865850254003	723.299717642267	10.3335233622024	0.586	543	95	LUAD	TAK-733	Clinical trials in cancer	KRAS | NF1 | NRAS
924.4597252439283	-67.3174343706525	940.7713770983013	23.3188849058997	0.822	435	185	THCA	ERLOTINIB	Approved in cancer	KRAS | BRAF
680.5565407517994	-46.0435298914119	726.9009592301243	-12.4960621523851	0.596	264	41	SKCM	MASITINIB	Clinical trials in cancer	KIT | PTEN | HSPG2
338.8428503112409	53.1358311258446	177.1242415870215	-24.25909283801	0.0004	264	105	SKCM	UNII-Y2H4S74Y8U	Experimental	BRAF | RAF1
532.7833663908384	-21.638450330468	563.9170796237362	-1.76450093937473	0.412	57	24	PAAD	CUDC-907	Clinical trials in cancer	KRAS
502.905469634339	109.99901775418	574.5259116805203	11.2951186634828	0.412	57	24	PAAD	RALIMETINIB	Clinical trials in cancer	KRAS
819.4182596609877	67.3968640872677	723.3519047802769	4.04904825198349	0.565	57	24	PAAD	ALPELISIB	Clinical trials in cancer	KRAS
972.0346260085573	-11.1609440192512	948.5725728745332	4.43204469947113	0.832	512	108	UCEC	CAPECITABINE	Approved in cancer	KRAS | PIK3CA | ERBB2
626.3864127127043	135.768944201454	565.3561903180953	-46.1308986673366	0.422	57	24	PAAD	AZD4547	Clinical trials in cancer	KRAS | ETV6
279.59027380835533	-26.5671295711831	179.10528464201556	18.3375510035296	0.0004	934	217	BRCA	OLIGOMYCIN A	Experimental	PIK3CA | ERBB3
959.0522955584245	-28.9345168476887	948.3061321039768	-3.27418396794656	0.833	343	46	HNSC	DOXORUBICIN	Approved in cancer	AKT1 | PIK3CA
817.594560747201	-48.7021949612509	760.2412781329679	-12.1055651290383	0.593	512	165	UCEC	XL147	Clinical trials in cancer	KRAS | NRAS | ZAP70
796.7570170682368	-57.1378078329255	673.9265198240844	48.6630600178808	0.523	435	183	THCA	ARQ736	Clinical trials in cancer	BRAF | SOS1 | ESR1
155.74177189245577	-1.42127014537604	193.8921638311339	2.36535894924646	0.0004	153	23	BLCA	PIPERLONGUMINE	Experimental	CTNNB1 | FGFR3 | PIK3CA
189.46177537685574	46.7804195717001	179.84193026029396	33.1540459672256	0.0006	512	94	UCEC	CHEMBL56904	Experimental	PTEN | KDR | GNAS
492.77734753483276	-30.7694493641797	495.7052844852853	2.6848704940237	0.325	502	64	KIRC	CARVEDILOL	Approved in other pathologies	VHL | AKT3 | MTOR
158.8072613752417	-47.7853711034136	202.52603868169896	-17.7438481403337	0.0006	264	35	SKCM	8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM	Experimental	CYBB | AKT3 | GNAS
204.61459037759926	-7.00079586016122	207.87630208022713	-15.9809472057873	0.0004	343	46	HNSC	ML214	Experimental	PIK3CA | MAP2K1
147.34401277941973	-58.2206448604413	250.41227673857972	62.3768027677143	0.0004	264	104	SKCM	1166227-08-2	Experimental	BRAF | PIK3CA
527.4170994650561	-31.8910669401465	538.9911332194896	2.41285809845283	0.381	169	28	READ	EDARAVONE	Approved in other pathologies	BRAF | TP53 | RAF1
1075.5507091776678	-47.3813975312542	1084.7016594680495	-3.41114451903013	0.984	153	20	BLCA	ARSENIC TRIOXIDE	Approved in cancer	RB1 | NRAS | CREBBP
193.63128183031213	50.9957290808587	211.899954904332	-2.17621239818567	0.0006	57	6	PAAD	OBLIMERSEN	Experimental	TP53
566.6373593257367	-8.08917720787755	606.0001156351761	-0.000369738457266067	0.451	343	47	HNSC	141400-58-0	Clinical trials in cancer	PIK3CA | AFF4 | EGFR
778.5553673444482	-47.0942243332867	741.3790792149154	-13.0390780130242	0.595	543	98	LUAD	PKI-587	Clinical trials in cancer	KRAS | NRAS | STK11
332.24843215366053	-57.4260441177809	237.62481946541266	-0.891913122153483	0.0004	222	138	LGG	PARBENDAZOLE	Experimental	IDH1 | MTOR | PIK3CA
750.9770528571694	161.075401850785	695.5955877451775	-51.4085770648335	0.593	264	196	SKCM	XL147	Clinical trials in cancer	NRAS | KIT | KRAS
300.63366961287676	71.2719962956861	183.81609068514274	40.9239338494342	0.0008	512	122	UCEC	761437-28-9	Experimental	KRAS | PTEN | BRAF
182.05336129348234	41.8886106079829	177.53535195131138	-13.7239100093266	0.0006	512	71	UCEC	N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE	Experimental	KRAS | SOS1 | MAP3K8
154.1736659453043	121.466921018905	264.0343897595979	-0.415938141078641	0.0004	435	183	THCA	NVP-AEW541	Experimental	BRAF | PIK3CA
202.355031092941	1.18851764866918	167.02008605764823	-4.7268026083625	0.0004	512	77	UCEC	IPI549	Experimental	PIK3CA
348.73413391570585	1.0256524676546	347.0001183869781	0.000260967107237775	0.163	599	72	GBM	QUERCETIN	Clinical trials	NRAS | KRAS | PTPN11
167.10500887821286	-35.677552083253	219.5752466735891	19.0347454590606	0.0004	264	35	SKCM	PNU-74654	Experimental	CTNNB1 | PIK3CA | IDH1
885.0944902868821	8.72692854313181	907.1652928153252	24.7868003363594	0.822	435	209	THCA	LENVATINIB	Approved in same tumor type	NRAS | BRAF
584.2577817480875	-59.9727501948772	588.3761888001529	6.58285552967209	0.422	264	76	SKCM	BAY1125976	Clinical trials in cancer	NRAS | KRAS | AKT1
234.0001658925427	113.844694682475	225.62765050342236	11.4247933715654	0.0004	169	40	READ	AZD8186	Experimental	KRAS | PIK3CA
991.3815729693991	41.1030716057547	1079.8745893569287	6.39167356900884	0.993	512	143	UCEC	DOCETAXEL	Approved in cancer	KRAS | TP53 | VHL
317.46335959983986	-23.3739730736325	187.88896345392791	15.4964910189835	0.0004	934	217	BRCA	PWT-33587	Experimental	PIK3CA | MTOR
1114.1128906171082	90.6476786422904	1079.5090183083319	9.44788087741927	0.932	435	211	THCA	ARSENIC TRIOXIDE	Approved in cancer	KRAS | NRAS | BRAF
112.19046994916219	33.4815227389788	194.2335772281898	32.8852471370672	0.0006	512	52	UCEC	CHEMBL202609	Experimental	CTNNB1 | CHD8 | GSK3B
947.6262126378847	-45.1562726234687	1026.0624262050399	-3.91190164657041	0.922	502	70	KIRC	BORTEZOMIB	Approved in cancer	VHL | AKT3 | MTOR
280.9426802038027	57.0247239237792	220.0553040725172	22.3826300527969	0.0008	512	119	UCEC	AT7867	Experimental	KRAS | PIK3CA | ERBB2
701.9615973099399	38.0874076209311	711.4408021625612	-0.169364746531528	0.563	599	72	GBM	PX-866	Clinical trials in cancer	NRAS | KRAS | PTPN11
599.1196127216804	-51.2995831137325	574.6167513486229	-25.6483819562377	0.422	934	216	BRCA	1375469-38-7	Clinical trials in cancer	KRAS | PIK3CA
417.8579464287097	-1.15021807843647	418.00004763420634	-0.000225771892019111	0.242	512	54	UCEC	NIVOLUMAB	Approved in other pathologies	KRAS | BRAF | EGFR
698.4749655199612	-48.7818143225726	701.9800842316221	-0.232983876779144	0.555	153	19	BLCA	GDC-0068	Clinical trials in cancer	PTEN | PIK3CA | SOS1
1113.4561026427145	-37.0835352191656	1104.3001522452719	-16.470890387925	1.0	423	97	COAD	SORAFENIB	Approved in cancer	KRAS | NRAS | ESR1
1158.5136589638967	-27.7814084588302	1114.6943979745647	9.64598465115228	0.994	512	140	UCEC	ABT-199	Approved in cancer	KRAS | TP53 | VHL
1126.8531766869908	5.77703144144826	1112.8364787054102	10.1607064465252	1.0	423	100	COAD	REGORAFENIB	Approved in same tumor type	KRAS | NRAS | SMAD4
1077.9610932991966	-58.8329462304417	1090.946772523864	10.6125584168608	0.987	423	83	COAD	BEVACIZUMAB	Approved in same tumor type	KRAS | MTOR | BRAF
530.9415161476561	-90.2183530610929	587.6555691048519	-11.3195733160602	0.431	222	132	LGG	INDISULAM	Clinical trials in cancer	IDH1 | BRAF
967.9180587432675	-62.5538486735419	965.9872363039067	-11.3886682726902	0.862	264	109	SKCM	DOXORUBICIN	Approved in cancer	KMT2A | BRAF | AKT1
184.09130694922194	28.1171289432549	177.5787734334692	27.4875160400741	0.0006	934	217	BRCA	HERBIMYCIN A	Experimental	PTEN | PIK3CA | FN1
228.03088029614727	2.95004794866327	199.6732874582651	-35.2072504652315	0.0004	512	77	UCEC	GDC-0077	Experimental	PIK3CA
934.081526961301	-23.4786865395031	946.0397077532916	1.84759601043606	0.832	343	50	HNSC	GEMCITABINE	Approved in cancer	AKT1 | PIK3CA | HRAS
1077.0840839846335	51.3963879466968	1079.2135000840706	3.56454169090694	0.987	423	81	COAD	ABEMACICLIB	Approved in cancer	KRAS | NRAS | SMAD4
536.1232558538464	101.766600569998	723.4929556060348	18.2224056600232	0.538	435	211	THCA	TAK-733	Clinical trials in cancer	KRAS | NRAS | BRAF
743.8701451219019	15.7659134863105	731.381583024054	14.7487002522219	0.583	512	95	UCEC	7-HYDROXYSTAUROSPORINE	Clinical trials in cancer	PTEN | SOS1 | PTPN11
1095.2158630451459	-2.92404007554165	1106.2280096818313	3.0046119458359	0.987	512	136	UCEC	BEVACIZUMAB	Approved in cancer	KRAS | VHL | CTNNB1
649.1091584746803	-17.6954398459683	566.3697680780656	8.36839349687853	0.422	512	106	UCEC	DEMCIZUMAB	Clinical trials in cancer	KRAS | PIK3CA
1043.0840140467328	101.949241855597	1014.5100345199121	-22.7930225645366	0.917	57	25	PAAD	ROMIDEPSIN	Approved in cancer	KRAS | SMAD4
408.00895920706796	-14.9436227224552	388.0301263113993	-8.41569958911555	0.212	435	185	THCA	NIVOLUMAB	Approved in other pathologies	KRAS | BRAF
734.9453705457236	55.988472779707	639.9186904962592	3.22641988264581	0.491	512	108	UCEC	TANESPIMYCIN	Clinical trials in cancer	CTNNB1 | PIK3CA | PDGFRA
615.3263790665385	173.389090748522	655.7481647916477	32.6644540157049	0.555	264	182	SKCM	GSK2126458	Clinical trials in cancer	NRAS | GNAQ | BRAF
191.0070113071985	41.2527532669287	208.33153532777598	-12.5385001754532	0.0006	502	62	KIRC	N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE	Experimental	VHL | AKT3 | MTOR
516.4552828664373	99.9647799129103	571.282476931458	-61.9096387186662	0.435	57	24	PAAD	TAK-733	Clinical trials in cancer	KRAS
727.2191089506742	-46.0822644700547	759.6250242724459	5.69713867883411	0.6	423	92	COAD	REFAMETINIB	Clinical trials in cancer	KRAS | NRAS | NF1
214.81549008632277	-159.497446029461	129.94297191956704	-40.6438788325913	0.0008	264	185	SKCM	TURPENTINE	Experimental	NRAS | KRAS | AKT3
1146.8542331809826	20.0818528408591	1088.7130133722396	0.67674217543339	0.984	169	40	READ	VANDETANIB	Approved in cancer	KRAS | ERBB2 | ARNT
1048.1016614012626	9.52924738970768	1056.4001732265883	-3.31074635017035	0.927	934	223	BRCA	BEVACIZUMAB	Approved in cancer	KRAS | ERBB2 | PIK3CA
169.2569466362261	-26.9547698059528	204.43231481690236	6.82374990200492	0.0004	543	64	LUAD	AT13148	Experimental	KRAS | PIK3CA
739.7525338376165	-3.35910211528901	671.7246908427575	20.9440598943027	0.537	934	241	BRCA	GDC-0068	Clinical trials in cancer	KRAS | AKT1 | PTEN
